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Abstract 
Introduction 
Motor neurone disease (MND) is a degenerative disease that adversely 
affects the nervous system and muscular control.  Eventually respiratory 
muscles weaken, causing breathing, communication and swallowing difficulties, 
and ultimately, respiratory failure and death. Improved quality of life and 
potentially a short extension of life can be provided with non-invasive ventilation 
(NIV), which is offered to people with MND when symptoms of respiratory 
distress become evident.  
It is recommended that end-of-life communication, encompassing the 
benefits and burdens of symptom-relieving interventions (NIV and percutaneous 
gastrostomy tube to assist with nutrition), NIV withdrawal (proposed when 
continued use is considered futile) and other respiratory distress-relieving 
interventions (e.g., opioids), is initiated either before respiratory symptoms 
emerge or at that time. Little is known, however, about whether, when and how 
this communication occurs.  
Methods 
This qualitative research sought to address this gap in knowledge by 
determining the content and timing of end-of-life options clinicians communicate 
to people with MND and their families. Nineteen clinician participants and six 
families, all experienced with MND, were interviewed. Clinicians’ accounts of 
their communication were compared to bereaved families’ recollections of 
communication by clinicians. A framework incorporating patient-centred care 
principles and evidence-based medicine was used to link clinicians’ 
communication to the most recent MND guideline recommendations. The data 
collected were coded and categorised manually for each participant transcript 
and again using NVivo 10 software. Trustworthiness was established through 
independent coding of randomly selected participant interviews by one of the 
candidate’s supervisors. Symbolic interactionism and interpretive description 
vi 
provided the theoretical lens and methodology, respectively, through which the 
data were interpreted.  
Findings 
Despite the existence of comprehensive evidence-based guidelines 
reflecting international consensus, this research found some clinicians were 
unaware of the recommended timing and content of end-of-life communication, 
some chose to depart from or adapt the recommendations and some found the 
recommendations too difficult to implement. Clinicians stated they had 
insufficient time to communicate and reiterate the benefits and burdens of care 
options to ensure understanding. The recommendation to refer people with 
MND to palliative care soon after diagnosis was reported to happen 
infrequently. Clinicians stated that they felt discussion recommending early 
palliative care referral was confrontational for people with MND and their 
families; family participants confirmed this view.  
Recommendations 
Despite their ethos of patient-centred care, clinicians were concerned 
that early end-of-life communication would take away any hope the person with 
MND and their family may have. Consequently, many of the family participants 
appeared unprepared for the consequences of NIV, not having understood the 
potential of NIV withdrawal, with several turning to the Internet for answers. 
Compounding confusion was the disjointed nature of the care provided to 
people with MND often involving several health care providers.  
This research recommends the establishment of a progressive 
interactive timeline, incorporating a case manager and reducing the number of 
external care providers particularly in the terminal phase of the disease.  
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Glossary of Terms 
A “good death”: A dignified death in which symptoms are well controlled, the 
patient’s choice of end-of-life care is known and followed and emotional support 
for the patient and family/significant other and clarity of communication and 
explanation are provided (Steinhauser et al., 2000). 
Advance care planning: A care plan put together by an individual, often in 
discussion with family and doctors. The plan directs a person’s medical care for 
a time when poor health and verbal communication may be adversely affected. 
Advance care plan: A request for end-of-life care, whilst not a legal document 
(less formal than an advance health directive), clinicians are required to follow if 
known to exist. 
Advance health directive: A legal document that ideally clearly stipulates a 
person’s end-of-life care preferences and acceptable interventions.  
Caregiver: Those employed through organisations to provide professional 
personal care and assistance to patients with MND and their families. This may 
also include a member of the family who is employed by the person diagnosed 
with MND and their significant other, or it could be a person volunteering their 
time to attend to the patient and assist the family. In a hospital situation, a 
caregiver would be a personal care assistant, or assistant to the nurses.  
Clinician: Health professional involved with people with MND at the stage of 
respiratory decline and/or involved with the terminal stage of the disease 
process when the withdrawal of the NIV is considered. The type of clinician may 
differ depending on the region where the patient with MND resides. In more 
rural areas, initial discussions and subsequent palliation may occur with general 
practitioners, whereas in larger urban locations, respiratory physicians, 
neurologists, palliative care specialists, palliative care nurses, neurology nurses 
and allied health professionals may all be involved as part of a multidisciplinary 
team.  
Content of NIV communication:  The information provided to the person with 
MND and their family regarding NIV use: benefits, burdens, limitations, process 
of initiation and withdrawal, the relatively temporary symptom control due to the 
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aggressive nature of the disease at the stage of respiratory distress, and 
medication use as alternative and/or in addition to NIV. Inclusion of NIV 
withdrawal and end-of-life choices is recommended (National Institute for Health 
and Care Excellence, 2016).  
Diagnosis: The identification of a health issue by examining the signs and 
symptoms (The Oxford English Dictionary, 2013). 
Dyspnoea: Difficulty in breathing or breathlessness (Mosby, 2002). 
Effective communication: When the person with MND and family have 
received explicit communication from a healthcare professional regarding NIV, 
PEG and end-of-life choices, and the patient and family have understood the 
benefits, burdens and limitations of NIV, the temporary nature of its effect, and 
know what to expect in the process of initiation and withdrawal of NIV (National 
Institute for Health and Care Excellence, 2016).  
Epidemiology: The study of the distribution, incidence and prevalence of 
health-related events or diseases and the application of this information to the 
recognition and improvement of health outcomes (Mosby, 2012) 
Hospice care: All care required for a dying person, often delivered within a 
specific hospice unit during the terminal phase of life (Connolly, Galvin, & 
Hardiman, 2015). Hospice care may also be delivered at a dying person’s 
home, aged care facility or within a palliative care unit. 
Hyperreflexia: Over extended and increased reflexes (Mosby, 2002). 
Inspiration: The action of the diaphragm contracting and pulling down which 
draws air into the lungs (Mosby, 2002).  
Motor neurone disease (MND): A progressive, degenerative disease affecting 
motor neurones (Oliver, Borasio, & Walsh, 2006). MND is used to describe the 
disease entity in Australia, the United Kingdom and other Commonwealth 
countries. Amyotrophic lateral sclerosis (ALS) is the most common form of 
MND. ALS (Lerum, Solbrække, Holmøy, & Frich, 2015) is used interchangeably 
with MND in the global literature but is a favoured description of MND in the 
United States, where MND is also referred to as Lou Gehrig’s disease after the 
famous U.S. baseball player (Oliver et al., 2006). 
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Multidisciplinary team/care: A team of multidisciplinary health professionals 
(MDT) generally including physiotherapists, social workers, dieticians, specialist 
palliative care doctors and nurses, occupational therapists and, often for people 
with MND, respiratory specialists and neurologists. Multidisciplinary teams may 
vary with availability of health professionals, and patients may only be able to 
access a few of the specialists relevant to their disease. Ideally, MDT 
professionals work as a team within an organisation and can meet to discuss 
preferred treatment and management of a patient. 
Non-invasive ventilation: Used in people with MND for symptoms of 
respiratory distress, often commenced to alleviate nocturnal respiratory 
symptoms with increasing dependency as the disease progresses. Generally, 
bilevel positive airway pressure (BiPap) is offered. This is a method of non-
invasive ventilation that delivers inspiratory and expiratory pressures at a 
variable rate via a face or nasal mask to help a patient breath. Regular 
respiratory functional testing, including the sniff nasal inspiratory pressure 
(SNIP) test, is used as a screening tool for the deterioration of the respiratory 
muscles and this may be used by clinicians to offer or increase the use of NIV 
(NICE, 2010). Eventually the respiratory muscles are unable to respond to NIV 
and its use becomes futile.  NIV is withdrawn at this stage and death occurs. 
Occupational therapist: A health professional who assists and enables people 
with their daily life activities. This may include provision of equipment such as 
walking frames, patient specific chairs, ramps and handrails.  
Opioids: A broad term used to describe both natural (opiates e.g., morphine) 
and synthetic medications (opioids e.g., oxycodone) which act on the brain’s 
opioid receptors to relieve pain (Doyle, Hanks, Cherny, & Calman, 2005). 
Palliative care: The World Health Organisation (WHO) describes palliative care 
as: “… an approach that improves quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the 
prevention of suffering by early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychological and spiritual” 
(World Health Organization, 1998). 
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Palliative care management for people with MND:  A specific system of care 
structured around the priorities and needs of the patient and their significant 
others, incorporating a multi-disciplinary approach where possible, and where 
the benefits, burdens and limitations of all options have been considered (Motor 
Neurone Disease Australia, 2012). 
Paresis: A partial paralysis caused by nerve damage which may affect any 
muscles of the body (Mosby, 2002).  
Patient: A person receiving treatment for a particular ailment or disease, or a 
client using a healthcare service (Mosby, 2002).  
Percutaneous endoscopic gastrostomy tube: A permanent feeding tube 
inserted into the stomach in an attempt to maintain nutrition and hydration when 
swallowing food becomes difficult. In Australia, two types of gastrostomy tubes 
are commonly used, differing only in their method of insertion: percutaneous 
endoscopic gastronomy (PEG), inserted via the stomach wall and radiologically 
inserted gastronomy (RIG).  
Process of communication about NIV: How, when and where discussions 
about NIV take place and who is involved in the communication, as this is 
defined above. 
Prognosis: The Oxford Dictionary defines prognosis as “An opinion, based on 
medical experience, of the likely course of a medical condition” and an opinion 
which could outline the outcome of the disease (The Oxford English Dictionary, 
2013). An explanation of the course and outcome of a disease, in this case 
MND, is not necessarily a prediction of time.  
Respiratory failure: Inadequate gas exchange in the lungs due to the nerves 
which activate muscles (in particular the diaphragm) involved with intake and 
expulsion of air in the lungs becoming too weak to function adequately. This 
may result in generalised fatigue, headaches and, ultimately, death.  
Significant others: Family and friends who are significantly and emotionally 
involved with the person with MND.  
Successful communication about NIV: The patient and family have had the 
content of communication regarding NIV explained effectively and have 
understood the benefits, burdens and limitations of NIV, the temporary nature of 
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its effect and know what to expect in the process of initiation and withdrawal of 
NIV.  
Terminal care and end-of-life care: The dignified management of a patient 
who has reached the stage of disease progression where prognosis is one of 
imminent decline and death (Doyle et al., 2005).   
The literature: For this thesis, this includes information written in English, peer 
reviewed prior to publication from January 2000 to July 2016 and published 
either as an electronic or hardcopy journal article or guidelines in a reputable 
journal or website.
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A qualitative study into the communication surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in people with motor neurone disease 
Chapter 1: 
Introduction 
 
 Motor neurone disease (MND), of which amyotrophic lateral sclerosis 
(ALS) is the most usual form, is a degenerative disease affecting the nervous 
system which in turn adversely affects muscular control (Borasio, Voltz, & Miller, 
2001; Gent, 2012; Oliver et al., 2006). The disease is most commonly 
diagnosed after the age of 40 years and is usually slowly progressive over 3-5 
years, with an average life expectancy of approximately three years. The 
average length of survival from MND symptom onset is approximately 20-48 
months although there is considerable variability within the disease. Most 
studies report a survival rate of 10 years or more in approximately 5-10% of 
people with MND (Chiò et al., 2013; Motor Neurone Disease  Australia 
(MNDAust), 2014).  
 
1.1. Epidemiology  
The most recent published estimate of the global incidence of MND is 1.5 
– 2 per 100,000 per year (Doyle et al., 2005), with an approximate lifetime risk 
of developing the disease of 1 in 800 (Phukan & Hardiman, 2009). A more 
recent systematic review of European literature suggests an incidence rate of 
2.08 per 100,000 (Chiò et al., 2013). In a population-based study by Alonso, 
Logroscino, Jick and Hernán (2009), which utilised data from the General 
Practice Research Database (UK), the incidence was found to be higher in men 
than women with a lifetime risk of 2.7 per 1000 in men and 2.1 per 1000 in 
women, and the peak age at diagnosis to be 75-79 years (Alonso, Logroscino, 
Jick, & Hernán, 2009). 
In 2013, 787 persons died from MND in Australia compared to 592 in 
2001 (AIHW, 2015). According to current MNDAust statistics, two people are 
diagnosed with MND and two people die from MND daily (MNDAust, 2013). 
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Approximately 1,900 people have MND throughout Australia, and the MNDA 
estimates a further 14 people per person with MND live with the consequences 
of caring for a family member with MND (MNDAust, 2013). Therefore, 
approximately 26,600 people live with or have lives affected by a person living 
with MND at any time. In Western Australia, the Motor Neurone Disease 
Association of Western Australia (MNDAWA) reported that it assists 
approximately 145 people with MND and their families at any time, including 
approximately six months grief support (Department of Health, 2008 [WA 
Health]). 
 
Despite ongoing research, the cause of the disease is unknown, and it 
remains incurable. However, autosomal dominant genetic defects that appear in 
over half of the 5-10% of familial cases diagnosed with mutations in the SOD1, 
TDP-43, FUS and C90RF72 genes have been closely linked to the disease 
(Gent, 2012; Oliver et al., 2006; Oliver & Faull, 2013). In addition to the 
suggestion that autoimmunity and viral infections are involved in the causation 
of MND, more recently a bacterial toxin, beta-N-methylamino-l-alanine (BMAA), 
has been found to create a faulty protein within cells, causing protein clumping 
and ultimately cell death (Dunlop, Cox, Banack, & Rodgers, 2013; Oliver et al., 
2006). Dunlop et al. (2013) suggest that motor neurones appear to be 
susceptible to BMAA, and that the effect may be linked to neurodegenerative 
diseases such as MND.  
 
1.2. Clinical Presentation and Disease Trajectory  
The clinical presentation in MND is muscle weakness, which may involve 
all muscles (general paralysis), or partial paralysis corresponding to a single 
muscle group, with possible hyperreflexia (over-responsive reflexes) and 
neurone degeneration affecting both the upper and lower neurological pathways 
(Gent, 2012; Huether & McCance, 2014). The progressive neurological 
degeneration causes muscles to weaken, leading to communication and 
swallowing difficulties, potential aspiration and choking, respiratory distress and 
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ultimately, respiratory failure and death (ProGas Study Group, 2015; Skelton, 
2005). The main cause of death from MND is respiratory failure (inadequate 
gaseous exchange in the lungs) caused by respiratory muscle weakness and 
often complicated by respiratory infection (Gruis & Lechtzin, 2012; Oliver et al., 
2006). These infections may be caused or complicated by dysphagia (the 
inability to swallow effectively) resulting in involuntary aspiration of oral 
secretions, food or hydrating fluids. 
 
Given the devastating implications of the disease certainty of diagnosis is 
sought. The current lack of a single diagnostic test means there may be a 
protracted period of symptoms, often up to a year, with exhaustive testing to 
eliminate alternative diseases prior to confirming a diagnosis (Andersen et al., 
2012; Oliver et al., 2006). 
 
1.3. Symptom Management 
Unlike cancer there is no cure for MND, so interventions to improve 
symptom management are recommended to ensure optimum levels of comfort 
prior to the stage when the deteriorating patient can no longer benefit from such 
interventions (National Institute for Health and Care Excellence [NICE], 2016; 
NICE, 2010; Palliative Care Expert Group, 2010). These symptom-modifying 
treatments include non-invasive ventilation (NIV) for respiration assistance, 
gastrostomy tube placements (for nutrition and hydration when the ability to 
swallow is adversely affected) and medications to reduce pain, respiratory 
distress, secretions and anxiety.  
1.3.1. NIV 
The onset of declining respiratory function, reflected in symptoms such 
as headaches on waking or dyspnoea (difficulty in breathing), is a distressing 
and at times frightening experience for a person, and can severely diminish 
their quality of life (Rafiq, Proctor, McDermott, & Shaw, 2012). At this stage, NIV 
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to support a person’s failing respiratory effort is generally offered by respiratory 
physicians.  
 
Respiratory failure cannot be prevented or reversed; however, improved 
quality of life and potentially a short extension of life can be provided by 
palliating the symptoms with NIV (Bourke et al., 2006; Rafiq et al., 2012). NIV 
delivers positive airway pressure to assist breathing and is administered via 
either a face mask covering the nose and mouth or by a nasal appliance. In 
MND, the positive pressure is usually delivered with a changeable inspiration 
and expiration pressure, known as a bi-level positive airways pressure (Rafiq et 
al., 2012). NIV is normally offered to people with MND via a device called a Bi-
level Positive Pressure Airway Device often referred to by the registered trade 
name BiPap (Phillips Respironics, Inc., Murrysville, PA). These machines are 
programmed to assist inspiration (helping the diaphragm to contract and pull 
downwards) by delivering a precise airway pressure and can be set for either 
spontaneous or timed inspiration, depending on the strength and ability of a 
person with MND to breathe (Gruis & Lechtzin, 2012). NIV is thought to facilitate 
some resting of the respiratory muscles and improve comfort and quality of life 
by easing symptoms related to respiratory function, thereby potentially 
improving survival (Faull, Rowe-Haynes, & Oliver, 2014; Rafiq et al., 2012). 
 
A Cochrane systematic review (Radunovic, Annane, Rafiq, & Mustfa, 
2013) provides evidence that NIV prolongs the life expectancy of people with 
MND who do not have severe bulbar (lower cranial nerve involvement) 
involvement. The reason for improved survival in people with MND using NIV is 
not fully understood. However, it has been suggested that by resting and 
reducing the workload of the respiratory muscles, oxygen intake and absorption 
are improved; thus, NIV may contribute to a small increase in life expectancy 
(Rafiq et al., 2012). There is  widespread agreement that NIV increases 
potential life expectancy due to improvement of symptoms associated with 
respiratory insufficiency, as stated in both the NICE (this organisation has 
formally be known as the National Institute for Health and Clinical Excellence 
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but will be referred to by its current name in this thesis) clinical guidelines 
(2010) and the more recent  NICE MND Assessment and Management 
Guidelines (NICE, 2016), but not by improving the underlying disease 
progression (Doyle et al., 2005; Hardiman, 2011). Assuming no bulbar 
involvement, for which the research indicates no survival improvement with NIV, 
a median survival improvement of 205 days has been suggested (Bourke et al., 
2012). Bourke et al. (2012) note that the timing of commencement of NIV may 
influence the length of survival, but the optimal timing of NIV initiation remains 
uncertain. As Bourke et al. show, early introduction of NIV may also be linked to 
poor adherence to NIV.  
 
Approximately 20% of people with MND in Western Australia, who are 
physically suitable for and able to use NIV, will choose to use it in the latter 
stage of their disease (Baxter et al., 2013). Research has shown that almost all 
people diagnosed with MND will develop respiratory problems. Regardless of 
whether NIV is used or not, respiratory complications are the most common 
cause of death and one of the most accurate prognostic indicators (Miller et al., 
2009; Rafiq et al., 2012). A small proportion of people with MND (five per cent) 
present with respiratory failure on diagnosis, whilst 30% present with bulbar 
dysfunction. NIV may be contraindicated in this instance due to disturbed 
swallow and gag reflexes resulting in increased secretions and risk of aspiration 
(Hardiman, Van Den Berg, & Kiernan, 2011).  
 
The progressive weakness of the muscles of the neck region involved 
with swallowing and upper respiratory airway function (bulbar muscles), can 
adversely affect the symptomatic advantages of NIV due to an increased 
inability to clear secretions and risk of aspiration (D. Oliver et al., 2006). Whilst 
the majority of people with MND will experience respiratory symptoms and be 
offered NIV management, many do not accept nor tolerate NIV (Hardiman, 
2011). The tightly fitting mask has the potential to cause areas of pressure 
discomfort often resulting in sores. Hardiman (2011) reports that some people 
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find the mask claustrophobic and may trial the nasal appliance or decline further 
use.  
 
 A proportion of people who tolerate NIV in hospital do not continue to 
use it at home due to a decline in the manual dexterity necessary to adjust the 
mask for comfort, increased secretions which may cause aspiration difficulties 
or a person’s general deteriorating functional level (Hardiman, 2011). An 
increase in symptoms and declining dexterity may be countered by increased 
caregiver support. However, this extra care may not necessarily be available, 
nor is it always part of a person’s care preferences as it increases the 
responsibilities and burdens of the caregiver.  
 
Declining respiratory function becomes increasingly burdensome for 
people with MND and their caregivers and is often used as an indicator of 
nearing the terminal phase of the disease (Eng, 2006; Hardiman, 2011). 
Importantly, the time at which NIV commencement is indicated is generally 
acknowledged to be an opportunity to discuss patient preferences in end-of-life 
options including the use of medications, and the benefits and burdens of NIV 
including withdrawal (MNDAust, 2014; NICE 2010, 2016).  
 
Some people living with MND may elect not to commence NIV at the 
time of respiratory distress, deciding instead to have well medicated symptom 
control and perhaps a shorter life (NICE, 2016). Comfort-giving and symptom-
relieving palliating medications may be chosen because the person with MND 
does not wish to prolong their inevitable suffering, or perhaps because the 
person does not want to become an increasing burden on their family (Ando et 
al., 2014; Faull, Phelps, Regen, Rowe-Haynes, et al., 2014). Increased 
dependency on NIV is inevitable with disease progression as the respiratory 
muscles continue to weaken (Faull, Phelps, Regen, Oliver, et al., 2014). NIV is 
withdrawn when the respiratory muscles fail completely and prolonging its use 
becomes futile, or at the patient’s clear request. Death then typically occurs 
within minutes or hours of ceasing NIV (NICE, 2016). The withdrawal of NIV can 
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be an extremely traumatic and ethically challenging experience for both families 
and attending clinicians (Baxter et al., 2013; Phelps, Regen, Oliver, McDermott, 
& Faull, 2015). Families and some clinicians may have the perception that 
withdrawing NIV is a form of euthanasia, despite the futility of using NIV further 
and the terminal stage of the disease (Baxter et al., 2013; Faull, Rowe-Haynes, 
et al., 2014). 
1.3.2. Swallowing and nutrition 
People with MND may experience swallowing difficulties resulting in poor 
nutrition and weight loss in addition to respiratory weakness. The insertion of a 
percutaneous endoscopic gastrostomy (PEG) tube prior to the commencement 
of NIV is recommended, as later PEG insertion may increase respiratory 
complications (NICE, 2016). Further risks of late gastrostomy placement include 
potential insertion difficulties, which are associated with a higher incidence of 
mortality, and difficulty maintaining nutrition and hydration. However, as 
insertion of a PEG offers little or no life extension, and may cause possible 
discomfort, some people with MND reject the idea (Andersen et al., 2012; 
ProGas Study Group, 2015). Discussion of gastrostomy tube insertion and its 
implications early in the course of MND is recommended particularly if 
swallowing is affected (NICE, 2016). Despite the use of interventions, the 
disease progresses relentlessly toward the terminal stage.  
1.3.3 Choices during disease progression 
Figure 1.1 represents the course of MND in relation to the options of NIV 
initiation or refusal and the timing of suggested PEG insertion and outlines the 
progression of the disease to palliation. The flow chart is based on statistics 
obtained from the Motor Neurone Disease Association of Western Australia 
(MNDAWA, 2008) and does not necessarily reflect the percentages in other 
parts of Australia or the world. The intervention points for the communication 
recommendations (Figure 1.1) are based on recommendations from the NICE 
MND Assessment and Management Guidelines (‘the NICE Guidelines’) (NICE, 
2016), which are discussed further in Chapter 2. The incidence of PEG tube 
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insertion is added to present a more complete picture of the progression of 
MND as the respiratory muscles start to fail, and as an indication of 
recommended communication points. Within each stage of the disease 
progressive an outline of the recommended communication, according to the 
NICE (2016) Assessment and Management Guidelines, is included. The red 
arrows indicate advancement to the terminal stage and end-of-life. 
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Figure 1.1. Disease Progression and Non-invasive Ventilation Flow Chart                                                                                                         
(Flow chart created by the candidate with information from the Motor Neurone Disease Association of Western Australia, 2015) 
MND diagnosed: 
A small number of people with MND present 
with primary respiratory problems. 
Communication recommended on:
Palliative care, NIV (including benefits and 
burdens), PEG and advance care planning.
Respiratory muscles fail: 
NIV offered.
Communication recommended on:
End-of-life issues, potential of NIV 
withdrawal and PEG tubes. 
NIV unsuitable:
For MND with bulbar symptoms. 
Communication recommended on:
PEG tubes and end-of-life choices.
NIV suitable:
In WA approx. 20% of those able will 
eventually use NIV and approx. 
20% will accept PEG tubes.
Communication recommended on:
End-of-life choices and advance care 
planning.
NIV refused or unable to be 
tolerated:
Of those commenced on NIV, 
30% will not tolerate it.
Communication recommended 
on: 
Palliating symptom 
management, end-of-lifechoices 
and advance care planning.
People continuing on NIV: 
Those who are able, continue on 
NIV but continue to decline as 
disease progresses.
Communication recommended on:
The potential for withdrawal of NIV 
as the disease continues to 
progress.
Palliation:
Palliating medications offered for pain, 
secretion control, anxiety and depression.
Death: 
People with MND die from co-morbidities such as aspiration infection 
whilst on NIV, stop NIV due to discomfort/incompatability or 
withdrawal of NIV by choice. 
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1.4. Communication Experiences of People Living with MND 
Research into the experiences of people with MND and their families 
frequently suggests that clinician communication is generally inadequate, 
particularly when delivering the diagnosis (Aoun, Connors, Priddis, Breen, & 
Colyer, 2012; Belkora, 2003; Faull, Rowe-Haynes, et al., 2014). For people with 
MND, deteriorating health and increasing symptoms mean that treatment 
decisions involving potential life-sustaining technologies are often faced early in 
the person’s clinical care. Thus, accurate information about the benefits and 
burdens as well as the life extension limitations of such treatments needs to be 
communicated early and revisited as the disease progresses (NICE, 2016). 
   
A potential complication lies in how MND is perceived and characterised 
by clinicians. The variants of MND and the sometimes unpredictable timing of 
progression of the disease can mean that the point at which a person is 
perceived as having a chronic and terminal disease becomes difficult to predict. 
Whilst MND cannot be understood to be other than a terminal disease, it does 
have an indefinite illness course with a small prospect of technology extending 
life for some people, but not halting the disease progression. The point at which 
chronic illness becomes defined as terminal may confuse the timing of support 
required by the person with MND and their caregivers (Lerum et al., 2015). A 
further challenge for clinicians is the consideration of when to involve palliative 
care services. These may be restricted by the capacity of local amenities to 
support the necessary technology, the preparedness of caregivers for palliative 
care team involvement and the quality of life the patient desires. Given the 
relentless progression of MND and the common misunderstanding that 
“palliative” means “no hope”, there is uncertainty among clinicians as to when to 
introduce the support of the palliative care team to the patient and family. The 
World Health Organisation (WHO) states that early palliative care reduces 
unnecessary hospital admissions and that health professionals’ lack of palliative 
care training and knowledge poses a real barrier to admission to a specialist 
palliative care service (WHO, 2015b).  
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Anecdotally, multiple health professionals and several different service 
organisations may be involved with the person with MND from diagnosis, which 
has the potential to cause confusion and lead to conflicting messages. The 
often unpredictable nature of the disease and the changeable requirements of 
people with MND requires easily accessible support to maintain the person at 
home, less disruption for patient and family, and to prevent lengthy and costly 
admissions to acute hospitals. The most recent WA HEALTH data available on 
this topic is from 2008, when an average length of stay at a tertiary hospital for 
a person with MND was between two and four weeks at an approximate cost of 
between AUD10,000-AUD25,000 (Department of Health, 2008). Consequently, 
the report recommended early involvement of palliative care specialists and 
other members of a multidisciplinary team (MDT) in order to maintain people 
with MND within their home environment and to closely monitor their changing 
requirements those of their caregivers (Department of Health, 2008).  
 
1.5. Death from MND 
 Patient preferences in relation to choices for end-of-life care require 
sensitive, explicit discussion and clear documentation by clinicians to reflect and 
achieve patient wishes (Smith & O'Neill, 2008). Hogden, Greenfield, Nugus and 
Kiernan (2013) found that the caregiver is as occupied and affected by the 
complex decisions surrounding patient care as the patient, and acknowledge 
that communication between patient, caregiver and clinical team is vital to 
achieve optimum patient care (patient-centred care). While there are guidelines 
regarding general end-of-life care containing recommendations specific to 
people with MND, these guidelines are mostly general in nature, broadly 
concerned with “what should be done”, and do not specifically define, describe, 
or detail the implementation steps for recommended best practice (National 
Health and Medical Research Council [NHMRC], 2012).  
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As death occurs soon after the removal of NIV and opiates are used to 
ease the distress associated with extreme difficulty breathing, families and 
significant others may feel confused and concerned if they have not understood 
the information provided to them or expected the events leading up to the end of 
life. Therefore, clear, unambiguous communication addressing the link between 
initiation and withdrawal of NIV and the end of life is critical for people with MND 
and their families. In order to make a fully informed decision about NIV, 
discussion and a shared understanding of all salient considerations prior to the 
onset of respiratory distress and loss of verbal communication is vital. This 
communication must include the limitations of NIV on disease prognosis.  
 
Death can cause distress and fear for the patient and their family. Ideally, 
therefore, caregivers facilitate an early understanding for the patient and their 
family that, whilst death is inevitable, a “good death” is possible. Over the past 
40-50 years end-of-life research has led to an agreement on what constitutes 
good end-of-life care and, through a series of exploratory studies, a consensus 
between clinicians, patients and caregivers has emerged on the definition of a 
good death (Steinhauser et al., 2000). Early studies show a remarkable degree 
of agreement concerning what components of clinical, psychological, financial, 
and social support are deemed important to patients and families at the end of 
life. Complexities arise around differences in ethnicity, gender, religion, 
spirituality and culture (Meffert, Becker, Körner, & Stößel, 2015). In 1969 Kubler-
Ross published a book “On Death and Dying”, which identified patient choices 
and personal decisions relating to terminal care including place of end-of-life 
care and treatment. Kubler-Ross suggested that the dying and aged tend to be 
isolated, as they are reminders of the inevitability of life, but she argued more 
resources should be made available to ensure a more caring end of life at home 
which might ensure a good death (Kubler-Ross, 1969). 
 
In 2000, Steinhauser et al. conducted a study into what constitutes a 
good death by collecting descriptions of areas of importance from patients and 
families experiencing end-of-life care. Six factors were identified: symptom 
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management, clear communication for decision-making, preparation for death, 
attention to family and close friends, reciprocity of care and concern for the 
wellbeing of others and recognition of the patient as an individual rather than a 
disease entity (Steinhauser et al., 2000; Steinhauser, Voils, Bosworth, & Tulsky, 
2015). In the later study by Steinhauser, Voils, Bosworth and Tulsky (2015) a 
more comprehensive form of end-of-life care, including understanding and 
supporting the choices of care made by the patient and family, is identified as 
contributing to a good death.  
 
Understanding a person’s end-of-life choices is particularly important 
when their ability to clearly verbalise or communicate their wishes has been 
adversely affected. The clinician/patient interaction is especially relevant in 
MND when clear communication is often extremely difficult due to the person’s 
disease progression. Consequently, to achieve a good death, clinicians need to 
engage in clear, honest and comprehensive communication in order to develop 
a shared understanding of the goals of care for the patient and their family. 
Therefore, clinicians must not only be compassionate but clinically informed 
and, ideally, experienced if they are to conduct such conversations effectively 
(McConigley et al., 2012; NICE, 2016). Determining when a person with MND 
and their family are ready to accept and receive such honest communication, 
however, adds further complexity.  
 
1.6. Hospice Care and Specialised Palliative Care 
Palliative care management for people with MND is focused on the 
symptoms, support and needs of the patient and their family. Ideally, this 
management would integrate an MDT approach where the benefits, burdens 
and limitations of all options would be discussed between all health 
professionals, the patient and their family (MNDAust, 2012). The integration of a 
centralised, rather than a delegated community-based system, MDT 
incorporating palliative care has been found to reduce hospital admissions and 
have a positive effect on the survival of people with MND (Rooney et al., 2015). 
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Specialist palliative care has become more accessible throughout Australia over 
the last 30 years and should be central to discussions concerning end-of-life 
communication. The following section describes the development and 
significance of hospice and specialised palliative care in Australia. The role of 
specialist palliative care in the delivery of treatment options and the importance 
of unambiguous communication is discussed. This historical overview of 
hospice and palliative care provides contextual background to the current study.  
 
The history and significance of the concept of “hospice” care dates back 
to the 12th century, when religious orders offered a place of rest to those 
severely ill or dying (Palliative Care South Australia, 2015). The idea of a 
medical specialty focused on caring for the dying was developed after the 
Second World War by Dame Cicely Saunders, who established St Christopher’s 
Hospice for the terminally ill in London. She presented her idea in a lecture in 
1963 at Yale University in the United States and her thinking laid the 
foundations for end-of-life care as an area of expertise, a medical speciality and 
the development of modern hospices. Dame Saunders recognised the many 
facets, depths and causes of pain and the need for psychosocial and 
psychological support for the patient and their family. In 1975, the term 
“palliative care” was introduced in Canada by the physician, surgeon and 
academic Balfour Mount, who was concerned the term hospice evoked places 
of impoverishment and hardship (Palliative Care South Australia, 2015). 
 
 In 1990, each state and territory in Australia formed the Australian 
Hospice and Palliative Care Association which was renamed Palliative Care 
Australia in 1998 (Palliative Care South Australia, 2015). Palliative Care 
Australia has provided recommendations for the standardisation of palliative 
care within Australia as well as assisting with end-of-life research and the 
development of quality standards. Historically, palliative and hospice care 
focused on cancer patients and most research focused on efficacy, service 
provision and cost (Palliative Care South Australia, 2015). More recently 
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palliative care has come to be considered relevant to and appropriate for all 
people with a life-limiting, progressive disease (e.g., heart and lung disease, 
other neuro-degenerative diseases) (National Palliative Care Strategy, 2010).  
 
Hospice care and palliative care are terms often used interchangeably. 
However, palliative care may be considered a specific system of patient care 
ideally introduced when a life-limiting disease is diagnosed, whereas hospice 
care could reasonably describe palliating care at the terminal stage of a disease 
(Connolly et al., 2015). Both community- and hospital-based specialist palliative 
care focus on the quality of a person’s end-of-life, their physical and emotional 
suffering and the appropriateness of ongoing treatments (Palliative Care 
Australia, 2005; Palliative Care Expert Group, 2010).  
 
Hospice and palliative care in Australia are provided in various settings: 
acute, specialist, aged care facilities, medical/generalist and community. 
Funding for these services comes from a complex mix of state and federal 
monies plus donations and bequests (Community Affairs References 
Committee & Siewert, 2012). The cost of providing a community palliative care 
service is less than that provided in an acute care setting and is often the 
preferred place of treatment and death (Hodgson, 2010). Hospice and palliative 
care, whether as a community service or in an aged care setting, has been 
shown to decrease health care costs by reducing admissions, inappropriate 
diagnoses, re-admissions and length of hospital stay (Allen, O’Connor, 
Chapman, & Francis, 2008; Hodgson, 2010). Community-based palliative care 
improves care and symptom control in a preferred place of care and adds to 
provider clinician satisfaction (Hodgson, 2010; Palliative Care Australia, 2005). 
 
The main components of palliative care services include symptom 
control, the management of disease and spiritual and psychological support for 
patients and their families in order to allow a good death and choice in where to 
die (Palliative Care Australia, 2005). Implicit within this description is the support 
and care of a patient’s family and significant others. 
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Early palliative care team involvement assists the development of trusted 
relationships between clinicians, patients and families by establishing good 
communication, understanding patient preferences and optimising care. Ideally 
early trusted relationships facilitate discussion and documentation of end-of-life 
treatment choices, known in the literature as advance health directives (AHD) 
(WA Health, 2011). Generally, there has been some attempt at a cure prior to 
the offer of such care but MND does not come with hope of cure, and it is, 
therefore, argued that palliation should commence at diagnosis (Aoun et al., 
2012; Connolly et al., 2015; Motor Neurone Disease Association, 2012; Motor 
Neurone Disease Australia, 2010). In order to monitor disease progression and 
optimise the quality of life for people with MND and their family members, a care 
plan incorporating palliative care from the time of diagnosis is recommended to 
improve communication and support (Connolly et al., 2015; MNDA, 2012; 
MNDAustr, 2014). However, barriers to this approach exist, for both clinicians 
and people with MND. 
 
Consideration if the broader approach to patient (and family) care within 
the healthcare system is relevant because it impacts service users’ and carers’ 
(and clinicians’) readiness to accept or propose palliative care. One popular 
approach to the timing and content of end-of-life communication is through the 
framework of a patient-centred model of care This is discussed in the following 
section. 
 
1.7. Patient-Centered Care 
 A patient-centred model of care is incorporated into current medical 
teaching, but there is some ambiguity around how it is defined (Bertakis & Azari, 
2011). Patient-centred care is generally understood to encapsulate a holistic 
approach within which the patient is an integral decision maker in care choices. 
The term was first introduced in the United Kingdom. It emphasised the 
importance of an individual’s involvement in their own medical care and   
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required explicit clarification for the patient of their disease prognosis and 
ongoing care (Balint, 1969). In 1995 patient-centered care was explored as a 
model of care more from the doctor’s perspective (Schofield, 1995). Patient-
centred care incorporates the idea of enhancing the doctor-patient relationship 
through a sharing of health issues whilst understanding the individual within 
their social and familial context.  Incorporated within this model are health 
promotion and prevention, plus consideration of the doctor’s time and resource 
restrictions.  
 
A systematic review undertaken more recently identified a failure to 
define patient-centred care within articles which either incorporated the term in 
the title or within the abstract (Scholl, Zill, Härter, & Dirmaier, 2014). From the 
articles that did offer a definition, Scholl et al. (2014) were able to categorise 15 
dimensions to patient-centred care. Clinical communication was identified by 
Scholl et al. as an important element of patient-centred care. However, 
characteristics of the clinician, coordination and continuity of care and the 
psychosocial perspective are all aspects of the patient-centred care model 
(Scholl et al., 2014). 
 
In Australia, the definition of patient-centred care includes understanding 
the patient within their social/familial context as well as being responsive to the 
preferences and principles of the individual. Incorporating informative 
communication, emotional and physical support and respect is the definitive 
holistic approach to patient-centered care in Australia (Australian Commission 
on Safety and Quality in Health Care, 2011). One of the recommendations from 
the Australian Commission into the delivery of care, is that research funding and 
its distribution acknowledge the importance of patient-centered care (Australian 
Commission on Safety and Quality in Health Care, 2011). 
 
Similarly, the definition of patient-centred care in the United Kingdom 
encourages consulting with a patient to ascertain their preferences and 
incorporating shared control and management of their health issues (Farrell, 
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2004). In the United States, an analysis into the determinants of patient 
centered-care found the more educated and healthier patients cared for by their 
family physician were more likely to have participated in patient-centered care 
(Bertakis & Azari, 2011). Bertakis and Azari (2011) suggest that patients with 
more serious illnesses are more encumbered by their medical needs and have 
less time to partake in patient-centered communication. Berkaki and Azari, 
however, found no correlation between increased patient satisfaction and 
patient-centred care. 
 
Patient-centred care stresses clarity in communication between clinicians 
and those they are treating. The communication, whilst being informative, 
should uphold the dignity of the person affected by the health issue. The WHO 
promotes people-centred health by educating and supporting patients and their 
families to make informed decisions based on their health requirements, 
expectations and, importantly, preserving dignity (WHO, 2015a). However, this 
ideal health care model can only be delivered with correct training of care 
providers and a setting conducive to sensitive and dignified communication 
(Pringle, Johnston, & Buchanan, 2015). 
 
The following section explains the development of evidence-based 
guidelines and identifies the inclusion of patient-centred care within these 
guidelines. The interpretation of how recommended evidence-based, patient-
centred communication is delivered and understood is central to the research 
reported in this thesis. 
 
1.8. Evidence-Based Guidelines 
Following the initial work by Steinhauser et al. (2000) in defining a good 
death, researchers began to investigate what the best clinical practices were to 
achieve elements identified as important to patients and families at the end of 
life. Clinical guidelines have appeared, based primarily on clinical and expert 
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opinion, first for cancer patients and more recently for non-cancer and chronic 
illness end-of-life care (Steinhauser et al., 2000; Thomas & Free, 2006). 
Evidence-based clinical guidelines provide up-to-date information and 
direct best clinical practice and recommendations for care in a particular field.  
Within the Australian clinical setting, NHMRC guidelines provide direction for 
clinical care and inform clinical decisions on a variety of disease areas 
(NHMRC, 2016). The NHMRC guidelines, as well as guidelines in other 
developed countries, are based on a thorough review of research evidence and 
current clinical consensus. Multidisciplinary panels incorporate experts within 
their field, educational institutions, consumer groups and professional bodies all 
of whom contribute to inform best practice.  
 
In the United Kingdom the NICE, an independent public organisation, 
provides evidence-based recommendations to improve and guide health and 
social outcomes. The development of the guidelines is based on accepted 
international standards of research and assessment, undertaken by clinical 
experts, NICE committee members and stakeholders (NICE, 2014). The 
American College of Physicians’ development of clinical guidelines includes 
systematic reviews of the research evidence plus committee support in much 
the same way as the NICE and NHMRC guidelines (Qaseem, Snow, Owens, & 
Shekelle, 2010). The NHMRC and NICE clinical guidelines are commonly 
updated every 5-10 years (NHMRC, 2016; NICE, 2014).  In the United States 
the clinical practice guidelines are withdrawn or considered invalid if not updated 
within five years after publication (Qaseem et al., 2010).  
 
However, there are shortcomings with evidence-based guidelines, not 
least their implementation into practice (Greenhalgh, Howick, & Maskrey, 2014). 
As an example, Greenhalgh, Howick and Maskrey (2014) state that despite the 
lack of evidence for arthroscopy in all but those who medically need it, 
arthroscopies continue at an extremely high rate in a much broader population. 
A further disadvantage is that the sheer volume of evidence may have become 
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too great and time consuming to be absorbed by already busy clinicians. In 
addition, clinicians often fear that clinical expertise founded on the accumulation 
of years of medical practise could be overshadowed by the fear of litigation if 
specific evidence-based pathways are not followed (Glasziou, Moynihan, 
Richards, & Godlee, 2013). Nonetheless, clinical guidelines provide a way to 
consider the issues in providing effective care. 
 
In MND this includes communicating symptom control options such as 
NIV initiation and possible removal and end-of-life options (Andersen et al., 
2012; NICE, 2016). The recommendations for timing, content and delivery of 
communication within the most recent MND guidelines (NICE, 2016) incorporate 
patient-centred care in their ethos. The combination of patient-centred care, 
evidence-based care and a good death is represented in the most recent MND 
recommendations and guidelines and provide the framework for data analysis 
for the current study. 
 
1.9. Rationale for the Research 
Over the past 10 years throughout Australia there has been a rise in the 
number of deaths from MND, although the cause of the increase is not known 
(Motor Neurone Disease Australia, 2013). Global statistical data on MND/ALS is 
not uniformly collected and the statistics within this thesis are sourced primarily 
from Australian and United Kingdom publications.  
 
In MND, early discussion of end-of-life symptom relieving choices has 
been found to be particularly pertinent, as from diagnosis the person with MND 
and their family need to understand there is no cure and that the progression of 
disease can be rapid and unpredictable. Respiratory failure is the most 
debilitating and critical symptom in MND and is the most common cause of 
death. Non-invasive ventilation (NIV) is offered for respiratory symptom relief in 
people with MND but has its limitations. Therefore, communicating symptom 
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control alternatives and their limitations is recommended to occur soon after 
diagnosis and certainly by the onset of respiratory symptoms.  
 
Current palliative care guidelines recommend that MDT including clinical 
specialists, physiotherapists, dietitians and social workers are involved with 
people with a life limiting illness to ensure that all aspects of patient care are 
covered (Bede et al., 2011; Rooney et al., 2015). A systematic review by Oishi 
and Murtagh (2014), however, highlighted uncertainty about responsibility for 
coordinated end-of-life care in non-cancer patients. Oishi and Murtagh found 
that some of the clinician roles and responsibilities were unclear both to the 
patients and caregivers and in some cases to the clinicians themselves (Oishi & 
Murtagh, 2014). Arguably, this uncertainty may affect the nature of the timing 
and content of any discussions relating to symptom control options such as 
PEG and NIV. 
 
Established patient-centred, evidence-based medicine and palliative care 
clinical guidelines have all recommended that communication for people with 
MND surrounding the initiation of NIV should occur early and include 
discussions relating to gastrostomy tube insertion into the stomach (NICE, 
2016). It is important to understand that the impact of these interventions on 
people with MND and their caregivers can be significant, and the quality of life 
gain may be small (ProGas Study Group, 2015). It is suggested by others that 
these discussions should clearly inform people with MND and their 
families/caregivers of their options, so they can make informed choices and 
share these with all involved. This will in turn minimise the influence of the 
healthcare professionals’ personal attitude toward initiation and potential later 
discontinuation of treatment (Motor Neurone Disease  Australia, 2014; Ruffell et 
al., 2013). Unambiguous discussions about preferences relating to nutrition and 
hydration via gastrostomy insertion are recommended to occur well in advance 
of respiratory symptoms, but there is uncertainty in relation to the actual content 
and timing of these discussions within the literature (Connolly et al., 2015; 
Oliver, Campbell, Sykes, Tallon, & Edwards, 2011). Further, it is not clear 
 22 
 
whether intervention to maintain hydration and nutrition is discussed as a life-
prolonging measure despite the minimal evidence (Connolly et al., 2015), nor 
whether the benefits and burdens of PEG insertion are included in the content 
of effective communication. It is acknowledged that predicting the exact course 
of an individual’s disease can be difficult; the call to avoid ambiguity, therefore, 
refers only to the content of communication relating to symptom control options, 
AHD and end-of-life choices delivered by health professionals.  
 
Despite the existence of specific MND guidelines recommending early 
and explicit communication about end-of-life care choices, there is a perception 
among health care professionals that for some people with MND and their 
families, symptom control and end-of-life options are neither well 
communicated, understood, nor documented (Baxter et al., 2013; Faull, Phelps, 
Regen, Oliver, et al., 2014). Unclear communication has the potential to lead to 
confusion and emotional uncertainty for families and their health care 
professionals, and to result in insufficient information to make and document 
informed care choices. Of concern, and explored within this research, is the 
perceived difficulty in communicating and comprehending vital information to 
people with MND and their families, which acts as a barrier to informed 
symptom control and end-of-life choices. The research reported in this thesis 
investigated overall accountability for communicating information to people with 
MND and their families to uncover how this may have affected the clarity of their 
understanding. It is these issues of communication surrounding respiratory 
failure and symptom control (especially NIV) in people with MND that are the 
focus of this study.  
 
More specifically, the objective of this research is to determine whether 
patient-centred care, evidence-based medicine and guideline recommendations 
relating to symptom control in respiratory failure and end-of-life choices were 
being adequately practised by clinicians working with people and families 
affected by MND. Of particular interest is the timing and content of 
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communication, how effectively and comprehensively clinicians felt they 
delivered the required information and consequently how they perceived people 
with MND and their families understood the intended meaning of these 
communications. In addition, the study examines whether clinicians involved 
with people with MND were concerned that, as clinicians, they may not fully 
understand their patients’ wishes for palliation and end-of-life choices.  
 
The first part of this chapter has explained the background to the current 
study. Next, the focus of the research will be presented, followed by an overview 
of the subsequent chapters.  
 
1.10. The Research Focus   
The focus of the research presented in this thesis is clinical 
communication about respiratory failure and symptom control at the end of life 
in people with MND. Specifically, the research questions generated, and data 
collection conducted for this thesis were designed to explore what information 
clinicians communicate regarding NIV and end-of-life issues and what the 
experience and understanding of that information was for the MND caregiver 
after the death of the patient. The research sought to ascertain whether MND 
communication content explaining treatment options conforms to the available 
recommended guidelines (National Institute for Care and Health Excellence, 
2016; National Institute for Health and Clinical Excellence, 2010). The aims of 
the research reported in this thesis are described below: 
1. To describe clinician communication surrounding NIV including end-of-
life choices. 
2. To understand how clinicians check the level of understanding among 
patients and family members of the benefits, burdens and potential of 
NIV withdrawal prior to NIV commencement.  
3. To understand the impact of clinician communication about the benefits, 
burdens and limitations of NIV on family members’ choices in relation to 
NIV introduction. 
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4. To understand what timing, content and style of communication most 
effectively helps the families of people with MND to make decisions 
about NIV initiation and withdrawal. 
5. To compare the content, process and outcomes of NIV communication 
as described by clinicians and families of people with MND within this 
study against the currently available recommendations relating to 
commencement and withdrawal of NIV and related end-of-life care 
options. 
The following questions were answered where possible by the literature 
review and formed the foundation for the questions asked of the participants. 
 
1.10.1. Research questions 
  
1. In considering the available literature and guidelines, what are the 
most salient components of best practice relating to the 
communication about NIV in MND prior to NIV initiation and 
withdrawal? 
2. What is the evidence that the best practice communication content 
(benefits and burdens of NIV, continued disease progression, 
explanation and offer of a PEG, end-of-life discussions and 
understanding the potential for NIV withdrawal prior to the 
commencement of NIV) is incorporated into the actual communication 
by clinicians to people with MND and families at the time of offering 
NIV? 
3. What do MND families/significant others recall about the 
communication (benefits and burdens, continued disease 
progression, PEG insertion, potential NIV withdrawal and end-of-life 
discussions) provided by clinicians at the time of respiratory failure 
and the offer of NIV? 
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4. To what degree do MND families/significant others feel that the NIV 
communication provided by the clinicians at the time of the offer of 
NIV prepared them for and helped them to understand the 
implications of potential NIV withdrawal resulting in the death of their 
family member? 
5. What if any unmet needs for information, support, palliative care, or 
other services do the clinicians and the families/significant others (or 
patients themselves) with experience of MND identify? 
6. Following the literature review and clinician and family/significant 
other interviews regarding NIV communication, what 
recommendations can be identified that would improve end-of-life 
communication and process for people with MND, families and 
clinicians? 
Communication content surrounding the initiation of NIV and 
encompassing the potential of NIV withdrawal is sparsely covered in the 
literature and is an area where further research has been recommended (NICE, 
2010). The most recent NICE MND Assessment and Management Guidelines 
(NICE, 2016) recommend including discussions relating to “advantages and 
disadvantages” of NIV when discussing its initiation. The guidelines recommend 
that those diagnosed with MND have adequate information relating to what NIV 
can offer, that it can be stopped at any time and that the discussions occur 
sensitively and at an appropriate time (NICE, 2016).  
 
 This research examines the content of communication between clinicians 
and people diagnosed with MND and their families which, if based on the 
evidence-based clinical guidelines, should incorporate symptom control and 
end-of-life issues. The study identifies two distinct participant groups: those that 
provide the communication (the clinicians) and those that receive the 
communication (the people with MND and their families). The research 
questioned the clinicians involved as to when they imparted the relevant 
information and whether they felt they had done so with enough clarity to allow 
 26 
 
the person with MND and their family to make informed choices. In particular, 
clinicians’ views about understandings held by people with MND and their family 
members around the possibility of NIV withdrawal followed by death when NIV 
was deemed to be of no further benefit were explored. Whether and how the 
implications of commencing NIV were understood by the bereaved families of a 
family member with MND were also investigated. In addition, the research 
explored whether the families/significant others involved with the person with 
MND felt able to ask all the questions they wanted to ask, whether they felt 
adequately informed and whether all the participants could offer suggestions to 
improve communication between clinicians and people with MND and their 
families.  
 
This study provides a much-needed contribution to the literature on the 
experiences of caregivers and families who have had a family member die from 
MND and had experience with, or refusal of, NIV as a palliation measure. 
Family and clinician experiences with the withdrawal of NIV are included. The 
study offers valuable insights into clinicians’ experiences of communicating with 
each other within an MDT, and with people with MND and their families. The 
thesis explores perceived barriers to clear communication both between 
clinicians as well as between clinicians and people with MND and their families. 
The variation of care available to rural and metropolitan people living with MND 
is also highlighted and discussed. 
 
1.11. The Structure of the Thesis 
Much of the existing literature on MND and end-of-life contains terms that 
may be unfamiliar to those outside the clinical/practice domain concerned with 
supporting and caring for those with a life-limiting condition. Definitions are, 
therefore, provided within the glossary of terms (page XIX) to help the reader 
navigate the remainder of this thesis. 
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The thesis comprises six chapters. In Chapter 1 the context and broad 
rationale for the study have been indicated, and the research focus, aims and 
questions have been presented. 
 
  Chapter 2 contains a comprehensive review of relevant literature on the 
topic of clinical communication relative to MND.  This review identifies the 
precise gap in knowledge that the research questions in this thesis have been 
designed to address. A fully replicable literature search and selection strategy is 
also detailed.  
 
The study methodology and methods are the subject of Chapter 3. The 
compatibility of interpretive description (methodology) and symbolic 
interactionism (theoretical framework) are introduced. First, the purpose, aims 
and significance of this investigation are restated. Next, a discussion of possible 
approaches to this study and justification for the one chosen is provided. The 
steps followed to conduct the research are then presented. In this chapter, the 
involvement of a stakeholder advisory group formed to confirm and refine the 
research questions and participant interview questions is reported, as are the 
ethical considerations and measures used for trustworthiness.  
 
Chapter 4 reports the findings of the study, which include clinicians’ 
reasons for not always following recommendations, and barriers to 
communication between clinicians and families/caregivers of people with MND 
from the perspective of both cohorts. Illustrative clinician and family participant 
quotations from interview transcripts are included where relevant. 
Misunderstandings around definitions of some words used in communicating, as 
reported by many of the participants, are discussed. 
 
 Chapter 5 includes the discussion of the study findings. The theoretical 
perspective that guided this study is also considered. This chapter also 
compares existing knowledge about MND communication to the new 
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information this study reveals, and incorporates any relevant literature published 
since the completion of the literature review (Chapter 2 and Appendix A).  
 
 In conclusion, Chapter 6 brings the research and the thesis to a close 
with recommendations for further research and suggestions for clinical practice. 
Limitations identified within this study are also discussed. Chapter 6 concludes 
with a reflective account of the candidate’s experience of conducting this study 
(within the Epilogue). Lessons learned are identified for use in future research 
endeavours.  
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A qualitative study into the communication surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in people with motor neurone disease 
Chapter 2: 
Literature Review 
2.1. Section 1: Chapter Overview  
In this chapter, the argument for the current study is further developed. 
Chapter 1 provided the context for this research and a broad overview of the 
current study. This chapter is presented in five sections, beginning with an 
overview of the context of end-of-life communication in cases of MND and 
identifying the need for a focused review of the literature on communication 
between healthcare professionals and those with MND and their family 
members in Section 1. Section 2 provides a summary of the steps taken in a 
systematic (black) literature search, retrieval and selection process, conducted 
to answer the question “What is known about communication between 
caregivers and families about NIV in MND prior to NIV initiation and 
withdrawal?”.  Section 3 reports and discusses the results of this process in the 
form of narrative critical review. The report of an environmental scan conducted 
in which clinical guidelines pertinent to the phenomenon of interest were 
retrieved and summarised is provided in Section 4. This is followed by a 
statement about what is and is not known and discussed in relation to the 
introduction, use and withdrawal of NIV in MND. The need for a study to 
address current knowledge gap is then summarised, and the research 
questions are listed in Section 5.  
2.1.1. Epistemological and ontological position 
To understand the nature and effect of communication in relation to end-
of-life treatment choices delivered by clinicians to people with MND and their 
families, both the study reported in this thesis and the review of literature are 
positioned within a relativist ontology and a subjective epistemological position. 
These two decisions reflect an understanding that delivery of vocal 
communication depends upon the clarity and specificity of the language of the 
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individual delivering it, and that how the “receiving” individual understands the 
delivered communication depends on a range of influencing individual factors 
(Raskin, 2008).  
2.1.2. The context of end-of-life communication in MND  
The importance of clear communication in which the benefits, burdens 
and limitations of NIV are explained to people with MND and their families has 
been recommended by many in the field of MND care (Baxter et al., 2013; 
NICE, 2010, 2016). Explicit communication enables people with MND to make 
informed treatment choices. Studies show the use of NIV in people with MND 
with good bulbar function can prolong a person’s life by 7-18 months (Bourke et 
al., 2006; Jenkins, Hiollinger, & McDermott, 2014; Radunovic et al., 2013). 
Nevertheless, with or without the use of NIV, complications can arise for people 
with MND such as an inability to clear oropharyngeal secretions (respiratory 
secretions which can become copious or viscous in MND) leading to chest 
infections, or increased difficulty breathing, which in turn commonly lead to 
death by respiratory failure (Rafiq et al., 2012). Additional considerations, such 
as clarifying and documenting the patients’ and families’ wishes for end-of-life 
treatments, such as incorporating AHDs into advance care planning, are 
recommended for clear direction to clinicians. Patient comfort, caregiver support 
and the value the individual places on a potentially longer life in relation to the 
possible trade-off of poorer quality of life are recommended as essential 
components of conversations. This communication must be undertaken when 
proposing potentially life extending technologies such as NIV (Lerum, 
Solbrække, & Frich, 2016; NICE, 2016). Thus, the inclusion of end-of-life issues 
and documented patient wishes in communication surrounding NIV is vital for 
ensuring a clear and shared understanding between all concerned.  
 Recent end-of-life and clinical palliative care literature suggests that NIV 
is being increasingly employed as a palliating intervention for dyspnoea, not 
only in MND, but also in other progressive respiratory diseases such as lung 
cancer and emphysema (Gifford, 2014). NIV can also be used as a palliating 
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measure in illnesses with a long trajectory such as chronic obstructive 
pulmonary disease (COPD) (Gale, Jawad, Dave, & Turner, 2015). Although NIV 
has been recommended for palliating respiratory symptom relief in MND, it is 
unclear whether clinicians who specialise in all progressive respiratory 
conditions are communicating clear and precise information about its initiation 
and potential withdrawal to patients and their caregivers. Understanding what 
this communication involves, at what stage the discussions occur, how well the 
necessary information is being delivered and comprehended by people with 
MND and their families is, therefore, becoming increasingly relevant to other 
diseases (Gifford, 2014; Quill & Quill, 2014). The benefits of relieving respiratory 
failure associated with MND and the burdens of wearing an NIV mask 
(associated feelings of claustrophobia and discomfort) appear similar in people 
with MND and those with chronic respiratory disease. People with MND and 
those with COPD experience increased dependence on both NIV and caregiver 
support (Ando et al., 2014; Gale et al., 2015).  
2.1.3. The timing of palliative care involvement and triggers for NIV 
and end-of-life discussions. 
 The WHO recommends a palliative approach at the end of life, to ensure 
quality of care for all life-limiting illnesses (Sawatzky et al., 2016). The WHO 
(1998) describes palliative care as:  
…an approach that improves quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the 
prevention of suffering by early identification and impeccable assessment 
and treatment of pain and other problems, physical, psychological and 
spiritual. 
The WHO definition does not specify an individual’s anticipated life 
duration for referral to a specialist palliative care organisation. In MND, not 
knowing the best time for referral of those living with the disease to specialist 
palliative care can make the transfer difficult (Dharmadasa, Matamala, & 
Kiernan, 2016).  
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Whilst MND is generally associated with a life expectancy of 
approximately 2-5 years, some people live with the disease for more than 10 
years, which potentially changes the prognostic category to chronic (rather than 
terminal) disease (Lerum et al., 2015). The MND recommendations referenced 
within this study discuss referral to specialist palliative care at diagnosis. 
However, consideration of a palliative care approach which incorporates a GP 
and organised community care as opposed to early incorporation of a specialist 
palliative care service may be appropriate. This may be particularly relevant 
when considering life-limiting chronic diseases, which in the instance of MND 
may describe the course of some variants of the disease (Burgess, Braunack 
Mayer, Crawford, & Beilby, 2013). Burgess, Braunack, Crawford and Beilby 
(2013) suggest a referral to specialist palliative care is based on patient needs 
as well as their symptoms rather than diagnosis alone. 
The Standards for Providing Palliative Care in Australia (Palliative Care 
Australia, 2005), which are generally accepted in principle throughout the world, 
include acknowledging the unique holistic requirements of the patient and their 
family. Ongoing assessment and communication are particularly important. 
According to these standards, palliative care should be available to all but is 
difficult for those with a life-limiting disease irrespective of diagnosis., based on 
clinical need. The availability of coordinated assisted care to lessen the 
caregiver burden, provide comfort and meet individual requirements for end-of-
life care should be considered (Palliative Care Australia, 2005). In MND there is 
no potential of a cure but a prolonged physical and mental decline. The timing 
of referral to palliative care for people with MND has been addressed in the 
general palliative care literature and current recommendations, although there is 
confusion as to the optimal timing (Dharmadasa et al., 2016). Whether 
specialist palliative care is introduced from diagnosis or when MND symptoms 
worsen and symptom management technology (such as NIV) is needed is 
dependent on when the patient and family are judged ready to receive such 
information. Leaving referral too late can lead to hospital admissions and crisis 
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situations, should clear information not have been forthcoming (Connolly et al., 
2015).  
Opinions about when specialist palliative and end-of-life care are 
introduced abound with little consensus, due in part due to the wide variation in 
the trajectory of diseases (e.g., cancer versus non-cancer). However, most 
experts agree that palliative care should be started soon after diagnosis and 
thus, end-of-life communication needs to start early (NICE, 2016; Oliver et al., 
2006). A study in the United Kingdom investigated whether the Preferred 
Priorities for Care document developed as a communication tool by the End of 
Life Care Strategy (Lancashire and South Cumbria Cancer Network, 2007) had 
any impact on the actual end-of-life care offered to people with MND. This plan 
was developed as a patient-held advance care planning tool principally to assist 
patients to make their preferred place of death clear. However, this document 
was not found to improve patient end-of-life care and many health care 
professionals seemed unaware of its existence (Preston, Fineberg, Callagher, & 
Mitchell, 2011). Another study examined clinical support tools. The Lothian 
National Health Service in the United Kingdom developed what it called the 
‘Supportive and Palliative Care Indicator Tool’, which suggests general and 
clinical indicators to identify those in need of immediate palliative care (Boyd & 
Murray, 2010). This indicator tool does not recommend commencement of 
palliative care when the neurological diagnosis is given. It suggests that 
palliative care services should become involved when symptom deterioration 
such as breathlessness, swallowing difficulties or communication issues occur.  
Other researchers have investigated the timing of discussions between 
clinicians and patients. In an article that suggests early open and honest 
communication of end-of-life issues in ALS, Connolly, Galvin and Hardiman 
(2015) examined published scientific literature to identify end-of-life issues 
pertaining to the management of MND. They suggested that early symptom 
control communication may enable patients and families time for informed 
discussion and to plan and prepare, and that these discussions may prevent 
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unwanted symptom control interventions such as NIV, gastrostomy tubes and 
the potential of invasive ventilation. Other studies tend to support these 
conclusions (Dharmadasa et al., 2016). Thus, honest communication 
surrounding end-of-life options for care is recommended from initiation of 
symptom control interventions (NIV/PEG), particularly if such discussions have 
not previously occurred, and especially as MND has an unpredictable disease 
course.  
The introduction of palliative care soon after (or at) diagnosis is 
discussed by Connolly et al., (2015) and is encouraged for alleviating 
symptoms, improving communication, providing support to patients and families 
and enhancing quality of life in a terminal disease. Some health professionals 
may lack experience and confidence to manage the complex and sensitive 
discussions associated with ongoing care in a relatively rare disease such as 
MND, and some may perceive a sense of hopelessness should end-of-life care 
be discussed too soon (MNDA, 2012). As the disease progresses and 
symptoms of respiratory distress develop, the person with MND should be 
referred by their primary health care provider to a respiratory physician or 
neurologist for detailed specialist management and discussions regarding 
appropriate forms of psychological support, ventilation options, palliating 
alternatives and guidance by an MDT (NICE, 2016).  
An MNDAust submission made to the Australian Senate Committee 
inquiry into palliative care in Australia advised that access to MND specific 
information for patients and their families is required to maintain a palliative care 
approach and to support clear communication about end-of-life issues 
(MNDAust, 2012). The submission also recommended referral to palliative care 
services as soon as possible after diagnosis to optimise quality of life and 
professional support to inform and assist with advance care planning. MNDAust 
recommends that a palliative care approach to MND is initiated on diagnosis, 
with discussions incorporating end-of-life decisions commencing when the 
person with MND is ready (MNDAust, 2010). Although the MNDA agrees that 
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the timing of such discussions is uncertain and ought to be individualised, 
triggers for commencing such discussions are suggested, with one 
indicator/prompt being dyspnoea (difficulty with breathing) and offering NIV 
(NICE, 2010).  
A survey amongst the members of the European ALS Study Group on 
standards of palliative care found discrepancies in care offered amongst 
palliative care providers, such as the timing of the introduction of palliative care 
and MDTs, and the availability and maintenance of NIV (Borasio, Shaw, 
Ludolph, Sales Luis, & Silani, 2001). Discussions relating to terminal care were 
reported to occur at the request of the patient or when the patient was close to 
death, highlighting the possibility that the patient and family may have worried 
over symptoms such as choking in respiratory failure for the duration of the 
illness. The authors recommended development of a set of common standards 
for the management of ALS (Borasio, Shaw, et al., 2001).  
The European Federation of Neurological Societies (EFNS) have 
recently revised guidelines for the care of people with ALS and made 
recommendations for further research such as studies into the quality of life 
relating to NIV and PEG use (Andersen et al., 2012). Recommendations for 
care within the guidelines include input from a palliative care team early after 
diagnosis, initiation of end-of-life discussions when an individual is ready and at 
the time of provision of potentially life-sustaining interventions. Respiratory 
distress symptoms ought to prompt end-of-life discussions and trigger the 
AHDs. More recently, a paper presented at the 24th Meeting of the EFNS 
(European Federation of Neurological Societies and European Association of 
Palliative Care, 2015) reiterated the need for communication regarding end-of-
life issues prior to any impairment of communication abilities. A review of the 
current international palliative care guidelines indicates that clear 
communication between medical specialties and people with MND is required 
(NICE, 2016). The recommendations include the need for international palliative 
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care MND/ALS guidelines incorporating respiratory failure options (Bede et al., 
2011; NICE, 2016).  
Finally, the NICE clinical guidelines (2010) for the use of non-invasive 
ventilation in the management of MND recommend that respiratory physicians 
should be part of the MDT and this is reiterated in the NICE (2016) MND 
Assessment and Management Guideline. Eng (2006) suggests a general 
acknowledgement amongst clinicians specialising in MND that involvement of a 
palliative care service at the stage of respiratory decline, if not before, is 
important. Hardiman (2011) and Borasio, Voltz and Miller (2001) agree a 
palliative care approach should commence from the onset of symptoms and 
initial diagnosis of MND, and recommend discussions involving the patient, 
significant others and the medical team to optimise appropriate ongoing care, 
understanding and support. Borasio et al. (2001) also suggest discussion and 
information for families and people with MND about the terminal stage should 
commence, at the latest, with the onset of symptoms of dyspnoea.  
Whilst there is agreement in the literature for early palliative care 
involvement and the potential usefulness for AHDs (Borasio, Voltz, et al., 2001; 
Hardiman, Bede, Oliver, & Obrannagain, 2011), the optimal time for 
involvement of the specialist palliative care team from the perspective of the 
patient or family remains unclear. The concept of improved communication 
surrounding the implementation of NIV and ongoing disease progression is 
acknowledged as an area requiring further research (NICE, 2010). 
In summary, people with MND can present with different palliative care 
issues compared to cancer patients. Clear communication surrounding the 
introduction of palliative care and symptom control delivered at a pace directed 
by the person with MND and their family is an important element in quality end-
of-life care and is explored within this thesis. 
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2.1.4. Patient and family perspectives on end-of-life communication 
 The literature published over the past 16 years has been reviewed for 
this chapter. It identifies clear communication as a priority of end-of-life patients 
and their families. Understanding the disease process is essential for them to 
make appropriate and timely symptom control and end-of-life decisions. People 
with MND and their caregivers can be assisted to make clear decisions relating 
to their ongoing care if they know the facts of their disease and if the support is 
available to ensure their wishes are upheld. In a retrospective study of 42 
people with MND, Anderson, Kuru, Munroe, and Sirdofsky (2007) agree that 
end-of-life discussions should commence from the time of the person’s MND 
diagnosis and continue over the duration of the disease especially as patient 
preferences often change over time. Anderson et al. found that people with 
MND are generally agreeable to participate in end-of-life discussions particularly 
relating to invasive measures soon after diagnosis, but also found that this does 
not necessarily occur. Despite guidelines for clinicians recommending honest 
discussions relating to interventions for symptom control prior to the need for 
those interventions (Motor Neurone Disease  Australia, 2014; National Institute 
for Health and Clinical Excellence, 2010c), one study has identified that these 
discussions may be experienced as “pressure” by some people with MND 
(Greenaway et al., 2015). 
In a systematic review to find the most important aspects of end-of-life 
care identified by patients and their families in an inpatient setting within 
Australian hospitals, Virdun, Luckett, Davidson and Phillips (2015) identified 
clear communication and the ability to contribute to decision-making as priorities 
in end-of-life care. From the patient’s perspective, multiple studies have 
suggested that most would welcome more honest and up-front discussions 
concerning prognosis, benefits and burdens of various treatment options and 
their effect on patient and family quality of life (Astrow et al., 2008; Virdun, 
Luckett, Davidson, & Phillips, 2015). Several studies show that people with 
MND would like the opportunity to discuss their treatment options and would like 
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as much information as is available, believing that doctors should initiate such 
conversations (Anderson, Kuru, Munroe, & Sirdofsky, 2007; Blackhall, 2012).  
A comparative study of decision-making in patients with advanced 
cancer (n= 60 patients) and MND/ALS (n= 32 patients), found communicating 
end-of-life issues was significantly less well discussed in the advanced cancer 
patients than in MND/ALS patients (Astrow et al., 2008). Astrow et al. (2008) 
suggests this may be due to the variable prognosis in cancer, with periods of 
remission and the potential of a cure. Astrow et al. propose that as people with 
MND have fewer treatment options and a more predictable prognostic pathway 
than cancer patients, the discussions relating to the end of life occur earlier 
during the disease. Astrow et al. (2008) reports a lack of evidence on whether a 
patient’s diagnosis influences end-of-life discussions. Reflecting the 1999 
American Academy of Neurology standards which recommend discussions well 
in advance of the terminal stage, Astrow et al. (2008) encourage further 
research into the relationship between diagnosis and the impact of end-of-life 
communication. This is supported by others in the field of MND research (Miller 
et al., 2009; Miller et al., 1999).  
Communication regarding ongoing support and potential complications 
are acknowledged as vital for all concerned, and advance care planning should 
be continually revisited along the disease continuum (Anderson et al., 2007; 
Oliver & Faull, 2013). Hardiman (2011) and Doyle et al. (2005) stress the 
importance of keeping people with MND informed about their disease 
progression and reassuring them that appropriate care and medications will be 
available to ensure a comfortable death. When NIV is suggested by the clinician 
either for a trial or for ongoing use, it is recommended that the benefits and 
limitations of NIV are fully discussed with the patient and significant others 
(NICE, 2016). 
2.1.5. Content of end-of-life communication in MND  
 A U.K. telephone audit of specialist palliative care doctors caring for 
people with MND in the United Kingdom (Oliver et al., 2011) found the majority 
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of palliative care specialists interviewed were only involved at the terminal stage 
of the patient’s care, by which stage, discussions relating to interventions which 
may have an influence on patient symptoms and quality of life should have 
occurred. However, this audit found wide variation in the understanding of 
specialist roles and low levels of referrals to palliative care specialists by other 
doctors, resulting in some patients not being offered interventions to improve 
their quality of life (Oliver et al., 2011). Nearly 16 years ago a report by the 
Quality Standards Subcommittee of the American Academy of Neurology (Miller 
et al.,1999) recommended communicating patient information on respiratory 
care in MND/ALS to ensure appropriate decision-making. The committee 
recommended that such communication occur well in advance of declining 
respiratory function to enable patient understanding and avoid inappropriate 
emergency care (Miller et al., 2009; Miller et al., 1999). Using a combination of 
focus groups and interviews with clinicians having some experience with 
palliative care, McConigley et al. (2014) explored the complex communication 
requirements provided to people with MND and their families. Acknowledging 
the often disjointed care for people with MND in Australia and the unpredictable 
speed at which MND can progress, The results from this study showed the 
need for improved clinician communication, and education for clinicians 
providing care (McConigley et al., 2012; McConigley et al., 2014).  
 
 The EFNS recommends that the diagnosis and prognosis of MND/ALS 
could be communicated to patients and families, and that this as a skill a 
clinician needs to develop. The EFNS recommends allowing adequate time for 
a clinician who knows the patient and who has ascertained the patient’s level of 
knowledge to provide information. The recommendations also suggest providing 
written information, or a support organisation website relating to MND, with the 
choices of symptom control and reassurance of ongoing support. The EFNS 
highlights the importance of effective communication between patients, 
caregivers and all members of the MDTs, yet patients and families are not 
always satisfied with the communication they receive (Andersen et al., 2012).  
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 An American study completed in 2004 found age and level of education 
had a significant influence on whether a patient wished to actively participate in 
their healthcare decisions; those who were older and more highly educated 
expressed a greater desire to participate (Levinson, Kao, Kuby, & Thisted, 
2005). Clinician perceptions of patient preferred end-of-life care preferences 
and the extent of honest communication can be unrepresentative, as indicated 
by recent research from Taiwan (Huang et al., 2015). Huang et al. (2015) 
collected data from 314 terminally ill patients (diseases unspecified) and 177 
physicians involved with their end-of-life care via a questionnaire. Their 
questions pertained to honesty with patients about prognosis and treatment 
preferences. Whereas most of the study patients preferred to be well informed 
(94.3%), only 80% of the physicians believed that their patients wanted this. 
The research indicated a discrepancy between 90% of the patients preferring 
supportive care only at the terminal stage, compared to 15.8% of the physicians 
who felt this was their patient’s preference, and 33% who thought active 
treatment was their patient’s preferred option.  
 
 Similarly, a German study found the majority of terminally ill patients 
wanted and expected clear communication from their health providers about 
their treatment despite the authors acknowledging that death and dying are not 
widely discussed in German society (Meffert et al., 2015). Blackhall (2012), in a 
review of palliative care and ALS/MND literature, suggests, as many palliative 
care experts do, that usual care and specialist physicians who have not had 
much exposure to palliative care education or training may avoid end-of-life 
discussions with those with MND. Blackhall (2012) suggests this may be 
because they fear it could lead to a sense of hopelessness, and often wait until 
the patient initiates the subject. This hesitation to discuss end-of-life issues by 
clinicians and their belief that such discussions should be initiated by the patient 
is singled out as a particular problem in end-of-life care medicine by Lemoignan 
and Ells (2010), who recommended further research into this phenomenon.  
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2.1.6. Recommended communication and frontotemporal dementia 
The most recent guidelines relating to MND assessment and 
management, published in February 2016, recommend information about 
prognosis and management of symptoms is provided at diagnosis and delivered 
by a highly trained and experienced specialist such as a neurologist (NICE, 
2016). Health professionals are urged to ask patients how much information 
they wish to have explained at diagnosis and whether they wish their families to 
be involved. In relation to PEG insertion, which is recommended prior to the 
introduction of NIV, it is suggested that advice and support is offered either at 
the time of diagnosis or when any concerns about swallowing or weight loss 
emerge. The NICE (2016) recommendations also suggest that prior to any 
decision on PEG insertion, assessment should be made of the patient’s ability 
to give consent and whether frontotemporal dementia (FTD) has been 
diagnosed.  
Oliver et al. (2011) have argued that the impact of cognitive changes on 
communication, decision-making, and understanding should be recognised by 
health professionals to avoid inappropriately implementing symptom control 
systems such as NIV and gastrostomy tubes. Frontotemporal dementia 
(behavioural or language disorder) has more recently been recognised as an 
overlapping disease component of MND, with clinical implications for patient 
management (Phukan, 2007; Phukan et al., 2012). Phukan et al. (2012) 
suggest 14% of people diagnosed with MND/ALS may present with dementia at 
diagnosis, with more than 40% of patients experiencing cognitive changes but 
without evidence of dementia. Cognitive changes, which can be subtle, have 
potential implications for the capability of a patient to either understand or have 
the ability to communicate adequately with clinicians, particularly in relation to 
treatment options (Phukan et al., 2012). The process and ability to assess for 
the presence of cognitive changes in people with MND was considered by the 
candidate to be a substantial area of research so was not included in this study. 
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How FTD impacts on families was touched upon by the clinician participants 
and considered by some of the family participants in this study. This is 
discussed further in Chapter 4.  
2.2. Caregiver and Patient End-of-Life Concerns 
2.2.1. NIV communication from initiation to withdrawal 
incorporating advance health directives and multidisciplinary 
teams. 
There is little in the general MND literature covering what specific 
information should be discussed surrounding initiation, non-initiation or 
withdrawal of NIV, although several studies suggest detailed communication 
should occur (Faull, Rowe-Haynes, et al., 2014; Lemoignan & Ells, 2010; NICE, 
2010; Oliver & Faull, 2013; Preston et al., 2011).  
The NICE (2016) Assessment and Management Guidelines for MND 
recommend that the person with MND, their family, the respiratory 
service/physician and those incorporated into the MDT, should draw up a 
detailed plan which includes regular opportunities to discuss withdrawing NIV 
(NICE, 2016). Anderson et al. (2007) suggest that signs of respiratory distress 
should prompt discussion and documentation of patient preferred treatment 
alternatives including options for the terminal phase.  
The American Academy of Neurology (2012) recommend that all people 
diagnosed with ALS/MND should have documented discussions relating to NIV 
options with their clinician annually, and any reasons for not having such 
discussions should also be clearly documented (American Academy of 
Neurology, 2012). Information relating to NIV commencement remains 
unchanged from the NICE (2010) guidelines. It is suggested that discussions 
about NIV be “appropriate to the stage of a person’s illness” and delivered in a 
sensitive manner (NICE 2016: Recommendation1.14.2, page 23). The latest 
version of these guidelines recommends the patient should be reassured that 
NIV can be stopped at any time and given many opportunities to discuss the 
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option of withdrawal. It is not made clear, though, who should initiate these 
discussions or the content of the discussions (NICE, 2016). 
Preston, Fineberg, Callagher and Mitchell (2011) interviewed 11 
bereaved family members/MND caregivers and found that despite patient 
preferences of care being documented and read by family members, there was 
an apparent lack of awareness among health professionals of the care priorities 
for people with MND. Early effective communication was acknowledged to 
enable advance care planning, offering peace of mind to people with MND and 
their family members. However, the content of the communication between 
clinicians and people with MND to enable treatment choice was not reported 
(Preston et al., 2011).  
Oliver and Faull (2013) recommend ongoing discussion with the patient 
and family from the commencement of NIV, offering support and covering all 
aspects of care including emergency care and advance health care planning. 
Oliver and Faull note the lack of published literature regarding the deterioration 
of patients using NIV and associated communication. For example, the 
understanding of deteriorating symptoms and medications required to relieve 
them, the possible medication side effects of increased sedation, and the 
implications of NIV withdrawal are rarely addressed. This lack of evidence 
inevitably makes conversation about these issues with patients and significant 
others difficult (Oliver & Faull, 2013). However, despite considerable agreement 
on the need for discussions to include withdrawal of NIV as part of usual care 
provision and some suggested trigger points in the patient’s disease trajectory 
for honest end-of-life discussions, in practice, it remains unclear as to who has 
or should have these discussions, their content, the impact these discussions 
have on the patient, significant others and clinicians at the terminal stage of the 
disease, or when patients and families feel these discussions should occur. 
2.2.2. Triggers for communication 
Based on a consensus of expert clinical opinion, triggers for initiating 
clinician and patient discussions relating to MND end-of-life discussions are 
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recommended in the NICE (2010) NIV guidelines and re-iterated by Mitsumoto 
and Rabkin (2007), Rafiq et al. (2012) and NICE (2016) MND Assessment and 
Management Guidelines. These triggers include, for example, pain requiring 
high dosages of analgesia, dyspnoea or symptoms of hypoventilation when NIV 
would be offered, or when the patient or family requests information relating to 
end-of-life care (Mitsumoto & Rabkin, 2007; NICE, 2010; Rafiq et al., 2012). 
Another discussion in the MND literature is whether NIV initiation/respiratory 
failure would be an appropriate time for explicit end-of-life discussions, 
however, the input of the person living with MND or the views of their families 
has been minimal (Baxter et al., 2013; Eng, 2006; National Institute for Health 
and Clinical Excellence, 2010, 2016).  
2.2.3. Communicating the benefits and burdens of NIV 
Experiences with NIV for people with MND appear to be as varied as the 
communication that surrounds the intervention. Lemoignan and Ells (2010) 
interviewed nine people with MND, all of whom were suffering adverse 
respiratory symptoms, regarding their decisions to use NIV. Those interviewed 
felt they had a poor understanding of how respiratory failure, NIV technology, 
and their own disease progression could affect their quality of life. Fear relating 
to the possibility of choking, or fear of being a burden to their family members 
were found to be factors in a patient’s decision-making process relating to NIV 
in the study by Lemoignan and Ells (2010). Their study concluded that the 
consideration of when to discuss NIV and provide information should be guided 
by the person with MND and significant others, suggesting further research 
regarding decisions surrounding NIV is necessary.  
In another study, nine people with MND with respiratory distress were 
offered NIV but declined for reasons of loss of self-control and a perception that 
NIV was not of value to them (Ando et al., 2014). Ando et al. (2014) concluded 
that the prolonging of life was less important to these patients than their “sense 
of self” and the preservation of control and dignity (p. 341). Some participants in 
the study had negative experiences using NIV with discomfort and anxiety 
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relating to the mask and forced air, and some had poor experiences with health 
services and technological support. Some of the participants in the study by 
Ando et al. seemed to doubt their breathlessness was really a part of the 
disease or felt that they could control the symptom without the burden of NIV. 
Greenaway et al. (2015), in their study involving 21 people with MND diagnosed 
for longer than six months, suggested that timely communication to ensure 
adequate information is received to enable an informed choice relating to NIV 
and gastrostomy feeding tubes is an individualised, changing process often 
influenced by relationships with healthcare providers and previous medical 
experiences. 
Recognising the difficulty healthcare professionals have when trying to 
assess the amount and depth of information to provide to a person when 
offering NIV, Greenaway et al. (2015) imply that concise information which 
includes the benefits and burdens may alleviate some patient and caregiver 
fears and assist the decision-making process. However, the study also 
recognises that clinicians move toward interventions may be perceived by 
people with MND as being pressured into an option. Greenway et al. suggest 
that individualised and patient-centered symptom control alternatives may be 
preferred to strict adherence to guidelines as the patient decision-making 
process for interventions can be influenced by complex relationships with family 
and clinicians. Whilst the participants in the study identified an apparent “lack of 
accuracy of information” (p.1008) to enable a decision for or against NIV/PEG 
from the clinicians, the actual content of the communication verbalised by the 
clinicians surrounding the offering of interventions was not reported. 
Communication about treatment options at all points in the disease 
trajectory is influenced by a myriad of complex factors, including the distinctive 
individual characteristics of the participants in the conversation, the content of 
the information provided, what was heard and understood by those present, and 
the discussion and individual decision-making mechanisms resulting from the 
information. Such complexity requires that discussions regarding the benefits, 
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burdens and limitations of NIV be specific and provide clarity for the patient and 
their significant others. There is a great deal of ambiguity in the literature 
regarding how and when clinicians should discuss significant end-of-life 
decision-making issues with patients and their significant others. In addition, the 
literature suggests that the benefits and burdens of various end-of-life treatment 
options including the use of palliating comfort and symptom-relieving treatment 
alternatives should be discussed and patient decisions relating to end-of-life 
care understood and documented (Faull, Phelps, Regen, Rowe-Haynes, et al., 
2014; National Institute for Health and Clinical Excellence, 2010, 2016; Oliver & 
Aoun, 2013).  
Because of the progressive neurological deterioration and subsequent 
decrease in independence of the person with MND, the reliance on caregivers 
increases. This dependence includes the adjustment of the NIV mask, attention 
to potential pressure ulcers particularly where the mask fits over the nose and 
being able to remove the mask when necessary. Caregiver burden and stress 
have been highlighted in recent MND literature, with a focus on a need for 
improved contact with palliative care services for both patient and caregiver, 
and an acknowledgement of complex decisions regarding symptom control and 
quality of life (Aoun et al., 2013; Hogden, Greenfield, Nugus, & Kiernan, 2013; 
Phukan & Hardiman, 2009). In an extensive review of the literature over 10 
years (January 2000-April 2011), Aoun et al. (2013) identified respiratory 
distress as a difficult symptom for caregivers to cope with, particularly in the 
terminal stage of MND. Their review also emphasised the importance of clear 
communication for patients and caregivers by health care providers, and the 
need for improved access to palliative care (Aoun et al., 2013). However, the 
potential of NIV, its benefits, burdens, limitations and eventual withdrawal, or 
how discussion affected caregivers, were not clarified in the review by Aoun and 
colleagues.  
Reasons for not initiating or discontinuing NIV may include the desire to 
not prolong patient suffering or discomfort relating to its use, which may become 
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more pronounced as the patient becomes increasingly immobile and 
incapacitated. The stage at which the respiratory muscles start to weaken and 
palliation by medications and/or initiation of NIV is chosen, may be considered 
to mark the commencement of the terminal stage of life (Eng, 2006).  This 
highlights the need to discuss all potential outcomes of NIV including the end of 
life and the eventual need for end-of-life care, at the commencement of NIV.  
This will ensure the clinicians are confident that caregivers/family understand 
what happens when NIV is removed or if the MND patient dies of co-morbidities 
whilst remaining on NIV (some people die of co-morbidities such as pneumonia 
prior to withdrawal of NIV). Thus, there is a gap between recommended 
discussions relating to MND and NIV use in guidelines and the reality of what 
some family members and people with MND hear, remember or understand.  
2.2.4. The impact of poor health communication on patients and 
families 
Uncertainty related to the diagnosis or prognosis of MND combined with 
poor communication and understanding of technical treatment details and 
information can cause severe stress and strain on the patients and their 
families/significant others (Belkora, 2003; Jarvis, 2014). This uncertainty and 
confusion may lead those diagnosed with the disease to attempt to collect as 
much information as possible and seek out several doctors and other resources 
to find answers and inform decisions. This information-seeking has the potential 
to result in competing and potentially conflicting care providers with their distinct 
views of the case, perhaps adding to confusion (Belkora, 2003; Borasio, Voltz, 
et al., 2001). In addition, Belkora (2003) discusses the possibility for patients 
and families to be overwhelmed when a diagnosis of a life-limiting disease is 
communicated, and who may, therefore, leave decision-making to those with 
clinical expertise. Decision-making is both an emotional and cognitive process, 
and clinicians could adopt a decision dialogue process to assist people with 
their choice of management and care (Belkora, 2003; Jarvis, 2014). Further 
research into the content of communication between patient, 
caregiver/significant other and clinical team may provide insight. 
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The MND literature does not appear to incorporate or reflect the 
viewpoint of the person with MND, nor their significant others, regarding when 
and how communication explaining NIV initiation and potential withdrawal is 
imparted. Foley, Timonen and Hardiman (2014) identified a lack of research 
surrounding patient understanding of health services and studied how people 
with MND engage with healthcare professionals. In their study of 34 people with 
MND, each person was interviewed once, and each had involvement with 
medical and support care. However, only eight of these participants had 
accepted either NIV or PEG. The study found that interviewees believed NIV 
and PEG were interventions to sustain life and not palliating interventions to 
alleviate suffering (Foley, Timonen, & Hardiman, 2014). This poses a question 
as to whether people with MND and clinicians may have varying views on 
“suffering”; people with MND tend to perceive NIV as assisting symptoms of 
respiratory distress and potentially extending their suffering, but clinicians 
perceive NIV as relieving their suffering by assisting their symptoms.  
In a study by Lerum et al. (2016), 25 MND caregivers were interviewed to 
explore their experiences of caring for a person with MND. The aim of the study 
was to understand the difficulties and priorities of care. Lerum et al. found 
caregivers’ attitudes to seeking clarity of MND information was mixed. Some 
participants found a sense of control through clarity of information, whilst others 
found it spoilt the present moment which they treasured. Others used 
knowledge to challenge the diagnosis (Lerum et al., 2016).  
Martin et al. (2014) followed 78 people with MND and 50 MND caregivers 
regarding circumstances which influenced and enabled decision-making relating 
to options of symptom control. Martin et al. explored the complexity around 
whether to accept interventions such as NIV and gastrostomy in people with 
ALS/MND. It appeared that decisions were related to variables such as the 
health status of the patient; those who were more unwell were more likely to 
decide to use an intervention. People with MND and their caregivers with more 
years of education and a higher IQ, according to Martin et al., were more 
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capable of seeking information and more likely to decide to use an intervention. 
The study also found employment status, disease management in the early 
stages of illness and caregivers with a well-balanced and strong psychological 
approach to the care of their family member influenced some of the decisions 
made by the person with MND. It is recommended, therefore, that healthcare 
professionals assess the coping ability of the caregivers and consider this along 
with other decision-making factors, when advising patients about treatment 
choices (Martin et al., 2014). However, the research by Martin et al. did not 
include research into specific communication used to deliver the treatment 
choices nor who should deliver the information.   
In summary, the amount of information both the person with MND and 
the family wish to hear from clinicians, and when they wish to hear it, is unclear 
from the literature. Avoidance of difficult discussions by clinicians relating to 
disease deterioration and progression and particularly the withdrawal of NIV 
complicates this issue and is discussed by Faull, Rowe-Haynes and Oliver 
(2014). Their research suggests that the prognostic conversations are 
overwhelming and are laden with grief and loss, and so are avoided by patients, 
significant others and clinicians alike (Faull, Rowe-Haynes, et al., 2014).  
2.3. Unresolved Issues Relating to End-of-life Communication 
2.3.1. Controversies and clinician/patient difficulties with NIV 
withdrawal and end-of-life discussions  
There is minimal evidence in the literature indicating whether or how 
people with MND evaluate their quality of life or gauge their quality of death. A 
lack of communication that encourages effective discussion between patients, 
families and health care professionals surrounding the terminal stage and death 
of a person with MND is a significant finding of a secondary data analysis 
combined study conducted in Australia and England (Ray, Brown, & Street, 
2014). Despite the use of advance care planning, Ray et al. (2014) highlight the 
difficulties in initiating conversations about ongoing care requirements and state 
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that the development of strategies for clear communication between patient, 
clinicians and families is vital to ensure patient preferences of care.  
A small study of eight MND caregivers identified possible conflicts of 
interest between patients and caregivers when prioritising work, family and the 
needs of the person with MND (Hogden et al., 2013). The complexity of 
changing care requirements for people with MND, communicating with and 
involving the caregiver plus gauging caregiver level of involvement can present 
barriers to optimal care and challenges for clinicians (Hogden et al., 2013). 
Furthermore, a correlation has been found between respiratory function in 
people with MND and their caregivers’ level of distress, affecting the person 
with MND (Pagnini et al., 2012). Pagnini et al. (2012) suggest the perceived 
level of social support and caregiver psychological well-being may influence the 
respiratory symptoms of a patient with MND. Conversely, Pagnini et al. (2012) 
also suggest that well managed caregiver depression and anxiety may 
positively affect a patient’s respiratory symptoms.  
Whilst there is research which extends the knowledge and understanding 
of clinicians’ difficulties with the withdrawal and ongoing use of NIV as well as 
literature acknowledging the emotional burden of caregivers, there is little work 
on the actual communication surrounding the initiation of NIV, non-
initiation/refusal or withdrawal of NIV, and the patient and caregiver 
understanding of the benefits, burdens and limitations of commencing on NIV. 
The gap in understanding the end-of-life expectations of the person with MND in 
relation to their treatment alternatives, and the recommendation that patients 
should be provided with all their palliative care options, is a finding in an 
investigation into depression and quality of life in people with MND/ALS (Kübler, 
Winter, Ludolph, Hautzinger, & Birbaumer, 2005). 
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2.3.2. Ethical issues 
A complex ethical situation arises when the person with MND severely 
deteriorates and NIV is no longer able to provide a level of support that is 
effective and positively contributes to the person’s quality of life (Faull, Rowe-
Haynes, et al., 2014; Phelps et al., 2015). Faull, Rowe-Haynes et al. (2014) and 
Phelps, Regan, Oliver, McDermott and Faull (2015) discuss the emotionally 
challenging aspects and practical implications of the experience of doctors who 
work in palliative care relating to the withdrawal of NIV in people with MND. 
They recommend detailed guidelines and conclude that the complex issues 
affecting the doctors may be difficult to solve. The loss of the ability to 
communicate with people with MND as their disease progresses is suggested in 
the literature as a trigger for NIV withdrawal by doctors, and while the wishes of 
the patient are considered essential, they are not always known (Faull, Phelps, 
Regen, Oliver, et al., 2014; Faull, Rowe-Haynes, et al., 2014). There is minimal 
literature relating to patient and family understandings of the limitations of NIV 
and its potential withdrawal, although fears of choking and symptom control 
have been discussed (Neudert, Oliver, Wasner, & Borasio, 2001).  
As a consequence of disease progression, the patient may end up in 
what has been labelled as locked in syndrome. This is more common with 
tracheostomy and invasive positive ventilation but acknowledged to occur with 
NIV when used constantly, or where the inability to move occurs and clear 
verbal communication becomes impossible but the brain remains intact and 
active (Back, 2001; Borasio, Voltz, et al., 2001; Oliver et al., 2006). An ethical 
dilemma occurs at this point as to the appropriateness of prolonging life with the 
continued use of NIV or the possibility of an emergency procedure of 
tracheostomy to maintain respiration with positive ventilation, if the 
consequences of these choices have not been clearly explained to the patient 
and their significant others (Faull, Phelps, Regen, Oliver, et al., 2014).  
Discussions to ensure full comprehension of the consequences of 
various treatment choices including a patient’s choice to decline potentially life-
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prolonging interventions such as NIV, and the patient’s and family’s decisions 
for treatment or refusal, should be documented in their medical record early in 
the disease process (Back, 2001; Oliver et al., 2006; Rafiq et al., 2012). Clear 
communication from clinicians to those with MND relating to end-of-life issues, 
which may not only influence their treatment options but help prepare them for a 
potentially unpredictable disease course, have been found in several studies to 
be welcomed by most people with MND (Anderson et al., 2007). In a study of 42 
people with MND, Anderson et al. (2007) found that end-of-life discussions 
relating to invasive mechanical ventilation via tracheostomy treatment options 
were poorly covered by clinicians despite the patient wanting open and honest 
conversation. Whilst NIV is not as medically invasive as mechanical ventilation, 
it has burdens, so it is reasonable to suppose that honest and explicit 
communication is important to clarify the patient’s preferences for treatment.  
2.3.3. Patient autonomy: NIV withdrawal 
On the first page of the Motor Neurone Disease Australia Patients’ Rights 
document (MNDAust, 2008) the right of each patient to choose “to accept, 
refuse or discontinue treatment within the legal framework of each state or 
territory” is emphasised. In a study by Baxter et al. (2013), healthcare 
professionals associated with people with MND using NIV in the terminal stage 
found caregivers/families experienced some confusion about when to withdraw 
NIV and the impact. Health professionals interviewed within the study 
expressed concern that families/significant others had a perception of killing the 
patient on withdrawal of NIV. Misunderstanding relating to management of 
people with MND and NIV was found in this study to result in some patients 
receiving emergency resuscitation attempts at the end of life. Whilst indicating 
that NIV has a generally positive effect on the end of life for people with MND 
using it, Baxter et al. highlighted the importance of end-of-life directives and 
making the wishes of the patient known. 
Some research literature supports people with MND, who wish to discuss 
end-of-life issues, receiving information to enable them to make informed 
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choices (Faull, Phelps, Regen, Rowe-Haynes, et al., 2014). The literature 
identifies potentially stressful and controversial issues that may arise with the 
cessation and withdrawal of NIV (Baxter et al., 2013; Faull, Phelps, Regen, 
Rowe-Haynes, et al., 2014; Faull, Rowe-Haynes, et al., 2014; NICE, 2010). For 
example, Baxter et al. (2013) identify the impact of the withdrawal of NIV on the 
clinician’s psychological state, regardless of how symptoms are managed and 
whether death is instantaneous. Faull et al. (2014) identify the communication 
and emotional difficulties clinicians encounter with NIV withdrawal, particularly 
NIV withdrawal at the request of the patient. In a recent retrospective study from 
England, the ethical and legal issues arising from patient requested NIV 
withdrawal were explored (Phelps et al., 2015). The study highlighted both the 
challenge for clinicians to provide honest and clear communication, and the 
difficulties for clinicians in having to deal with the emotional responses from 
both patients and families confused by the NIV withdrawal decision process.  
Patient and/or caregiver confusion and anguish has the potential to affect 
end-of-life patient care should healthcare providers be uncomfortable with the 
concept of NIV withdrawal (Phelps et al., 2015). If seen as an assisted death by 
the clinician, or if they are unable to communicate the expected outcome 
clearly, end-of-life care may be adversely affected (Phelps et al., 2015; Ruffell 
et al., 2013). The literature suggests the opportunity to discuss end-of-life 
decisions and potential issues is taken at the initiation of NIV and should be 
reiterated throughout its use (Baxter et al., 2013; NICE, 2010, 2016).  
 Within the NICE (2016) MND Assessment and Management Guidelines is 
a new recommendation to ask people with MND how much information they 
wish to receive about the disease and whether they wish this information to be 
shared with their families/caregivers (National Institute for Health and Care 
Excellence, 2016). Ensuring and acknowledging patient care and comfort is a 
priority as is understanding that clinicians require high level communication 
skills to establish the trust required for patients to make informed decisions. 
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Further research which may assist this situation was a recommendation of the 
NICE MND Assessment and Management Guidelines (2016). 
By highlighting the need to support all those involved with NIV withdrawal 
and to eliminate emotional challenges for both clinicians and families, Faull, 
Rowe-Haynes et al. (2014) recommend detailed discussions which include the 
timing, how withdrawal happens, and symptom management thereafter. The 
responsibility of who is to be involved (family, clinicians) with the NIV withdrawal 
should be included within these discussions and patient, family and clinicians 
should have a documented plan of end-of-life care. The suggestion by Faull, 
Rowe-Haynes et al. that an ethical statement incorporating the clinical aspects 
and outcome is included within these detailed discussions, and incorporated 
within MND guidelines for NIV withdrawal, is proposed to help alleviate the 
ethical and potentially legal dilemma associated with NIV withdrawal for clinician 
and family. The recent NICE MND Assessment and Management Guidelines 
(2016) recommend that the healthcare professional commencing NIV can 
ensure there is legal and emotional support available for other health 
professionals who may be involved with the withdrawal of NIV. The guidelines 
also recommend that prior to the decision to withdraw NIV, the patient and 
family should have support and clear legal and ethical information from 
clinicians experienced with NIV withdrawal. However, whilst this may assist the 
clinicians ethically, it may not assist the family members, or the clinicians 
emotionally with the consequences of NIV withdrawal (Faull, Rowe Haynes et 
al., 2014). 
This overview has identified some gaps in the literature on the topic of 
communication surrounding the initiation and withdrawal of NIV in MND and 
forms the background to the research reported in this thesis. In the next section, 
the methodology used to undertake a sharply focused review of clinicians’ NIV-
related communication practice is detailed. The review was conducted with 
reference to the process outlined in the Australian Journal of Nursing’s 
“Systematic Reviews, Step by Step” series of articles (Aromataris & Pearson, 
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2014; Aromataris & Riitano, 2014; Munn, Moola, Riitano, & Lisy, 2014; Porritt, 
Gomersall, & Lockwood, 2014; Robertson-Malt, 2014; Stern, Jordan, & 
McArthur, 2014). The question asked of the literature was formulated using the 
Population (P), phenomenon of Interest (I), Context (Co), or  “PICo” design 
(Forrest & Miller, 2001), and provided the basis for a systematic search and 
selection of quality scientific literature that justifies the current study. The report 
of the review follows the PRISMA checklist (Moher, Tetzlaff, Liberati, & Altman, 
2010), modified for reviews of qualitative literature (see Appendix S).  
2.4. Section 2: The Research Question and Systematic Literature Search 
Strategy 
2.4.1. Step 1: Developing the question to be answered by the 
literature review 
As stated previously, the question for this review of the literature was 
developed using the adapted PICo design in which the population, interest and 
context of scientific studies sought are denoted (Forrest & Miller, 2001; Moher 
et al., 2010).The question developed for this review was: “What is known about 
communication (I) between caregivers and families (P) about NIV in MND prior 
to NIV initiation and withdrawal (Co)?”. 
 
2.4.2. Step 2: Type of studies included 
  Information for this focused review was collected from qualitative studies 
in which data were collected via questionnaires, face-to-face interviews, focus 
groups and telephone interviews.  
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2.4.3. Step 3: Developing the logic grid 
The logic grid classifies the search terms or synonyms used for the 
literature search. The search terms were identified from and related to the PICo 
question. 
Table 2. 1 Logic grid and search words 
Population Phenomenon of 
Interest 
Context 
caregiver* 
clinician* 
nurse* 
doctor* 
physician* 
famil* 
relative* 
partner* 
communication 
discussion 
decision  
choice 
mnd 
als 
motor neurone 
disease 
amyotrophic lateral 
sclerosis 
end of life 
palliative 
NIV  
non-invasive 
ventilation 
initiation  
withdrawal 
 
 
2.4.4. Step 4: Defining the search strategy  
Boolean operators (AND,OR) were applied between keywords and 
categories. Within Medline and CINAHL MeSH terms were used in the context 
of alternate words with similar meaning. 
SEARCH 1: caregiver* OR clinician* OR nurse* OR doctor* OR 
physician* AND famil* OR relative* OR partner* OR loved one* AND 
communication* OR discussion* OR decision* OR choice* AND mnd OR 
als OR motor neurone disease OR amyotrophic lateral sclerosis AND 
end of life OR palliative AND NIV OR non-invasive ventilation AND 
initiation AND/OR withdrawal  
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SEARCH 2: caregiver* OR clinician* OR nurse* OR doctor* OR 
physician* AND famil* OR relative* OR partner* OR loved one* AND 
communication* OR discussion* OR decision* OR choice* AND mnd OR 
als OR motor neurone disease OR amyotrophic lateral sclerosis AND 
end of life OR palliative AND NIV OR non-invasive ventilation  
 
SEARCH 3: communication* OR discussion* OR decision* OR 
choice* AND mnd OR als OR motor neurone disease OR amyotrophic 
lateral sclerosis AND end of life OR palliative AND NIV OR non-invasive 
ventilation  
 
SEARCH 4: mnd OR als OR motor neurone disease OR amyotrophic 
lateral sclerosis AND end of life OR palliative AND NIV OR non-invasive 
ventilation. 
 
SEARCH 5: mnd OR als OR motor neurone disease OR amyotrophic 
lateral sclerosis AND NIV OR non-invasive ventilation 
2.4.5. Step 5: Parameters applied to the search  
The following limits were applied to the literature search:  
 Adult age of participants 
 Years of publication: 1990-2016 
 Peer reviewed journal articles 
 English language  
The search inclusion and exclusion criteria are defined more explicitly in 
Table 2.2. The criteria by which the included full articles were evaluated is 
shown within Table 2.3. 
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Table 2. 2 Inclusion and exclusion criteria for the initial literature search 
Inclusion Criteria 
 
Exclusion Criteria 
Peer reviewed journal articles  Non-reputable or non-peer reviewed 
articles  
Articles written in English  Articles not written in English  
Literature with concise titles and 
abstracts relevant to the research 
Literature with ambiguous or vague titles 
and/or abstracts 
Method considered rigorous and 
well defined with sufficient 
participant numbers  
Method poorly described with few 
participants 
Discussion and conclusion well 
defined and argued  
Discussion and conclusion considered to be 
written to fit the initial objective/hypothesis 
and not the results as found 
Articles able to generally clarify 
research thesis topic; found via 
search keywords 
Articles considered too general after 
reading abstract and articles where 
necessary 
Specific to literature review chapter: 
Articles able to help identify and 
clarify research questions 
Articles with some relevance to MND but 
not sufficiently specific to clarify research 
questions   
Where ‘communication’ related to 
communication between clinicians, 
people and families relating to MND 
disease management and end-of-
life care  
Where communication related to items to 
assist people with MND to communicate 
such as whiteboards, electronic devices 
and the research surrounding such 
innovations  
Literature which related directly to 
the search question    
Literature which was considered minimally 
relevant to the search questions   
2.4.6. Step 6: Deciding the databases to search 
MEDLINE, CINAHL, ProQuest Research Library, and the Cochrane 
Library of systematic reviews were searched for relevant published research 
journal articles. Initially article titles were reviewed for relevance, and those that 
did not resonate with the review question were discarded. The abstracts of the 
remaining articles were read again and those that did not reflect the review 
question were rejected. Finally, the full content of the remaining articles was 
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reviewed, and only those that would likely enable the review question to be 
answered were retained for quality appraisal (n=18). A hand search of the 
reference lists of the articles did not identify any new abstracts for review. The 
final number of articles retained for quality appraisal that met the inclusion 
criteria was n=8. 
2.4.7. Step 7: Example of full electronic search strategy 
The following is an example of the five-phase search protocol used for 
the systematic review. The Medline database search is used to illustrate and 
identify several peer reviewed research journal articles. The results of each 
search are shown in bold at the end of each search string:   
SEARCH 1: caregiver* OR clinician* OR nurse* OR doctor* OR physician* 
AND famil* OR relative* OR partner* OR loved one* AND communication* OR 
discussion* OR decision* OR choice* AND mnd OR als OR motor neurone 
disease OR amyotrophic lateral sclerosis AND end of life OR palliative AND 
NIV OR non-invasive ventilation AND initiation AND/OR withdrawal: (0) 
 
SEARCH 2: caregiver* OR clinician* OR nurse* OR doctor* OR physician* 
AND famil* OR relative* OR partner* OR loved one* AND communication* OR 
discussion* OR decision* OR choice* AND mnd OR als OR motor neurone 
disease OR amyotrophic lateral sclerosis AND end of life OR palliative AND 
NIV OR non-invasive ventilation (Total= 6 – 1 excluded as duplicate from 
CINAHL, 4 excluded as irrelevant by title; 1 kept for abstract/full article 
review) 
 
SEARCH 3: communication* OR discussion* OR decision* OR choice* AND 
mnd OR als OR motor neurone disease OR amyotrophic lateral sclerosis AND 
end of life OR palliative AND NIV OR non-invasive ventilation (Total= 6 – 5 
excluded as duplicates from CINAHL; excluded 25 either repetitive within 
the search or by title = 1 included for abstract/article review:) 
 
SEARCH 4: mnd OR als OR motor neurone disease OR amyotrophic lateral 
sclerosis AND end of life OR palliative AND NIV OR non-invasive ventilation. 
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(Total 52- 36 excluded from systematic review but 6 retained for further 
review guidelines and policy statements and retained for environmental 
review; 16 retained for abstract review) 
 
SEARCH 5: mnd OR als OR motor neurone disease OR amyotrophic 
lateral sclerosis AND NIV OR non-invasive ventilation (Total= 232-
duplicate or rejected on title 224; 6 retained for abstract review, 2 
retained for scoping review and as part of the environmental scan). 
2.4.8. Step 8: Study selection 
 The research literature retained for quality appraisal as a result of 
following the steps reported above could be categorised as qualitative, and as 
such was assessed using the Standards for Reporting Qualitative Research 
(SRQR) (O'Brien, el al, 2014). The COREQ checklist (Tong, Sainsbury &Craig, 
2007) and criteria for reporting qualitative research has been completed 
(Appendix T). 
The candidate and one supervisor assessed the literature proposed for 
inclusion in this review: first by title relevance and then by abstract significance 
to the search question and, by extension, the candidate’s research. Lastly the 
full articles were read by both the candidate and the supervisor and then 
appraised for quality using the SRQR checklist. The quality appraisal process 
resulted in three of the 18 retained articles being discarded. 
  
The quality appraisal results are summarised in Table 2.2. The quality of 
the papers is described more fully later in this chapter and in Table 2.3. In 
summary, the journal articles identified in red in Tables 2.3 and 2.4 were 
disqualified from the quality review as they did not comply with the research 
criteria. 
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Table 2. 3 Alignment of the 21 standards for reporting Qualitative research (SRQR) 
Study          
 
S1 
and 
S2 
S3 
and 
S4 
S5 
and 
S6 
S7 
and 
S8 
S9 
and 
S10 
S11 
and 
S12 
S13, 
S14 and 
S15 
S16 
and 
S17 
S18 
and 
S19 
S20 
and 
S21 
1 ×
× 
×
o 
×
o 
×
o 
×
o 
×
o 
×o
o 
×
o 
×
× 
×
o 
2 ×
× 
×
× 
×
o 
×
× 
×
o 
×
× 
×o
o 
×
× 
×
o 
×
× 
3 ×
o 
×
× 
×
o 
×
× 
×
× 
×
o 
××
o 
×
× 
×
× 
×
× 
4 ×
o 
×
× 
×
o 
×
o 
×
× 
×
o 
××
o 
×
× 
×
× 
×
× 
5 ×
× 
×
× 
×
× 
×
× 
×
× 
×
× 
××
o 
×
× 
× ×
× 
6 ×
× 
×
× 
×
o 
×
× 
×
o 
×
× 
××
o 
× ×
× 
× 
7 ×
× 
×
× 
×
× 
×
× 
×
× 
×
o 
××
o 
×
× 
× ×
× 
8 ×
× 
×
× 
×
× 
×
× 
×
× 
×
× 
××
o 
× ×
× 
×
× 
9 ×
× 
×
× 
×
o 
×
× 
×
× 
×
o 
××
o 
×
× 
×
× 
×
× 
10 ×
× 
×
× 
×
o 
×
× 
×
× 
×
o 
××
o 
×
× 
×
× 
×
× 
11 ×
× 
×
× 
×
o 
×
× 
×
× 
×
× 
××
o 
×
× 
×
× 
×
× 
12 ×
o 
×
× 
×
o 
×
× 
×
× 
×
× 
××
o 
×
× 
×
× 
×
× 
13 ×
o 
×
× 
×
o 
×
× 
×
o 
×
× 
××
o 
×
× 
×
× 
×
× 
14 ×
o 
×
× 
×
o 
×
× 
×
× 
×
o 
××
o 
×
× 
×
× 
×
× 
15 ×
× 
×
× 
×
o 
×
o 
×
o 
×
o 
×o
o 
×
× 
×
× 
×
× 
16 ×
× 
×
× 
×
× 
×
× 
×
× 
×
× 
××
o 
×
o 
×
× 
o
o 
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17 x
o 
         
18 ×
× 
×
× 
×
× 
× ×
× 
×
× 
××
o 
×
× 
×
o 
×
o 
 
Key to table: S= Standard; x= complies with standard; o= non-compliance with standard 
 63 
 
Table 2. 4 Research journal articles retained or discarded for review at quality appraisal stage 
Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
1) End-of-life 
decision making in 
42 patients with 
ALS (Anderson et 
al.2007) 
Purpose stated: 
Timing of 
discussion of EOL 
issues: (qualitative 
study) 
Retrospective chart 
review of people with 
ALS from diagnosis 
and then each 3-4 
month. Ethics 
approval 
 
Data collected from 
June 1999-
September 
2004.40/42 patients 
had EOL discussions 
at first visit 
Retrospective analysis. 
Limitations: All 
discussions by one 
clinician therefore personal 
bias may have been 
present 
No conflicts of interest 
2) Withdrawal of 
ventilation at a 
patient’s requests in 
MND: a 
retrospective 
exploration of the 
ethical and legal 
aspects that have 
arisen for doctors in 
the UK (Phelps et 
al.2014) 
Purpose clearly 
stated: To explore 
and identify legal 
and ethical issues 
of ventilator 
withdrawal: 
(qualitative study) 
Retrospective 
thematic analysis. 24 
clinicians interviewed; 
5 by phone,19 face to 
face. Email 
recruitment to doctors 
and via MND clinical 
study groups. Stated 
ethics approval 
 
Data taped and 
transcribed/coded. 
Saturation after 15 
interviews. Ethical 
challenges for HCP 
when withdrawal of 
NIV requested by a 
patient. 
Previous studies identified 
and integrated. 
Suggestions for scope of 
application discussed. No 
limitations identified. 
One of the authors on NICE 2015 
NIV/MND guidelines. 
Funding identified MNDA grant 
and LOROS (hospice UK) 
3) Physiological as 
well as illness 
factors influencing 
acceptance of NIV 
and gastrostomy in 
ALS (Martin et 
al.2014)  
 
Purpose stated: 
Identify factors 
relating to NIV 
and gastrostomy 
acceptance in 
people with ALS: 
(qualitative 
study) 
A prospective study; 
78 people with ALS 
and 50 caregivers. A 
descriptive analysis of 
baseline information. 
Ethics approval. 
Written consent from 
participants 
Main finding, those 
with fewer years of 
education and lower 
IQ may be more 
passive in their 
decisions regarding 
gastrostomy and NIV, 
rather than only 
influenced by 
symptoms and illness 
variables. 
Study identified potential 
limitations: interpretation of 
findings; no follow up data 
on those refusing NIV. 
NICE 2010 guidelines 
published mid study and 
may have influenced 
results. Previous studies 
identified and incorporated 
into study. 
No conflicts of interest. The 
research was supported by 
multiple associations/ 
organisations 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
4) Decision making 
about gastrostomy 
and NIV in ALS 
(Martin et al. 2016) 
Qualitative Health 
Research 26(10), 
1366-1381. 
Purpose clearly 
stated: 
Participants were 
subset of larger 
study. 
Interviewing 
participants 
occurred at point 
when they 
accepted or 
declined 
gastrostomy/NIV 
(qualitative study) 
Thematic analysis 
used to investigate 
symptom relieving 
options in ALS. Ethics 
approval obtained. 
Written consent from 
20 HCP (varied) 
participants who were 
selected 
representatives of 
people with ALS. 
Transcribed 
interviews with Nvivo 
9 used to code and 
organize data. 
Findings suggest 
themes relating to 
decisions, and 
previous work 
integrated into 
results. 
Limitation of study: 
potential bias in the 
patient’s selection of the 
HCP who represented 
them at interview. Few 
interviews conducted with 
patient’s who refused NIV 
mainly because they died 
before they could nominate 
a HCP to represent them 
Declared funding conflict by 
authors: grants and salaried 
support from trusts and 
organisations. Views expressed 
by authors not necessarily Dept of 
Health UK  
5) Decision-making 
for gastrostomy and 
ventilatory support 
for people with 
MND across UK 
hospices (Oliver et 
al.2011). Journal of 
Palliative Care 
27(3), 198-201. 
Purpose clearly 
stated: 
Involvement, 
attitudes and 
knowledge of 
specialist 
palliative care 
consultants with 
NIV and 
gastrostomy 
discussions. Are 
the guidelines 
known and/or 
applied? 
Studies undertaken to 
use two different 
methods:62 records 
analysed regarding 
symptom control in 
MND (previous study) 
then telephone audit 
(structured 
questionnaire) of 
palliative care 
consultants who had 
cared for the patients 
in previous study: 
referred for ethics 
approval but deemed 
unnecessary as 
considered an audit.  
Previous work 
integrated into 
findings. Study shows 
clear differences in 
timing of discussions 
of NIV/PEG by 
palliative care 
consultants and 
timing of involvement 
of consultants. The 
findings support other 
research previously 
published that 
clinicians are not 
always aware of 
guidelines.  
 
 
 
No limitations identified by 
the authors. 
 
No conflicts of interest identified 
by the authors 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
6) ALS and assisted 
ventilation: How 
patients decide 
(Lemoignan, J., 
Ells, C. 2008) 
Palliative and 
Supportive Care 8, 
207-213. 
Purpose of study 
clearly stated: to 
better understand 
the experience of 
decision-making 
in people with 
ALS 
Qualitative 
phenomenology 
methodology: 10 
semi-structured 
interviews with people 
with ALS and their 
caregivers. Ethics 
approval granted and 
consent from each 
participant. 
Interviews with 
patients or caregivers 
using open-ended 
questions, were taped 
and transcribed. Six 
main themes 
identified and were 
verified by the 
participants: meaning 
of intervention, the 
importance of 
context, fears, values, 
information and 
adaptation and 
acceptance  
Timing of ventilation 
discussions and relevant 
information/evidence/ 
QOL to be given at 
time to suit individual and 
caregiver. Limitations 
include that the interviewer 
knew the participants 
already. Some aspects of 
the interviewer’s clinical 
role may have influenced 
the findings. Small sample 
size. 
No declared funding or conflict of 
interest 
7) Why don’t they 
accept NIV? Insight 
into the 
interpersonal 
perspectives of 
patients with MND 
(Ando et al.2014) 
British Journal of 
Health Psychology 
20(2), 341-359. 
 
Purpose of study 
stated: To 
understand why 
people with MND 
decline or stop 
using NIV 
 
 
 
Qualitative research: 
From a cohort of 35 
people with MND who 
were offered NIV, 9 
participated in study. 
Semi-structured 
interviews and 
phenomenological 
analysis. Participants 
given information 
sheet and consent. 
Ethics approval 
granted 
 
 
Themes identified (4); 
preservation of self, 
negative perceptions 
of NIV, negative 
perceptions of health 
care services and not 
needing NIV. 
Authors identify that their 
interpretation of data may 
not be the only 
interpretation. Limitations 
identified: restricted verbal 
communication in some 
patients, almost all the data 
collected from patients who 
had decline or withdrawn 
from NIV at an early stage. 
No declared conflicts of interest 
identified 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
8) Advance care 
planning in MND: a 
qualitative study of 
caregiver 
perspectives 
(Murray et al.2016) 
Palliative Medicine 
50(5), 471-478. 
Purpose of the 
study clearly 
stated: caregiver 
perspectives on 
the accessibility 
and impact of 
advance care 
planning in MND 
Structured interviews 
with 18 caregivers of 
deceased people with 
MND. A qualitative, 
cross-sectional study 
analysed by narrative 
synthesis approach. 
Ethics approval from 
hospital undertaking 
study. 
Four themes 
emerged: readiness 
for death, 
empowerment, 
connections and 
clarifying decisions 
and choices.  
Limitation identified: Self-
selection bias are possible 
due to voluntary response 
to invitations to participate. 
Recall may have affected 
participants in retrospective 
study. Researcher 
subjectivity stated as 
possible during qualitative 
analysis. 
No conflicts of interest 
identified. 
9) The initiation of 
NIV for patients with 
MND: patient and 
carer perspectives 
of obstacles and 
outcomes (Baxter et 
al. 2012) 
Purpose of study 
stated: patient and 
carer perspectives 
of obstacles with 
NIV in MND 
Interviews with 20 
patients and 17 
caregivers in the first 
month following 
introduction of NIV. A 
qualitative study 
undertaken until 
saturation of data. 
Study identified 
themes for 
acceptance of NIV 
and the potential 
barriers which may be 
anticipated by 
clinicians to assist 
patients make 
decisions. 
Limitation identified by 
authors: sample was 
weighed towards older 
males and patients with 
limb-onset disease and 
tolerance may be a 
consideration. 
Authors report no conflict of 
interest. 
Research funded by research 
programs; views expressed are 
authors not Dept of Health. 
10) The use of NIV 
at the end of life in 
patients with MND: 
a qualitative 
exploration of family 
carer and health 
professionals 
experiences (Baxter 
et al. 2013) 
Palliative Medicine 
27(6), 516-523. 
Purpose of study 
clearly identified: 
to describe 
carer and health 
professional 
experience of 
end-of-life care 
in people with 
MND using NIV 
A qualitative 
longitudinal study 
incorporating in depth 
face to face 
interviews with 
patients and carers. 
Data collected 
between 5/2010 and 
4/2012, until 
saturation of data. 
Interviews audio-
recorded and 
transcribed verbatim.  
Study reports on 10 
patients followed 
through to their 
terminal stage. Total 
of 24 participant 
interviews: HCP 
nominated by carers, 
plus carers relating to 
the 10 NIV users, 
were analysed. Study 
confirmed importance 
of end-of-life 
discussions. 
Study consistent with other 
studies advising early end-
of-life discussion/ initiated 
at commencement of NIV  
Limitation: a relatively 
small study of carers and 
HCP in one small area of 
UK. Reported information 
from successful NIV users 
rather than those who 
discontinued or decided 
not to use.   
No conflicts of interest 
identified. Funding under 
grant: ref: PB-PG-1207-15122. 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
11) The impact on 
the family carer of 
MND and 
intervention with 
NIV (Baxter et al. 
2013) Journal of 
Palliative Medicine 
16(12), 1602-1609 
 
Purpose of the 
study clearly 
identified: to 
explore carer 
burden of person 
with MND using 
NIV and how/if 
NIV impacted on 
family/carer 
A mixed methods 
approach using 
questionnaires and 
qualitative interviews. 
Quantitative data 
analyzed using SPSS 
19.0. Qualitative data 
analyzed using 
thematic analysis. 
Ethics approval 
granted. All 
participants had 
information sheets 
and signed consent. 
Carer Strain Index 
used to assess level 
of carer strain.20 
patients recruited;15 
carers completed. 
Little evidence found 
of increased carer 
burden with NIV as 
disease progressed. 
 
Authors report and advise 
caution when interpreting 
very small sample for a 
quantitative study. 
Previous studies referred 
to. This study supports 
previous research in 
advising support for carers 
should start early although 
inundation of services soon 
after diagnosis was also 
reported. 
No conflicts of interest identified. 
Funding provided under Research 
for Patient Benefit, UK. 
12) Healthcare 
professionals’ views 
on the provision of 
gastrostomy and 
NIV to ALS patients 
in England, Wales 
and Northan Ireland 
(Ruffell, N et al. 
2013) Journal of 
Palliative Care 
29(4), 225-231. 
Purpose of the 
research clearly 
stated: study 
aimed to quantify 
HCP views on the 
provision of 
gastrostomy and 
ventilatory support 
for people with 
MND. 
An online survey of 
177 (1298 clinicians 
invited to participate) 
HCP’s in the UK 
following email 
invitation to 
participate. 
Questionnaire piloted 
by the clinic that 
helped to develop it 
and wording changed 
as necessary. Ethics 
approval granted. 
Demographic data 
collected and 
tabulated. Statistical 
data imported into 
SPSS 20.0 clearly 
described. Differing 
views between 
medical and allied 
health professional 
regarding the timing 
of initial discussions 
around NIV and 
gastrostomy. 
Implications of NIV 
withdrawal included 
 
 
Limitations as identified by 
the authors: Because the 
collection method was 
anonymous, unable to 
follow up on non-
responders. Low response 
rate could be due to lack of 
experience with MND. 
Practical consideration 
given to time constraints of 
clinicians; results may have 
been influenced by recent 
changes to NICE NIV 
guidelines. Too many 
limitations to be included in 
quality appraisal 
Authors acknowledge funding 
from MNDA UK and other funding 
grants. No conflict of interest 
identified. 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
13) Accepting or 
declining NIV or 
gastronomy in ALS: 
patients’ 
perspectives 
(Greenaway et 
al.2015) Journal of 
Neurology 264(4), 
1002-1013. 
Purpose of study 
identified: to 
identify factors 
associated with 
decision making in 
patients accepting 
or declining NIV 
and gastrostomy 
in ALS 
32 participants 
recruited via ALS 
register as part of 
larger prospective 
study. Semi- 
structured interviews 
and analyzed by 
inductive thematic 
approach. Ethics 
approval granted 
Three main themes 
identified: Personal 
experiences related 
to patient centric 
factors; external 
influence of HCP and 
family; the concept of 
time and the effect on 
decision making 
Limitations as identified by 
authors: study findings may 
generalize from a clinic 
population. Patients with 
communication difficulties 
were represented by their 
care givers so views may 
not have been exact. 
Authors state no conflict of 
interest 
 
14) Staying just one 
step ahead: 
providing care for 
patients with MND. 
(McConigley et al. 
2013) BMJ 
Supportive & 
Palliative Care 4(1), 
38-42. 
Unclear title: 
Purpose of study 
clear in abstract; 
to determine the 
experience of and 
need for, HCP 
education to 
enable care for 
people with MND 
particularly at end 
stage 
Descriptive qualitative 
design as part of a 
larger study. 250 
HCP attending MND 
conference (2008) 
sent invitation and 
interviews and focus 
groups conducted; 
audiotaped interviews 
were transcribed 
verbatim and data 
managed using Nvivo 
8. Data collected until 
saturation achieved. 
Ethics approval 
identified. 
 
 
 
 
Key theme identified: 
plan and prepare for 
disease changes. 
HCP had to be able 
to predict changes in 
an unpredictable 
disease. 
Acknowledgement 
that HCP care for 
patients can be 
fragmented and that 
communication vital 
to enable informed 
care choices.  
Limitations identified: Small 
number of participants 
within focus groups held 
within a conference with 
competing sessions. 
No competing interests. Research 
funded by NHMRC (425565) 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations   Funding/Conflicts 
15) Identifying who 
will benefit from NIV 
in ALS/MND in a 
clinical cohort 
(Berlowitz et al. 
2016) Journal of 
Neurology, 
Neurosurgery and 
Psychiatry 87(3), 
280-286 
Purpose of the 
study included 
within background 
section in 
abstract. 
Retrospective 
analysis of a 
prospectively 
collected cohort of 
people with 
ALS/MND. A 
quantitative study. 
Ethics approval 
identified. 
NIV was found to 
increase life by 13 
months compared to 
other symptom 
control methods. 
Study did not capture 
information on prolonged 
survival on QOL in people 
with MND on NIV. 
Research funded by two grants; 
authors state funders had no role 
in study design, analysis or 
results. 
16) Standards of 
palliative care for 
patients with ALS: 
results of a 
European study 
(Borasio et al. 2001) 
Amyotrophic Lateral 
Sclerosis and Other 
Motor Neuron 
Disorders 2, 159-
164. 
 
Study purpose 
identified as an 
investigation of 
care for people 
with ALS between 
and within 
countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A questionnaire was 
mailed to 110 
members of 
European ALS group.  
73 were completed 
and returned, from 18 
countries. Questions 
focused diagnosis, 
treatment, PEG, 
respiratory support, 
community services 
and terminal care. 
Ethics approval 
not reported. 
 
This study 
acknowledged NIV 
can increase survival 
but was not widely 
available in all 
areas/countries. 
Study suggested 
many patients with 
tracheostomies had 
them fitted in an 
emergency: validates 
need for early and 
improved 
communication.  
The results found a high 
level of care for people with 
ALS however was focused 
on information from 
specialist centers. Paucity 
of published controlled 
studies was identified (pre-
2001). Areas not covered 
by study include pain and 
psychological issues. 
Questionnaire only 
validated by experts. 
No conflict of interest identified. 
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Concise Title Specific 
research 
purpose 
Methods Results/finding Discussion/limitations Funding/Conflicts 
17) Withdrawing 
non-invasive 
ventilation in a 
patient with motor 
neurone disease. 
(Jenks A. 2014) 
European Journal of 
Palliative Care 
21(3), 119-121 
 
A case study of a 
patient with MND 
Appraisal 
discontinued as not 
specifically relevant to 
search question 
   
18) Issues for 
palliative medicine 
doctors surrounding 
the withdrawal of 
non-invasive 
ventilation at the 
request of a patient 
with motor neurone 
disease: a scoping 
study. Faull, 
Haynes, Oliver D 
(2014) BMJ 
Supportive & 
Palliative Care 4(1), 
43-49 
Purpose of study 
clearly described: 
to identify 
challenges that 
palliative doctors 
encounter in 
relation to NIV 
withdrawal in 
people (at 
patient’s request) 
with MND. 
Primary research: An 
electronic 
questionnaire sent via 
email to palliative 
care specialists (993) 
within UK and Ireland 
after pilot trialled with 
registrars in palliative 
medicine. 
Mixed methods: 
thematic analysis of 
free text. Ethics 
approval sought but 
not required as study 
‘service evaluation’ 
134 (4 discarded as 
not from doctors) 
respondents of which 
76 had experience 
with NIV withdrawal in 
MND; Practical, 
ethical and emotional 
challenges 
acknowledged but 
advance care 
planning may help. 
Better understanding 
required to inform 
future guidance for 
doctors. 
Limitations not clearly 
identified by authors 
although mention made 
that survey very superficial 
exploration of this difficult 
area. As only palliative 
care doctors surveyed, 
others involved with care of 
people with MND (nurses, 
allied health, respiratory 
specialists) could add 
further insight. Those that 
responded may be those 
with most challenging 
experiences in study area 
 
One of the authors of this study 
was a member of the NICE (2010) 
guideline committee on NIV. 
Research funded from LOROS 
and the Wisdom Hospice  
  
2.5. Section 3: Search Results   
Initial database (SEARCH 1-5: n=968) and manual journal reference list 
searches (n=16) identified a total of 984 possible relevant articles (n=984). 
However, articles were excluded using the selection criteria, leaving a total of 
18 articles retained from the initial search review for full article review, after 
which a further two were discarded. The number of articles retained for 
inclusion in the final review was eight. The literature review illustration below 
(Figure 2.1), adapted from the PRISMA Flow Diagram (Moher et al., 2010) 
summarises the method used for this literature search and its results. 
Articles were excluded at various stages due to the following reasons: 
the irrelevance of their titles to the key word search and the search question, 
non-English language, duplication of title or article, lack of specificity to MND 
and ALS and/or only mentioned in the context of many diseases with non-
specific aspects of palliative care, single case studies or an ill-defined 
methodology. Some articles had been superseded by the same author with 
updated research and were excluded. Many articles were editorials, and only 
the most relevant according to the selection criteria were selected for the 
environmental literature review. The candidate acknowledges there may have 
been some relevant journal articles missed due to the quantity found within the 
initial search and since some articles were disregarded if their title appeared too 
vague.  
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Additional records identified 
through other sources (reference 
lists) (n = 16) 
Records after duplicates removed 
(n =84) 
Records screened by 
abstract (n = 52) 
Records excluded 
(n = 34) 
Full-text articles assessed 
for eligibility 
(n =18) 
Full-text articles 
excluded as not 
sufficiently relevant 
(n = 10) 
Studies included in 
qualitative synthesis 
(n = 8) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
 
 
 
Figure 2. 1 Literature Search and Retrieval Process (Moher et al., 2010)  
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2.6. Overview of Retained Articles 
 The literature generated through the systematic searches and selection 
process outlined above identified knowledge gaps within the topics relevant to 
this thesis. Several of the journal articles (n=15) included within the systematic 
review reflected more than one theme. The themes identified within the eight 
research articles retained for this review include: 
1. The communication and moral challenges doctors face when 
discussing the possibility of NIV withdrawal with people with MND 
and their families 
2. The role of healthcare professionals and influence of families on 
people with MND making symptom management (NIV) decisions 
3. The importance of well-timed, effective and individualised 
communication by health care professionals to people with MND 
and their families. 
 
 
Theme 1: The communication and moral challenges doctors face 
when discussing the possibility of NIV withdrawal with people with 
MND and their families. 
The withdrawal of NIV is not well documented within the literature. Within 
the systematic search, only one article was found which explored the potential 
dilemmas doctors face when asked to withdraw NIV from a person with MND. In 
the United Kingdom, a retrospective qualitative analysis of 24 doctors with 
experience of ventilatory withdrawal from people with MND were interviewed 
(Phelps et al., 2015). The doctors experience of withdrawal of NIV (n=16) 
undertaken at a patient’s request was explored.  Whilst this research was 
predominantly exploring the complexity of legal and ethical issues arising for the 
doctors requested to withdraw NIV, individual perspectives and emotional 
issues relating to the families concerned were not explored. However, Phelps et 
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al. (2015) acknowledged that the influence of such complex emotional issues 
for doctors might have an impact on families of and people with MND. 
 
Theme 2: The role of healthcare professionals and influence of 
families on people with MND making symptom management (NIV) 
decisions. 
The decision by people with MND as to whether to use symptom 
relieving measures such as NIV and gastrostomy may be influenced by 
a healthcare professional’s own perspectives (Martin et al., 2016). In 
the study by Martin et al. (2016) health care professionals were 
nominated by people with MND to represent their decision to use (or 
not) NIV and gastrostomy. Whilst quality of life was related to the 
practicality of the intervention, the pressures involved with making 
multiple decisions because of clinical need was expressed. The 
healthcare professionals found the timing of discussions relating to NIV 
and PEG difficult, with some stating early discussions were vital. All 
acknowledged that such discussions depended on the emotional and 
social factors relating to the individual with MND. The study by Martin et 
al. (2016) is limited by the small number of NIV related interviews, and 
by possible bias in the selection of the healthcare professionals who 
took part. 
Decision-making for NIV and gastrostomy in MND and how these 
decisions may be influenced by healthcare professionals, is further 
explored by Oliver, Campbell, Sykes, Tallon and Edwards (2011). Their 
study focused on the involvement of 22 palliative care consultants who 
took part in a telephone audit. Only a small group of consultants (n=5) 
was involved with early discussions with people with MND and involved 
an MDT approach to discussion. The other 17 consultants were either 
involved at the terminal stage of the disease or reported that the 
consultant was rarely involved with a patient’s decision-making. The 
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consultants with a special interest in MND or within a specialist MND 
unit were more likely to involve an MDT and acknowledge the need to 
develop a rapport with the person with MND. The study by Oliver et al. 
(2011) suggested that the guidelines for these symptom control 
measures may not be considered (or known) by healthcare 
professionals involved with the care of people with MND.  
 
Theme 3: The importance of well-timed, effective and individualised 
communication by health care professionals to people with MND and 
their families. 
 
In two articles by Baxter et al. (2012, 2013), family and carer experiences 
of the initiation and use of NIV in people with MND are explored. In the first 
qualitative study, 20 people with MND using NIV and 17 carers were 
interviewed within one month of the commencement of NIV.  The aim of the 
study was to investigate personal attitudes and initial concerns around using 
NIV. Some of the perceived barriers to NIV, as voiced by people with MND in 
the study, included the sensation of air being blown over the face, fear of the 
machine itself, sleep difficulties due to machine noise and dryness of mouth, 
lips and nose. Most people with MND within the study stated the need for 
perseverance with NIV. The study concluded the importance of pre-empting 
potential difficulties of NIV, the need for accessible advice plus the importance 
of discussing NIV in detail with people affected with MND and their families. 
However, this study did not discuss the content of the communication delivered 
by the health care professionals to the study participants prior to the initiation of 
NIV.  
In the second qualitative study by Baxter et al. (2013) the difficult issues 
associated with potential NIV withdrawal in people with MND were explored. 
Interviews were conducted with nine bereaved family carers and 15 healthcare 
professionals, in relation to 10 people with MND using NIV at the end of their 
 76 
 
lives. The often unexpectedly rapid deterioration of the person with MND led in 
two instances to resuscitation attempts by emergency departments. This 
reiterates the need for clear direction in end-of-life care planning. Rapid 
deterioration within the terminal phase was described as a surprise by some of 
the health professionals within the study by Baxter et al. (2013) who reiterated 
the NICE (2016) guideline recommending that communication of end-of-life 
issues should be ongoing once NIV is initiated. 
Identifying factors which influence decisions relating to accepting or 
declining NIV and gastrostomy was studied through face to face interviews with 
21 people with MND by Greenaway et al. (2015). Within a thematic analysis 
three themes were identified; patient-centred issues such as fear, control and 
need; the role of and information provided by health care professionals; and the 
concept of time. Greenaway et al. found that some health care professionals 
directed their patients towards some interventions stressing the consequences 
of late decisions. In some instances, this was perceived as being pressured into 
a decision by the person with MND and their family. A lack of knowledge about 
MND and the disease process among health professionals was also found 
which caused some participants to feel under supported. Acknowledging the 
complex communication dilemma for health professionals was highlighted by 
Greenaway et al. Offering clarity relating to quality of life and the intervention 
itself, before and after commencement, may assist people with MND make their 
decisions. 
The need for health professionals who have the appropriate experience 
and education to assist and care for people with MND is explored in a study of 
31 health professionals involved with MND and palliative care (McConigley et 
al., 2014). Communication within the care team as well as a rapport between 
health care professional and the person and family coping with MND was 
highlighted by McConigley et al. (2014) and other studies (Faull, Rowe-Haynes, 
et al., 2014; Oliver et al., 2011). The introduction of palliative care to the person 
with MND and their families was admitted as being met with resistance at times, 
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particularly by those families unwilling to acknowledge the terminal stage of the 
disease. Skilled and accurate communication was found to be essential to 
navigate the complexity, unpredictability and possible speed of change of the 
disease. 
Members of a professional body specifically involved with palliative care 
and with experience of people with MND were asked to complete an electronic 
questionnaire relating to NIV withdrawal (Faull, Rowe-Haynes, et al., 2014). The 
research corresponded with the study by Phelps et al. (2015) in highlighting the 
emotional and ethical challenges doctors face when asked to withdraw NIV. Of 
more importance to the candidate’s study, is the research by Faull et al. (2014) 
which found communication regarding the benefits and challenges of NIV 
should be (but not always are) incorporated earlier in the disease rather than 
when deemed necessary. Discussions relating to AHDs may assist patient care 
relating to NIV withdrawal but can be overwhelming and, therefore, avoided by 
families and health professionals alike.  
2.6.1. Summary of retained articles 
It is not clear whether or how frequently non-initiation of NIV is discussed, 
when referral to a multidisciplinary palliative care team is offered, whether this 
option is practically available (for example in rural Australia), and what level of 
comprehension of the prognosis and options the patient and their family have. 
Furthermore, when do clinicians routinely discuss the emotional, psychological 
and physical impacts of NIV? Is the possibility of withdrawal of NIV and 
subsequent imminent death discussed as the present guidelines recommend? 
Whether the amount of extra life that NIV therapy typically offers is discussed, 
but if the relentless disease progression, despite the NIV, is explained are there 
also questions as yet unanswered? Finally, whether clinicians routinely 
introduce the idea of not initiating NIV to avoid prolonged suffering and offer 
alternatives such as medication for symptom control is unknown.  
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2.7 Section 4: Environmental and Targeted Scans  
More generally relevant literature sourced from the environmental scan 
was included in the background to the research literature. Google scholar 
produced 9,990 results for the initial search which was reduced (n=292) after 
eliminating irrelevant titles, repeat articles within the same search, and 
duplicates. The remaining abstracts considered broadly relevant were read 
(n=50). Any peer reviewed articles considered generally relevant which could 
enlighten the research question and identified gaps within the literature were 
included within the background of the literature review (n= 32). These articles 
are listed and described in Appendix A. 
2.7.1. Environmental scan 
As NIV is relevant to MND-related respiratory failure as well as several 
other chronic diseases, an environmental scan of contextual literature about the 
issue in relation to both MND and a variety of other healthcare conditions was 
conducted. This helped to determine what care is recommended in relation to 
end-of-life communication concerning NIV in people with a life-limiting health 
conditions including MND. The scan resulted in a review of the contextualising 
grey literature that proved essential to the candidates overall understanding of 
the topic of interest and further confirmed the need for the current study (Martin-
Misener et al., 2012).  
2.7.2. Targeted scan 
The targeted search was aimed at data bases where published 
recommendations for care could be found. The databases accessed included 
NICE, NHMRC, WHO and the Motor Neurone Association databases for the 
United Kingdom and Australia. Of particular interest for this research was the 
unanswered question of how the present MND NIV Assessment and 
Management Guidelines, previously the Use of Non-invasive Ventilation in the 
Management of Motor Neurone Disease (NICE, 2010), in relation to the benefits 
and burdens of NIV and end-of-life communication are being reflected in 
practice (NICE, 2016). The NICE Assessment and Management Guidelines 
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(2016) were published toward the end of the research process for this study. 
The targeted search identified several MND recommendations including the 
European consensus on palliative care in neurological disease (European 
Federation of Neurological Societies and European Association of Palliative 
Care, 2015) and a guide to ALS patient care for primary care physicians 
(Amyotrophic Lateral Sclerosis Society of Canada, 2010). However, the NICE 
guidelines (initially version 2010 and later 2016) were found to be the most 
comprehensive and agreed with other MND management guidelines found 
(Amyotrophic Lateral Sclerosis Society of Canada, 2010; Andersen et al., 
2012). 
The following focus areas were identified in the documents retrieved: 
1. General palliative care/MND specific palliative care research, 
including patient-centered care, evidence-based medicine, clinical 
guidelines and recommendations regarding best practice in end-of-life 
care and a good death, and ethical issues/communication 
surrounding NIV and end-of-life 
2. The timing of palliative care service involvement in the illness 
trajectory of the person with MND and triggers for NIV and end-of-life 
communication for people with MND and their families 
3. Content of communication in NIV and end-of-life discussions for 
people with MND and their families 
4. Factors influencing decisions, for example, MND related dementia 
and the barriers to essential communication   
5. Caregiver and patient concerns at the end of life and during MND and 
the identification of various issues in the delivery of end-of-life care 
that are still unresolved in the literature and clinical practice  
6. Clinician concerns with communicating NIV benefits and burdens and 
end-of-life concerns 
7. The impact of insufficient NIV/end-of-life communication in people 
with MND. 
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As each of these focus areas is considered, what remains unknown 
about each is also explored. This informs the development of a research 
question to address that gap. As these focus areas are inextricably linked, they 
are discussed together within the summary of evidence. 
2.7.3. The development of clinical guidelines and recommendations 
regarding best practice in end-of-life care 
Clinical guidelines incorporate expert clinical opinion and research on 
“how patients actually die” to determine optimum standards for palliative care. 
For example, the WHO Policy Statement (WHO, 2015b), the NICE quality 
standards for end of life care (NICE, 2011), the Gold Standards Framework for 
palliative care (Thomas & Free, 2006) and guidelines from Palliative Care 
Australia (The National End of Life Framework Forum Planning Group, 2010) all 
agree that the following elements are vital to good end-of-life care: 
communication, co-ordination of care, symptom control, continuity of care, 
caregiver support and adequate practical physical and psychological care in the 
terminal phase. Although there is consensus across a wide variety of clinical 
specialties and disease categories on what kinds of care should be provided to 
those facing the end of life, implementing these guidelines for patients across 
the continuum of care has proven difficult.  
2.7.4. MND specific palliative care guidelines 
The few end-of-life recommendations identified specifically for people 
with MND tend to mirror those guidelines identified for general end-of-life 
patients. However, the literature points to some special circumstances that 
people with MND and their significant others face, specifically around the 
initiation, non-initiation, or withdrawal of NIV (National Institute for Health and 
Clinical Excellence, 2010, 2016). For example, the earlier The Use of Non-
Invasive Ventilation in The Management of Motor Neurone Disease Guidelines 
(NICE, 2010) provided evidence-based recommendations regarding treatment 
and care of people with MND.  
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The guidelines recommended that the choices of symptom-relieving 
measures which may be beneficial to patients, including NIV, be honestly 
communicated to people with MND at a time appropriate to the individual’s 
capacity to emotionally comprehend the information. The later NICE (2016) 
Management and Assessment Guidelines, which supersede the NICE (2010) 
MND NIV guidelines, recommend being “sensitive about the timing of 
discussion” (p.14; section1.7.1) particularly relating to any cognitive or 
communication issues, without providing further detail to assist clinicians in 
interpreting and applying these recommendations. In addition, these 
recommendations suggest that when considering the process of initiation, non-
initiation or withdrawal of NIV, patients and significant others should be 
reassured that all comfort measures and medication will be provided to prevent 
distress from symptoms. While this aspect of care is widely discussed in the 
literature (Borasio, Voltz, et al., 2001; NICE, 2010, 2016; Oliver et al., 2006), 
insufficient detail about the content of such discussions to guide clinicians was 
identified.  
People with MND have been found to feel more demoralised and 
hopeless than cancer patients, with increased dependency on social support 
and prolonged and ever worsening, physical incapacity (Clarke, McLeod, Smith, 
Trauer, & Kissane, 2005). 
Tables 2.5 and 2.6 summarise and compare general palliative care 
guidelines with motor neurone specific recommendations found within a 
targeted literature search. The two tables highlight the recommendation in all 
the guidelines relating to palliative care, that clear communication is one of the 
most important components of good end-of-life care. This enabling 
communication style allows patients to make informed treatment choices 
relating to their end-of-life care. The most pertinent take-away message from 
this comparison is the uncertainty about when palliative care should commence 
in MND, whereas it is understood to be relevant for cancer patients as their 
condition becomes unresponsive to curative treatment. There is notable 
 82 
 
similarity between the recommendations in general palliative care and MND 
relating to optimum symptom control and the availability of end-of-life 
information. In MND, communication surrounding NIV and end-of-life care is 
recommended to occur prior to the initiation of NIV and to be documented within 
an AHD (NICE, 2016). Within the general palliative care guidelines 
individualised care plans are recommended, although AHDs are encouraged by 
the clinicians to clarify the patient’s end-of-life care wishes. 
 
Table 2. 5 MND Specific Palliative Care Recommendations 
MND Palliative 
Guidelines        
Palliative Care Recommendations 
 
European Federation of 
Neurological Societies (EFNS) 
guidelines on the clinical 
management of amyotrophic 
lateral sclerosis (MALS) - revised 
report of an EFNS task force 
(2014). 
 
 
Percutaneous endoscopic gastrostomy tubes should be placed 
before respiratory insufficiency develops. 
Non-invasive positive-pressure ventilation also improves survival 
and quality of life. 
Maintaining the patient's ability to communicate is essential.  
During the entire course of the disease, every effort should be 
made to maintain patient autonomy. 
Advance directives for end-of-life care should be discussed early 
with the patient and caregivers, respecting the patient's social and 
cultural background (Andersen et al., 2012). 
National Institute for Health and 
Clinical Excellence (2010) Motor 
Neurone Disease. The use of 
non-invasive ventilation in the 
management of motor neurone 
disease. 
 Updated and superseded 
NICE (2016) MND Assessment 
and management.    
Multidisciplinary team to provide and coordinate ongoing 
management. 
Information and support for patient and families. 
Discussions use withdrawal of NIV, alternative palliating strategies 
and disease progression. 
Discuss end-of-life decisions with patient, and if possible, families 
Early palliative care involvement (NICE, 2010, 2016). 
Motor Neurone Disease Australia 
Quality Measures (Motor 
Neurone Disease Australia, 
2010). 
Multidisciplinary approach. 
Delivery of MND specific end-of-life communication to patient and 
families when appropriate. 
Maintain quality of life and symptom relief; promote palliative care. 
End of life planning / advance heath directives.  
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Table 2. 6. General Palliative Care Recommendations and Policy Statements 
General Palliative 
Guidelines/Policy              
Palliative Care Recommendations 
World Health 
Organisation (World 
Health Organization, 
1998) Definition of 
Palliative Care  
 Provides relief from pain and other distressing symptoms. 
 Affirms life and regards dying as a normal process. 
 Intends neither to hasten nor postpone death. 
 Integrates the psychological and spiritual aspects of patient care. 
 Offers a support system to help patients live as actively as possible until 
death. 
 Offers a support system to help the family cope during the patient’s 
illness and in their own bereavement; 
 Uses a team approach to address the needs of patients and their 
families, including bereavement counselling, if indicated. 
 Will enhance quality of life and may also positively influence the course 
of illness. 
 Is applicable early in the course of illness, in conjunction with other 
therapies that are intended to prolong life, such as chemotherapy or 
radiation therapy, and includes those investigations needed to better 
understand and manage distressing clinical complications (World Health 
Organization, 1998).   
Therapeutic Guidelines; 
Palliative Care 
(Palliative Care Expert 
Group, 2010) 
 Provides relief from distressing symptoms. 
 Neither hastens or postpones death. 
 Includes all aspects of culturally sensitive support and care for patient, 
families and caregivers. 
 Avoids futile interventions. 
 Acknowledges death as a normal process. 
 Uses a multidisciplinary team to maximise requirements of 
patients/families/caregivers.  
National Institute for Care 
and Health Excellence 
(2011) Quality standard 
for end of life care for 
adults 
 Local availability of end-of-life information. 
 Symptom relief; information relating to care options.  
 Sensitive and clear communication. 
 Advice freely available to patients and caregivers including support 
groups. 
Department of Health 
(UK) (2010) End of life 
strategy; quality markers 
 Action plan for delivery of high-quality care. 
 Ensure people approaching end-of-life offered care plan. 
 Ensure effective identification of those nearing end-of-life. 
 Ensure patients preferences and choices are documented and 
expressed when they wish. 
 Ensure that the needs of caregivers are addressed.  
 Ensure 24 hr coordinated care for patients. 
Palliative Care Australia 
(4th Ed) (2005) Standards 
for providing quality 
palliative care for all 
Australians 
 Care planning based on individual and on respect for patient, caregiver 
and family. 
 Sensitive communication skills used by providers to ensure holistic 
needs of the family. 
 Ongoing assessment and care planning.  
 Co-ordinate care with good communication. 
 End-of-life issues discussed honestly with patient and family. 
 Primary caregiver given information and support.  
 Access to palliative care.  
Thomas, K, & Free, A. 
(2006). Guidelines in 
Practice, 9(6). 
www.goldstandardsframe
work.nhs.uk 
 
 To improve the quality of care for people near the end of life, in line with 
their preferences; assess patient physical and psychological needs. 
 To develop the generalist workforce, leading to better collaboration and 
coordination of care; anticipate patient requirements. 
 To improve cost effectiveness by decreasing hospitalisation.  
 Clear communication between patients, families and clinicians. 
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2.8. Section 5: Summary of Evidence  
The lack of clarity in the current literature regarding the content and 
process of communication between clinicians, people with MND and their 
significant others, as well as the level of comprehension of this information by 
the patient and the family at the time of discussing NIV, forms the basis of the 
research reported in this thesis. Most guidelines and recommendations are 
based upon expert specialist clinical opinion rather than scientific research. 
Further research regarding the withdrawal of NIV in people with MND and 
specific practice guidelines may need to be developed to ensure optimum 
patient care and understanding, and this remains the case as little has emerged 
since this recommendation was made by Eng (2006) and endorsed by the Motor 
Neurone Disease NIV Guidelines (NICE, 2010). Subsequent endorsement in the 
Motor Neurone Disease Assessment and Management Guidelines (NICE, 2016) 
is based on much of the same expert clinical opinion. 
The procedure and communication surrounding NIV withdrawal is 
included as a recommendation for further research in the NICE (2010) clinical 
guidelines into the use of NIV. The importance of clear communication delivered 
in a sensitive manner, is emphasised in the NICE (2016) Motor Neurone 
Disease Management and Assessment Guidelines, with recommendations on 
delivering concise information when the person with MND is ready to accept it. 
Moreover, the Mechanical Ventilation for Amyotrophic Lateral Sclerosis/Motor 
Neurone Disease Cochrane review (Radunovic et al., 2013) suggests that 
further research is required in order to understand the personal factors 
surrounding the use of NIV.  
The influences on clinicians in initiating, conducting, ensuring patient and 
family comprehension of MND respiratory symptom control and focusing on NIV 
are extremely diverse. They include the factors that influence when to have the 
conversation as well as what the patient and/or family is ready to hear about in 
terms of the benefits, burdens, limitations and potential impacts of disease 
progression and symptom control. The identification of which clinician is 
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responsible for ensuring that the patient and family are told the appropriate 
information relating to end-of-life care, symptom control and quality of life issues 
and their level of understanding of this information also appears uncertain at 
this point. While it is clear that there are accepted trigger points in illness 
trajectories at which honest discussion should occur - the proposal to initiate 
NIV is one - it is also evident that these discussions are often delayed as health 
professionals perceive a lack of readiness to engage in such discussions on the 
part of the patient or family and they may be unwilling to acknowledge that 
when the patient’s condition deteriorates these discussions are necessary 
(Mitsumoto & Rabkin, 2007).  
In addition, whilst MDTs are seen as important for effective symptom 
control and support for the person with MND, the timing of the introduction of 
multidisciplinary palliative care also remains uncertain and unpredictable (Bede 
et al., 2011). Early palliative care is generally accepted as preferred practice 
(Andersen et al., 2012; MNDAust, 2014); however, there are barriers to this 
occurring, including ineffective communication within the MDT and between the 
MDT, MND patient and their family. Some identified communication barriers to 
an early palliative care referral include health professionals’ reluctance to confer 
a lack of hope of recovery on the person with MND and lack of appreciation of 
the potential for rapidly changing patient needs, support and symptom 
management (Boersma, Miyasaki, Kutner, & Kluger, 2014).  
The availability of a group of specialists to form an MDT within the same 
health facility, inclusive of a palliative care specialist, who have the capacity to 
meet and communicate as an interconnected team including the person with 
MND and their family may prove difficult. This MDT is more likely to occur in 
larger hospitals and cities. The absence of this in rural areas may prove to be a 
barrier to aspects of necessary care and overall responsibility for the person 
with MND and their family members. Palliative care MDTs, the variability in the 
quality of the palliative care available and the inconsistency of palliative care 
provision in urban versus rural areas may all create barriers to the move to 
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palliation for people with MND. These have been explored within the 
parameters of this research and are discussed later in the thesis.  
The potential for timely, effective and explicit discussions relating to 
AHDs, symptom control and end-of-life preferences are vital prior to the time 
when speech becomes adversely affected and while clear communication 
remains possible. Whilst these discussions are generally considered to be the 
domain of the palliative care specialist, aspects relating to end-of-life care for 
people with MND are considered appropriate for discussion shortly after 
diagnosis so that the patient and their family can make choices prior to any 
deterioration of symptoms. Particularly in rural areas, the person with MND may 
not have local access to a palliative care specialist or MDT or may not be 
referred by their GP. These difficult discussions become the responsibility of the 
GP or are delayed until the patient’s disease progresses sufficiently that 
palliative care become involved. There is a possibility for assumed responsibility 
for the end-of-life discussions, and this aspect is also explored within this 
research and identified within the discussion chapter. Palliative care, according 
to international guidelines, should be offered to all patients when identified with 
an incurable, life-limiting disease in order to alleviate adverse symptoms and 
promote quality of remaining life (NICE, 2011; WHO, 2015b). It follows that 
people with MND and other neurological diseases, as well as those with chronic 
diseases such as renal or heart failure, should not only have equal access to 
palliative care but their care should reflect evidence-based treatment pathways 
and recommendations, much as cancer patients’ care is informed by evidence-
based guidelines (National Institute for Care and Health Excellence, 2011; 
Palliative Care Australia, 2005). 
However, as MND is a rare neurological disease, many clinicians are 
relatively inexperienced with the symptom control issues, the delivery of difficult 
prognostic information and with optimal timing for referral to palliative care 
specialist teams. Palliative care guidelines relative to those with cancer include 
recommendations that value and encourage partnerships within health care 
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organisations and the formation of a framework according to which care is 
delivered wherever the cancer patient wishes to die (National Institute of Clinical 
Excellence, 2004; Palliative Care Expert Group, 2010). Recommended end-of-
life communication for cancer, chronic disease and neurological patients all 
include well-coordinated patient-centered care and symptom control, 
psychosocial support for patient and families and the provision of generally 
detailed information about disease trajectory (NICE, 2013; Palliative Care 
Australia, 2005).  
The 2016 NICE guidelines recommend early referral of people with MND 
to palliative care and an MDT (Anderson et al., 2007). The guidelines 
encourage early discussion with the person with MND and their family about 
end-of-life issues and the complications surrounding the initiation and 
withdrawal of NIV. The description of points to include within conversations, 
previously described as honest communication (National Institute for Health and 
Clinical Excellence, 2010), is now more prescriptive; it is now considered 
necessary to ensure the person with MND understands what NIV is and what it 
can achieve. While the recommendations have become more precise, the in-
practice content of clinician communication between people with MND and their 
families about NIV and end-of-life choices is still not known. It is this gap that 
the research reported in this thesis seeks to address.  
2.8.1. Research questions resulting from the literature review 
The research questions were formulated from the gaps evident in the 
black and grey literature reviewed and are summarised as follows (Table 2.7). 
The first question has been answered by the literature reviewed in this chapter.  
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Table 2. 7 The Research Questions 
1. In considering the available literature and guidelines, what are the most salient 
components of best practice relating to the communication about NIV in MND prior to 
NIV initiation and withdrawal? 
2. What is the evidence that the best practice communication content (benefits and 
burdens of NIV, continued disease progression, explanation and offer of a PEG, end-
of-life discussions and understanding the potential for NIV withdrawal prior to the 
commencement of NIV) is incorporated into the actual communication by clinicians to 
people with MND and their families at the time of offering NIV? 
3. What do MND families/significant others recall about the communication 
(benefits and burdens, continued disease progression, PEG insertion, potential NIV 
withdrawal and end-of-life discussions) provided by clinicians at the time of respiratory 
failure and the offer of NIV? 
4. To what degree do MND families/significant others feel that the NIV 
communication provided by the clinicians at the time of the offer of NIV prepared them 
for and helped them to understand the implications of potential NIV withdrawal resulting 
in the death of their family member? 
5. What if any unmet needs for information, support, palliative care, or other 
services do the clinicians and the families/significant others (or patients themselves) 
with experience of MND identify? 
6. Following the literature review and clinician and family/significant other interviews 
regarding NIV communication, what recommendations can be identified that would 
improve end-of-life communication and process for people with MND, families and 
clinicians? 
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2.9. Theoretical Framework: Domains of Influences on the Phenomenon of 
Interest 
The impact of MND on family members has been described in the 
literature as potentially devastating. The lack of any possible cure for MND 
restricts the communication to the patient and family to issues of adequate 
symptom control, comfort and caregiver support. The communication 
surrounding NIV initiation and its potential removal resulting in death, deciding if 
and when to remove NIV and whether or not to have a PEG inserted prior to 
weakening of the swallowing reflex and respiratory muscles, are all highly 
emotional issues. In the context of a disease whose course can be so diverse 
and individualistic, trying to remove all ambiguity from these complex 
discussions is difficult. There are many interacting factors that influence the 
effectiveness of the communication surrounding NIV, and these are 
summarised in the Domains of Influence matrix provided in Figure 2.2.  
It is necessary to consider the complexity of the communication 
recommended to occur at various trigger points by the clinicians, the link 
between commencing NIV and its potential withdrawal and death, and the way 
in which communication may be interpreted by those who hear it. The Domains 
of Influence framework derived from the existing literature and developed by the 
candidate, is used to present and contextualise the discussion of findings of this 
study in Chapters 4 and 5.  
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Figure 2. 2 Domains of influences. 
References: (1) (Anderson et al., 2007); (2) (Andersen et al., 2012); (3) (Foley et al., 2014); (4) 
(Martin et al., 2014); (5) (McConigley et al., 2014); (6) (National Institute for Health and Care 
Excellence, 2016); (7) (Phelps et al., 2015) 
 
NIV and end-of-life Communication Concerns:
When does the communication about NIV by clinicians to 
people with MND and their families occur?
What is the content of the communication relating to NIV 
communicated by the clinicians?
What do the families /significant others of the person with 
MND recall about the communication?
How did this communication help to prepare them for the 
potential for NIV dependance, withdrawal and death?
What are the unmet needs identified for families and 
clinicians involved with people with MND?
= Outcomes and recommendations from research identifying 
limitations and possibilities for further research
Communication from 
families influenced by:
Health literacy (4)
Previous experience 
with death of a family 
member (4)
Communication 
ability/experience (7)
Their concept of 
suffering(3)
Understanding by clinicians 
influenced by:
Interpretation of recommendations 
for communication: NIV/end-of-life 
(6)
Timimg of NIV/end-of-life 
communication (1)
Their concept of suffering (3)
Communication from clinicians 
influenced by:
Experience with end-of-life 
communication (5)
Awareness /adherence to 
recommended guidelines (5)
Understanding by 
families influenced by:
Families recollection 
of communication (7)
Understanding  of 
end-of-life issues (7)
Timing of End-of-life 
communication influenced by: 
The expectation from 
patient/family/clinician that each 
other will raise the issue (1) 
 
Uncertainty about timing (2) 
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2.10. Chapter Summary    
As respiratory failure is the most common cause of death in people with 
MND, alleviating respiratory distress either with technology or medications is 
important. The clarity of communication which surrounds initiation of NIV and 
the end-of-life care choices of the person with MND is, therefore, vital. 
Extensive review of the literature to fully understand the implications of what the 
guidelines recommend is imparted to people with MND and their families has 
been undertaken and the gaps in knowledge about this phenomenon identified. 
A tabulated description of the most relevant peer-reviewed journal articles is 
provided in Appendix A. 
Whilst there is extensive literature and numerous guidelines concerning 
general end-of-life care, and specific recommendations guiding the use and 
recommended communication surrounding NIV in people with MND, there is a 
paucity of research examining whether and how the communication 
recommendations specific to NIV in MND are applied in practice. The existing 
literature does not elucidate the actual content of discussions between 
clinicians, people with MND and their significant others regarding the initiation, 
non-initiation or withdrawal of NIV; the benefits, burdens, and limitations of NIV; 
alternatives to NIV; nor their impact on the quality of life of the patient and 
family. Moreover, it is not apparent from the literature whether these discussions 
are reiterated at any time during the disease progression and with whom they 
occur, nor how much the patient and family comprehend the realities regarding 
NIV. The lack of specific research into content and detail of communication 
surrounding the experiences of people with MND, their families and their 
clinicians points to the need for further research (NICE, 2010; Oliver & Faull, 
2013).  
This chapter has provided the foundations of this thesis and has 
presented the five research questions to be answered, relating to the 
communication surrounding initiation and withdrawal of NIV in people with 
MND. Investigation of the literature to find how well caregivers and families of 
people with MND understand the benefits, burdens and limitations of NIV prior 
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to commencement; how this impacts their end-of-life decisions and subsequent 
experience of their family member’s death; and how clinicians communicated 
has exposed knowledge gaps and answered the first research question. 
Literature concerning PEG tubes and, more broadly, on hydration and nutrition 
has also been included in this literature review. The inclusion of communication 
surrounding PEG tube insertion was considered relevant as PEG tubes are 
generally considered for symptom control at approximately the same time as 
NIV, have related clinical benefits and limitations and are recommended to be 
incorporated into communication surrounding end-of-life issues. In the following 
chapter, the research methodology and methods used in this study are defined, 
an explanation as to why the approach taken was chosen is provided, and the 
study processes and considerations are detailed.  
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A qualitative study into the communication surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in people with motor neurone disease 
Chapter 3: 
Method and Methodology 
3.1. Chapter Overview  
In Chapter 2 the need for this study, its purpose and aims and the 
specific research questions to be asked of the data, which were informed by the 
gap in available evidence, were presented. Although the published literature 
touches on many aspects of MND, NIV and end-of-life care, little evidence was 
found that enabled comparison of the present guideline recommendations 
relating to the timing and content of a clinician’s delivery of NIV communication 
with actual patient and caregiver understanding and recollections of 
communication. The complexities of communicating respiratory failure symptom 
relief and end-of-life choices for people with MND are, therefore, the focus of 
the research questions asked in the current study.  
 
Whilst clarity of communication in any context is difficult to verify and 
measure, for this research the most recent published guidelines and 
recommendations for communicating respiratory failure symptom relief and end-
of-life choices to people with MND were used as an indicator of what these 
conversations should feature. Therefore, this study investigated what 
information clinicians report they communicate, when and how they assess 
patient and family understanding of the information presented to them, how its 
presentation compares to guideline recommendations, and what was 
understood by the recipients of this communication, that is, family members of 
people with MND. This information, along with insights from an expert advisory 
panel, or stakeholder advisory group (SAG), described below, helped inform the 
approach to data collection in the current research.   
 
To answer the questions and aims posed for this study, clinicians 
working with people with MND and members of families of those with MND 
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were asked in-depth questions about communication relative to NIV and related 
end-of-life care issues. Their responses were then analysed qualitatively and 
made sense of in the context of the literature on this topic. It is these research 
processes and outcomes that are reported in this chapter and the two that 
follow. 
  
This chapter comprises two sections. The first section is concerned with 
the philosophical, methodological and theoretical approach underpinning the 
current study, and the second section reports the methods and processes 
followed in the conduct of this research.  
 
Section 1 (Methodology) begins with an overview of the four predominant 
research paradigms within which contemporary health researchers work, and 
the ontological and epistemological tenets of each. The broad approach to the 
conduct of research by scientists working within each paradigm is then 
described. Those employed for the current study are then identified as 
naturalistic-interpretivism and the qualitative approach, and the rationale for 
their selection is provided.  
 
Several specific methodologies that reflect the qualitative approach are 
then visited, and the one selected for the current study – interpretive descriptive 
(ID) methodology - is presented and defended. Examples of theoretical lenses 
through which health researchers make sense and meaning of the data they 
collect are then provided. This section concludes with a statement about the 
theoretical framework that was chosen to underpin the current study – symbolic 
interactionism (SI) - and the reasons for its selection.  
 
In Section 2 (Methods) the fully replicable steps taken in the current 
study are detailed. This section includes information about sampling and 
recruitment processes, data collection, analysis and sense-making processes 
and measures taken to ensure the study is ethical and trustworthy.  
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3.1.1. Research questions and aims 
As a reminder to the reader, the research questions and aims pursued in 
this study were as follows (the first question has already been answered 
in Chapter 2): 
 
1. In considering the available literature and guidelines, what are the 
most salient components of best practice relating to the 
communication about NIV in MND prior to NIV initiation and 
withdrawal? 
2. What is the evidence that the best practice communication content 
(benefits and burdens of NIV, continued disease progression, 
explanation and offer of a PEG, end-of-life discussions and 
understanding the potential for NIV withdrawal prior to the 
commencement of NIV) is incorporated into the actual communication 
by clinicians to people with MND and families at the time of offering 
NIV? 
3. What do MND families/significant others recall about the 
communication (benefits and burdens, continued disease 
progression, PEG insertion, potential NIV withdrawal and end-of-life 
discussions) provided by clinicians at the time of respiratory failure 
and the offer of NIV? 
4. To what degree do MND families/significant others feel that the NIV 
communication provided by the clinicians at the time of the offer of 
NIV prepared them for and helped them to understand the 
implications of potential NIV withdrawal resulting in the death of their 
family member? 
5. What if any unmet needs for information, support, palliative care, or 
other services do the clinicians and the families/significant others (or 
patients themselves) with experience of MND identify? 
6. Following the literature review and clinician and family/significant 
other interviews regarding NIV communication, what 
recommendations can be identified that would improve end-of-life 
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communication and process for people with MND, families and 
clinicians? 
The study aims to be answered by the research questions are as follows: 
 
1. To describe clinician communication surrounding NIV including end-
of-life choices 
2. To understand how clinicians check the level of patient and family 
members’ understanding of NIV benefits and burdens and the 
potential of NIV withdrawal prior to NIV commencement  
3. To understand the impact of clinician communication about the 
benefits, burdens and limitations of NIV on family members’ choices 
in relation to NIV introduction 
4. To understand what timing, content and style of communication most 
effectively helps the families of people with MND to make decisions 
about NIV initiation and withdrawal 
5. To compare the content, process and outcomes of NIV 
communication as described by clinicians and families of people with 
MND within this study against the currently available 
recommendations relating to commencement and withdrawal of NIV 
and related end-of-life options for care. 
 
3.2. Stakeholder Advisory Group (SAG)  
Once the research questions were derived from the identified gaps in the 
literature, the questions for the semi-structured interviews were developed. 
These were informed by a small SAG of leading MND clinicians convened for 
this purpose. The SAG provided valuable insights into the experience and care 
of those with MND and of end-of-life clinical practices in a range of contexts and 
settings. This yielded information that was extremely useful when considering 
the possible reach of the study findings and recommendations both within and 
outside Australia. 
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Approval to convene the SAG as a process step in the current study was 
obtained from both the Wisdom Hospice in Rochester, Kent, United Kingdom 
(Appendix R) and Edith Cowan University Human Research Ethics Committee 
(Human Research Ethics Committee, Approval number 12099: Appendix B). 
Two aspects of clinician expertise were explored in the SAG conversations. The 
first aspect concerned explanations about NIV and how it was offered to and 
initiated for people with MND. The second aspect was about care, symptom 
control and ongoing communication relating to the end-of-life wishes of the 
person with MND and their family. Based on the information gleaned in these 
conversations, the nature and order of the clinician participant questions was 
refined to ensure relevance to the research aims and to reflect participants’ 
likely thought processes; this included the omission of two questions originally 
proposed that were found to be repetitive. 
 
3.3.  Significance of the Study  
The literature suggests that for some families, end-of-life treatment options 
and the availability of palliating medication alternatives are not well 
communicated or comprehended, leading to an end-of-life decision-making 
crisis and potentially creating emotional indecision and confusion for families, 
significant others and the clinicians involved (MNDAust, 2012; NICE, 2010; 
NICE, 2016). The overall objective of this thesis is to determine to what extent 
the communication between health professionals and people diagnosed with 
Motor Neurone Disease (MND) incorporates symptom control and end-of-life 
choices. The significance of such a study is to ascertain whether recommended 
patient-centred best care communication is occurring and whether those 
involved with delivering and receiving the recommended communication 
consider this to be the best timing and most useful communication regarding 
end-of-life choices for people with MND. Importantly the communication 
experiences of those affected by a diagnosis of MND have been explored and 
compared to the clinician experiences. This study is significant as it identifies 
 98 
 
areas for communication improvement and consequently the end-of-life care for 
those living with MND.  
The findings of this study are presented in Chapter 4 (Results) 
 
3.4. Section 1: Methodology 
3.4.1. Positivism versus interpretivism 
Health research is most commonly situated within one of two scientific 
paradigms depending on the philosophical stance of the researcher and on the 
research problem. Those who subscribe to the positivist worldview assert that 
there is one truth, and that research should measure and statistically “make 
sense of” data about phenomena of interest to reach that truth. Researchers 
working in this paradigm almost exclusively use quantitative methods to deduce 
“what is going on”, having first developed a hypothesis about the topic of focus. 
In contrast, the naturalistic-interpretive worldview takes the position that truth 
consists of multiple realities that arise through individuals’ constructs of it as a 
result of their experiences and interactions, and that the aim of research 
conducted within this paradigm is to explore and understand personal 
experiences and the meaning of social or individual situations to reach those 
truths (Burns & Grove, 2007; Streubert & Carpenter, 2011). Researchers who 
take a naturalistic-interpretive stance most usually subscribe to inductive 
qualitative methodologies in which no prior assumption is made about “what is” 
in relation to the topic of interest, but rather the understanding of the 
phenomenon of interest emerges from the data itself.  
 
An inductive, learning-by-understanding technique was used for this 
study to analyse ideas and experiences as they emerged from clinician and 
bereaved caregiver answers. To ascertain the most effective method to capture 
the required information, several approaches were considered. As MND is a 
relatively rare disease some difficulty was anticipated in collecting enough data 
to enable research questions to be answered through quantitative means. 
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Therefore, a qualitative method was considered the most appropriate approach; 
although quantitative participant data may be limited the depth of qualitative 
interviews would likely be informative and personal (Wertz, 2011).  
 
The study reflects the lived experience of the participants and relies on 
information collected from in-depth semi-structured interviews with clinicians 
and bereaved families of people with MND. Additional information, generously 
given by an individual diagnosed with MND who asked to be part of the 
research, offers valuable insight into the MND experience. This supplementary 
information provided a deeper understanding of the topic not anticipated in the 
original design of the research protocol. The research process for this study has 
four main steps with further steps within in each of these. The theoretical 
rationale (naturalistic-interpretive / qualitative), initially described within the 
Chapter 2, is expanded on further in this chapter.  
  
Given the likelihood of an insufficient quantitative sample size and having 
considered the gap in knowledge and the research questions posed to address 
that gap, it was determined that a quantitative approach would be inappropriate 
for exploring the complexities of the communication that takes place around the 
emotionally-laden topic of end-of-life care options. Rather, the phenomenon 
under investigation demanded a naturalistic-interpretive / qualitative approach 
to enable the candidate to fully explore participants’ experiences and views. 
However, some quantifiable demographic data was collected to help 
demonstrate the representativeness of the sample, and this is presented within 
Chapter 4 (Tables 4.1, 4.2 and 4.3). 
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3.5. Overview of Predominant Theoretical Perspectives for Health 
Research and Their Epistemological Tenets 
 
In selecting the most appropriate approach for this study, the following 
criteria were considered: of most importance, the methodology should enable 
the inquiry to achieve the most useful outcomes; it should also identify the 
techniques of the research; and the theoretical or conceptual perspectives 
should provide rational context and enlighten the methodology and 
epistemology, or the theory of knowledge. Several methodological options are 
available to the naturalistic-interpretive researcher (Crotty, 1998). Among others 
these include phenomenology, grounded theory, ethnomethodology (Crotty, 
1998), and ID (Thorne, Reimer Kirkham, & MacDonald-Emes, 1997). The key 
features of the four qualitative perspectives considered for this study and their 
benefits and disadvantages in relation to it are outlined in Table 3.1. 
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 Table 3. 1. Four possible qualitative research methodologies for a study 
investigating end-of-life care decision-making in relation to MND 
 
Perspectives Advantage Disadvantages Selected/Rejected 
Phenomenological 
Methodology 
Based on the lived 
experiences as 
expressed by 
participants. 
1) Includes imagination, 
emotion, thought, 
sensory perception but 
not specifically 
communication. 
2) May be unaware of an 
experience if experienced 
by the semi-conscious.  
Rejected:  
Personal experiences 
considered too imprecise for 
this research.  
Grounded Theory 
Methodology 
How social norms 
are investigated 
which when 
developed 
generally build a 
theory from 
specific gathered 
data. 
1) Data gathered with 
intention of building a 
theory which was not 
necessarily the intention 
of this research.  
2) Questions tend to 
be unstructured. 
Rejected:  
Specific questions were 
required to be asked of 
participants and intent was 
not to seek a theory. 
Ethnomethodology 
Methodology 
Behaviour of a 
group may be 
changed by their 
social constructs. 
1) Very specifically 
studying a group who 
perhaps may not even 
think about their 
behaviour as it is 
influenced by their social 
norms. 
Rejected:  
Too specific to social groups 
and cultures. 
Interpretive 
Description 
Methodology 
Knowledge gained 
through the 
research can 
result in immediate 
change in practice. 
As a methodology, 
works in 
conjunction with 
SI. 
1) Involves critical 
analysis and 
understanding of current 
clinical recommendations 
and guidelines 
(theoretical knowledge). 
2) Results must be 
practical to enable 
change.  
Selected:  
Provides information by 
understanding and therefore 
informing, by seeking 
personal experiences.  
 
3.5.1. Phenomenology  
Phenomenology is a philosophical method which studies the lived 
experience of individuals and how they interpret their experiences, originating 
from the work of Edmund Husserl (1889-1938) and variously developed 
creating a broad method for qualitative research (Streubert & Carpenter, 2011). 
Much of Husserl’s work was incorporated into lectures and research 
manuscripts rather than books. His ideas in developing phenomenology have 
been further incorporated into more recent literature, for example by the 
philosopher Martin Heidegger (Fieser & Dowden, n.d.). Phenomenology 
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describes an experience of an individual’s life which, when used as a method of 
research, gathers those experiences to describe and understand a particular 
occurrence (Streubert & Carpenter, 2011). The theory is based on the concept 
that events and objects in life create an individual’s sense of reality as they 
occur and as perceived by the individual (Edgar & Sedgwick, 2008).  
 
Phenomenology emphasises an individual’s singular view of the world 
and does not attempt to reach a consensus view about phenomena of interest 
Streubert & Carpenter, 2011). It was rejected for this reason. One of the key 
imperatives of this study was to discover information that could be used by all 
stakeholders in end-of-life care decision-making; it was, therefore, important to 
use an approach that would enable a consensus about what is going on to be 
reached. Phenomenology may be useful as a methodological option if MND 
was being explored to see whether the person with the disease thought that 
they may defined by the label of MND when perhaps they perceived the disease 
as only a small part of who they were. In this situation, phenomenology could be 
used to explore the individual’s feelings and mechanisms for coping with MND. 
3.5.2. Grounded theory 
Grounded theory is an approach developed in the 1960s by Anselm 
Strauss and Barney Glaser with a view to developing a theory by collecting data 
from interviews, observation and evidence relevant to the study. Grounded 
theory involves purposely selecting a group with similar lived experiences which 
may provide the researcher with contextual understanding of an event or 
circumstance (Schreiber & Stern, 2001). Historically, grounded theory 
developed from two schools of thought, one emerging from Chicago University 
and the other from Iowa University. As a student of Chicago University, Blumer 
(1969) described and developed social interaction theory, the philosophical 
underpinning of grounded theory. The concept of an individual taking meaning 
from oneself as well as through interactions with others, became the foundation 
of SI (De Chesnay & Banner, 2015). Using grounded theory as a research 
framework, the research questions are open-ended rather than specific, 
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allowing for the research to broaden and change direction depending on the 
data gathered (Maltby, Williams, McGarry, & Day, 2014). For this research, 
which requires specific information, a grounded theory methodological 
framework was considered too broad and ill-defined. 
3.5.3. Ethnomethodology  
Ethnomethodology, which was founded by Harold Garkinkel in the 
1960s, is a methodological perspective derived from a collective of people or a 
social group who have unique or specific practices or ways of life (Maltby et al., 
2014). In the context of MND this method could be used if the study focused on 
one particular group, and to study the group as a whole would enlighten all 
others who may be diagnosed with MND. Using ethnomethodology would not 
be suitable for this research, however, as I wanted to illuminate the 
phenomenon of interest from a range of sources. 
3.5.4. Interpretive description 
To understand the phenomena of interest, namely, the end-of 
life/symptom control communication between clinicians and people with MND 
and their families, an inductive analytic approach was selected. Interpretive 
description was developed principally as a process for obtaining knowledge 
within the context of clinical events to elicit change (Thorne et al., 1997). 
Originally designed as an alternate research method to understand the 
subjective individual experience for clinical nursing research, ID has been 
developed over the past 20 years. Interpretive description starts with an 
analysis of current clinical knowledge and understanding. By purposeful 
sampling and capturing subjective insights by interviewing participants, themes 
develop which can inform clinical norms.  
 
Interpretive description incorporates aspects from grounded theory and 
ethnomethodology in its approach to purposive data collection; however, it 
rejects the sometimes restrictive development of a theory (Thorne, Reimer 
Kirkham, & O'Flynn-Magee, 2004). How people act, interact and communicate 
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in their lives is the foundation of this research wherein what the individual 
considers to be true is uppermost; ID throws light on a collection of expressed 
truths to inform a practical change. For these reasons, ID was selected as the 
most appropriate methodology for the current study.   
  
3.5.5. Theoretical perspective  
The social interaction of interest in this study is the communication 
between the clinician and the person with MND and their family, and the 
interpretation of meaning ascribed to this communication as remembered by 
participants. By understanding and appreciating the meaning of events and 
participants’ interpretations of the communication engaged in, this study 
attempts to identify the factors that influenced the choices of symptom control 
and end-of-life care made by the person with MND. Symbolic interactionism 
was selected as the most appropriate theoretical perspective for this study. By 
listening and questioning people with experience of MND, understanding and 
meaning were created through an interpretive process.  
 
 Communication can be confusing and misinterpreted if not clearly 
delivered or left open to supposition. The understanding of words and the 
nuances of interactive verbal and non-verbal delivery can lead to 
communication problems and this in turn can change the meaning an individual 
may give to a situation. The theory of SI involves the interaction of the meaning 
individuals attribute to a situation or person, the language used to comprehend, 
and the thought which allows interpretation of meaning and language. 
 
The methodology selected for this study, ID, and SI are highly compatible 
for the conduct of qualitative research studies that could effectively inform 
nursing practice. In fact, the underlying assumptions of ID are considered 
symbolic interactionist, and SI is considered an important part of ID’s theoretical 
heritage (Oliver, 2012). 
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3.6. Understanding the History of Symbolic Interactionism 
 The origin of SI is attributed to George Herbert Mead (1863-1931) 
despite the further development of the perspective by Mead’s student, Herbert 
Blumer. Symbolic interactionism focuses on the meaning and interpretation 
ascribed to communication and social and interpersonal interaction (Oliver, 
2012). The basic principle of SI is that how an individual perceives the world 
and acts is based on their individual interpretation of the meaning of the 
influences on their actions (Blumer, 1969). 
 
Since the inception of SI, there have been several variations emanating 
from different universities, including from philosophical leaders such as John 
Dewey and Charles Cooley from Chicago University. The University of Iowa 
developed their own variant of SI largely founded on the thoughts of Manford 
Kuhn and Carl Couch (De Chesnay & Banner, 2015). Kuhn differed from the 
Chicago school of thought, believing that there were some basic meanings for 
an individual which remained constant despite external influences (De Chesnay 
& Banner, 2015).  
 
Mead was influenced by the work of Charles Darwin and the theory of 
evolution, sharing his belief that human behaviour is a constant adaptation to 
the environment (Mead & Morris, 1934). Mead considered that social interaction 
influenced the way in which humans learnt or were influenced to react (Mead & 
Morris, 1934). Within this social construct, Mead differentiated between mind as 
an essentially social process and the brain as a human organ.  
 
Cooley was a sociologist who developed the concept of the “looking 
glass self”: how an individual perceives themselves is based on how a person 
believes others sees them (Cooley, 1998). The individual appears to others in a 
way that reflects how that individual believes they are seen, which in turn 
involves a perceived judgement based on appearance, and an imagining of how 
others feel about the individual. According to Cooley, this concept can lead to 
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behavioural change based upon the perception of others toward an individual 
(Cooley, 1998).  
 
John Dewey, also from Chicago University, suggested that the way an 
individual respond to a situation relates to learned responses within a social 
order (Dewey, 1922). Dewey maintained that personal awareness of a social 
situation by attributing certain characteristics is a habit (trait) of social 
classification resulting in a personal judgement (Dewey, 1922). Dewey 
described mind as intrinsically involved with the environment in its ability to 
adapt behaviour. In particular, language and communication were identified by 
Dewey as responses to environmental factors (Dewey, 1922). The perception of 
instinct as a cause of social behaviour was rejected by Dewey who thought 
spontaneity affected old habits and that consequently thought deliberation could 
change a person’s behaviour (Dewey, 1922). 
 
The development of SI at Chicago University throughout the 20th century 
continued to be based on the concept of reality as constructed by social 
interaction (Blumer, 1969). Following the teachings of Blumer, Straus 
commenced development of a research method based on the concepts of SI. 
Straus transferred to the University of California where he and Barney Glaser 
developed grounded theory in the 1960s (De Chesnay & Banner, 2015). 
Grounded theory is the structured collection and analysis of data which has the 
potential to lead to the development of a theory (Ezzy, 2013). Grounded theory 
investigates social normalities which when the data has been gathered and 
analysed enables a theory to be developed. 
  
The intellectual theories, particularly emanating from the Chicago school 
of SI, have informed the choice of theoretical perspective used for this study. 
The exploration of communication between those involved with MND, the 
interpretation of this communication as heard and recalled, and the meaning 
assumed by the individuals all fit within the scope of SI. The meanings 
participants constructed, particularly from verbal communication, and to a lesser 
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extent, non-verbal communication, is presented throughout this thesis.  This 
study has drawn on the SI concept of meanings influenced by situations and 
communication, and how individuals’ interpretations influence their life choices. 
3.6.1. Limitations and examples of SI and ID in research 
When SI was considered for this study, any reported limitations or 
criticisms of the approach were explored to ensure its appropriate use. The 
approach has been criticised as insufficient to address the influences of social 
structure, historical events, culture and power (Dennis & Martin, 2005; Meltzer, 
1975). Symbolic interactionism has also been accused of not considering the 
influence of human emotions or the influences of organisations, both factors 
which have the potential to change human life (Meltzer, 1975). However, 
Dennis and Martin (2005) counter-argue that SI does explain the phenomena of 
power, citing studies in the areas of education and deviance where the 
consequences of power are enforced within social processes. Roles and 
behaviours can be influenced by circumstances and an individual can be 
defined by behaving in a way that is consistent with that circumstantial situation 
(Cast, 2003). Cast (2003) suggests that an individual may be able to influence 
the behaviours of people by accepting the influences of others. Cast gives an 
example of intravenous cannulation (IVC) and how children may be influenced 
by parents and health care providers who describe the impending situation. This 
has the potential of influencing the situational behaviour the child has ascribed 
to the meaning of the procedure. Cast used SI as a theoretical perspective to 
study and understand the communication between health care provider and 
parents throughout IVC procedure in children. On balance, SI was confirmed to 
be appropriate for the current study 
 
Interpretive description was similarly considered and was confirmed to be 
suitable on the basis of its application in other nursing research. In a study 
exploring the moral experience of health professionals in humanitarian work, the 
strengths and challenges of using ID as a qualitative method are discussed 
(Hunt, 2009). Using ID in his doctoral research, Hunt (2009) found coherent 
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structure to enable his research development and others have effectively 
employed this methodology in the exploration of nursing topics (Kimber, 
Georgiades, Jack, Couturier, & Wahoush, 2015; Nkulu Kalengayi, Hurtig, Ahlm, 
& Ahlberg, 2012; Thorne, Con, McGuinness, McPherson, & Harris, 2004; 
Williams & Haverkamp, 2015).  
 
The broader interpretation of a situation and how it influences action was 
addressed by Blumer in his discussion of the importance of organisation on 
human society (Blumer, 1969). Blumer appeared to acknowledge aspects of a 
broad environmental influence and how aspects of it may influence human 
behaviour. An example in this research is the influence of the commonly held 
understanding of palliative care being a place of death and how this 
environmental aspect influences human behaviour. The compatibility between 
ID (framework) and SI (theoretical perspective) is used in the candidate’s 
research to understand and make meaning of the subjective participant insights 
and to potentiate change (Oliver, 2012). The following section incorporates and 
discusses SI within the research design, and how SI is used to understand the 
communication which influences end-of-life choices made by or for people with 
MND. 
3.6.2. Theoretical perspective of SI within the research design 
Initially using a perspective based on SI as a study of social interaction, 
concepts and behaviour, a construction for explaining and understanding each 
person’s decision-making process, and subsequent course of action relating to 
the initiation and withdrawal of NIV in people with MND was developed (Blumer, 
1969; Stryker, 2002). For example, studying individual participant interpretation 
of communication surrounding NIV initiation, its benefits, burdens and 
limitations, and how this communication related to the experience of relief from 
respiratory failure and subsequent death in a person with MND, has provided 
participant shared agreement or non-agreement of what constitutes useful 
communication. Studying the content of communication and understanding 
among the participants at the time when the person with MND was offered and 
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either accepted or refused NIV, had NIV withdrawn or died of co-morbidities, 
has informed several aspects of this research. These include whether 
communication between participants resulted in similar memories and 
understandings of any discussions relating to commencement and withdrawal of 
NIV, and how their individual interpretation influenced their decisions.   
 
Building upon the perspective of SI, and based on the literature review, a 
more prescriptive framework was developed to understand the complexities and 
ambiguities of NIV end-of-life communication. This enabled further refinement of 
the research questions, design, and analysis plan for this study. During data 
collection, the researcher found that while the theoretical perspective of SI 
provided a working guide, the interacting variables created the potential for 
verbal communication imprecision and misinterpretation. For example, a 
number of factors interacted to complicate communication: the complexity of the 
language used and the education level of participants, the capacity of the 
patient and family to question the clinicians, finding and interpreting information 
from the Internet by some and participants’ financial and social situations. The 
additional and often undisclosed or undiagnosed cognitive changes which can 
present in MND added further challenges for the person with MND, their 
families and clinicians in ensuring that what was said and heard was 
understood. Therefore, the theoretical perspective is grounded in an 
understanding of the unique experiences and individual interpretation of each 
participant.  
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3.7. Section 1: Summary 
The first section of this chapter focused on the importance of selecting a 
methodology and theoretical framework. Various theoretical stances and 
methodological approaches have been examined and their advantages, 
disadvantages and relevance for this research identified. A subjective 
epistemology and SI were selected for this study as the theoretical perspectives 
and ID was selected as the framework for informing change. The development 
of a framework representing the influences on the phenomenon of interest was 
presented as the basis for the research questions. The research questions, in 
turn, were designed to enable the accumulation of participant perspectives 
which would inform change, broaden how communication may be delivered and 
influence the care choices of people with MND and their families. The following 
section of this chapter outlines how this qualitative study was designed. 
 
3.8. Section 2: Methods 
The research process is diagrammatically shown in Figure 3.1 which 
identifies the order of steps taken in the study once the first draft of the research 
questions had been developed.  
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Literature review; identify the 
knowledge gap and develop 
research questions 
Stakeholder Advisory 
Group 
Relate themes to original research 
questions and short summary of 
results to clinician participants 
 
Clinician participants: Data 
analyses using Nvivo10 and 
researcher coding of themes  
Clinical participants: collect data 
using semi-structured questions in 
the setting of their choice 
(generally their office at place of 
work) 
Family participants: Data 
analyses using Nvivo10 and 
researcher coding of themes  
 
Family participants: collect data 
using semi-structured questions in 
the setting of their choice (generally 
their home) 
 
Relate themes to original 
research questions and short 
summary of results to family 
participants 
Reliability: Recorded 
interviews 
transcribed verbatim 
by professional 
transcriber 
Analysis 
Validity: transcripts returned 
to participants for veracity of 
content 
Slight amendment to 
clinician questions; no 
change to family 
participant questions 
Apply Research Ethics 
approval 
 
Ensure reliability, validity, and transferability of 
research data:  Discussion with limitations of research 
identified.  Conclusion: recommendations and 
suggestions for further research 
 
Clinician participants recruited via 
invitation through place of work 
Family participants recruited via 
invitation through the MNDA 
(Australia) newsletter  
 
Figure 3. 1. The Research Process 
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3.8.1. Setting 
 The research was initially confined to interviews within Western Australia. 
However, due to insufficient participant numbers, the research was broadened 
to include New South Wales. In respect of the sensitive nature of the research, 
the clinician interviews all took place within the clinician participants’ workplace 
in a suitably private room, or via a telephone/Skype recorded interview. All 
family participants could determine a suitable venue of their choice and were 
encouraged to bring a support person along if they felt this was appropriate 
given the nature of the conversations. Only one of the participants had a 
support person present, and as this was another family member who had been 
involved with the care of the person with MND, they requested to be interviewed 
jointly. The family and caregiver interviews all took place in their respective 
homes, as chosen by each participant.  
3.8.2. Qualitative data collection and analysis 
 A generic approach to qualitative data collection was employed for this 
study. Qualitative data collection is used for various lines of inquiry which allows 
the respondent the freedom to provide more than just a quantitative answer. For 
example, conducting open-ended and/or semi open-ended interviews allows the 
respondent to give detailed information in answering questions. This can add 
meaning or context to experiences and a deeper understanding of the way 
aspects of life work. These are important to inform and instruct process change 
that becomes transparent and accessible to the interviewer. The process of 
inquiry for qualitative research may be from interviews, observation or material 
collection such as questionnaires or analysis of official records. For this study, 
data were collected from semi-structured interviews with two types of 
participant. Data were analysed to ensure rigor, reliability and minimisation of 
researcher bias to enable others to replicate the research (Munn et al., 2014).  
3.8.3. Semi-structured interviews 
 The interviews conducted for this study were intended to answer the 
research questions shown in Table 3.2. It was anticipated that by using a 
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personal semi-structured interview method, the researcher would be able to 
obtain in-depth responses. Semi-structured interviews have a flexible structure 
which, despite pre-organised questions, allow for detailed and personal 
answers and accounts (Streubert & Carpenter, 2011). Semi-structured 
interviewing requires that the researcher builds a trusting relationship with the 
participant, so the participant feels listened to and able to describe their 
experiences with the assurance of complete confidentiality.  
 
  The ability to observe the participants’ reactions and emotions when 
describing their recollections enabled the researcher to ensure the willingness 
and appropriateness of the participant continuing with the research questions. 
The observation of the participants and any degree of distress dictated whether 
the interview should pause or terminate, had the participant appeared 
emotionally distressed. Individuals were invited to rest or cease the interview 
and seek support through their place of work, or through the MNDAWA or MND 
NSW emotional support staff who kindly agreed to support this research. The 
researcher explained to the participants at the commencement of the interview 
that they may elect not to answer any of the questions they found distressing. It 
was also explained that they could choose to continue with the interview and 
seek support from MNDAWA or MND NSW or they could choose to continue 
with the research without seeking further support.  
3.8.4. Development of the interview schedule 
 When considering the aims of this research, and after extensive 
exploration of the literature, the research questions (Table 3.2) were formulated 
and the most searching and pertinent participant questions constructed with the 
assistance of a SAG (Appendices D and E). The decision to interview 
participants was chosen in preference to a format of questionnaires. The 
candidate felt a more personal approach may elicit more insightful information, 
particularly as the subject matter was deeply personal and may cause some 
emotional distress (Streubert & Carpenter, 2011). The candidate was 
concerned that questionnaires may restrict the participant responses and whilst 
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a larger number of participants could have responded, the information may not 
have been as broad and informative. The candidate also felt that questionnaires 
may be given less in-depth thought by the participants and any clarification of 
questions or tangential thoughts would be less easy to obtain (Streubert & 
Carpenter, 2011). 
 
3.9. Sample Selection: Participants 
3.9.1. Clinician participant identification and recruitment  
Purposeful sampling was used to identify and obtain the most pertinent 
group of participants. This method of sampling ensures that the participants 
targeted are representative of the information required for the research (Patton, 
2015). In this case, clinicians involved with the effects of adverse respiratory 
symptoms in people with MND, clinicians who are involved with the initiation of 
NIV, those involved with end-of-life care for people with MND, and bereaved 
family/caregivers involved with people with MND were identified as best 
positioned to provide information about the topic of interest. By targeting and 
selecting participants with MND experience and with extensive knowledge of 
the research topic, optimal insight throughout the study was ensured. Purposive 
sampling and snowball sampling (information discussed and communicated to 
others not previously in the study, enabling relevant and interested others to 
participate) were used as a means of directing the research to the most relevant 
clinicians.  
3.9.2. Clinician participants: inclusion criteria 
 Two participant groups were identified within the clinician participant 
cohort: those who were responsible for the conversation regarding initiation and 
use of NIV (respiratory physicians, or neurologists) and those who interacted 
with people living with MND in the terminal phase of care and were involved 
with withdrawal of NIV. Community neurological and/or palliative care nurses 
and allied health workers who provided ongoing support for the person with 
MND and their families were included as communicators of ongoing care. All 
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clinicians, whether at initiation or withdrawal of NIV in MND, were asked the 
same set of questions to ascertain any areas of assumed knowledge, or 
communication supposed to have occurred. The interview protocol included 
questions being asked in the same order for each participant, although because 
of the open-ended questions at the beginning of each interview, some parts of 
the questions were answered at that time and were not asked again. Protocol 
also demanded the consent of the participant for the interview to be recorded 
(Appendix F). 
3.9.3. Clinician participants: recruitment of interview subjects  
Clinician participants were identified through their association with MND 
in palliative care services, hospitals, specialist centres (neurologists, respiratory 
physicians and specialist nurses) and invited by email, letter or face-to-face to 
partake in the research. Any interested clinical participant was emailed or sent 
the Clinician Respondent Information Sheet (Appendix G) explaining the project 
and an Informed Consent Form containing further information regarding 
participants’ involvement (Appendix F). All participants were provided with a 
written letter explaining the purpose of the research, how the research was to 
be undertaken and how long each interview was anticipated to take. Prior to the 
interview commencing, participants were also provided with a written consent 
form which they were asked to read and sign. Confidentiality was assured 
through the process of de-identification of each interviewee and allocation of a 
code (for example P1). Only the researcher had access to the link between the 
identity of the participant and their code. Some of the participant quotes have 
been used in the thesis to capture sentences or statements to lend meaning to 
themes that have resulted from the research. 
3.9.4. Family participants: recruitment of interview subjects  
Bereaved families and caregivers involved with a person with MND were 
targeted through advertising in MNDAust newsletters (Appendix G) and word of 
mouth among the interviewees. A web-based invitation to participate was 
posted on the MNDA WA website and incorporated into their monthly newsletter 
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(Appendix H). The invitation was advertised twice and included details of the 
research project and the expected timeframe, methods of responding to the 
researcher if interested in participating and an assurance that participants’ 
privacy would be protected. As participant numbers were low in Western 
Australia, an application was made to the ECU Human Research Ethics 
Committee to extend the research via both MND NSW and interested doctors to 
disseminate details of the research to bereaved caregivers. Once an interested 
caregiver participant contacted the candidate, a letter/email with a Family 
Respondent Information Sheet explaining the project (Appendix J) and Informed 
Consent Form (Appendix F) containing further information regarding 
participants’ involvement was sent to the participant. Entry into the study only 
occurred after verbal and written informed consent had been confirmed. The 
initial research design did not incorporate people with MND as it was thought 
that the candidate’s questions relating to end-of-life decisions may cause 
distress. However, a person with MND who was using NIV who wished to 
explain and discuss his experiences contacted the candidate and asked to be 
included. An amended ethics application and subsequent approval from the 
Edith Cowan University Human Research Ethics Committee (ECUHREC) was 
obtained (Appendix C). Therefore, one interview was conducted with a person 
with MND. These data were used to illuminate and contextualise the two 
primary data sets. 
  
 A convenient appointment date and time was subsequently organised by 
the candidate in response to each potential participant’s initial responding email, 
with further communication with the participant via their preferred method of 
email or telephone. It was anticipated this invitation would be discussed 
between family members and significant others with experience with MND and 
NIV who might have wished to participate and share their communication 
experience producing a snowball effect. This approach produced one further 
family member participant. Within this cohort, there were six respondents and 
one person with MND wishing to assist the research.  
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3.9.5. Clinician participants profile: initiation of NIV 
The first cohort of interview participants were respiratory clinicians, 
respiratory nurses and social workers responsible for the conversations 
regarding use of NIV and palliative care options, specifically at the time of 
commencing NIV when respiratory muscles of the person with MND weaken 
causing breathing difficulties (e.g., when NIV is offered to alleviate distressing 
symptoms). A gastroenterologist was incorporated into the study and asked the 
same set of questions as all the clinicians regarding communication surrounding 
gastrostomy tube placement and how this communication related to NIV 
commencement. Clinicians from the first group were asked what specific 
information they communicated to people with MND about the benefits, 
limitations and potential withdrawal of NIV; PEG insertion; when they discussed 
the involvement of palliative care and end-of-life choices; and how they made 
sure that the information they had given the person with MND and their families, 
had been understood. Eight respondents were interviewed in this cohort. 
 
3.9.6. Clinician participants profile: withdrawal of NIV 
Clinicians from the second group - palliative care specialists, allied health 
(generally as part of an MDT) and nurses involved with palliative care or 
neurological nursing - were asked to recall episodes of care for people with 
MND where NIV was withdrawn during the terminal phase of the disease. Of 
specific interest in relation to this group were their observations and feelings 
surrounding the withdrawal of ventilation support in people with MND and how 
this affected the caregivers and families. They were asked to reflect on their 
perception of the preparedness of families and significant others in relation to 
understanding the outcome of withdrawing NIV, even if not directly involved with 
the withdrawal. The clinician participants were also asked to reflect on their 
feelings the preparation and communication from an MDT had on their capacity 
to provide holistic support to the families and significant others at the time of 
withdrawal. Any difficulty in people with MND accessing an MDT or palliative 
care specialist was noted. Within this cohort of participants there were 11 
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respondents interviewed. Two of the first cohort, those responsible for the 
initiation of NIV, were also in a team of clinicians responsible for the removal of 
NIV; however, only one of the palliative care clinicians had referred a person 
with MND for NIV prior to the terminal phase. 
3.9.7. Family/caregiver participants profile  
Families and significant others, who have lived with a person with a 
diagnosis of MND, were asked to recall their experience(s) of the conversations 
which may (or may not) have occurred prior to the commencement (or refusal) 
of NIV and communication relating to placement of gastrostomy tubes for their 
family member diagnosed with MND. They were encouraged to reflect on how 
these conversations may (or may not) have prepared them for the outcome 
associated with the choice to initiate or not to initiate NIV, the limitations of NIV 
as explained to them, end-of-life discussions as they occurred and withdrawal of 
NIV at the terminal phase of care. Six bereaved family participants were 
interviewed, in one instance a brother and sister interviewed together (F1 and 
F2). 
  
3.10. Data Collection: Clinician and Family Participants 
Data was obtained using individual semi-structured interviews from the 
three groups of respondents outlined above, each of whom were asked to 
consider two points in time along the disease trajectory: the first point was when 
the respiratory muscles of the person with MND weakened and breathing 
became difficult and NIV is offered and the second point was when NIV is 
withdrawn. As discussed in Chapter 1, communication relating to PEG 
placement and the commencement of NIV are closely linked and are 
recommended to occur prior to respiratory distress (NICE, 2016). Therefore, 
questions relating to PEG insertion and use were incorporated within the semi-
structured questions.  
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The long, in-depth interviews were recorded with the consent of each 
participant and transcribed verbatim by an appointed professional transcriber 
(transcription confidentiality agreement: Appendix Q) who identified the 
participants by codes known only to the researcher. Statistical analysis and 
demographic data were collected and collated: clinician roles, MND years of 
experience, whether working within an MDT and familiarity with the most recent 
NICE (2016) MND Assessment and Management Guidelines. Four of the 
interviews (three clinicians and one family participant) were conducted via 
recorded audio/visual SKYPE interviews. There were no interruptions or 
disturbances during these interviews and they were all transcribed verbatim. 
Both telephone and the face-to-face individual interviews lasted for between 60-
90 minutes. The interviews were terminated when the participant indicated they 
had nothing further to add. A thank you email was sent to each participant 
within 24 hours. 
 
 In considering the methodology, research questions (Table 3.2.) and 
participant semi-structured questions, the research method was developed to 
obtain the most accurate and dependable information.  
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Table 3. 2. Research Questions and Strategy 
Research Question Strategy and Method  
1. In considering the available literature and 
guidelines, what are the most salient components of 
best practice relating to the communication about NIV 
in MND prior to NIV initiation and withdrawal? 
Extensive search of published literature through 
databases, guidelines and recommendations, 
reference lists in published articles and 
conference material. Answered in Chapter 2. 
2. What is the evidence that the best practice 
communication content (benefits and burdens of NIV, 
continued disease progression, explanation and offer 
of a PEG, end-of-life discussions and understanding 
potential NIV withdrawal prior to commencement of 
NIV) is incorporated into the reported communication 
by clinicians to people with MND and their families at 
the time of offering NIV? 
Search of Australian and International MND 
guidelines relating to MND and symptom control 
particularly relating to end-of-life care. 
 
Semi-structured interviews with clinicians a) to 
understand what, how and when recommended 
information is being communicated at the time 
of respiratory failure and how clinicians assess 
patient understanding of communication and b) 
what the clinicians involved at the end-of-life 
experience with patient and family 
comprehension of prior recommended 
communication 
3. What do MND families/significant others recall 
about the communication (benefits and burdens, 
continued disease progression, PEG insertion, 
potential NIV withdrawal and end-of-life discussions) 
provided by clinicians at the time of respiratory failure 
and the offer of NIV? 
Semi-structured interviews including ‘their story’ 
with families to understand the communication 
as heard and understood at the time of 
respiratory decline particularly relating to end-
of-life 
Included within this research was a person with 
MND describing his experience with 
communication 
4.  To what degree do MND families/significant others 
feel that the NIV communication provided by the 
clinicians at the time of the offer of NIV prepared them 
for and helped them to understand the implications of 
potential NIV withdrawal resulting in the death of their 
family member? 
Semi-structured interviews with the bereaved 
families and caregivers at least 3 months post 
death of a person with MND 
5. What, if any, unmet needs for information, support, 
palliative care, or other services do the clinicians and 
the families/significant others (or patients themselves) 
with experience of MND identify? 
Suggestions made in answer to an open 
question asking participants of their 
experiences and recommendations 
6. Following the literature review and clinician and 
family/significant other interviews regarding NIV 
communication, what recommendations can be 
identified that would improve end-of-life 
communication and process for the patients, families 
and clinicians involved with the end-of-life care for 
people with MND? 
Reviewing the data and comprehensive 
analysing and coding of the interviews to 
identify and clarify any recommendations 
verbalised by participants. This area of the 
study has identified limitations of the research 
and areas which may be considered for further 
research 
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3.10.1. Bracketing and reflexivity 
 An ability to reflect and be self-aware has assisted the candidate to 
minimise researcher bias. By understanding the social, educational, cultural and 
personal influences in her own life, a generally more empathetic stance has 
been taken on interviewing techniques and analysing data (Patton, 2015). 
Personal perspectives and preconceived ideas, where they existed, were put 
aside, and the data collected was analysed without prejudice. The researcher 
made every attempt to exclude researcher bias by using the method of 
“bracketing” (Patton, 2015). This involves a process by which constant reflection 
(reflexivity) by the researcher and discussion with university supervisors, 
reduces and tries to eliminate any researcher preconceptions. The credibility of 
the candidate’s research is inextricably linked to the researcher’s ability to justify 
and analyse the evidence without bias. 
 
3.11. Data Handling and Management 
3.11.1. Data storage 
 The digital recordings obtained during the interview phase of this 
research were transcribed from the digital recorder and onto the researcher’s 
password protected computer which remained locked in the candidate’s home 
office. The recorded interview data were erased once transcribed onto the 
candidate’s password protected computer. As per NHMRC guidelines, all hard 
copy data collected for this project and records of any work associated with this 
research have been kept securely locked in a designated area in the student’s 
home or at Edith Cowan University retained on the candidate’s password 
protected computer. At the completion of the research transcripts and analysis 
data will be kept for five years (as per NHMRC (2012) requirements) on an 
Edith Cowan University password protected computer which is located inside a 
locked office that is in turn located in a swipe card protected area. 
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3.12. Data Analysis 
Descriptive demographic information was collected for analysis, including 
clinicians’ specialisation and experience, whether part of an MDT and the 
number of NIV withdrawals and MND deaths the clinicians had been involved 
with. The gender and age of the person with MND as stated by the family 
participant, and whether the person with MND was seen by an MDT is included 
in information for this research. The tabulated data are presented in Table 4.1 in 
the discussion chapter of this thesis as an overview of participant demographics 
and distribution of specialised services.  
 
Data analysis commenced following the first participant interview, with 
relevant and emergent themes noted. The NVivo10 software package was used 
to assist this process. All the interviews were de-identified, coded and 
transcribed verbatim. The quantifiable raw data were tabulated and are 
contained within the results in Chapter 4 (Tables 4.1 and 4.2).  
3.12.1. Stage 1 analysis: coding 
The first phase of analysis included the identification of codes, or 
phrases in the interview transcripts that related to the research questions. 
These were colour coded on the printed verbatim transcripts, examples of which 
are provided in Table 3.3. and contained within the appendices of this thesis 
(Appendix M). These phrases were then extracted and alike codes were 
grouped (Stage 2). Several exemplar codes are used to illustrate the findings in 
Chapter 4.  
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Table 3. 3. Example of first level analysis 
Raw data Level 1 codes 
1) So his wife wanted a definite sign of 
when she would stop the PEG fees, if he was 
no longer able to communicate.  I haven’t 
seen the Advance Health Directive, but she 
did say there was a special sign that they 
would have. 
 
2) No. I think there’s very little work done 
around AHDs, because there is just not 
enough knowledge, experience or time. 
 
3) They really do need to think about 
withdrawal of NIV, which I don’t know is 
discussed with clients in detail, or if it is 
they’re not processing that information.  I’m 
not involved in any of those discussions, so I 
really don’t know what has been said.  But 
when I have asked if that has been 
discussed, people have said, “No.”   
 
 
1)Hydration and nutrition; discussions 
about disease progression and timing of 
gastrostomy 
 
 
 
2) Advance health directives 
 
 
 
3) NIV withdrawal; is this discussed at 
the time of commencement of NIV  
prognosis and limitations of treatment 
included in ongoing honest discussions 
timing of end of life discussions. 
 
 
3.12.2. Stage 2 analysis: sub-categorising 
The second phase of analysis involved grouping of alike codes into sub-
categories.  The points at which no new sub-categories were emerging from 
participant interview codes was when initial saturation of the data was assumed, 
and no further interviews took place once each sub-category was sufficiently 
“thick” (representative of the sample). Table 3.4. provides an example of the 
sub-categorising second stage of analysis, and additional examples are 
provided in Appendices K and L.  
Table 3. 4. Example of second level analysis 
Codes Sub-category 
1) NIV initiation; is end of life care 
discussed at this time 
 
2) NIV benefits, burdens and limitations 
discussed including increased dependency 
 
3) NIV withdrawal; is this discussed at 
the time of commencement of NIV 
 
 
 
1) Family satisfaction with end-of-life 
care 
2) Other clinicians involved  
 
1) Patient and family understanding  
2) Experience of refusal of NIV 
  
1) Withdrawal experience  
2) Tracheostomy as emergency 
procedure by ED 
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A list of all the sub-categories and categories that emerged from this stage are 
provided in Table 3.5. below. 
 
Table 3. 5. Categories and sub-categories included in data analysis 
 
1) Advance health directives 
2) Hydration and nutrition; discussions about disease progression and timing of gastrostomy: 
hydration  
how is this described 
3) Multidisciplinary team:  
responsibility for overall care 
interdisciplinary communication 
4) NIV benefits, burdens and limitations discussed including increased dependency 
patient and family understanding (NIV): Guideline recommendation (NICE, 2016)  
experience of refusal of NIV 
5) NIV initiation; is end of life care discussed at this time: Guideline recommendation (NICE, 
2016)     
 other clinicians involved 
family satisfaction with end-of-life care 
6) NIV withdrawal; is this discussed at the time of commencement of NIV: Guideline 
recommendation (NICE, 2016) 
prognosis and limitations of treatment included in ongoing honest discussions 
timing of end of life discussions 
withdrawal experience 
tracheostomy as emergency procedure by ED 
7) Prognosis and limitations of treatment included in ongoing honest discussions 
introduction to palliative care (Symbolic Interactionism: influence and understanding) 
ethical dilemma 
8) Understanding and obtaining the MND diagnosis family perspective 
symptoms of frontotemporal changes 
age at diagnosis 
9) Timing of end of life discussions 
 barriers to clear communication 
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3.12.3. Stage 3 analysis: categorising 
Once all sub-categories were developed and saturated (no new 
information found from the interviews), those that resonated with or reflected 
with others were collapsed into major categories. Table 3.5 provides the list of 
the final major categories and their component sub-categories.  
 
3.13. Trustworthiness 
3.13.1. Trustworthiness of the research candidate 
 The candidate conducting the interviews is an experienced registered 
nurse working in palliative care, where sensitive communication and 
interviewing of both patients and families is a vital skill. The candidate 
understood and had the ability to separate the two roles involved with palliative 
care nursing and research interviewing: to be empathetic, reflective and 
understanding of the participants’ experiences whilst remaining supportive and 
respectful in the researcher role. The researcher had read extensively on 
sensitive interviewing techniques and followed appropriate guidelines on 
interviewing (Patton, 2015). Of concern, was the potential for participants, 
particularly the clinician participants, to supply information thought to be useful 
to the researcher’s background as a palliative care nurse. Whilst this may 
impede complete data accuracy and transferability, the researcher also 
recognised that understanding clinical terminology and a familiarity of clinical 
issues may have enabled greater engagement with the participants. To ensure 
that data collection and analysis was conducted as objectively as possible and 
reflected the research questions, the candidate and her supervisory team had 
regular discussions regarding interpretation of the data. To verify the 
candidate’s results, independent analysis of a selection of interview transcripts 
was conducted by one of her supervisors. Comparing the findings of both the 
candidate and the supervisor found the themes to be compatible.  
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3.13.2. Research credibility  
 Guba and Lincoln (1994) suggested four criteria, which if adhered to, 
should confirm the rigor of research: credibility, dependability, confirmability and 
transferability. The trustworthiness, or credibility, of the research was aided by 
clarity of the questions asked of the participants, which were designed to 
encourage the participants to describe the conversations surrounding the 
initiation, use and ultimate removal of NIV in patients with MND (Streubert & 
Carpenter, 2011). The professionally transcribed interviews (Appendix Q) were 
returned to the participants to ensure validation and approval for use in the data 
analysis and to establish trustworthiness and credibility of the researched 
information (Polit, Beck, & Hungler, 2001; Pope & Mays, 2006; Streubert & 
Carpenter, 2011). Analysis of a sample of the interviews was undertaken by one 
of the candidate’s supervisors post analysis by the researcher, in order to verify 
credibility of the results. Data and supporting documentation allow for an audit 
trail ensuring dependability of the research. The audit trail includes interview 
transcripts, analysis of data, notes relating to the process and any difficulties 
encountered with the method, personal notes and all copies of drafts relating to 
the final work presented (Guba & Lincoln, 1994; Polit et al., 2001; Pope & Mays, 
2006). Confirmability was conferred on the study by an independent reviewer’s 
verification of the data analysis decisions and research audit trail. Further 
confirmability will be assured by other researchers substantiating the findings as 
a result of their own research in the future. Finally, the transferability of the 
outcomes of the research is proven through the resonance of the findings with 
clinicians from a range of practice contexts through several member-checking 
opportunities. These included sharing the finding that communication between 
healthcare providers and people with MND can be poor and potentially affect an 
individual’s decision for end-of-life care. The finding in this research that families 
find multiple healthcare providers to be confusing and to affect their 
communication and decisions has been discussed by the candidate in her work 
setting with agreement from palliative care patients and families alike. 
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3.14. Ethical Considerations 
3.14.1. Ethics approvals and considerations 
 The Human Research Ethics Committee at Edith Cowan University 
(ECUHREC) (Number 12099: Appendix B) approved commencement of 
participant interviews in June 2015. Subsequently, ethics approvals were 
sought from Silver Chain Hospice Nursing (Appendix N), St John of God 
Hospital Bunbury and Murdoch, WA (Appendix O) and the Neurological Council 
of WA (Appendix P) and granted in mid-2015. Ethics approval from ECUHREC 
was further obtained to include data from people with MND who volunteered to 
participate after two people diagnosed with MND responded to the 
advertisement in the MNDAWA newsletter targeted at bereaved family 
members. The participants wished to tell their stories to assist others with MND, 
and ethics approval was subsequently granted to allow their experiences to be 
heard (Appendix C). Only one of the people with MND was ultimately 
interviewed. The second potential MND participant was considered too unwell 
and emotionally fragile to participate without the possibility of causing the 
participant further adversity. As a means of increasing participant involvement, 
subsequent ethics approval was sought and granted from ECU to include 
clinicians from New South Wales via snowball effect, word of mouth and email 
information between clinicians. All amendments to the original ethics application 
to ECU are included in Appendix C. 
3.14.2. Ethical considerations: bereaved caregivers 
 Recalling conversations surrounding the initiation and withdrawal of NIV 
may prompt mixed memories for the caregivers, with feelings of sadness, anger 
and loss. Consideration was given to the potential for feelings of profound 
sadness and grief during the interviews with the bereaved families/significant 
others. The candidate was particularly aware of any possible emotional ill 
effects the one person with MND who chose to be interviewed for this study 
may have suffered. The style of interview differed from the other participants.  
The interviewee told his story and was periodically prompted rather than using 
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the schedule of semi-structured questions. The interview was conducted at a 
pace which suited the participant and finished when indicated by the participant.  
  
The candidate ensured that the person with MND and bereaved family 
participants were all clients of the MNDAWA and had access to pastoral and 
psychological support as part of the service this organisation provides. While 
funding for this service provision is limited until six months after the death of the 
person diagnosed with MND, the Association agreed to provide this service to 
any bereaved caregiver participants from this research that may be outside the 
technically funded bereavement period. All bereaved caregiver participants and 
the one person with MND were provided with written information about the 
support offered by MNDAWA and support from the more generic support 
counselling service offered by Lifeline at the conclusion of the interview. This 
was to provide support to those who may have felt inclined to ask for emotional 
assistance well after the interview. 
 
 The ethical considerations for researching patient-focused palliative care 
include its acceptability for patients and families at the end of life, since 
participation in research may create further intrusion and distress at such a 
difficult time. For people with MND, this ethical predicament may be 
compounded by cognitive changes and difficulty with communication particularly 
towards the end of life. For the bereaved families, timing of the interviews was 
considered and a precedent in published research was sought. In a study which 
specifically investigated interviewing bereaved families of MND and cancer 
patients, the timing of interviews after the death of their family member was 
found to be an individual and crucial factor (Bentley & O'Connor, 2015). Bentley 
and O’Connor (2015) found that offering choice in timing of the research 
interviews post death of a family member enabled appropriate arrangement to 
be made for each individual family and led to their willingness to participate 
(Bentley & O'Connor, 2015). Therefore, when considering timing and the need 
to be respectful of the grieving process, the bereaved participant interviews for 
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this thesis were conducted when the bereaved families contacted the 
researcher, but all more than three months post death of their family member. 
3.14.3. Ethical considerations: clinician participants 
 Clinician participants involved with the decline of the respiratory muscles 
and the initiation of NIV (respiratory clinicians and allied health), and those 
providing end-of-life care to people with MND (palliative care specialists, allied 
health practitioners and nurses) were interviewed regarding the content and 
timing of the communication surrounding the initiation of NIV in people with 
MND and any experience of NIV withdrawal. Whilst this difficult conversation 
may include end-of-life and withdrawal of NIV issues, the research questions 
specifically related to the clinicians normal practice protocol. Therefore, a low 
level of discomfort was anticipated and found in this group. The group of 
clinicians specifically responsible for end-of-life and palliative care was 
interviewed regarding their experiences relating to MND and the withdrawal of 
NIV, including the subsequent death of the patient and the preparedness of the 
family/significant other for the outcome. The interviewing of this group of 
clinicians was anticipated to elicit varied feelings associated with sadness, 
frustration and loss, some of which were captured within the interviews but none 
of which caused distress to the participants. All clinician participants were 
reminded of their Employer Assistance Programs (free counselling programs 
offered by health services) through which participants are offered support and 
an opportunity to debrief. All participants were offered written information on 
Lifeline, a counselling support service which they were encouraged to access at 
their convenience. 
3.14.4. Consent 
 Permission was sought from participants to undertake recorded 
interviews and discussions, with consideration to a participant’s state of health 
and mind throughout the research. It was emphasised at the commencement of 
the research that participants can decide to withdraw from the project at any 
time they chose, and that participants’ wellbeing took precedence over the 
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research. The participants were supplied with information regarding the 
structure and purpose of the research (Appendix J), information on free 
counsellor support and examples of the potential questions that may be 
included at the recorded interviews (where requested) enabling the participants 
to make an informed decision as to whether to participate in the research. The 
candidate ensured all participants had signed consent prior to the 
commencement of the interview (Appendix F). 
   
 Whilst it may be supposed that some unanticipated information may be 
forthcoming within the interviews, the participants were reassured they were 
under no obligation to proceed with the interview and may stop the discussion 
at any time. In this situation, the researcher would re-confirm consent from the 
participant as an ongoing process to ensure the willingness of the participant to 
participate, particularly if considered to be in a vulnerable condition or situation 
(Oliver & Faull, 2013). As the research was obtained from families and 
significant others some time post death of a family member with MND, the 
information obtained for the research was reliant on the memories and 
experiences of the family members, caregivers and clinical team prepared to 
participate in the study.  
 
 3.15. Section 2 Summary 
 In Section 2 of this chapter, the method used to recruit the participants 
for this research has been explained. The researcher aimed for sufficient 
participant representation through an indirect approach to ensure that those 
participants who became involved did so completely voluntarily. Therefore, an 
advertising and/or word of mouth approach was directed electronically via 
websites, newsletters or general information email toward the desired 
participant groups. As MND is a rare disease the sample population is limited, 
however, the small number of bereaved caregiver participants volunteering for 
this research is felt to be usefully representative. Another possible limitation to 
the study sampling (further identified and discussed in Chapter 6) may be those 
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without electronic information access or those not supported through the 
Neurological Nurses (Neurological Council of WA) who snowballed the invitation 
to participate in the research through their network of nurses. 
 
The research method of an extensive literature review and in-depth 
qualitative interviews has started to address the gap in understanding the 
communication which is recommended to occur at the initiation of NIV. This has 
been achieved by comparing the findings of this research with the present MND 
assessment and treatment recommendations concerning when and what should 
be included in clinician communication. The clinician interview information has 
been compared with the understandings and recollections of bereaved families 
regarding the information given to them relating to their family member when 
symptom control measures were discussed, implemented, refused or 
withdrawn.  
 
3.16. Chapter Summary 
 Clear communication is required for people with MND and their families 
so they can make informed end-of-life decisions. This chapter has outlined the 
method by which this research has undertaken credible and reproducible inquiry 
into the communication surrounding NIV by interviewing selected participant 
groups involved with MND.  
 
The complexity of the communication recommended (NICE, 2016) to 
occur at various trigger points along the MND trajectory by the clinicians, the 
link between commencing NIV and its potential withdrawal and death, and the 
way in which such communication may be interpreted by those who hear it are 
all necessary to consider. The emotional and ethical considerations necessary 
to conduct research into the end-of-life options, particularly when considering 
removal of NIV, have also been discussed. The theoretical perspective of SI 
and the Domains of Influence framework derived from the existing literature on 
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the topic of interest are used to present and contextualise the findings of this 
thesis in Chapter 4 and discussed more fully in Chapter 5.  
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A qualitative study into the communication surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in people with motor neurone disease 
 
Chapter 4: 
Findings 
4.1. Chapter Overview 
In this chapter, the results from 26 participant interviews is presented in 
relationship to the research questions and the NICE MND Assessment and 
Management Guidelines (NICE, 2016). Seven major themes emerged from 
analysis of the data. These are identified in Section 4.4 of this chapter, 
expanded upon throughout the chapter and discussed in Chapter 5. 
 
Quotations from participants are included where relevant to illustrate the 
results, and the context of the quotes is explained within the narrative. The 
substantial amount of information gathered from the in-depth participant 
interviews not only sheds light upon the research questions but provides insight 
into a range of associated issues. At times information not directly relating to the 
research questions is included where it helps to clarify and broaden the 
understanding of end-of-life and NIV communication in MND.  
 
 The communication difficulties and factors encountered in relation to the 
research questions are discussed under specific headings derived from the 
themes identified. The significance of the influences on the participant data 
analysis and outcomes identified are further considered in the Chapter 5. This 
chapter commences by presenting the background to participants and their 
involvement. 
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4.2. Background to the Family Participants 
 The seven family participants (n=7) included a brother and sister 
interviewed together (F1, F2), in accordance with their preference. At times the 
brother and sister had different recollections on specific issues and different 
viewpoints, making the interview particularly useful in providing depth and 
perspective. Four other family participants (F3, F4, F5, F6) who had 
experienced the death of a family member with MND were interviewed. The 
seventh participant (P1) was diagnosed with MND and actively sought 
participation. While people with MND were not the target of this study, P1 
thought his experiences should be heard to assist others diagnosed with the 
disease, and ethics approval was subsequently granted (Appendix C). As P1 
was the only person interviewed with MND, his comments have been included 
with the bereaved family participants. All the family participants were from 
Western Australia (n=7). They were asked a range of questions (Appendix E) 
with attention directed toward their understanding of symptom control, end-of-
life choices and their involvement with palliative care. 
  
 Table 4.1 describes family participants in terms of their level of health 
knowledge, use of the Internet for health information, their rural/remote 
classification, the primary clinical responsibility for overall care and whether 
their care was provided as part of a structured MDT. Health literacy was not the 
focus of this study and, therefore, was not formally assessed. However, the 
participants themselves acknowledged use of the Internet where they had 
access to it, and if they were conversant with health and health systems. 
Emphasis was placed on creating a good rapport with participants to help 
discuss and understand their experiences.  
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Table 4. 1. Family Participant Demographics 
Family 
Participants 
Health 
knowledge and/or 
health information 
from internet 
Regional, 
rural 
or remote 
Primary 
clinical 
responsibility 
for overall care 
Part of 
structured 
MDT 
F 1/2 No Regional/rural Unclear: GP 
and 
neurologist 
No 
F 3 Yes Regional Neurologist in 
association 
with GP 
Yes 
F 4 No Rural GP No 
 
F 5 Yes Remote GP No 
 
F 6 Yes Rural  GP No 
 
P 1 No Regional  Neurologist Intermittently 
 
Note: General Practitioner (GP), Multidisciplinary team (MDT)  
 
  
4.3. Background to the Clinical Participants 
 The clinicians involved in this study were from two cohorts of specialties: 
those involved with respiratory decline and symptom intervention (NIV/PEG) 
and those involved with palliation and end-of-life care. The two clinician 
participant groups were further subdivided into doctors, nurses and allied health 
providers. The medical participants included four palliative care specialists, one 
rehabilitation specialist, three respiratory specialists and a gastroenterologist. 
The nurse participants included four MND/neurological specialist nurses, three 
palliative care nurses and a respiratory clinical nurse specialist. The two allied 
health participants were a social worker and a respiratory physiotherapist, both 
of whom worked with people with MND within an organised MND specific MDT. 
At the time of interview, the participants worked in Western Australia (n=8), New 
South Wales (n=9) and the United Kingdom (n=2). Table 4.2 shows a summary 
of participants, their de-identifying codes and professions. Also included are the 
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clinicians’ years of experience working with people with MND and the 
percentage of their work involving people with MND. Table 4.1 also shows 
whether the clinicians worked in regional, rural or remote areas and whether 
they were involved with NIV withdrawal and end-of-life discussions.  
 
There are similarities and differences between clinical specialties 
regarding views about when and who should have the discussions about the 
initiation and withdrawal of NIV and end-of-life choices. Both clinician cohorts in 
this study had experience with the withdrawal of NIV.  
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Table 4. 2. Clinician Participant Demographics  
 
 
Clinician 
 
Specialty 
Years (y) of MND 
experience 
and workload 
Involved with 
NIV withdrawal 
discussions 
Regional, 
rural or 
remote 
C1 
 
Palliative Care 
Consultant 
10+ y 
Varies 
 
Yes Regional and 
rural 
C2 
 
Palliative Care 
Specialist 
10 y 
Varies 
 
Yes Regional 
C3 Palliative Care 
Specialist 
17 y 
Varies 
Yes 
 
Regional 
C4 Respiratory Specialist 12 y 
Varies 
 
Sometimes Regional and 
rural 
C5 Respiratory Specialist 6 y 
75% 
 
Yes Regional and 
rural 
C6 Neurological Nurse 4.5 y 
Intermittent 
 
No 
Regional and 
rural 
C7 Neurological Nurse 8 y 
Intermittent 
Indirectly; when 
patient requires 
information 
Regional and 
rural 
C8 
 
Palliative Care Nurse 16 y  
Intermittent 
Yes Regional 
C9 
 
Palliative Care Nurse 14 y 
Intermittent 
Yes Regional 
C10 Palliative Care Nurse 5 y 
Intermittent 
Yes Regional and 
rural 
C11 Respiratory Specialist 10 y Yes Regional and 
rural 
C12 Physiotherapist 
 
5% of annual work Yes Regional 
C13 Social Worker 
 
approx. 30 MND pts 
ongoing 
Sometimes  
Regional 
C14 MND Clinical Nurse 
Specialist  
14 y 
Ongoing 
 
Yes  
Regional 
C15 Gastroenterologist 
 
Sees 2-4 people with MND 
monthly 
 
No  
Regional 
C16 MND Clinical Nurse 
Consultant 
15 y 
Ongoing 
 
Yes  
Regional 
C17 Respiratory Clinical 
Nurse Consultant 
 
22 y 
Varies 
Yes  
Regional 
C18 Rehabilitation MND 
Specialist 
 
16 y 
approx. 30 MND/year 
No  
Regional 
C19 Palliative Care 
Consultant 
11 y 
approx. 30 MND/year 
 
Yes  
Regional 
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4.4. Themes Identified from the Findings 
Seven major themes emerged from analysis of the categories identified 
from participant interviews (Chapter 3). Together these were found to 
characterise communication between clinicians and people with MND and their 
family members/caregivers and are summarised in Table 4.3 below. 
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Table 4. 3. Themes and Key Findings 
Major Themes Identified Key Findings  
1) Experience of clinicians with end-of-life 
communication and NIV withdrawal (4.5 below) 
1) Reluctance to communicate end-of-life choices 
by the clinicians involved with symptom control 
prior to palliative care involvement.  
2) Clinicians with longer experience in their field 
may be less likely to be fully cognizant with the 
most recent recommendations and guidelines. 
2)Timing and content of communication about the 
benefits and burdens of NIV, PEGs and end-of-life 
choices (4.6 below) 
1) Many clinicians found the recommended timing 
of end-of-life communication unrealistic. 
2) Confusion with understanding the benefits 
burdens of PEGS and NIV by people with MND 
and their families. 
3) Palliative care clinicians reported patients often 
had end-of-life choices communication too late 
and not prior to their involvement.  
3)Time allocated for communicating and 
discussing end-of-life choices (4.7 below) 
1) Respiratory clinicians state they have 
insufficient allocated time to communicate end-of-
life whilst having to discuss how NIV works and 
how to use the device. 
2) Respiratory clinicians state because many of 
their clients are from the country and they may 
only meet them once, they must prioritise the 
mechanics of NIV above emotional issues.  
3) Time required to recognise FTD in people with 
MND and the implications for end-of-life choices. 
4) Early referral to palliative care and family 
understanding of palliative care (4.8 below) 
1) Clinicians reluctant to refer soon after MND 
diagnosed. 
2) Families overwhelmed by the concept of 
palliative care. 
5) Communication within a multi-disciplinary team 
(4.9 below) 
1) Frequent poor communication and differing 
opinions between members of MDT. This was 
found to be worse where a group of health care 
professionals made up a MDT from different areas 
and organisations.  
2) AHD poorly discussed and documented, and 
not re-visited when NIV or PEGS became part of a 
person with MNDs symptom control. 
6) Patient and family communication and 
understanding (4.10 below) 
1) People with MND and their families were under-
prepared for the burdens of NIV, often feeling they 
had little choice as to whether to use it or not. 
2) Potential withdrawal prior to commencement of 
NIV was poorly communicated if at all. 
7) Communication barriers from clinician and 
family perspective (4.11 below and listed in Table 
4.5) 
1) Clinicians report patient denial, not wanting to 
take away hope and lack of adequate time to have 
clear end-of-life communication; clinicians often 
wait until asked for information. 
2) Family members suggested lack of health 
literacy may prevent confidence to ask for 
information. 
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4.5. Experience of Clinicians with End-of-Life Communication and NIV 
Withdrawal 
 One of the influences on the willingness and capacity to have end-of-life 
communication with people with MND identified from the literature review was 
years of clinician experience (Blackhall., 2011). All the clinician participants 
interviewed had many years of experience with communication surrounding 
end-of-life decisions (4.5-22 years), with 12 of the 19 clinicians having had 10 
years or more.  
 Anecdotally, experience with communicating end-of-life choices to 
palliative care patients generally enhances a clinician’s ability to sensitively 
discuss options of care. Clinical experience in palliative care and respiratory 
medicine of the participant clinicians was, therefore, anticipated to facilitate the 
difficult discussions (relating to the end of life and the potential withdrawal of 
NIV) soon after diagnosis. In relation to MND, however, the experience of 
having prior involvement with withdrawal of NIV, an important aspect of MND, 
did not always appear to make such communication any easier for the 
clinicians. Despite their years of experience, the respiratory clinicians 
interviewed expressed the difficulty they encountered in having end-of-life 
discussions when offering NIV to ease symptom control; framed by three 
participants as giving NIV with one hand and discussing NIV withdrawal and the 
end of life with the other (C4, C11, and C12). As C12 said: 
 
C12 (physiotherapist): You’re offering them something that potentially may 
treat their symptoms, but then at the same time saying, “Oh, by the way, you 
know, let’s also talk about, you know, end of life as well.” 
 
The experiences of clinicians in communicating end-of-life choices and 
the potential withdrawal of NIV were relatively limited. The point was also made 
by C2 (palliative care doctor) that as MND is such a rare disease, while the 
clinician may feel comfortable with withdrawing NIV and having discussions 
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associated with withdrawal, the nurses may be lacking in experience and 
confidence to do so. This possibility was confirmed by C10 (nurse), who felt the 
experience necessary to explain to the patient that NIV could be removed and 
that death could follow was beyond her experience. The nurse said she felt 
confident to reiterate communication relating to NIV removal only if a specialist 
doctor had initiated the conversation. She did, however, feel confident to talk 
generally about end-of-life as did the other nurse participants. The palliative 
care and neurological nurses interviewed agreed that they felt confident and 
able to discuss end-of-life issues and the possibility of NIV withdrawal if the 
person with MND had some prior knowledge of the possibility of NIV withdrawal 
(C6, C7, C8, C9, C10, C14, C16 and C17). All the nurses stated that they 
discussed end-of-life choices despite the difficulties, preferring an approach of 
gentle honesty. This is exemplified by the following quote from C8: 
C8 (palliative care nurse): But it’s got to be about making sure that things are 
said, even if they’re unpalatable. And, you know, there are ways – we’ve all 
heard some very, you know, inappropriate ways of breaking bad news and 
certainly just being right out there and unemotional, but gentle, is the only way 
to go. People will respect that you’ve been honest with them, you know. They 
might hate you, but that’s okay, they need to hate someone. Someone has got 
to be hated. 
  
All the clinicians were asked if they had been involved with the process 
of NIV withdrawal in a person with MND and all except four (C15, C18, C6, and 
C7) had been present at least once. Therefore, the experience of being present 
at NIV withdrawal, and how the experience had affected the clinicians was 
considered potentially relevant to future communication skills surrounding early 
end-of-life discussions. Although some clinicians described well controlled and 
positive experiences with NIV withdrawal, the experience was not always like 
that. Despite the best protocols and recommendations, clinicians reported 
difficulty with giving good information when certainty is lacking. Emotionally and 
clinically, being able to decide the exact protocol and timing for NIV withdrawal, 
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to assess their family dynamics and, most importantly, to maintain comfort until 
death, was described by C11:  
 
C11 (respiratory specialist): Bloody awful, because – the when, how, 
pharmacotherapy, you know. What do you do? Do you necessarily withdraw 
NIV or do you let people die on NIV? …  I suspect it’s enormously difficult from 
the family’s point of view unless the conversations leading up to it have been 
really good and really clear. 
 
C14 also described the difficulties experienced with the emotional 
communication involved with NIV withdrawal:  
 
C14 (MND clinical nurse specialist): It’s a conversation that we dread, I think, 
to remove it, because the breathing is so essential to stay alive. And there’s no 
good or there’s no best timing for it. It really depends on the relationship and the 
time that – how much the patient trusts you to talk about it; how much the family 
trust you, what you’re telling them actually makes sense, not killing her – killing 
your mum. It’s – I think it’s more difficult than talking about stopping the PEG. I 
certainly feel that.  
 
 This negative clinician experience, which might influence communicating 
the potential of withdrawal of NIV in other people with MND, was reiterated by 
C8 who, despite not being personally affected, stated that others involved had 
been: 
 
C8 (palliative care nurse): A number of staff were really confronted. A number 
of staff said they didn’t want to be involved, and so then we set it up for 24 
hours later. 
 
A very specific element of clinicians’ experiences of dealing with the emotional 
impact of communicating NIV withdrawal was noted by a palliative care 
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consultant. C1 highlighted the confusion amongst families and clinicians as to 
whether NIV withdrawal is euthanasia:  
 
C1 (palliative care consultant): We had one example in a general hospital 
where we had to spend a lot of time with the whole nursing staff, and also the 
support afterwards – partly the family, who actually coped quite well, but also 
the professionals - and having a debriefing after the instant so that 
professionals could say how they were feeling, particularly those who perhaps 
had contacted defence organisations or professional organisations and been 
given misinformation. 
  
 In this research, the years of participants clinical experience did not 
appear to make the early (recommended) discussions of NIV withdrawal any 
easier or more likely. To the contrary, negative experiences of NIV withdrawal 
and knowing the potential difficulties involved both emotionally and ethically 
could lead to hesitancy in communicating the information. This research was 
unable to ascertain the level of experience or education clinicians require to 
enable them to initiate difficult end-of-life communication.  
  
4.6. Timing and Content of Communication about the Benefits and 
Burdens of NIV, PEGs and End-of-Life Choices 
 
Clinicians in this study frequently assumed that communication about 
NIV withdrawal and the end of life had occurred with the person with MND and 
their families prior to their own involvement. The responsibility for the role of 
communicating difficult end-of-life choices appeared unclear to the clinicians 
and this task was sometimes left to the palliative care clinicians involved late in 
the disease process. Whilst some of the clinicians (C7, C8, C14, C16, C19, C1, 
and C2) were largely aware of the existence of the NICE MND Management 
and Assessment Guidelines published in 2016 and their content regarding MND 
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communication and end-of-life choices, the timing of these recommended 
discussions was reported to be difficult. Most of the clinician participants felt that 
in practice the recommended timing of end-of-life communication was not 
always realistic.  
 
Clinicians who initiated NIV stated that they try to commence end-of-life 
discussions and the possibility of NIV withdrawal early on (C4, C11 and C12) 
but are often faced with hesitancy or denial from the person with MND or their 
family, who do not wish to discuss it: 
  
C4 (respiratory specialist): I mean, you’re talking about end-of-life issues, 
which many health practitioners are uncomfortable talking about. And then I 
would think 20 to 40 to 50 per cent of patients will tend to say, “Well, we don’t 
want to talk about that. We’ll think about it when the time comes.” So even 
though you may have the best intentions of trying to have all this out in the open 
and discussed and documented, it’s not always the case that the patients wish 
to discuss it. 
 
 The four respiratory clinicians (C11, C12, C4 and C5) said they tried to 
ascertain what other specialists had already said to the person with MND, and 
two said they would initiate end-of-life discussions if they had not already been 
broached (C11, C12). One palliative care consultant considered discussing NIV 
withdrawal at the stage at which it was offered to be a logical and important for 
transparency. He maintained that this ensured informed consent for 
commencing and that clear information about the potential to withdraw NIV was 
provided at the same time (C19):  
 
C19 (palliative care consultant): I guess the pros is a very transparent 
discussion, isn’t it, that you’re actually, at the time of putting the – sorry, of 
starting the machine, the NIV, you’re also talking about the possibility of 
withdrawal.  I can see the merit of that.  I guess on the other hand – I’m just 
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thinking of the emotional dimension of that, and I guess that may – I’d have to 
think of the sensitivity of that conversation at that time.   
C19 also stated that the emotional dimension and sensitivity of that 
communication would have to be considered on an individual (person with 
MND) basis. C19 was unaware of the guideline recommendation to discuss the 
potential withdrawal of NIV prior to the initiation of NIV until interviewed by the 
candidate, despite being broadly aware of the MND guidelines. 
  
 However, the preservation of hope can underlie a family’s wish to not 
discuss the end of life. The following is an account of how one healthcare 
professional dealt with the issue: 
 
F3 (family): And then when [person with MND] was, you know, eventually 
diagnosed, we – by that stage we’d been reading up on best practice and, you 
know, we knew all about the multi-disciplinary team approach, etcetera, 
etcetera, etcetera. And [the health care professional’s] response was, “Oh, 
you’re not going to need that for a long, long time. And don’t talk to MNDAWA. 
They’re way too negative and I’ll see you in a year.” 
 The nurses interviewed for this study suggested that prior to their 
involvement, doctors should initiate communication about the potential of NIV 
withdrawal and end-of-life issues. The nurses assumed, but were uncertain, that 
this was the case (C6, C7, C10, C14, C16 and C17). This further highlights the 
communication issues between groups of healthcare professionals and 
between healthcare organisations which is discussed in Section 4.9.  
 
 Clinicians found the timing of communication about the end of life and 
NIV withdrawal challenging. There was confusion about which healthcare 
professional was responsible for the communication and concern that patients 
might not be prepared for the conversations. Most of the specialist clinicians 
tried to ascertain how much the person with MND and their family knew about 
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the course of the disease and gauged their communication content on the 
response.  
4.6.1. Communicating the benefits and burdens of NIV  
 The respiratory clinicians in this study indicated that communicating the 
benefits and burdens does not necessarily occur when initiating NIV. There are 
several reasons given: too much information all at once, insufficient time, 
fatigue of the person with MND and the priority given to necessary technical 
aspects of NIV (C4, C11, and C12):  
  
C11 (respiratory specialist): You know, how to set up the mask, how to set up 
the machine, how to plug it in, what to do if it leaks, what to do if they get rain 
out, what to do if they get this, that and something else. And sometimes a lot of 
the attention can be focused on the sort of practicality of the machine, and the 
sort of softer, more difficult conversations often get a little bit left to the side. 
  
C12 (physiotherapist): We were going to start them on non-invasive ventilation 
and that’s a really difficult time because trying to explain where and what NIV 
can and can’t do, but also the other longer-term implications. It’s a little bit hard 
to talk about deterioration and death and dying when it’s the first time you’ve 
ever seen a patient. You’re throwing a machine at them, potentially – or at least 
trying to get them started on it because you’ve probably got two days before 
they go back to the country. 
 
 Some of the burdens mentioned by the respiratory specialists and 
neurological and MND nurses involved with the support of country people with 
MND were the practicalities of obtaining an NIV machine, battery backup and 
emergency planning for that eventuality (C6, C7 and C11). The practicalities of 
NIV may become overwhelming for the families if not adequately explained and 
if emergency backup plans have not been formulated. The family participants 
F1 and F2 supported the importance of contingency planning: 
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F1 (family): And then if something went wrong with the machine, Dad would 
ring me. I’d go to their place and then I’d try and work it out and if I couldn’t I’d 
ring [the hospital], and often they couldn’t really answer my questions. So, the 
technical back-up of that was really difficult. If it didn’t work I ended up finding a 
chemist around here that dealt with BiPAP machines and stuff like that, so we 
could get new parts … Finding the filters was something I had to research, so 
finding replacement filters. And if something – it wasn’t really discussed if it 
broke down or anything like that.  
  
 C6 discussed the issue that some people with MND had a backup plan of 
going to a hospital with their NIV in the event of a power cut and that this was a 
huge worry for the families. The initial cost of the machine appeared to depend 
on whether the person with MND had health insurance cover, which clinic they 
were linked with, and where they happened to live (C6, C11). The point was 
made by C11 and C12 that as referral to them was often late in the disease they 
had to condense vital information regarding the use of NIV to fit within the brief 
time available before the person returned to the country.  
 
 One of the clinicians (C14) mentioned hospital admission would be 
necessary should withdrawal of NIV be considered, which, as reported by C6, 
could be very upsetting for the person who wished to die at home: 
  
C6 (neurological nurse): The lady that couldn’t tolerate NIV, when she was 
going on it, was very clear that she wanted to die at home, and it was explained 
to her by the doctor that that would not happen if she was on NIV and had it 
withdrawn; it would have to be done in hospital, which was very upsetting. It 
didn’t eventuate, but I know that caused a lot of stress for the family. 
  
 Increased dependency on family support and caregiver strain was 
mentioned as a burden of commencing NIV (C5, C11 and C2) and its long-term 
use, as the person with MND is less able to adjust the mask or take it off: 
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C11 (respiratory specialist): And I upfront say that, you know, “As this disease 
progresses, that more and more the burden of actually putting it on and actually 
making it go falls more and more on the carer as people lose the dexterity in 
their upper limbs.” And that, you know, that’s something that they need to know 
about upfront. 
 
 The possible benefit of improving survival with the use of NIV was 
questioned by some of the clinicians who made the point that there was only 
one study published (at the time of the interview) (Rafiq, Proctor, McDermott, & 
Shaw, 2012). However, as added by one of the respiratory specialists: 
 
C11 (respiratory specialist): it depends a bit on how savvy the patient is and 
how good they are at understanding the idea of a survival benefit, because I 
think that there probably is. But I won’t use that to push people into having NIV. 
 
Therefore, some clinicians did not say anything about increased survival (C12, 
C18), however, some respiratory clinicians did discuss improved survival as a 
benefit of using NIV with their patients (C11, C14, C5): 
 
C11 (respiratory specialist):   If they’re saying, you know, “No, I don’t want it,” 
I will, you know, make some sort of allusion to the idea that there might be a 
survival benefit and if they want to chase it, I’ll talk about how there probably is, 
but, you know, for some people surviving longer with a progressive neurological 
disease may not be a benefit, in fact, and may be more of a burden.  
 
 All the clinician participants interviewed stated that they communicated 
that NIV would not stop the progression of the disease, and that the person with 
MND would become more dependent on it. The community nurses reiterated 
dependency and disease progression, and all the bereaved family participants 
and the person with MND agreed they were fully informed about this and 
understood the continuation of disease progression despite the use of NIV. 
However, a few of the family participants recall being told of the practical 
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burdens of NIV: issues of skin tears, particularly on the bridge of the nose; 
feelings of claustrophobia from the mask; and increased dependency on 
caregivers to adjust or remove the mask as muscle movement becomes more 
difficult (F1, F2, F5, P1). This may have been due to professional caregivers’ 
views of NIV, as a comment from one of the clinicians suggests:  
 
C18 (rehabilitation specialist): But, you know, I’m actually in favour of it [NIV], 
so I don’t tend to talk too negatively about it.  
 
 As previously stated, the respiratory specialist participants in this study, 
whilst acknowledging the guideline recommendation of communicating the 
benefits and burdens of NIV and potential of NIV withdrawal prior to NIV 
commencement, had difficulty discussing those sensitive issues in practice: 
 
C17 (respiratory nurse consultant): I mean, you can’t give the patients – if 
you told them every problem that might occur in the next four years they’d go, 
“I’m not using that.”  Do you know what I mean? 
Some of the clinicians involved at the time of respiratory failure and 
distress were honest in their admission that the “lack of hope” end-of-life 
discussions relating to possible withdrawal of NIV meant that these discussions 
were left to the palliative care service to address later (C18, C4). Some 
clinicians, whilst accepting that palliative care should be involved from the time 
of diagnosis, did not acknowledge NIV as palliative care symptom control nor 
explain it in such a way to the person with MND (C18, C16, C17, and C14). 
Virtually all the clinicians involved with initiation of NIV felt that as NIV may 
relieve much respiratory distress and had the potential to prolong life, it should 
be encouraged (C5, C4). However, C11 made the point that the potential to 
increase life with NIV was not always a good thing, as a longer life may equate 
to longer suffering. There was some uncertainty from clinicians relating to NIV 
use, who generally confirmed its usefulness but admitted it did not suit everyone 
(C19, C11, C4 and C12):  
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C4 (respiratory specialist): … and, you know, we talk about length of life 
versus of quality of life. We say that – I’ve no doubt in certain circumstances 
non-invasive ventilation can extend the life of some people with motor neuron 
disease, but that has to be balanced against quality of life.   
 
  Prolonging life and hope were considered important to the clinicians and 
influenced their decisions to discuss NIV withdrawal potential and end-of-life 
choices. However, prolonging life (and possible suffering) was not always a 
priority of the person with MND and their family (F1, F2, and F6). None of the 
bereaved family participants said that the potential of prolonging life in the 
context of possible suffering was alluded to or discussed. However, thinking 
retrospectively, some of the bereaved family participants said that their family 
member did suffer as a consequence of their lack of understanding that the NIV 
could be withdrawn, as stated by F1 and F2:  
  
F2 (family): Just get this thing [NIV] off. I just – maybe she was thinking, “I just 
want to go. I’ve had enough.” 
 
F1 (family): I think now, I would have opted for that option [NIV withdrawal] 
because Mum was so uncomfortable and so suffering that I would have opted to 
say, “Let’s, you know, ditch that, and let’s, you know” – and I think now Dad 
would have taken that option. But from what we knew, and what we – while we 
were going through it, I don’t think we would have done any different to what we 
did do. But do you know what I mean, hindsight’s a wonderful thing . . .  
I regret – and you can use that as a quote if you want – but I regret the last 
three nights that mum had at home. It was awful for her, for dad, for me. It was 
just – still burned in my memory, and it’s hard to sort of go away.’ 
 
The difficulties with NIV and the discomfort of a mask caused ongoing suffering 
for some people with MND, as illustrated by F1 describing her family member 
coping with the NIV mask towards the end of her life:  
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F1 (family): … putting it [NIV] on, pulling it off, and putting it on, and she was 
trying to stand up and sit down, and she was just all over the place. And I just 
said to her, “Look” – I was in tears, and I just said, “I can’t do this again. We 
need somebody that knows what to do for you to have you [referring to the 
hospice].”  
 
 Some of the respiratory clinicians stated that they provided the person 
with MND information regarding withdrawal at the time of offering the NIV (C5), 
however, this doesn’t seem to have occurred for F1 and F2’s family. All the 
respiratory clinicians stated they tried to gauge whether the person was ready to 
engage with end-of-life discussions and intended to provide withdrawal 
information if appropriate, time allowed and the person with MND was not too 
fatigued (C11, C12, and C4).  
 
In summary, this research has found that the family participants did not 
understand the benefits and burdens of symptom control and any potential life-
extension in relation to possible prolonged suffering. Most of the clinician 
participants stated that they try to discuss the benefits and burdens of symptom 
control measures, but that generally the benefits, rather than the burdens, of 
symptom control are more the focus of discussions. 
4.6.2. Communication at end-of-life trigger points 
 Patient deterioration or implementation of symptom control measures 
such as NIV or PEGs are also times when end-of-life discussions are 
recommended to occur (NICE, 2016). Clinician participants of both cohorts 
(palliative care and respiratory) were asked when they commenced end-of-life 
communication and whether there were any trigger points used as openings for 
such discussions. 
  
 The respiratory clinicians varied in their responses. C5 involved the 
palliative care specialist at the initiation of NIV and stated that whilst some 
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discussion was presumed to have occurred prior to the respiratory specialist 
involvement, it was certainly reiterated by C5 at that time: 
 
C5 (respiratory specialist): End-of-life information is provided on the first 
outpatient visit. We do discuss this in great detail during the subsequent clinic 
visits … through the regular reviews we do make them fully aware of the 
prognosis and the limitations of treatment and the likely outcome of treatment 
strategies. 
 
Respiratory clinicians C11, C12, and C4 and the social worker, C13, stated that 
they tried to ascertain how much the person with MND understood about their 
disease whenever they met them and were guided by the person as to how 
much information they wanted rather than waiting for recommended trigger 
points and proceeding regardless of the patient’s preference: 
 
C11 (respiratory specialist): Okay, you know, if you’re going to have – I kind 
of – as a respiratory physician it depends a little bit on who the neurologist that 
I’m working with is and how much they’ve done already. 
 
C12 (physiotherapist): I guess the patient that we hate to see the most if 
sometimes we get outside referrals from – not from the MND clinic ****, but 
they’re being sent to us by another respiratory physician or elsewhere, and 
these patients are extremely end-stage there.  It’s the first time we’ve ever seen 
them.   
 
The respiratory clinicians all stated how difficult it was to have discussions 
about the end of life when initiating symptom relief with NIV, suggesting that 
those discussions may not always occur as recommended (C12): 
 
C12 (physiotherapist): That’s a really difficult conversation because it’s – one 
of the things we’ve found is that non-invasive ventilation is sometimes used as – 
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almost as the end point. So, people will offer it, but then not talk about the 
limitations of that therapy … you’re offering them something that potentially may 
treat their symptoms, but then at the same time saying, “Oh, by the way, you 
know, let’s also talk about, you know, end of life as well.” 
 
The gastroenterologist (C15) interviewed stated that he was generally not 
involved with discussions relating to end-of-life: 
  
C15 (gastroenterologist): If I get a sense that prognosis has yet to be 
discussed, or they don’t know, then I often don’t go down that path unless it’s 
necessary for my care, only because I think the person – the team that I guess 
is going to be most responsible in coordinating this person’s care should be 
having that discussion rather than an external specialist they may only see 
once. 
The community palliative care nurses all said they commenced end-of-life 
discussions at admission to their service (C8, C9 and C10) whilst the 
neurological nurses (C6, C7) who were involved earlier in the disease process, 
said they were open to end-of-life discussions as soon as they were involved 
and particularly when they recognised deterioration within the person with MND. 
The two MND specialist nurses (C14 and C16) both said that they commenced 
symptom control and end-of-life discussions soon after diagnosis. C4 and C16 
felt able to discuss NIV and PEGs as a positive method of controlling 
symptoms, and explained end-of-life choices particularly to alleviate any fear of 
a frightening, choking death:  
 
C4 (respiratory specialist): So, yes, I do indicate that PEG tube feeding may 
prolong life by that mechanism but make it very clear that again that’s not a cure 
for motor neurone disease; ultimately it’s not going to change the outcome.   
 
The palliative care clinicians acknowledged they were generally involved 
late in the disease process so tended to reiterate rather than initiate such 
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discussions. The palliative care clinicians made the point that end-of-life 
discussions when the patient was first introduced to palliative care may not be 
an acceptable initial conversation to have, and that, while discussions were 
patient-led, they did prompt the discussions as the person physically declined 
(C3, C2, C1, and C19). Despite the NICE (2016) guidelines and the European 
guidelines on the clinical management of amyotrophic lateral sclerosis 
(Andersen et al., 2012) recommending various trigger points for end-of-life 
communication to occur, one clinician did not see NIV initiation as one of those 
trigger points (C18). Instead, the clinician felt it was a stage a person with MND 
had to go through, and not a trigger for considering the end of life:  
 
C18 (rehabilitation specialist): I don’t actually see that as end of life. I just see 
that as a stage in their illness that they all seem to go through. So, I’ve never 
actually considered non-invasive ventilatory support as a trigger for end of life 
[discussions].  
 In addition to being asked if there were any trigger points in MND that 
would initiate end-of-life communication, the clinicians were asked by the 
interviewer if end-of-life choices of care were initiated when NIV was offered: 
C19 (palliative care consultant): It’s a good question. I may not necessarily 
bring the two together. I think at the beginning with the NIV I’m mainly focusing 
on the fact that, “I’m concerned about your breathing” – sorry, “concerned about 
your respiratory function. You’re having the NIV and I want to see how you’re 
feeling with that.” I may not necessarily at that time, right at the beginning, 
embark on a conversation about what might happen if – I guess if the future 
were to be that there was a discussion about withdrawing from NIV. So, I may 
not have that right at the beginning. 
One of the nurses suggested that clinicians avoid the difficult end-of-life 
communication, fearing the effect the conversation may have on their patients 
and families: 
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C8 (palliative care nurse): I think health professionals’ fear addressing those 
issues [end-of-life choices], and the response that they might get from the 
clients and the caregivers raising those issues. 
 
 In summary, the communication guideline recommendations are 
generally adopted by clinicians in a manner which supports their patients and 
are considered the best by the individual delivering the communication, but not 
necessarily as the guidelines recommend (NICE, 2016). Some of the clinician 
participants in this research focussed on the positives surrounding symptom 
control rather than any prolonged suffering that may occur. The palliative care 
specialists stated that they often had to clearly point out, and belatedly discuss, 
end-of-life options which had not been triggered earlier in the disease process.   
4.6.3. Communicating prognosis  
 Within the NICE MND Assessment and Recommendation Guidelines 
(NICE, 2016) it is proposed that the person with MND can expect to understand 
their prognosis from early diagnosis. The clinician participants were asked if 
they included the prognosis within early communication with the person with 
MND and their family. All the clinicians considered that giving the prognosis as 
length of survival was difficult; all said that if asked for a prognosis by the 
person with MND, their answer was not reflective of the course of the disease 
but rather an attempt to ascribe a survival time factor: 
 
C19 (palliative care specialist): I do say – and I couple that with the fact that, 
“We don’t know how long you’ll have to live; that a prognosis is difficult to know, 
and that we will do our very best to support you and keep you comfortable 
through this whole process.”  
There appears to be an unchecked assumption about what patients and 
a family want to know when asking for a prognosis; for example, they may have 
requested a description of the course of the disease rather than merely an 
estimate of time until death. Family member participants F1, F2, F4 and F5 
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described having been unclear of the specifics of MND when interviewed, or of 
which symptoms to look out for that may have been responsive to intervention, 
despite using the Internet for information.   
 
All the clinician participants made the point that with the Internet so readily 
available, people with MND and their caregivers either had already researched 
or could have obtained information prior to their (clinician) involvement: 
 
C1 (palliative care consultant): Some are [well informed]. Some are very 
much ahead. Some may have read a lot on the Internet. Some may have read 
some awful things on the internet.  
 
C18 (rehabilitation specialist): And, you know, in the days of – living in the 
days of Google and Internet they’re not restricted to doctors’ opinions and – you 
know, these people have all been on the Net before they come to us.  And I 
think they’ve formed a pretty strong opinion about where they’re heading. 
Table 4.3 indicates the types of communication family participants had 
with clinicians prior to the offer or commencement of NIV. Specifically, the 
benefits and burdens, end-of-life options, PEG insertion and at what stage of 
the disease palliative care referral was recommended. The table also shows 
whether the family participants interviewed had AHDs in place and whether 
these had been formalised with their clinicians.  
 
 This research questioned whether the clinician participants discussed 
prognosis with their patients. All the clinicians stated that they did but could not 
give definitive timelines. Prognosis was not discussed in terms of how the 
disease may progress or what the person with MND could expect to experience. 
Throughout the course of the disease, only two families stated that they fully 
understood the end-of-life care options (F3, F6).  
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Table 4. 4. Family Communication with Clinician Pre-Commencement of NIV  
Family 
Participant 
AHDs 
formalised 
Benefits 
and 
Burdens of 
NIV 
discussed 
 
Increased 
use of 
NIV 
discussed  
End-of-life 
options 
discussed 
Palliative 
care 
referral 
and 
options 
discussed 
PEG 
insertion: 
timing and 
discussions 
F 1/2 Discussed 
between 
family 
members. 
Not 
physical 
problems; 
some 
mechanical 
issues 
discussed 
Yes, 
although 
some 
confusion 
Not fully 
understood 
until 
palliative 
care 
involved 
Late in 
disease 
trajectory 
Pushed by 
clinicians 
but refused 
by person 
with MND 
F 3 
 
Yes, and 
discussed 
within 
family 
Yes, and 
researched 
on internet 
Yes Yes Yes Yes, pre-
respiratory 
problems 
F 4 No, but 
wishes 
known by 
husband  
Very late 
and then 
NIV 
refused by 
person with 
MND 
N/A Too late; 
patient 
already in 
palliative 
care 
Late in 
disease 
trajectory 
Recommen
ded by GP; 
patient 
pulled PEG 
out; 
hospital 
reinserted 
F 5 No, but  
wishes 
known by 
family. 
No No No patient 
and wife 
in denial 
Yes; prior 
to 
respiratory 
distress 
F 6 Yes, with 
GP 
Yes: but 
emphasis 
on machine 
mechanics 
and sorting 
out costs 
Yes Yes Yes Initially 
refused but 
agreed RIG 
later when 
swallow 
affected 
P 1 Family 
discussed 
and 
organised 
No  Yes Late in 
disease 
Late in 
disease 
Yes, but 
unsure 
when? 
4.6.4. Delivering the diagnosis 
 Research participants were not directly asked how the MND diagnosis 
was delivered to the family, however, several of the family participants 
volunteered this information. One of the main causes of distress was the way 
the MND diagnosis was delivered by the specialists (F1, F3, F5 and F6). F1 
describes the situation where various tests had been performed on her family 
member and the specialist phoned F1 to arrange an appointment for the 
following day. F1 asked whether they now had a diagnosis and was told that 
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they had, but the specialist told F1 that he would not discuss it over the phone 
but would “deliver the news face-to-face tomorrow”. This caused much anxiety, 
as F1 felt that had she known the diagnosis of MND she could have prepared 
herself and prepared relevant questions: 
 
F1 (family): Yes, I was quite frustrated when I was talking to him on the phone, 
because I was – I knew I was going to get bad news. I just wanted to have that 
so that I could research it before I spoke to Mum and Dad. 
 
This point was confirmed when the family received the news, but it did not really 
register on them until some 15 minutes later. Apparently, the person with MND 
was only able to write on a white board at that time, and wrote: 
 
F1 (family): “Is there a cure?” And he [doctor] said, “I’m afraid there’s not.” And 
she said, “How long do I have to live?” 
 
Unlike the experience of F3, the unexpected diagnosis of MND for the partner of 
F5 was delivered by phone. F5 and the family member receiving the diagnosis 
of MND stated they had little idea of what MND was: 
 
F5 (family): No. [person with MND] did, because he – after we got rung up on 
the phone, he did, you know, Dr Google. 
 
The experience of F3 when receiving the diagnosis of her family member was 
equally confusing: 
 
F3 (family): Oh, yeah, initial diagnosis discussions. That was horrendous. … 
So we were referred to a neurologist who will remain nameless. The first 
appointment we had with him was in early July of 2011. He told us at that 
meeting, “Well, either it’s bad, and I can help you, or it’s very bad and I can’t.” 
And our immediate reaction is panic. You know, “Please tell us more.” “Oh, no, I 
don’t want to worry you.” 
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F4 described how his family member had become progressively 
emotional (crying often) and developed slurred speech. Eventually, and after 
the affected person had seen a neurologist, the family was referred to an ear, 
nose and throat specialist for a speech impediment and it was he who 
recognised fasciculation (quivering) of the tongue and diagnosed MND.  
  
 The family participant involved with F6 described how her family member 
had various investigations including an MRI (Magnetic Resonance Imaging) the 
results of which apparently showed no abnormality. At a later date the MRI was 
reviewed by another specialist who found reportable changes. That the changes 
had not been recognised earlier was quite distressing for the person concerned 
and the family. F6 went on to say that the diagnosis was then confirmed many 
times by various means which to the family seemed “ridiculous”:  
F6 (family): So, you know, there was about a consultant and three neurologists 
that they’d seen, and they all had a reconfirmation of diagnosis. So, it got a bit 
beyond a joke, for want of some other words, to be told this. 
 The person with MND interviewed for this study (P1) described how he 
was referred to a neurologist who, despite fasciculation being present in his 
lower legs, did not perform an MRI. Instead the neurologist believed that the 
fact that P1 had Type 2 diabetes explained the clinical manifestations. Ten 
years later the fasciculations were in P1’s upper legs so he sought a further 
neurological opinion. Again, he was told the issue was not MND. The partner of 
P1 explained to the neurologist that P1 was often “quite violent in bed” with 
uncontrolled movements: 
 
P1 (person with MND): Uncontrolled movement. So, his suggestion was that 
we sleep in separate beds. That didn’t go down very well with either [partner] or 
myself. [Partner didn’t ask to go in. He [doctor] invited her in, and he was really 
quite rude to her [partner].  
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 Inappropriate communication by doctors as illustrated by the dialogue 
above (P1) was raised again by F6. This encounter involved a doctor who had 
stood beside her family member’s bed and, because the number of bed days 
allocated in an acute setting depends on a person’s condition, proceeded to 
discuss aged care facilities: 
  
F6 (family): … doctor, was very inappropriate about discussions over Mum’s 
bed, like it’s that not including the client as such, to say that “she would need to 
be out of here in a nursing home.” And that was particularly upsetting for Mum 
and Dad. 
 
Given that there is no specific diagnostic test for MND, diagnosis can be 
arduous and protracted. However, frustration was voiced by families that MND 
was not considered earlier in the illness as a potential diagnosis and the person 
affected was not sent to see a neurologist. For example, F1 and F2 describe 
how their family member had post anaesthetic respiratory difficulties relating to 
an operation followed by heavy mucous secretions. Apparently, the person with 
MND went to see at least three specialists (unsure which specialties) over 
approximately 12 months who all stated there was nothing wrong. Finally, their 
family member, already at the stage of losing her voice, saw a sleep specialist 
who referred the person to a neurologist. As the consequences are so 
devastating, it is understandable that clinicians want to undertake various tests 
to ensure the correct diagnosis. However, this research has found that the way 
the diagnosis has been given to the family participants caused considerable 
distress and had implications for patient and family readiness to discuss end-of-
life symptom control. 
4.6.5. Communicating end-of-life options into NIV initiation 
discussions  
 Many of the clinicians in this study, despite their years of experience, 
found it extremely difficult to uphold the recommendation that discussion of the 
potential for withdrawal of NIV occurs at the time of the offer or prior to the 
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initiation of NIV (NICE, 2016). The priorities for symptom control and end-of-life 
care in a person with MND may not be consistent with the clinician’s care aims 
and preferences, so clear dialogue between health professional and patient is 
essential. Whilst MND is a disease that progresses relentlessly, some symptom 
relieving therapies may offer a short extension of life; NIV is one of those 
therapies. However, prolonging life may not be the ultimate aim of people with 
MND and any prolongation may be considered by them as an extension of their 
suffering: 
  
F2 (family): They talked about the end of life, but they [specialists] didn’t talk 
about the fact that, you know, they [person with MND] might … be getting 
confused and not be able to make the decision in the end. 
 
Therefore, early understanding of and an agreement about end-of-life care 
priorities and preferences is recommended to occur soon after diagnosis, and 
especially when there is a deterioration of symptoms (Andersen et al., 2012; 
Borasio, Voltz, et al., 2001; NICE, 2016).  
4.6.6. Withdrawal of NIV communication: ethical and legal concerns 
 
 Most of the clinicians interviewed reported controlled experiences with 
the withdrawal of NIV, generally undertaken within the comfort and security of 
the family home with the full support of family members (C8, C9, C1, C2, C4, 
and C19). However, there were some experiences that were not so controlled 
and which, because of this, caused distress both to the clinicians and the 
families. One of the nurses detailed an experience of when she had been 
requested to remove NIV by a doctor without any discussion or contextual 
information. Although she was in a hospital situation she felt unsupported and 
unprepared for the outcome (C10). The nurse concerned refused to comply with 
the request to remove the NIV, believing that this was outside her scope of 
practice. The doctor making the request eventually came to sedate the patient 
and remove the NIV. A concern expressed by one of the palliative care 
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specialists was the ethical side of withdrawing NIV, and that communication had 
to be very clear to prevent the person’s family misunderstanding and 
experiencing the process as euthanasia rather than a person declining further 
treatment (C1, C17): 
  
C1 (palliative care consultant): It’s talking about end of life, which no-one 
wants to do. Often people don’t want to hear. It’s talking about these quite 
complicated ethical decisions, and certainly [in the U.K.] ethical education is 
pretty minimal in medical, I think, and in nursing. So, people haven’t got a 
background.   
 
 The importance of all members of a family understanding their family 
member’s end-of-life choice in refusing ongoing symptom treatment was 
emphasised by many of the clinician participants. 
  
C2 (palliative care specialist): I guess the other difficulty that I worry about is 
conflict within the family and if someone comes back later and says, “What were 
you doing?” And support for the team, you know? Clearly this is a big deal for 
any palliative care team to undertake at home. 
 
C11 (respiratory specialist): I suspect it’s enormously difficult from the family’s 
point of view unless the conversations leading up to it [NIV withdrawal] have 
been really good and really clear.  
 
  As well as the ethical considerations, C5 highlighted the importance of 
understanding the legalities and policies concerned with NIV withdrawal to 
prevent emotional and lasting psychological issues particularly for the health 
professionals and family members. The fear that unclear communication may 
lead a bereaved family member to carry the scars of perceiving NIV withdrawal 
as killing was expressed by one experienced MND nurse (C14), who had in fact 
experienced this situation. 
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 Ideally the explanation that NIV can be stopped at any time, and that 
medications can be used to alleviate any symptoms that may occur, should be 
part of the initial NIV communication. Questions that may continue to worry a 
person with MND can be answered and reiterated as the disease progresses, 
hopefully reducing psychological stress. One of the palliative care specialists 
(C13) made the point that it is difficult to know what amount of information is 
sufficient regarding the removal of NIV, as it depends so much on the stage of 
disease acceptance of the diagnosed person. Uncertainty around how or when 
death may occur for each individual poses an additional barrier for the clinician 
considering when to initiate such conversations (C13, C4): 
   
C13 (social worker): The barrier is where they have enough information about 
“if I take it [NIV mask] off” and where they’re at, at what stage they’re at, “Am I 
going to die straight away and how is that going to be, and what symptoms am I 
going to have, and will I be able to cope with them,” and so forth. 
 
The concern of providing symptom relief with NIV and later in the same 
conversation discussing the option of taking the NIV mask off when it was no 
longer useful was dreaded by some clinicians (C4, C1).  
 
 The idea of killing, or being perceived to kill, with the withdrawal of NIV 
was mentioned as a barrier (Table 4.4) to communicating withdrawal (C14). 
C11 thought that the death-defying culture in which we live was a 
communication barrier to discussing the end of life at the time of NIV initiation. 
This was reinforced by C11 who, whilst acknowledging that the clinical 
guidelines were a good idea in theory, felt that the real world frequently forced 
their hand. C12 stated that some people who were symptomatically ready to 
commence NIV were psychologically unprepared for the recommended 
communication surrounding NIV withdrawal and the end of life. Such patients 
would halt conversations relating to the end of life which were upsetting for 
them (C6, C7, C8, C10, C4, and C12). One palliative care specialist (C3) 
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confirmed that the potential of withdrawal of NIV and end-of-life choices are not 
discussed often enough at the point when NIV is started. The specialist added 
that this meant decisions relating to treatment choices were sometimes too late 
to be useful. 
4.6.7. PEGs as a symptom control measure 
 The discussions surrounding the potential usefulness of a PEG tube and 
the explanation of the need for insertion prior to respiratory failure is a 
recommendation of current MND guidelines (Andersen et al., 2012; NICE, 
2016). It is recommended that communication about this occurs soon after 
diagnosis and certainly when symptom control measures including NIV are first 
offered. However, some of the clinicians felt that communicating the benefits 
and burdens of PEG tubes and whether they had the potential to prolong life 
was inadequately explained (C2, C3, and C5):  
 
C3 (palliative care specialist): Just touching on PEG tubes again, I think 
they’re often sold to people as more of a solution than they are, and I don’t think 
the difficulties of PEG tubes are adequately communicated: the risks of leakage, 
the risk of infection and the risk of aspiration. So, I think, you know, they’re kind 
of seen as an easy option when someone can’t swallow, and the reality of 
dealing with the other side of it isn’t always discussed as well. 
 
 C12 suggested that some people with MND and their families were 
unsure why they had been sent to a respiratory specialist prior to insertion of a 
PEG. They were also unsure if they wanted one and concerned they were being 
“pushed” in that direction by well-meaning clinicians. In a discussion about PEG 
insertion, one gastroenterologist stated: 
 
C15 (gastroenterologist): [Clinicians are] always tempted, too tempted, to 
make value judgments about quality [of life] on behalf of other people and we 
really don’t have the right to. 
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 Further, PEG use appeared to be commonly described by clinicians to 
patients and families in the context of potential increased survival, but the 
potential of increased suffering appears to be less well addressed, if at all (C8, 
C16). C19 and C17 did say that in some circumstances they would describe 
survival in the context of suffering, particularly if the person had MND with 
frontotemporal involvement (in which case C19 did not mention PEGs at all) or 
older onset of MND. 
 
C19 (palliative care consultant): The group that I don’t go down the PEG line 
at all is – and I don’t know whether this is just me, but I don’t do it with the 
frontotemporal group. I just avoid that now. Sometimes that can be an open 
question, “Why aren’t you speaking about it?” But I guess I’m just concerned – 
two things, one if the dementia – if the behavioural story becomes more difficult 
and the person’s now pulling at their PEG or RIG, and second is really is this 
the appropriate thing to be doing that may extend someone’s life? 
 
The benefits and burdens of PEG tubes are often inadequately 
discussed by clinicians leading to misunderstanding by the families. This 
research could not clearly ascertain if this was confusion on behalf of some of 
the clinicians who then passed on misinformation to the patients, or as C2 
proposes: 
 
C2 (palliative care specialist): I think that the discussions around PEG tubes 
are done poorly, and the number of well-meaning people who think that they 
can prevent aspiration, whereas clearly that’s not true, whereas if you ask 
nearly all of my patients why their PEG tube was inserted they tell me it was to 
prevent aspiration pneumonia, which is clearly not true, but it’s the myth that’s 
out there. 
 
 The understanding that a PEG tube will not alleviate the risk of aspiration 
was a point brought up by respiratory clinicians (RS1 and RS2) and the 
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gastroenterologist (RS5) interviewed for this study. All these clinicians said that 
this was frequently misunderstood by patients. Some of the families of people 
with MND were confused about the timing of PEG being offered, particularly as 
PEGs were encouraged prior to the appearance of symptoms that they might 
relieve (swallowing difficulties and inadequate nutrition), or symptoms which 
may prevent insertion of the PEG (respiratory insufficiency as an increased 
anaesthetic risk). According to (F5):  
 
F5 (family): I’m pretty sure we were never told to make a decision about 
wanting to have a PEG, because the symptoms weren’t even slight at the 
beginning.  
 
The respiratory clinician C12 made the point that some families and people with 
MND may not understand the potential of PEG tubes and may feel pressured by 
clinicians, particularly if they were asymptomatic:  
 
C12 (physiotherapist): “Gee, everybody’s been at them at the PEG, and we’ve 
blundered in and said exactly the same thing, and, you know, making them feel 
as though, you know, maybe they’re being pushed down a pathway that they 
don’t want to go.”  I think that’s really – you know, that’s not fair on them. 
 
Whilst the insertion of a PEG tube is recommended prior to the 
respiratory muscles decreasing in efficiency and the time at which NIV is 
offered, communication of the benefits and burdens of both symptom control 
methods are recommended early in the course of the disease. The aim was 
generally to get a PEG inserted prior to weakening of the respiratory muscles, 
at which point an anaesthetic would be too dangerous:  
 
F5 (family): Yeah, but I only learnt by reading myself, I’m pretty sure, that the 
PEG would have had to go in. 
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F1 and F2 stated that their family member with MND was offered a PEG but it 
was apparently too much of an anaesthetic risk by that time. Neither F1 nor F2 
were sure if a PEG had been mentioned before then. None of the family 
participants or the person with MND interviewed recall being told of the risks of 
aspiration with a PEG or the possibility of infection. The dialogue below 
indicates that one family, despite their good health literacy, thought (incorrectly) 
the insertion of a PEG would improve the risk of aspiration: 
 
F6 (family): She did, yeah, so in February, because of the distress caused by 
choking on food and fluids. And because Dad was her main carer – Mum’s main 
carer – he, I feel, probably more strongly advocated for it, because of the 
distress on him as well in managing the choking with the aspiration. 
 
Both C3 and C15 brought up the point that patient and family 
understanding of medical complexities relating to NIV and PEG tubes need a 
degree of health literacy. For example, the understanding that a PEG tube may 
be offered and need to be inserted prior to any obvious swallowing difficulties in 
a person with MND because of the risk that respiratory decline can make the 
PEG insertion a significant anaesthetic risk: 
 
C15 (gastroenterologist): And perhaps that’s health literacy, perhaps that’s my 
fault for not explaining it clearly enough.  But, yeah, I mean, I guess it’s a barrier 
in terms of understanding the complexities of why they might need it earlier than 
the need to use it; that is, if their respiratory involvement, or their respiratory 
disease, is mild, but definitely present, but they’re swallowing beautifully at the 
moment, the idea of putting in a PEG now for the future – even though you don’t 
need to use it now – can be difficult to get across. 
  Family member F5 indicated that their understanding of PEG tubes was 
due to their own investigation and that not one health professional indicated that 
it would have to be fitted prior to respiratory muscle loss. Conversely, 
participants F6 and F3 and their family members were very aware of the course 
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of MND and had investigated symptom control options extensively. The health 
literacy of F6 and F3 enabled them to ask pertinent questions of the clinicians 
and make more informed decisions. 
  
In summary, this research has found that there remains considerable 
misunderstanding between clinicians and families about the benefits and 
burdens of having a PEG in people with MND. The risk of aspiration is not 
improved with a PEG in situ. The understanding by families that a person with 
MND can develop swallowing difficulties as the disease progresses seems not 
to have been well communicated. This research also identified that the 
tardiness of referral for a PEG (described by some of the respiratory clinicians), 
is often too late for the person with MND.  
 
4.7. Time Allocated for Communicating and Discussing End-of-Life 
Choices 
 Sufficient time to have detailed, emotional and difficult communication 
relating to end-of-life choices with a person with MND and their caregivers was 
considered a huge communication barrier (Table 4.4) and was mentioned by 
the majority of the clinicians interviewed: 
  
C2 (palliative care specialist): Time, you know. We’re all very time 
poor, and these conversations take time, need to be re-visited, the patient’s 
cognitive ability, family issues. You know, conflict within a family. All sorts of 
things come into play. Like I say, when it’s easy it’s easy, and when it’s hard it’s 
nearly impossible. 
 
Adequate time is needed to explain possibilities such as risk of aspiration 
infection if a PEG is inserted, whether to be treated by oral or intravenous 
antibiotics or whether to be treated at all under such circumstances (C3). C3 
made the point that allowing 10 minutes for such discussions, particularly when 
a person with MND is already fatigued, is completely inadequate. The 
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expectation that the person with MND will be able to meet with the necessary 
clinicians in a short amount of time and be able to fully comprehend all that was 
said to them is another issue: 
  
C12 (physiotherapist): One of the things, you know, when we see the patients, 
I’d like to spend a lot more time with some of them but some of them are just – 
by the time they’ve seen the speech therapist and the dietician that morning, 
and maybe spoken to [the nurse], and then they’re going to see us in the 
afternoon to do some lung function, they’re just exhausted. … 
 So they’re fairly long conversations for a lot of people … the worst patients to 
see is when you feel like you’re being rushed and you’re trying to introduce a 
new therapy plus manage all the back end, knowing that you’re not going to see 
them again, and knowing that they may be going to an area where there’s very 
limited multi-disciplinary or specialist care to manage some of these more 
difficult issues. 
 
 Adjusting communication to a person’s cognitive ability and health 
literacy and ascertaining any family conflict was reported to require a great deal 
of time. Clinicians spoke of the necessity to re-visit the same conversations to 
ensure understanding but again, they find this very time consuming and not 
always possible for people returning to the country (C11, C1, C2, and C3):  
  
C11 (respiratory specialist): There are some people that are willing to engage 
in this, and then there are other people where you can’t get them to engage in 
discussions about end-of-life care. And so, my goal is to do it early and to do it 
often until I feel like the patient and I, and family and I, are on the same page. 
But it’s sometimes, in the real practical world, more difficult than that.  
 
C2 (palliative care specialist):  If it’s not in your routine practice, and you look 
after an MND patient once every decade, then I think that’s really hard, you 
know?  So, yeah, I think that’s a barrier, lack of experience, yeah.  And I think 
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time.  I mean, that’s – you know, if we think about – I mean, I think it would take 
two to three visits of an hour each, you know? 
 
C11 (respiratory specialist):  I can imagine that in trying to teach people how 
to do something that’s complicated there is a great temptation to focus on the 
functional at the expense of the emotional, because the emotional is difficult, 
and the conversations are difficult, and you have to talk about death and dying 
and uncertainty and difficulty and what’s going to happen when this brand new 
shiny machine that I’m just introducing you to doesn’t work anymore. 
 
The family participants interviewed made the point that unless they were 
assertive and asked the right questions, they could miss the relevant 
information at the specialist appointments: 
  
F5 (family): Because in these appointments you – particularly with a 
neurologist who gives you an overall reading on how the whole thing’s going, if 
you don’t ask questions, and you’re not an assertive sort of person, sometimes I 
think you could walk out missing a lot, do you know what I mean? 
 
Family participant F6 suggested that the communication recommendations 
within the MND guidelines may not be relevant to all cases of MND. F6 went on 
to suggest clinicians involved with communicating end-of-life choices make time 
to listen to the person with MND and their family members: 
  
F6 (person with MND): So, you know, some health professionals – I think 
periods of silence to listen to the client are needed without the health 
professional thinking, “I’ve got to tell them X, Y, Z, you know, because this is 
what the evidence-based guidelines say.”  
 
To summarise, both the clinician and family participants made the point 
that significant time was required at specialist appointments to deliver the 
necessary information and understand the broad spectrum of emotional and 
 171 
 
practical issues involved with MND. Having time to listen to the person with 
MND and their family was considered particularly important. 
4.7.1. Influence of frontotemporal changes in people with MND 
 The need for time for communicating end-of-life choices has been 
identified in this research, but time and ability to recognise FTD in people with 
MND is a further challenge. The clinicians were asked if, in their experience, 
frontotemporal changes in a person with MND caused difficulties in decision-
making regarding their treatment choices and end-of-life care. The clinicians 
generally had little experience of poor decision-making that could be directly 
attributed to frontotemporal cognitive changes, however, C1 did make one 
observation relating to FTD:  
 
C1 (palliative care consultant): It does feel like an iceberg really. There is an 
awful lot under the water of how we do the communication. We’re not very good 
at basic communication anyway, and then we’ve got this huge great mass that 
we can’t quite see yet and we’re getting inklings of. 
 
 One of the respiratory clinicians observed that there may be increased 
impact on the caregivers of a person with MND if frontotemporal changes were 
affecting their understanding of symptom-relieving options: 
 
C13 (social worker): What concerns me sometimes with that [frontotemporal 
dementia] is that they [person with MND] don’t have a deeper understanding of 
the situation [as they would] if they didn’t have the FT [frontotemporal] 
happening, and it impacts on the carers, and that’s my concern.  
 
 Potentially prolonging the life and suffering of a person with MND by 
making choices for options which may ultimately be detrimental for them was a 
concern of C19 a palliative care consultant (4.6.7). 
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4.8. Early Involvement with Palliative Care and Family Understanding 
The majority of respiratory clinicians suggested that some end-of-life 
communication should have been attempted with people with MND from early 
diagnosis, prior to respiratory issues arising and their involvement in the 
patient’s care (C11, C17, and C4). The involvement of a palliative care team 
was identified as helpful in ensuring end-of-life communication occurred. C5 
(respiratory physician), for example, stated that in his experience, end-of-life 
communication commenced at or shortly after diagnosis and that the palliative 
care team was involved from diagnosis:  
C5 (respiratory specialist): From the very beginning. Palliative care team can 
provide vital support before the end stage of the disease arrives. Their 
involvement should not only revolve around end of life care. 
The palliative care and respiratory clinicians interviewed for this study 
were asked at what stage of the disease progression they became involved, 
and their opinion as to whether the timing to palliative care was appropriate. 
The clinicians responsible for offering NIV for symptom relief were also asked 
when they involved or referred the person with MND to a specialist palliative 
care service:  
 
C4 (respiratory specialist): I mean, ideally all patients very early on, close to 
the time of diagnosis.  For various reasons some patients don’t want that, and 
that’s okay, and it depends upon the support structure they have in place 
already.   
 
 Despite guidance for early referral, there was a perception amongst 
some of the clinicians that, at the time data for this research was collected, 
some doctors involved at diagnosis or early in the MND trajectory believed that 
palliative care was for the terminal stage or last few weeks of life only (C18, 
C19):  
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C19 (palliative care consultant): … or has inadvertently forgotten that we 
[palliative care service] exist, or some other - or perhaps holds an old-fashioned 
view that palliative care is simply for the dying - now, of course, motor neurone 
disease is an incurable disease from day one, so it ought to involve us.   
 
 The palliative care specialist participants reported that people with MND 
were frequently referred to them when already extremely ill and nearing the 
terminal stage, often underprepared and lacking the ability to communicate 
clearly their wishes for end of life (C1, C2 and C19): 
 
C2 (palliative care consultant): To be honest, most of my [MND] patients are 
referred very late, and we look after them for their end-of-life care. 
 
This was reflected by most palliative care clinician participants who at times felt 
frustrated that the referral to palliative care was made later than it should be to 
optimise the benefits of palliative care for the person with MND and their 
caregivers (C8, C2, C14, C18 and C19):  
 
C19 (palliative care consultant): It does happen, where the person is referred 
very late, and we think that’s disappointing because that patient has been 
known to have MND in our area for some time. 
  
Some respiratory clinicians report that occasionally difficulties in 
communicating with the community palliative care teams regarding assistance 
with NIV patient issues was an obstruction to adequate patient respiratory care 
(C12). Frustration was apparent amongst respiratory clinicians that their 
involvement was too late to adequately assist people with MND with developed 
respiratory failure (C11, C12 and C17). The safest option for insertion of a PEG 
tube is prior to failure of the respiratory system.   Late referral meant that this 
may not be possible, according to the gastroenterologist and the respiratory 
specialists interviewed (C15, C4, C11, and C12): 
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C11 (respiratory specialist):  If that [PEG] hasn’t been discussed by the time 
the patient gets to me as a respiratory physician, I almost see it as a failure of 
the system. 
 
C15 (gastroenterologist): Understanding the medical complexities of PEG 
tube insertion needs a fair degree of health literacy and that can sometimes be 
a barrier.  For example, the appreciation that respiratory involvement increases 
your anaesthetic risk of the procedure and hence for me the need to put PEG 
tubes in before significant respiratory involvement and that medical need for 
that to happen can sometimes not be 100% understood. 
 Whilst all the clinician participants thought early palliative care 
involvement for people with MND was a good idea, a referral to palliative care 
did not always occur close to diagnosis (C8, C1, C2, C3, C13 and C19). The 
reasons for this non-referral, or non-inclusion within an MDT (where available) 
from diagnosis were unclear from the clinician responses, although a desire not 
to undermine any hope that the person with MND may have, and patient denial, 
were given (C4). The information gathered for this study indicates this may be 
due to financial constraints, organisational policies of the local palliative care 
service, or non-referral by neurologists and respiratory specialists. Respiratory 
clinicians reported that palliative care services were often stretched and 
understood that in their area of patient responsibility, it was not always possible 
to keep people for ongoing specialist palliative care for protracted periods 
(C11): 
C11 (respiratory specialist): Now, I also know that, you know, there are a 
variety of workforce issues that mean that palliative care teams struggle to 
continue to see patients that are “on their books” for a long period of time. 
 
In some areas resource constraints and funding rules require the 
limitation of access to palliative care services, for example, a pre-requisite of 
having a life expectancy of 3-6 months as an entry requirement:  
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C16 (MND nurse consultant): Because I’ve had a palliative care specialist 
from central **** ring me up, and he goes, “Well, you’ve made this referral to a 
patient.  Has he got less than three months to live?”   
As the course and timing of MND is so difficult to predict, life expectancy and, 
therefore, suitability for access to a palliative care specialist becomes virtually 
impossible to forecast (C9, C13, C16, and C8):  
 
C13 (social worker): Oh. Well, that’s a – well, you see the definition of 
“palliative” – here at **** it’s about six months of life left approximately, right. 
 
C16 (MND nurse consultant): But some pall. care teams are quite open to that 
[early intervention], but some pall. care teams have this weird definition period 
that they will not accept the patient until they have three months or less to live. 
Recommended referral times, both to palliative care and to respiratory 
specialists, is discussed more fully in Chapter 5. The use of specialist palliative 
care too early in the diagnosis was questioned by one respiratory specialist, 
who said that other organisations or the GP should be able to manage the 
person with MND at least until symptoms became more complex (C4): 
 
C4 (respiratory specialist): If they have good support otherwise from partner, 
general practitioner, allied health staff, myself, then there may not be – from my 
point of view and the neurology nurses, there may not be a great need for the 
specific palliative care services to be involved.   
 
The clinician (C4) suggested that when more complex end-of-life 
treatment was required would be the time to involve palliative care specialists 
and nurses. Several palliative care clinician participants, whilst acknowledging 
early referral to the palliative care team to be important, thought that specialist 
palliative care involvement could remain intermittent until the person with MND 
became more symptomatic (C3, C16, C19, C8). This represents a departure 
from the recommendation in the current guidelines. The few specific MND 
clinics involved in this study were able to involve palliative care from diagnosis, 
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and then have sporadic involvement until respiratory or swallowing became 
problematic. However, the point was made that this presented a difficulty in 
knowing exactly at what stage those symptoms were occurring, and whether at 
times they were being missed (C1): 
 
C1 (palliative care consultant): Now, that sounds very clear in some ways but 
how do we know those stages are happening? And that’s why I think probably 
we need to be in most – a lot of the time, so we [palliative care team] can 
actually pick up some of those changes. 
  
Of the seven participants interviewed within the category of the bereaved 
families and people with MND, three were offered palliative care referral late in 
the course of the disease (F1/2, F4, and P1). Two families (F3, F6) considered 
the timing of their referral to palliative care appropriate (although it did not occur 
at the time of diagnosis). When early palliative care was mentioned to family F5, 
the benefits of what the service could provide were not adequately 
communicated to the family to alleviate their fear of what palliative care meant: 
 
F5 (family): That word “palliative” over-shone whatever they were saying to us. 
 
 The concept of palliative care was confronting to people with MND in this 
research. From a symbolic interactionist perspective, the public understanding 
of palliative care is of death and dying and is perpetuated by clinicians who 
remain reluctant to discuss or refer to palliative care. Early palliative care 
involvement for some people with MND and their families was confusing, 
particularly if they were minimally symptomatic at the time of palliative care 
discussions. From the clinician perspective, the way in which language is used 
was pointed out by C19 as important: 
 
C19 (palliative care consultant): I’m particularly conscious about technical 
language, how difficult, intimidating and troubling technical language can be, 
and it just is not a good communication style. So, it’s really clarity of language. 
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The confusion within families about the role of palliative care was apparent in 
the data. For example, participants F5 and F3 said: 
 
F5 (family): She’s a specialist. And she said, “Now, I’ve got a letter here from 
your GP saying that you’re in denial about all this.” And we said, “We’re 
definitely not in denial about what’s happening to us. We’re just in denial that we 
need to see a palliative care team so early.”  
 
F3 (family): It was discussed, and because sort of our initial – you know, sort of 
we now know that palliative care is really the only thing that you can do with 
motor neurone disease. To us at that stage we were thinking “end of life” and 
we’re getting a bit paranoid. 
 
 The provision of a holistic approach incorporating palliative care for 
people with MND and their families is still dreaded by some patients and 
families and adopted reluctantly by clinicians involved with diagnosis and early 
involvement with MND (Oliver et al., 2016). MNDA recommendations are 
generally accepted as a good thing by clinicians, but they are not always 
reflected in practice (C8, C1, C2, C3, C16 and C19). Early palliative care or, as 
recommended, palliative care referral from the time of diagnosis, is discussed 
further in Chapter 5. 
 
 A point raised by C12 as a reason for early palliative care involvement 
and referral from respiratory clinicians to palliative care specialists was a 
practical one: the cost of prescription medications. An example given was the 
high cost of glycopyrrolate (a medication used to assist in alleviating excessive 
secretions) if prescribed by a respiratory doctor compared to prescription 
through palliative care. This same prescribing issue exists in New South Wales 
and Western Australia.  
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 In summary, there is broad agreement with the guidelines on early 
referral to palliative care, but this does not necessarily translate into practice. 
Barriers from the clinician’s perspective include the difficulty in estimating the 
unpredictable course of the disease, reluctance to take further hope away from 
the patient and family and the availability of the palliative care service to accept 
the patient. From the perspective of the person with MND and their family, this 
research identified a reluctance to be referred largely due to misunderstanding 
what palliative care could provide and the support that could be offered. 
 
 
4.9. Communication within a Multidisciplinary Team 
 The information already given to people with MND and their caregivers 
was not always known by a subsequent healthcare professional, causing 
confusion between healthcare providers from various organisations involved 
with the same patient. One community nurse (C8) mentioned that the 
organisation she worked for did not give out much information on symptom 
control for people with MND, leaving it up to other organisations to provide this. 
Below, C16 describes the frustration with working within the private healthcare 
system and trying to access information from the public allied health system: 
  
C16 (MND clinical nurse consultant): . . . look, I know it’s public and private, 
or whatever it is, but there has to be some way that if, you know – and I can get 
that it’s probably maybe because the community allied healthcare team is busy, 
or whatever it is. But even having – knowing who the person has been referred 
to from an OT [Occupational Therapist] point of view, so I don’t have to ring, you 
know, three aged care teams to work out where the OT is, or even just having 
assessors, if I ring My Aged Care to tell me, “Okay, well, this OT has seen your 
patient,” so then I can follow up with that OT, I think would make it a bit easier 
for me so I’m not constantly chasing my tail. 
 The neurological and palliative care nurses working and supporting 
people with MND and their families within the community were described by the 
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family participants as an informative and wonderfully knowledgeable resource. 
However, the nurse participants in this study reported that they often had to 
initiate communication and referrals relating to symptom control including 
breathlessness and the potential for NIV even though they didn’t necessarily 
perceive that to be part of their role or professional remit. These issues had 
apparently not been broached by doctors: 
  
C6 (neurological nurse): A recent example was a client who I could see was 
noticeably becoming breathless and hadn’t at that stage been followed up by 
anyone about it. So, I initiated the discussion about respiratory issues and got 
them information about NIV so that they could be prepared when they saw the 
respiratory physician for talks about NIV. 
 
 In order to ensure the person with MND and their family receive all 
aspects of necessary care from diagnosis to death, an MDT approach to care 
has been considered the most beneficial (Miller et al., 2009). A coordinated 
team of specialists assists with advice on symptom control and identifying the 
individual requirements of each person with MND and their caregivers. The 
communication includes discussion about the introduction of NIV and the 
potential for the withdrawal and consequences of withdrawal. However, this 
research found that communication between health professionals within an 
MDT was sometimes poor, particularly if the team was fragmented between 
organisations, or split between metropolitan and country: 
 
C1 (palliative care consultant): I think my other fear is you can get so many 
teams of people involved. You’ve got specialist palliative care, GP and primary 
care, respiratory care, gastroenterologist who’s been involved with the PEG, the 
rehabilitation team, a neurologist who’s saying – you know, and the possibilities 
of confusion and misinformation are enormous. And the inter-team – I was 
going to say warfare.  
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Within metropolitan areas the MND MDTs were generally coordinated teams 
attached to a single area of healthcare. However, this was certainly not always 
the case: 
 
C19 (palliative care consultant): Now, the interesting thing in the city is that 
not everywhere has a multi-disciplinary team. So, it’s a bit of a patchwork quilt, 
and indeed would be the whole of Australia a patchwork quilt. 
 This perspective was found within urban and rural areas. Where 
structured and coordinated MDTs did not exist this sometimes led to multiple 
appointments in different facilities, and confusion as to which professional was 
attending to what clinical problem. Certainly, there was comment from some of 
the family participants that there was a lack of coordinated care, confusion with 
who was who and who did what, and that they felt they were repeating 
symptoms and issues many times to many different people (F1, F2). There was 
also some confusion even between family members as to who was coordinating 
their family member’s care and when asked if there was a specific team 
involved, as the following exchange illustrates: 
 
F1 (family): No … odd … they were very odd. 
F2 (family): But “K” was coordinating everyone, wasn’t she? 
F1 (family): No, no, she was just helping me – she’s the motor neurone group 
lady. 
 
 F1 and F2 agreed that the amount of different appointments with different 
organisations caused their family member with MND and her husband much 
confusion, fatigue and wasted much precious time:  
 
F1 (family): We’d been to a few speechies [speech therapist] and dietitians, 
which Dad was getting confused about. So, I sort of explained to them that the 
dietitian was about the nutrients that she was getting; the speechy was about … 
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how to swallow, and the muscles in the neck. And Dad said, “We’re saying the 
same things to the same people.” 
 
P1 (person with MND): So, he [doctor] made some comment about, “If you 
haven’t heard in two- or three-weeks’ time, ring me and up and I’ll see what’s 
going on.” So, we didn’t hear anything from anybody else. So, for three weeks 
we were absolutely left in limbo, which was quite traumatic. 
 
 The speed of disease progression and the inability to find assistance with 
immediate requirements was a recurring theme, and concurred with the findings 
of McConigley, et al. (2014), who found that whilst clinicians should try to pre-
empt the requirements of people with MND as their disease could progress 
rapidly, this was not necessarily occurring. Families and people with MND felt, 
for instance, that equipment needs from NIV to prosthesis requirements were 
too slow to materialise once a need for the particular item had been identified by 
health professionals (P1, F1, and F2). F5 acknowledged that their family 
member was provided with all the technology they may require and seemingly 
prior to their actual needs, which were well anticipated by their hospital and 
MDT providers. This is in stark contrast to P1 who felt the provision of 
necessary equipment was far too slow due, it was suggested, to poor 
communication between healthcare professionals: 
  
P1 (person with MND): So by the time that we went - the private contractor had 
all the measurements done and the prosthesis was made - I’d gone too far to 
use them. So, I think that’s probably an area where, particularly with MND, we 
felt that things were happening and deteriorating faster than what … we could 
get assistance with.’ 
 
 The provision of technology, services, an MDT and specific MND 
information and care seems to depend on where a person with MND lives or 
who they are able to access. Communication about and monitoring of changes 
in a patient’s health status and needs did not always occur within an MDT, 
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leading to confusion and emergency hospital admissions. The one participant 
(P1) with MND interviewed recalled how, following an overnight sleep study to 
ascertain health difficulties affecting sleep such as respiratory insufficiency, 
nothing was heard for several weeks and during which time P1’s breathing 
became more difficult. The situation was only addressed when a friend calling at 
P1’s home, finding P1 in respiratory distress, made a call to the MND specialist 
and was advised to take P1 to hospital straight away. The specialist clinicians 
interviewed for this study admitted that emergency presentations to hospital 
with respiratory distress occurred in people with MND, and at worst this led to 
tracheostomy insertion (C19). It was unclear from the data whether this was 
because of MDT confusion but certainly mixed messages from members of the 
MDT led to people with MND becoming confused about their care options: 
 
C1 (palliative care consultant): There was one person who was told it [MND] 
would – he’d known patients where it had burnt out after a few years and not 
progressed. So those patients – you know, it can be difficult because they may 
get mixed messages – different messages when they see a neurologist in a 
clinic who says, “Oh, you shouldn’t be thinking about a gastrostomy” when 
we’re already starting to talk about gastrostomy.  
 
 Some of the specialist teams discussed and prepared their patients for 
emergency MND presentations to hospitals by giving cards or information with 
their palliative care specialist contact details. This enabled the emergency 
department doctors to contact them for guidance on a disease they may have 
had little experience with (C14, C19 and C7).  
  
 The clinician participants within this study recognised that for some 
people with MND, travelling between health professionals within an MDT whose 
members were not co-located caused practical problems, particularly as the 
disease became more advanced. The point was made that fragmentation of the 
MDT also caused difficulties communicating between team members with 
repercussions for continuity of appropriate care for the patient (C12). 
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C1 (palliative care consultant): I feel it might be better if there was more of us 
in the clinic together. And I know in many clinics you see the doctor, and then 
they see the nurse, and then they see the OT, and then they see the physio, 
and then they see the speech and language therapist, and then they see the 
psychologist, and then – you know. And I can see the positives of that, but I 
also feel it would be exhausting.  
    
 C11(respiratory specialist): That’s often in the practical world really quite 
difficult with people who are, you know, poorly mobile, whose prognosis is very 
limited, and who you just want to maximise, you know, the time that they have, 
and you don’t want to waste their time by getting them in for lots of 
appointments. 
 
 The communication between organisations, particularly if there was no 
structured MDT incorporating palliative care or palliative care nurses with an 
understanding of MND, caused issues around patient “ownership” and 
perceived interference (C11, C12, and C1):  
C4 (respiratory specialist): Look, I don’t think it’s [communication between 
healthcare professionals] particularly ideal at all. The communication we have is 
by letter, very occasionally a phone call. I don’t get a lot of – I mean, I write 
letters, and I think I’m communicating, but I don’t feel I get a lot of feedback, 
unless there’s a big problem.  
 
C16 (MND clinical nurse consultant): Even though I might have requested 
certain things on referral be done, the person who picks up that referral – 
without even knowing the patient, and completely sometimes disregarding my 
clinical judgment – might just say to a patient, “Well, this person just needs a 
physio review, or an OT review,” forgetting all the other allied healthcare that 
might be needed. 
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Lack of co-ordinated care and communication between organisations 
within the same city was a concern of several clinicians, and there appeared to 
be a varying level of regard for the quality and approach of some services (C11, 
C16, and C1, C19). This is exemplified by C16:  
  
C16 (MND clinical nurse consultant): It’s like a hotchpotch. Like with 
anything, you know some palliative care teams we work really closely with; 
some palliative care teams don’t want to know about it … Some pall. care 
teams have this weird definition period that they will not accept the patient until 
they have three months or less to live. 
  
 Further, there were times when test result reports between health 
professionals appeared to be lost within a system and not available at specialist 
consultations (P1, C16). Families expressed concern and frustration that 
diagnostic reports did not ever reach their GP or specialists involved locally 
(F6). Delay in hearing from specialists was an issue for both health providers 
and families. This was raised as a concern by a person with MND who felt the 
delay in receiving results from a sleep test meant delay in getting the correct 
symptom relief measures: 
  
P1 (person with MND): I didn’t get – this is one of the things that sort of upset 
us a little bit. We didn’t get any feedback, you know, from the overnight [sleep 
study] stay. And I felt afterwards that I could have been on the machine two or 
three months before, because of the deterioration.  
 Inappropriate direction to other services was another concern voiced by 
one of the bereaved caregivers (F4). The example they gave was of a health 
professional who had felt a mobility device could ease an issue that the person 
with MND and their caregiver were experiencing, but it wasn’t practical and 
caused more worry: 
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F4 (family):  Then he started relating to the fact that, “Oh, we got all sorts of 
devices. You know, we got these lifts and we got this, and we put them on 
there,”. But, you know, the nurses have to have two people to operate it, but, 
you know, you’re expected to operate it by yourself, you know?  
 
Other family members wondered whether it was wise of healthcare 
professionals to suggest additional aids or other services knowing delays to 
getting them were likely, as typified by F6’s comment below: 
 
F6 (family): Oh, yeah, she, you know, had all the speech, dietitian. But I think at 
times, to be honest, people – the professionals – I think professionals should 
feel it’s okay to – they need to – if you can’t do anything. Or that the client has 
chosen they don’t want any more help as well, because it’s another person that 
Dad’s dealing with making appointments, receiving phone calls. So it’s almost 
taking the time out of the precious bit of time you’ve got left.  
This research found that the clinician participants agreed that 
communication between clinicians involved with the care of a person with MND 
could be improved and was at times confusing. The family participants made 
the point that time became increasingly valuable as the person with MND 
became more unwell. Having to repeat issues or symptoms to many people 
involved with the care of the person with MND took away valued time. 
4.9.1. Advance care directives or care plan to be in place prior to 
NIV 
 Planning for the end of life and discussing and preparing an AHD is a 
recommendation of the current MND guidelines (Andersen et al., 2012; NICE, 
2016). The AHD should detail what is to happen in the event of a concurrent 
infection such as aspiration pneumonia, where the person may wish to die, 
whether or when NIV should be removed or nutrition via PEG ceased. Being 
able to communicate or be understood when the ability to talk has gone, was a 
point illustrated by C6: 
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C6 (neurological nurse): His wife wanted a definite sign of when she would 
stop the PEG feeds, if he was no longer able to communicate. I haven’t seen 
the advance health directive, but she did say there was a special sign that they 
would have. 
  
 This example illustrates a problem that may exist more widely; although 
there was understanding between the couple about the cessation of treatment, 
it was unclear if this was an arrangement that had been documented or was 
known by healthcare professionals. C1 illustrated the challenge of ascertaining 
exactly what a person with MND may want, by describing a situation where he 
discussed when NIV was to be withdrawn with a patient if he can’t 
communicate. However, the issue then becomes what exactly does 
“communicate” mean? Clarity in documenting exactly what type of 
communication is acceptable to all and understood by clinicians and the person 
with MND (being able to talk, blink or by some special sign) in relation to ending 
NIV or nutrition via a PEG is vital, particularly if a concise AHD has not been 
documented. Some clinicians stated that to have a precise document 
expressing a person’s end-of-life wishes took more experience and time than 
they could provide (C8, C10); this further reinforces time poverty as an issue. 
  
 The clinician participants were asked at what point of the disease they 
discussed AHDs with people with MND and whether their families were involved 
with the decisions made. Clinicians appear to make the decision on when to 
initiate discussions about end-of-life care and document outcomes of these 
discussions in an AHD on an ad hoc basis: 
  
C13 (social worker): We go pretty much according to what the patients can 
cope with and what they seek, and if we feel they can deal with the information 
then, yes, we – we can do it even from the first visit if it comes up. 
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C7 (neurological nurse): The wife was quite happy with those choices, but one 
of his daughters, who was a nurse, was not. So, there was a lot of conflict about 
this daughter not - you know, wanting all interventions: PEG feeds, etc. So, 
there was a lot of conflict making it distressful for the client and for the spouse. 
 
Many of the clinicians discussed the importance of developing a rapport 
with their patient before discussing AHDs (C13, C14, C19), but as some 
clinicians only saw their country patients for one or two visits, this was not 
always possible (C11, C12).  
 
The clinicians were asked whether the AHDs were reviewed when a 
person with MND had interventions such as a PEG or NIV. Whilst believing the 
AHD should probably be discussed further at such times, few actually   
incorporated any possible issues associated with symptom control measures 
into the document: 
  
C2 (palliative care specialist): Not routinely. They should be, but I don’t think 
they are in clinical practice. And I think although we would assume that all of 
these patients do [revisit their AHDs], I think it would be very interesting to know 
how many actually did, because I’m not at all convinced that they do. 
 
C18 (rehabilitation consultant): Look, we haven’t [reviewed AHDs] a lot. We 
should have. xx [the palliative care consultant] does them all when they are – 
when they do need to be done, but, no, I think that’s a hole in our service. 
 The clinicians were also all asked whether they found that the AHDs 
were sufficiently detailed in order to be useful when clarity regarding treatment 
was required: 
  
C2 (palliative care specialist): Lots of people’s AHDs are very vague. They 
give you a – I think they give you a general direction, though, as to whether 
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someone wants aggressive or limited treatment. But they’re often not much 
more help than that. 
  
 C3 agreed with C2’s comment about the vagueness of some AHDs and 
gave the example of a recent document they received which had read pain 
relief only, but on further discussion, the person concerned actually wanted 
comfort measures such as medications for nausea and respiratory secretions. 
Apparently, the person had not been offered guidance from any healthcare 
professional or legal representative, so completed the document to the best of 
their ability. This was then signed by the GP and dated the day before the 
person had signed and dated it, making the document completely invalid. C11 
suggested that perhaps structured AHDs were not the best option in clarifying 
end-of-life choices, and that to prepare a person or proxy decision-maker who 
had a good understanding of the likely decisions which may have to be made, 
may be more effective than writing down every eventuality, which may not be 
possible. C12 and C13 made the point that when AHDs are initially discussed, 
the person with MND and their family may request all treatment possible, but as 
time goes on, their approach to living longer may change. Conversely C16 
shared the experience of caring for people with MND who initially stated they 
did not want any interventions, but when faced with an inability to swallow or 
breathe, requested PEG and NIV. C19 cited aspiration pneumonia as a good 
example of potential lack of consistency between what is stated in an AHD and 
actual patient and clinician behaviour at the pertinent time. The example he 
gave is one in which a patient stated that no antibiotics were to be used, but 
then presented to casualty with aspiration pneumonia and was given antibiotics: 
  
C19 (palliative care consultant): It’s almost like pulling of the – like a scene 
out of a western. One person’s pulling out an advance care [directive], the other 
person’s giving the antibiotic [that has been declined in that advance care 
directive], and you’re thinking, “Okay, well, everybody’s not harmed. Okay, it’s 
happened. Okay, let’s now think about the future.”  
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 A few of the clinicians either stated that they lacked sufficient experience 
to advise and assist with AHDs (C8, C10) or referred their patients back to the 
GP (C4). Several of the clinicians, like C19 above, described that in their 
experience, most AHDs lacked sufficient clarity to be useful (C7, C11, C15, 
C16, C2), although all saw the value of having them. As participant C5 says:  
 
C5 (gastroenterologist): The guidance surrounding [the] terminal stage of care 
is poor and can lead to difficult decisions especially if AHD are not in place. 
 
 Despite understanding the importance of AHDs, family members F4 and 
F5 had not managed to encourage their family member with MND to document 
their end-of-life choices, and each expressed regret about this. On reflection 
participant F5 thought this was probably a form of denial within the family, 
although F4 stated it was because the person with MND simply did not want the 
conversation as she “did not want to die” (F4).  
  
 Three of the families interviewed (Table 4.3) did appear to either have 
had a formal AHD (F3) or have had an informal written agreement between the 
person with MND and the family members (F1 and F2) about end-of-life care. In 
all cases these family participants reinforced the clinicians’ perception of the 
AHD as usually fairly ambiguous and not always known to all relevant persons. 
F1, for example, stated that the person with MND had refused anything invasive 
and that the document was unsigned by them. This document had apparently 
not been shown to the doctors but was known to the community palliative care 
team. Despite a formal AHD, F3 did admit that the person with MND 
procrastinated in writing and signing the document as the person “did not want 
to think about it too much” (F3). F3 reported that the document contained the 
following:  
F3 (family): If a sort of condition developed that was incapable of being sort of 
effectively treated then he was palliative care only. 
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Ambiguity and lack of clearly written AHDs was found in this research, with 
much of a patient’s end-of-life wishes known to the families but not necessarily 
to the attending clinicians. At times, this resulted in treatment that was perhaps 
futile and not what the person with MND had wanted. 
4.9.2. Family issues and suggestions 
 The country and outer metro families interviewed mentioned the 
difficulties with travelling to appointments particularly as their family member’s 
health deteriorated and increased fatigue and moving becoming increasingly 
difficult (F1, F2, F6): 
 
F1(family): She was exhausted by the time she got there and she just – we 
couldn’t get from the car to the hospital to get a wheelchair to wheel her to the 
doctor’s surgery.  
 
 One family from a rural area thought that the gap between specialist 
appointments was too long. Initially at least, the appointments were every three 
months and it felt a very long time for the family who accepted that they did not 
necessarily hear and fully comprehend what the specialists had said to them 
(F5). F5 went on to suggest that a mentoring system would be useful so that 
information could be obtained from people with experience of MND, particularly 
other caregivers. F5 observed that she would have appreciated more 
involvement with people who had been through the MND experience: 
 
F5: Yeah. I find that really difficult living in the country, because I don’t feel that 
a lot of local nurses or medical people have had a lot to do with it. I know they 
have, because we’ve had some people in our area with motor neurone. But it’s 
talking to carers is the biggest communication need that I have really, because 
they have the on-the-ground tips to give you, you know. 
 
 Family member F3 suggested that genetic testing should become more 
available and included in MND communication. F3 related the experience of her 
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family member with MND knowing that MND can be inherited and worrying 
about their children and grandchildren. However, this comes with its own 
problems as clearly outlined by a very experienced palliative care specialist: 
 
C1 (palliative care consultant): The family can’t help because they’re just 
terrified, and I think that’s the – the other issue, I think, is going to get worse – I 
mean, we’ve had it with two families now with C9orf [genetic link]. One lady had 
four daughters. So, while they were sitting there watching her die, two of them, 
in theory, would be seeing how they would die. And so, you know, the impartial 
family isn’t any more, because they’re even more involved than the patient, and 
the patient, if they have some insight, is seeing, “I’m putting this on my children 
who might be facing this as well.” 
 
F6, who had much experience in negotiating the nuances of the health 
system and had acquired excellent health literacy, suggested: 
 
F6 (family): They’ve still got to be professionally responsible, but maybe they 
need to start out differently by asking the question, “Do you want to eat, or do 
you want to have this intervention?” And it’s okay for the person to say, “No,” 
and the health professional has to accept that, and I suppose document … Not 
that I’m thinking of, because maybe we as a family do ask the right questions, 
and that’s a real key, is the health literacy, isn’t it, that people haven’t got. 
F1 recommended greater GP awareness of MND particularly relating to 
referral to a neurologist if there is no explanation for breathlessness or loss of 
speech. F2 felt that the hard questions and hard decisions must be addressed 
and not pushed to one side, by either families or clinicians. F4 was still affected 
by how his family member with MND had suffered for so long, and despite not 
liking to admit it, thought it would have been better if his family member had 
been allowed to die: 
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F4 (family): Yeah, basically, yes, yes … nine months to a year before she did 
[died].  
 
4.10. Patient and Family Communication and Understanding 
 The clinical participants were asked if, in their experience, people with 
MND and their families were adequately aware of the prognosis and limitations 
of the disease prior to their involvement. Denial and lack of understanding by 
some people with MND and their families relating to how quickly the disease 
can progress, was expressed as a communication barrier by some of the 
clinician participants. However, it was apparent to clinician participants that 
some people with MND and their families had experienced limited explanation 
of the disease: 
 
C2 (palliative care consultant): Some of them have clearly been told but don’t 
necessarily want to hear, understand or acknowledge, and some clearly have 
very limited explanation. 
 
 C13 (social worker): I don’t think they’ve always understood how quickly 
things might be changing for them as an individual.  And I don’t think they’ve 
always fully understood the complications that can happen, you know, and the 
interventions that may or may not be possible. 
 
The majority (n=14) of the respiratory and palliative care specialists and 
nurses interviewed talked of trying to ascertain the depth of knowledge of the 
person with MND relating to their diagnosis and what they had previously 
understood from other health professionals, prior to their own involvement. This 
was attempted in several ways: repetitive discussions, asking for further 
clarification on fragments of information from the person with MND, reflective 
discussion and repetition of what the person with MND and their family had 
understood. One clinician stated that trying to disentangle where people were in 
their journey and in their understanding, would “contextualise” any advice that 
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was then given to them (C11). An example of trying to ascertain what had been 
understood about all that had been communicated to the person with MND and 
their family is given by C11:  
 
C11 (respiratory specialist): In a perfect world I use, you know, a lot of 
communication skills like check back and cross-check, and things like that, to 
see what they’ve understood. In the real world, I use some of that. 
 
However, understanding how much a person understood and what they had 
previously been told was frequently found to be difficult, both to assess and to 
discuss, as C6 and C2 described: 
 
C6 (neurological nurse): Sometimes you can see that they’re not processing 
information. You can just see that look of confusion or terror, or blankness on 
their face. Others, you think that they’ve understood and then you find out later 
that they haven’t actually understood. They might be repetitive in a question or 
just say something that makes you realise they haven’t understood’  
 
C2 (palliative care specialist): We’re palliative care doctors. We like to think 
that we’re good at communicating, but I think, I acknowledge, that often families 
need to hear things multiple times. 
 
The NICE Assessment and Management Guidelines recommend that clinicians 
ask people with MND how much information they wish to receive and how much 
they would like to have shared with their families (NICE, 2016). One of the 
clinical nurse participants described how clinician communication can adversely 
affect people with MND: 
 
C16 (MND clinical nurse consultant): They’re kind of more psychologically 
scarred about how diagnosis was given to them, and then how they’ve been 
sent home to put their stuff in order, and, you know, wait for death to come. 
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 None of the six people with MND whose families were interviewed had 
chosen withdrawal of NIV as a method of ending their life. The family member 
of F3 with MND, a night time user of NIV only, chose instead to refuse food and 
water to end his life. However, a discussion had taken place with the family, 
although not documented within his AHD, that NIV could be withdrawn but it 
would be when the person with MND was ready. However, F3 did state that 
initially NIV had only been mentioned in passing as a treatment option for later 
and that the detail of NIV had been communicated by two neurological nurses, 
not specialists. F4 supposed that NIV may have been mentioned to his family 
member, but neither the person with MND nor F4 pushed for more information 
as F4 felt prolonging the illness or suffering was not their preferred option. F5 
stated that the NIV was given to them with little alternative, whilst P1 had no 
real idea or explanation of the implications of NIV: 
  
F5 (family): It was definitely, “This is what you need because your lungs aren’t 
working properly.” 
 
P1 (person with MND): I think probably I wasn’t aware of the importance with 
the breathing and I don’t think that that was probably adequately explained. 
Now, they were saying, “Well, you go and have a sleepover; we’ll test to see 
what – you know, how you’re sleeping, how you’re breathing,” all those sorts of 
things. But there wasn’t any sort of gutsy type of verbiage about why … the 
implications of it. 
 
 F1 and F2 said liquid morphine was suggested to assist their family 
member to breath but nothing else was suggested until their family member was 
entering the terminal stage at which point a syringe driver was offered. There 
was confusion between the siblings in their understanding regarding a syringe 
driver, as one had understood it to be intravenous delivery of medication (F2) 
whilst the other had understood subcutaneous infusion (F1); both had attended 
the same conversation with clinicians:  
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F2 (family): I think the reason Mum didn’t want … the IV was because she just 
didn’t want to accept that she was going to go, and that looked like another step 
towards the end of life.  And having someone in every day. 
 
 The candidate asked if the family member with MND was offered a 
subcutaneous cannula just under the skin, which is the more normal option with 
a syringe driver, rather than intravenous. The second family participant (F1) 
responded that she understood that it was the subcutaneous option offered not 
intravenous. Both F1 and F2 agreed that the partner of their family member with 
MND was very hesitant about allowing liquid morphine to be used as he felt his 
partner could become addicted to the morphine. This perhaps indicates a lack 
of either communication reassuring the family, or a lack of understanding and 
health literacy by the partner of the person with MND. Neither F1 nor F2 had 
any recollection of the burdens of NIV being discussed until such a time when 
their family member started to get pressure sores on her nose and mouth from 
the NIV mask. At this point they were informed: “Oh, yes, that happens – that 
has, you know, been known to happen before” (F1). Apparently, there had not 
been any communication with F1 and F2 about the potential of withdrawal of 
NIV when it was no longer effective or the person with MND had decided they 
had suffered enough. F2 stated that the lack of ability of the person with MND to 
communicate as the disease progressed was not discussed and that this led to 
him feeling his family member may have made some ill-defined choices, 
potentially resulting in increased suffering. F1 described a lack of recognition or 
at least indication to the family by the clinicians, that the person with MND had 
reached the terminal stage: 
 
F1 (family): But still they didn’t think she was at end-of-life stage, but I think she 
was at end-of-life stage at that stage, and we could have helped.  
 
 F4 was very determined to keep his family member with MND at home 
and wondered if this may have been why end-of-life choices were not discussed 
with him. F5 described that the communication surrounding NIV was well 
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covered particularly by the respiratory technician; however, this was not the 
case with communication relating to the PEG insertion, which was information 
F5 found out via the Internet. F3 had no recollection of end-of-life 
communication in the context of NIV and definitely none from the respiratory 
clinician. F3 candidly acknowledged that the family had the “intellectual and 
financial resources” to be able to look after their family member with MND at 
home: 
 
F3 (family): As I say, we were very lucky in the sense that we had the financial, 
intellectual and emotional resources to be able to manage the situation with 
assistance at home for most of the time. 
 
 As discussed earlier in this chapter, the clinicians interviewed for the 
study described several reasons for not broaching the difficult conversations 
surrounding NIV withdrawal and end-of-life choices. These reasons and the 
barriers for end-of-life communication and the benefits and burdens of symptom 
control measures offered, are discussed further in Section 4.11 of this chapter. 
4.10.1. Differentiating between hydration and nutrition 
 One of the questions asked of the clinician and family participants related 
to the hydration of the person with MND in the last few days of life, particularly if 
they were refusing food and water and especially if they had a PEG inserted. 
The clinicians were asked if, when detailing the consequences of stopping 
nutrition as a means of ending life, they had described nutrition and hydration 
separately. The clinicians were also asked if they had experience of people with 
MND indicating that they were dehydrated or that there was a possibility that 
they could be suffering as a consequence of dehydration if their fluid intake had 
been ceased when nutrition was ceased: 
C15 (gastroenterologist): Potentially, yes. 
C19 (palliative care consultant): That’s a really good question, isn’t it, 
hydration – differentiate hydration and nutrition. 
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Some clinicians stated that they had experience with people with MND 
apparently indicating symptoms of thirst or dehydration towards the end of life 
after stopping fluids and nutrition (C7, C8). C11 was unsure if hydration was 
related to the secretions (excessive or tenacious), and C18 felt nutrition was the 
most important aspect to discuss and did not really distinguish between nutrition 
and hydration. C14 stated that generally when the person with MND decided 
that nutrition should stop, water was continued to prevent dehydration although 
stopped if clinically indicated. C19 considered the symptoms of hunger and 
thirst stating that:  
 
C19 (palliative care consultant): They may well feel thirsty, and that needs to 
be attended to, because that’s a terrible symptom if you’re to sit – if you’re lying 
there and you can barely communicate. So, we need to – I agree, I agree. This 
[small amount of water via a PEG] is not going to cause any harm to the patient, 
and it’s not going to elongate life. 
 
C15 said that on consideration of the point that whilst the person with MND may 
want to stop nutrition, hydration may prevent the feelings of thirst. This was also 
asked in the context of the AHD and whether the AHD was changed in 
accordance with the patient’s wishes. The clinician participants were asked 
whether the differentiation between hydration and nutrition was ever offered, 
suggested or documented within an AHD: 
 
C15 (gastroenterologist): I have to say I haven’t really pushed that 
differentiation on advance care directives. But I think it is important, and 
perhaps in future I will.  
 C1 and C3 stated they would continue with hydration and did differentiate 
between nutrition and hydration for people with MND and their families. C4 and 
C2 did not particularly differentiate between food and fluids when discussing 
PEGs to people with MND but C4 acknowledged that for people using a mask 
for NIV, thirst and a dry mouth were a potential problem anyway. 
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 The families of people with MND were asked whether those who chose 
to refuse fluids as well as nutrition were comfortable or whether thirst and 
dryness may have caused adverse symptoms. F3 was asked whether the oral 
preparations they used were adequate to alleviate the feeling of dryness in the 
person with MND following a decision to stop food and water via the PEG/RIG 
by her family member with MND. F3 stated: “possibly not, you know”. Despite a 
recommendation of hydration and using various oral rehydration products for 
the symptoms of dryness for the person with MND, the family member F6 was 
sure suffering occurred as a consequence: 
 
F6: She was constantly, constantly, constantly trying to – yeah, absolutely she 
did [feel thirsty]. You know, with – it was an overwhelming feeling.  
F6 continued to explain how her family member had tenacious secretions and 
was being inadequately suctioned by nurses in the hospital. F6 suggested that 
suctioning is “not recommended by MNDA” and the health professionals were 
reluctant to assist. Apparently, and after much negotiating with the hospital, the 
partner of the person with MND was allowed to suction their family member. F6 
readily admitted that the entire process of suctioning her family member was 
distressing but did appear to improve her symptoms.  
 
F2: So, you know, Mum and Dad got to the point where they were so exhausted 
they couldn’t make decisions. 
 
 To summarise, this research has found that clinicians may not 
differentiate between nutrition and hydration when communicating end-of-life 
symptom control to people with MND and their families. Acknowledging that not 
all people with MND have PEG tubes at the end of their lives, this research has 
found that some people with MND were described by their families as appearing 
to suffer from thirst in the terminal stage of their disease. 
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4.11. Communication Barriers from Clinician and Family Perspective 
 Both clinician and family participants agreed there were barriers to 
communicating end-of-life choices, documenting patient wishes (AHDs or clear 
care plans/goals of care) and the implications of the withdrawal of NIV.  
 
C11 (respiratory specialist): For some other people, you know, an extra 
minute of life is unbelievably precious regardless of their state of health and 
ability to interact. I think that that means we need to re-imagine the workforce 
issues rather than we need to throw our hands in the air and say it can’t be 
done. 
 
One of the most noted barriers clinician participants was patient denial. When 
asked how the clinicians dealt with denial: 
 
C4 (respiratory specialist): “Oh, I just don’t want to think about it.  I don’t want 
to know.”  So that can be a bit of a challenge that their defence mechanism, 
their way of coping is one of, “That’s later on,” denial.   
 
C16 (family): I let them be in denial. 
Another barrier to communicating NIV withdrawal prior to 
commencement mentioned by one of the more experienced clinicians (C19 and 
reiterated by C18, C13, and C4) was the concern that having sensitive end-of-
life discussions would upset the patient or the family:  
C19 (palliative care consultant): I think one of the barriers is sensitivity or 
worrying that that’s – even having that conversation is going to upset the patient 
or the family. 
 
C4 (respiratory specialist): I’ve got one particular lady now that those issues 
are just too hard for her to discuss.  And there’s a lot – even I feel 
uncomfortable – I feel comfortable about discussing them.  
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A further barrier to effective communication suggested by a neurological nurse, 
was if the person with MND perceived themselves as a burden to their family. 
This was communicated by C7: 
C7 (neurological nurse): So mostly the reasons have been they don’t want 
their life prolonged, because that’s how they see it maybe. They don’t want the 
invasiveness. They don’t want even further carer burden. That seems to be 
another big thing, the carer burden: “I don’t want to do that to my spouse.”  
 
The information a person with MND and their family may have obtained 
from the Internet may also pose a barrier to effective communication if not 
adequately discussed:  
 
C16 (respiratory nurse consultant): In many ways we find when patients first 
come that’s a huge burden that they all have, because they’ve gone on the 
Internet, they’ve read a lot of stuff about dying and how horrible it is, and, you 
know – and most patients don’t want to die from that sense – you know, they’ll 
have that fear of dying from suffocation and pain. And, I guess, you know, 
having those early interventions – early conversations alleviate that sense. 
The following summary (Table 4.5) shows some of the issues which may 
present as a barrier to clear communication between clinician and people with 
MND and their families identified by the participants in this study.  
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Table 4. 5. Communication Barriers 
 
 Many of the clinicians were reluctant to discuss the poor prognosis of 
the person with MND too early but admitted that leaving those 
conversations too late was not a good option for the person with MND 
either (C6, C4).  
 Worrying that even the conversation will upset the family and person 
with MND (C19, C6, C7, C14). 
 Sufficient time for detailed communication was a factor mentioned by 
both clinicians (C2, C3, C4, C11, C12, C19, and C8) and the 
bereaved family participants (F1, F2).  
 Languages other than English were potential problems with 
communication, barriers to being able to communicate adequately 
and misunderstanding, despite the use of interpreters (C12). 
 Communication with a family member because the person with MND 
does not want to know (C7, C4). 
 Repetition of the end-of-life communication and readiness of the 
person to want to hear; a person may be told the same thing several 
times but must be ‘ready to hear it’ (C8, C9). 
 The stigma of MND as becoming a vegetative state or how alive they 
are until the end (C14). 
 Clinician admitting that a barrier was the uncertainty of the disease 
and admitting that clinicians did not want to face such uncertainty 
(C11). Being able to say that not knowing how, when or what will 
exactly happen and being honest from the beginning (C11) was a 
barrier. 
 Patients ‘shutting down’ and not wanting to hear or stating they have 
been told the same thing already (C12). 
 Denial or patient and family reluctance to engage in communicating 
with their specialists was highlighted by several clinicians (C1, C4, 
C12 and C16).  
 People with MND need to be ready to listen and hear end-of-life 
options (C8). 
 Uncertainty to the ethical situation and the law can be a barrier for 
clinicians to discuss withdrawal of NIV (C5). 
 Time (life) left as a barrier; communication should happen early 
particularly as families are from all over the world, conflict may be 
involved and planning for the whole family important (C3, C2). 
 People with MND delaying engaging in end-of-life symptom control 
choices as they wish to try alternative medicinal cures (C18).  
 People with MND and their families who lack assertiveness and 
confidence to ask questions (F5,F6, C3). 
 Clinicians just have a snapshot view of the disease and do not look at 
a trend (F3). 
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4.12. Chapter Summary 
 To answer the research questions, the candidate commenced by 
undertaking an extensive literature review to ascertain what was already known 
about the communication surrounding initiation and withdrawal of NIV (Chapter 
2). The depth and extent of relevant knowledge determined the independent 
variables and formulated the questions asked of the participants. The semi-
structured interviews with all participants were at least an hour in length and 
comprehensively covered communication and topics relevant to NIV, MND and 
the end of life.  
  
Whilst the discussion (Chapter 5) that follows explores in greater depth 
the areas of interest that have emerged from analysis of the data, a description 
of the analysis has been provided within this chapter. The research questions 
explored within this study include how clinicians explained the benefits and 
burdens of NIV, the continuation of disease progression, referral to palliative 
care and end-of-life care and choices including NIV withdrawal. The comments 
and views of the family participants have been included and woven throughout 
the chapter to add context and perspective to the clinicians’ descriptive 
narrative. The presented data have been compared against the most recently 
published recommendations for assessment and care of a person with MND, 
the use of and potential withdrawal of NIV and, in addition, the understanding 
and use of PEG tubes in MND. Some of the findings which relate to 
recommendations from both the family and clinician participants, are included in 
the recommendations and conclusion chapter, answering the last of the 
research questions. 
 
This research found that some of the difficult communication such as NIV 
withdrawal and choices of end-of-life care were either assumed to have 
occurred with other clinicians, were too difficult for a clinician to fully explain in 
the time available or left too late for sufficient patient benefit and family 
understanding. The time and repetition required for ongoing and lengthy 
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communication relating to end-of-life choices and the removal of NIV was an 
issue voiced by all the palliative care and respiratory specialists and some of 
the nurses. Aspects of the most recent recommendations and assessment 
guidelines (NICE, 2016) which have been referred to throughout this research, 
have been questioned by both clinicians and family participants. The concept of 
the need to preserve hope in relation to the difficult discussions and honest 
communication about end-of-life choices and the potential of NIV withdrawal is 
considered in the following discussion chapter. A comparison of the findings of 
this study against recommendations in guidelines is also presented in Chapter 
5.  
 
  It is hoped that by understanding both the participant clinician comments 
and the actuality of the bereaved families, particularly the one person with MND 
who so desired to have his opinions heard, that a greater understanding of 
MND/NIV/PEG and end-of-life communication has been achieved. The potential 
for the generation of practice knowledge is more fully discussed in Chapters 5 
and 6. 
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A qualitative study into the communication surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in people with motor neurone disease 
Chapter 5: 
Discussion 
5.1. Chapter Overview  
 This chapter integrates all that has been studied within this thesis, from 
the introduction of the subject, the gap identified from the literature and the 
findings of the participant interviews.  
 
To undertake a detailed discussion of the findings of this research it is 
important to highlight what is understood to be best practice and patient-centred 
care in relation to the area under enquiry.  The most recent MND 
recommendations and guidelines have informed the participant questions. 
Attention to the theoretical perspective, SI, which draws on the shared 
experiences of the participants, is woven throughout the discussion to make 
meaning of the findings. Using ID as the methodology to contextualise the 
findings of this research, the knowledge gained is argued to be relevant and 
applicable to clinical practice (Thorne, Reimer Kirkham, et al., 2004). 
 
The contribution this research has made to the existing knowledge 
concerning the communication and symptom control measures for people with 
MND is explained. Understanding the communication difficulties encountered by 
people with MND, their families and clinicians alike, formed the principal 
component of this study. The Dreyfus Model of Skill Acquisition (Dreyfus & 
Dreyfus, 1986) is used as a concept to understand clinician participant 
communication in relation to experience.  
 
 Identifying where issues arose has provided the opportunity to propose 
possible solutions and offer some suggestions for further research areas 
(detailed in Chapter 6). 
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The final five research questions (the first research question was answered by 
the literature review) are considered in turn: 
1) What is the evidence that the best practice communication content 
(benefits and burdens of NIV, continued disease progression, 
explanation and offer of a PEG, end-of-life discussions and 
understanding potential NIV withdrawal prior to commencement of NIV) 
is incorporated into the reported communication by clinicians to people 
with MND and their families at the time of offering NIV? 
2) What do MND families/significant others recall about the communication 
(benefits and burdens, continued disease progression, PEG insertion, 
potential NIV withdrawal and end-of-life discussions) provided by 
clinicians at the time of respiratory failure and the offer of NIV? 
3) To what degree do MND families/significant others feel that the NIV 
communication provided by the clinicians at the time of the offer of NIV 
prepared them for and helped them to understand the implications of 
potential NIV withdrawal resulting in the death of their family member? 
4) What, if any, unmet needs for information, support, palliative care, or 
other services do the clinicians and the families/significant others (or 
patients themselves) with experience of MND identify? 
5) Following the literature review and clinician and family/significant other 
interviews regarding NIV communication, what recommendations can be 
identified that would improve end-of-life communication and process for 
the patients, families and clinicians involved with the end-of-life care for 
people with MND? 
This chapter commences with a summary of the findings from this 
research to provide context for the discussion that follows. The chapter is then 
sub-divided under identified communication issues and discussed within the 
framework of the research questions which are outlined above.  
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5.2. Summary of the Key Findings from the Research  
The following is a summary of the key findings from this research which will 
be expanded upon in this chapter: 
1) Some of the clinicians are unaware of the specifics of the 
recommendations contained in the NICE MND Assessment and 
Management Guidelines (2016). 
2) These recommendations are open to clinician interpretation as far as 
what, when, how and if to communicate end-of-life care options.  
3) There is uncertainty around whether the clinicians with experience have 
the capacity to communicate more clearly with people with MND 
regarding symptom control and end-of-life choices, but they are known 
not to follow guideline recommendations about the timing of 
communication.  
4) Communicating end-of-life options and the potential withdrawal of NIV 
prior to the commencement of NIV is difficult for all involved regardless of 
a clinician’s years of experience.  
5) Clinicians experience limitations on the time available to talk to patients, 
and so prioritise explaining the technicalities, maintenance and 
mechanics of NIV to people with NIV and their families. Some of the 
respiratory clinicians reported that they often feel it is not appropriate to 
introduce NIV and its benefits and state its burdens and the potential of 
withdrawal as an end-of-life choice when NIV is no longer of any benefit, 
at the same time. 
6) Many clinicians are reluctant to make an early referral for people with 
MND to palliative care despite acknowledging this to be best practice.  
7) Some palliative care clinicians feel that on referral, people with MND are 
under-informed about the disease process, prognosis and symptom 
control options.  
8) Families are confused by the need for early involvement of palliative 
care. 
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9)  Structured MND MDTs were rarely available particularly outside the 
cities and often within cities. The benefits of an inclusive MND MDT for 
people with MND are unavailable in many areas (Rooney et al., 2015). 
10) NIV and PEGs are often encouraged by clinicians. Respiratory clinicians 
see NIV as improving the quality of life, perhaps equating quality of life 
with quantity, which may not be the priority of the people with MND and 
their caregivers.  
11) PEGs are commonly offered to people with MND to prevent or reduce 
the incidence of aspiration. 
12) Communication is often open to misinterpretation such as the word 
“prognosis” and what the speciality of palliative care can do.  
13) Families are confused about the roles and number of health 
professionals involved with their family member with MND’s care; having 
to repeat the same information is frustrating and exhausting for them. 
14)  There is confusion regarding who is involved with the patient’s ongoing 
care decisions, among both clinicians and family and caregivers. 
Between clinicians there appears to be confusion regarding which 
clinician has overall responsibility for care and for communicating and 
explaining the benefits and burdens of symptom control and end-of-life 
options. If information relating to symptom control and end-of-life choices 
is not clearly provided, the person with MND and their family have gaps 
in their understanding and interpretation of the situation. The family may 
be confused as to who they ask for clarity.  
 
5.3. Research Question 2:   
What is the evidence that the best practice communication content 
(benefits and burdens of NIV, continued disease progression, explanation 
and offer of a PEG, end-of-life discussions and understanding potential 
NIV withdrawal prior to commencement of NIV) is incorporated into the 
reported communication by clinicians to people with MND and their 
families at the time of offering NIV? 
 208 
 
This research question, concerning clinicians’ communication practice, 
was answered by asking clinicians rather than through an objective assessment 
of what clinicians did. This sets the context and limitations of interpretation. 
Clinicians were asked whether they were aware of aspects of the NICE MND 
guidelines and if there were specific trigger points they used as an opening for 
honest discussions including assessing how the person with MND and their 
family had understood such communication. The clinicians were also asked 
whether they discussed end-of-life options as recommended by the most recent 
guidelines, or if they communicated the benefits, burdens and potential 
withdrawal of NIV when initiating NIV. Their answers reflect their insights into 
where they do not comply with current best practice as defined in the 
guidelines, and the barriers they experience in implementing the communication 
recommendations.   
 
The NICE MND Assessment and Management Guidelines (2016) is an 
extensive, detailed document easily obtainable online and available to 
download. However, the lengthy document covers an enormous amount of 
detail and time would be required to fully appreciate its recommendations. 
Whilst many of the clinicians were aware of the most recent NICE MND 
Assessment and Management Guidelines (2016) not all were aware of the 
recommendations on timing and content of NIV related end-of-life 
communication.  Detailed end-of-life communication was assessed to be 
necessary by the clinicians involved later in the disease, indicating that earlier 
discussions delivering the diagnosis and general prognosis may not have 
contained such communication. This research sought evidence for the 
occurrence of best practice communication relating to the benefits and burdens 
of NIV, end-of-life choices and potential of NIV withdrawal.  This research has 
found that communication recommended to occur soon after diagnosis and at 
certain trigger points in the disease process, particularly at the commencement 
of NIV, frequently does not happen.  
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Understanding the communication experiences family participants have 
with clinicians is an important aspect of answering this research question. The 
family perspective is addressed within this question but covered more 
comprehensively under the third research question (Section 5.5). This research 
could not correlate the family participants’ experiences of communication with 
those of the clinician participants. 
 
 The ability to initiate end-of-life communication on patient deterioration 
and increased reliance on caregivers is extremely difficult for all concerned 
(Aoun et al., 2012). This difficult judgement of timing appears to be complicated 
by the clinician perspective of maintaining hope for the person with MND and 
their family members. Preserving the feeling of hope by clinicians and, 
therefore, not initiating these discussions was found to be a barrier and a strong 
theme throughout this research. This finding is mirrored by the results of a study 
which surveyed neurologists involved with the delivery of an MND diagnosis 
and found the communication caused much stress for the clinicians for the 
same reason (Aoun et al., 2016).  Maintaining hope, however, may be 
detrimental to the patient and family if referral to palliative care specialists is 
delayed until well into the deteriorating phase of the disease. Despite many of 
the clinicians identifying the barriers, having the confidence to know that the 
communication is appropriate and the timing correct for the recipient is a 
challenge. The respiratory clinicians in this research indicated that their priority 
when initiating NIV was of a more practical nature: explaining the machine and 
familiarising the family with its use. The respiratory clinicians acknowledged the 
difficulty they had with introducing end-of-life discussions at the stage of 
commencing NIV, although they understood it should happen.  
 
When communicating the benefits and burdens of NIV and initiating 
referral to palliative care, several of the clinicians stated they were reserved in 
their communication. The time required at appointments to introduce and 
reiterate the end-of-life options and potential withdrawal of NIV to ensure the 
person with MND understood, was described as a significant barrier. Both 
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communication and system barriers were identified in this research.  These and 
other barriers to the incorporation of best practice communication in the 
management of MND are detailed further below. A table of communication 
barriers identified by the clinician and family participants in this research is 
included in Chapter 4 (Table 4.5). The issues found to have most influence on 
clinicians’ communication with people and families coping with MND were the 
availability of time and the wish to preserve hope.  
5.3.1. System barrier: time allocated for significant communication 
 The MND Assessment and Management Guideline recommendations 
(NICE, 2016) emphasise the importance of psychological and caregiver support 
from the time of diagnosis. Proposed within the European Clinical MND 
guidelines are two long appointments with a neurologist in order that the 
diagnosis can be delivered in a sensitive, comprehensible and gentle manner 
(Andersen et al., 2012). As the delivery of a diagnosis of MND is recognised as 
requiring lengthy appointment times with the neurologist, so perhaps should the 
appointment time for communication which incorporates end-of-life choices. 
Many of the clinician participants within this study reported having insufficient 
time for these discussions (C2, C3, C4, C8, C10, C11, C12 and C19). A 
recently published journal article which addressed ethical considerations and 
palliative care in people with MND, notes the variation in how people process 
bad news (Danel-Brunaud et al., 2017). Danel-Brunaud et al. (2017, p. 301) 
reaffirm the need for time to explain and discuss issues with people with MND 
and their caregivers, suggesting several long interviews to make sure the 
communication has been understood. A study into the importance of 
compassion among health professionals from a cancer patient’s perspective 
found that patients wish to be treated like a person, not the illness they have 
(Sinclair et al., 2016). Family participants within the study recommended that 
health professionals understand their patients more holistically. Again, this 
ability to understand individual patients, their life, and their preferences of care 
requires time. Building a relationship between patient and clinician by involving 
palliative care services soon after diagnosis or by having a nurse case 
 211 
 
coordinator (neurological or palliative care) to build a trusting relationship may 
enhance end-of-life communication.  
 
 This research has extended existing knowledge on whether the most 
recent MND Assessment and Management (NICE, 2016) recommendations are 
being followed and, if not, why not. The candid statements from the clinicians 
explain the difficulty many find in judging the right time to introduce end-of-life 
communication without causing the person with MND and their family excessive 
distress.  They also shed light on the time constraints within the medical system 
which act as barriers to long and repetitive communication. In the Clinical 
Practice Guidelines for communicating end-of-life issues with adults in the 
advanced stages of a life limiting illness (Clayton, Tattersall, Currow, & 
Hancock, 2007), uninterrupted time for such communication is considered 
essential. Finding the right time and finding sufficient time are often inextricably 
linked. The lack of time required for such involved, emotional and often 
repetitive communication with people with MND was a concern voiced by many 
of the clinician participants (C2, C11 and C12), and reiterated by the families 
(F5, F6). The clinicians stated that they simply did not have time for the required 
conversations which included choices of symptom relief end-of-life care and 
hoped, and in many cases assumed, other health professionals did. As 
admitted by many of the clinician participants, adequate time to have sensitive 
discussions relating to the burdens of NIV and end-of-life choices became 
secondary to addressing the technical aspects of care (C2, C11, C12). Several 
of the respiratory clinicians explained that they only saw country people with 
MND when they became symptomatic and required NIV and so explaining the 
technicalities of the NIV machine took precedence and required explicit training 
prior to a patients’ return to the country. Adequate time to have the more 
sensitive communication was simply not factored into the appointments. This 
research did not delve into the reasons why time could not be allocated for 
longer specialist appointments to incorporate all aspects of communication 
surrounding the benefits and burdens of NIV and end-of-life choices, and this 
may be an area requiring further (political/financial) investigation.   
 212 
 
5.3.2. System barrier: delays and poor communication within the 
health system  
The timing of referral to a specialist (neurologist or respiratory specialist 
particularly) of symptomatic but not necessarily diagnosed people with MND 
was found to be slow. Families mentioned a delay or hesitancy in being referred 
on to a specialist for symptoms that had been investigated but not easily 
explained such as respiratory difficulties (F1, F6 and P1). Comments from some 
of the bereaved family participants suggested that MND was not often 
contemplated as a diagnosis by the more generalist doctors (F1, F6, and P1). 
This may not have been because the diagnosis of MND was not contemplated 
by clinicians but because they wanted to be sure of a diagnosis given the 
gravity of the disease. However, the family participants had not understood the 
delay in reacting to non-specific symptoms. Many and varied exploratory tests 
proved negative for any specific disease but difficulty breathing continued 
unexplained (F1, F2). All the family participants understood that there is not a 
specific diagnostic test for MND and that diagnosis is more a process of 
eliminating other diseases. However, even once the MND diagnosis had been 
made one participant family described how their family member was subjected 
to further uncomfortable and seemingly unnecessary tests to reconfirm the 
diagnosis (F6). This again reflects the need for improved communication 
between clinicians and people with MND, particularly relating to potential 
respiratory issues. 
 
Family participants volunteered information about how the diagnosis of 
MND was given to their family member. Although this question was not 
specifically asked, their comments exposed further communication issues. The 
timing and delivery of the MND diagnosis in each of the participant families and 
the one person with MND interviewed was poorly conveyed by the specialists. 
This finding aligns with that of a recent national survey of neurologists 
undertaken to establish how MND diagnoses are given (Aoun et al., 2016), 
which found that once diagnosed there was frequently a delay in the results of 
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tests reaching the person with MND and at times, also in reaching the clinician 
most closely involved with the patient. By the time the results were made known 
to the person with MND, an increase in severity of the symptoms had frequently 
occurred. This finding was consistent with research conducted by McConigley 
et al. (2014). Their research found that symptom relieving needs had often 
changed by the time a person with MND had been assessed and subsequently 
provided with devices to relieve their symptoms (McConigley et al., 2014). 
Understandably, the difficulty was due to the progressive and often 
unpredictable course of the disease which can differ according to the variants of 
MND. The challenge for the clinician was to predict the course of the disease 
and act on the symptoms without delay. The family participants in this research 
acknowledged the work and advice given by MNDAust with the supply of 
equipment, information and support for people with MND and their families. A 
suggestion from one of the family participants (F5) living in a rural area was the 
implementation of an online support and discussion forum for people who were 
also traversing the MND journey so that others could benefit from shared 
experiences. One family (F6) learnt much of their MND knowledge and gained 
support from an online social site in the United States, having been unable to 
find such a resource in Australia.  
  
Practice that aligns with guidelines and recommendations may remain an 
aspiration: indeed, good intentions to implement these have been demonstrated 
by the sincere comments from clinician participants within this research (C1-
C19). The possibility of clinicians being guided by means other than formal 
recommendations and MND guidelines was considered a possibility. For 
example, early palliative care referral for people with MND is a guideline 
recommendation acknowledged by many of the clinician participants to be 
important but not necessarily reflected in practice. The clinicians involved prior 
to palliative care found early communication relating to referral to palliative care 
and end-of-life choices when these clinicians were offering symptom control 
measures such as NIV and PEGS could take away hope. This corresponds with 
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an article by O’Connor (2012) which highlights palliative care intervention 
occurring too late to be effective. O’Connor suggested that in many instances 
palliative care recommendations developed by experts were often regarded as 
optional by clinicians (O'Connor, 2012). The palliative care clinicians 
interviewed for this study said they were often involved late in the course of the 
disease and at times stated an earlier referral would have been more beneficial 
to the person with MND (C1, C2, C3 and C19). This was reiterated by some of 
the respiratory specialists (C11, C12, and C16) who also felt their input at an 
earlier stage of MND may improve adverse symptoms. This study found, as 
other research studies have before, that referral to palliative care in MND often 
occurs later than that recommended by the most recent guidelines (Bede et al., 
2011; Connolly et al., 2015). Referral to a palliative care service is discussed 
further in Section 5.6.3. When asked how they communicated (i.e., verbal, 
written document) end-of-life options, including the potential of NIV withdrawal, 
the specialists involved suggested to patients that they look at the MNDA 
website. Only in some cases had printed material from MNDA been prepared to 
give to the people with MND. One family participant stated that following 
diagnosis she was told not to contact MNDA, as they were described by the 
clinician as being too negative (F3). 
 
It was evident from the results of this research that when a structured 
MDT existed, relevant information was provided to the patient when it was 
considered appropriate after diagnosis, leading to clarity and choice in end-of-
life care. A structured MDT also incorporated a palliative care specialist at an 
earlier stage of the disease, which may have improved patient acceptability of 
incorporating palliative care earlier into their care. 
5.3.3. Communication barriers: clinician knowledge and experience  
Within this research the European (Andersen et al., 2012) and U.K. 
(NICE, 2016) guidelines in particular have been extensively quoted and referred 
to as the most recently published recommendations for MND. This research into 
communication surrounding NIV in MND and end-of-life choices sought expert 
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and experienced clinicians for their views. In order to clarify what may be 
understood to be an “expert” this research includes a reference to the Dreyfus 
Model of Skill Acquisition (Dreyfus & Dreyfus, 1986) which has been widely 
used in research on acquiring skills including the ability to communicate clearly. 
The Dreyfus model researched how people attained skills and was based on 
the study of chess players and members of the military, and subsequently used 
as a model in nursing research (Benner, 1984). The model is based on five 
levels of skill attainment from novice to expert, with experience and time as the 
factors for acquiring skills. The skill components include perspective, ability to 
make decisions and ability to decide relevance of a situation. The expert level 
suggests a minimal reliance on rules and guidelines as the expert intuitively 
knows what can be achieved (Dreyfus & Dreyfus, 1986). If the Dreyfus Model of 
Skill Acquisition is considered in the context of this research then the expert is 
the clinician (respiratory or palliative care) with experience of communicating 
with people with MND and who is able to achieve excellence without much 
difficulty (Benner, 1984). This excellence includes the ability to communicate 
the difficult end-of-life choices people with MND and their families must make. 
The findings in this research did not suggest that clinician experience in MND 
increased the likelihood of following guideline recommended communication, 
including end-of-life choices and NIV withdrawal, prior to the commencement of 
NIV.  
   
This research has identified that whilst the guidelines are generally 
recognised by the clinicians, aspects of their content are not widely followed. 
The length of time a clinician had been practising in their specialty did not 
necessarily make the sensitive communication surrounding the end of life and 
the potential of NIV withdrawal any easier and in some cases did not occur. The 
idea of acquiring clinical and communication knowledge without necessarily 
referring to guidelines was explored further in this research.  
 
A study by Gabbay and May (2004) suggested that expertise in clinical 
decision-making and care was achieved by unconscious assimilation of 
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knowledge. This knowledge was communally strengthened by collegial 
discussion and thought sharing (SI) rather than exploring specific clinical 
guidelines. This concept, known as mindlines (Gabbay & May, 2004), revealed 
that health professionals infrequently acquired guidance through clinical 
guidelines and research articles; more often they gained their knowledge 
through discussion with their peers and occasional readings. As identified in 
Chapter 2, the recommendations in the current MND guidelines are largely 
based on published studies and expert clinical opinion (Andersen et al., 2012; 
NICE, 2016). The clinician participants in this research appeared to be basing 
their communication decisions more on their own personal characteristics, 
those of the patient and their family, their ability to interact and level of skill in 
communication rather than reading and following the guideline 
recommendations. The possibility exists that the further away the clinicians are 
from their formal education and the more experienced they become, the less 
likely they are to adhere to guideline recommendations. The personal clinical 
experiences the participants had with NIV withdrawal in MND were found to 
have some influence on their communication. The reasons and barriers behind 
the clinician communication decisions are discussed in this chapter and the 
implications of their decisions for the families are explored. 
5.3.4. Communication barrier: preservation of hope  
The most recent MND guidelines recommend sensitive communication 
occurs when the person is ready to receive it and relies on an emotional 
judgment and assessment of readiness of the patient and family by the clinician 
(Andersen et al., 2012; NICE, 2016). However, if end-of-life choices have not 
previously been discussed or understood this communication should occur 
when the respiratory system fails and NIV/PEGs are offered (Andersen et al., 
2012; MNDA, 2014; NICE, 2016). Whilst the guideline recommendations 
advocate a specific trigger or time for such communication, this research found 
that sensitive end-of-life communication does not always occur when 
recommended. The timing of end-of-life communication identified within this 
research appears to be largely dependent on when a clinician is ready or feels 
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the person with MND is ready to receive it, concurring with previously published 
literature (Connolly et al., 2015; Smith, Disler, Jenkins, Ingham, & Davidson, 
2017). 
 
Clinicians assess patient and family readiness for end-of-life discussions 
and respond to patient and family triggering behaviour or emotional indications 
of wanting to have such communication (Clayton, Hancock, Butow, Tattersall, & 
Currow, 2007). Clinician knowledge of the guidelines and other literature 
relating to NIV was found to be variable and, understandably, appears to 
depend on their clinical specialty and involvement with MND. Any previous 
experience of NIV withdrawal in MND on the part of the clinician appeared to 
have little effect in easing difficult early end-of-life communication, particularly in 
relation to NIV withdrawal.  
 
Coming to terms with the diagnosis and its implications is extremely 
confronting and may be cloaked with the hope that “they got it wrong”. As this 
study has found, Blackhall (2012) has suggested that clinicians with little 
experience of people with MND wait for the patient or family to initiate the 
discussions relating to the end of life to lessen the sense of hopelessness.  
 
The preservation of hope and the concern that the conversation might 
upset the family was a barrier for many clinicians to pursuing end-of-life 
communication (C6, C7, C14 and C19).  Clinicians also stated that in their 
experience many people with MND and/or their families expressed the need to 
live in the present as the future looked so bleak. However, if the clinicians wait 
for the person with MND to initiate or ask relevant questions they may be 
assuming that the person with MND has sufficient health literacy or 
understanding to approach such difficult discussions. Studies that suggest 
people with MND would like the clinicians to initiate sensitive communication 
exist (Anderson et al., 2007; Blackhall, 2012). Commencing end-of-life 
communication without waiting for the patient to instigate the discussions may 
help to eliminate the possible difficulties encountered by those less able to ask 
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pertinent questions. As some of the bereaved family participants acknowledged, 
traversing the medical system and having the confidence and knowledge to ask 
the relevant questions required a high level of health literacy (F3, F6). All the 
bereaved family participants and the person with MND interviewed stated they 
searched the Internet for information, particularly if they had not understood fully 
what had been said by the health professionals. Potentially, the assumption that 
people with MND will turn to the Internet to address their questions and fears 
may lessen the urgency clinicians feel to initiate such sensitive communication.  
  
 If clinicians acknowledge that end-of-life discussions should happen 
early, but also feel that it takes away hope, when should these discussions 
occur? A recent German article (Löbbe, 2016) suggests that there are too many 
guidelines in existence and that they do not always prove useful in complex 
clinical situations. The article makes the point that evidence-based medicine 
strives to provide the most advantageous care to patients, but that there are 
other aspects of a clinician’s expertise which may equally provide the best care. 
Löbbe (2016. p. 275) suggests that good communication technique, experience 
and “willingness of the physician to make a decision contrary to the evidence-
based guidelines” are important factors in best practice. Importantly, this 
viewpoint may mean confusion regarding who should undertake the difficult 
end-of-life discussions relating to NIV and its withdrawal, and when they should 
or could occur. For the study reported in this research, 19 clinicians (eight of 
whom were nurses) were interviewed, and the majority (seven out of eight) 
nurse participants accepted the need to have these discussions and were 
willing and felt able to do so despite sometimes being “hated” (C8) by the 
patient for doing so. The nurses felt the person with MND and their family were 
entitled to be able to plan in the full understanding of their disease potential. 
This concurs with the findings of the study by Connolly, Galvin and Hardiman 
(2015) which concluded that families were better able to make plans and 
symptom-relieving treatment decisions early if given the options for care. The 
feeling amongst the clinicians in this research who felt able to undertake these 
discussions early in the diagnosis (C1, C16, C17) was that it alleviated the 
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worry associated with the unknown course of the disease, particularly the issue 
of choking to death which may concern them throughout the illness if not 
tackled early (Borasio, Shaw, et al., 2001).  
5.3.5. Communication barrier: frontotemporal dementia 
 Identifying FTD was difficult for health professionals particularly if they 
only met the patient once or twice, which was often the case, particularly 
between country patients and respiratory specialists (C1, C15, C19). The point 
was made, however, that a person with MND with changes related to FTD may 
not have a deep enough understanding of their health situation to make 
decisions, which would affect their caregivers (C13). The family participants in 
this research were largely unaware of FTD in MND as the condition had not 
been discussed by their clinicians, although two families had found information 
on the Internet (F3, F6). 
 
A palliative care specialist (C1) stated concerns that FTD in MND was an 
area requiring more research and understanding and often a condition going 
unrecognised by clinicians and families. One of the specialist clinicians had 
experience with people holding very strong beliefs against nutrition through the 
insertion of PEGs (C15). Whilst this was certainly presented as a barrier for 
PEG insertion in some people, the clinician wondered whether perhaps this 
indicated involvement of FTD affecting decision making. One of the family 
participants described a situation where their family member with MND was 
taken shopping and despite not being able to swallow solid food herself, kept 
collecting chocolate bars into the shopping basket (F1, F2). The family initially 
thought this was “naughty” behaviour but described how the person with MND 
was also insistent that her husband’s birthday was imminent and wanted to 
send a card when the birthday had been some months prior. Despite the family 
explaining correct dates, their family member with MND persisted. The family 
concerned were vaguely aware of dementia being associated with MND but had 
not associated this behaviour with FTD and had, therefore, not discussed it with 
their palliative care specialists.  
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The research question addressed in this section asked for evidence that 
best practice communication is incorporated into communication for people with 
MND at the time of offering NIV, as reported by clinicians. The clinician 
participants involved at the stage of required symptom control intervention (NIV 
and PEG) appeared not to follow the recommended best practice 
communication and stated their barriers and reasons. In this research, time to 
discuss and repeat sensitive end-of-life communication was found to be a major 
barrier to commencing such communication in many instances. This research 
found that communication is only as useful as the content is unambiguous, the 
clarity with which it is delivered (in this research communicated by the 
clinicians), and the willingness and ability to understand and remember by the 
one who receives the communication. This is particularly relevant when 
considering the often-subtle changes associated with FTD. The clinician 
participants in this research admitted that recognising FTD in MND was difficult 
especially if the family had not communicated personality changes in their 
family member to the clinician. The often-subtle changes that may indicate FTD 
could be an aspect of early support and coordination of care involving a case 
manager soon after diagnosis. The suggestions to improve communication 
difficulties made by participants in conjunction with the candidates own 
suggestions are encompassed in Chapter 6. 
 
 
5.4. Research Question 3:  
What do MND families/significant others recall about the communication 
(benefits and burdens, continued disease progression, PEG insertion, 
potential NIV withdrawal and end-of-life discussions) provided by 
clinicians at the time of respiratory failure and the offer of NIV? 
 
This question was answered by the bereaved families of people with 
MND through their recollections about the communication they had with 
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clinicians relating to when NIV was discussed, the content of the discussions 
and what they had understood about end-of-life care options. Their answers 
show what they understood of their choices and what, in retrospect, they realise 
they had not fully understood.  
 
The guidelines advise that the benefits and burdens of NIV and PEGs, 
and the option that NIV can be stopped at any time, should be communicated 
prior to the commencement of NIV (NICE, 2016. The families were asked about 
any alternatives to NIV and PEGs offered as symptom control methods. The 
point of this line of questioning was to ascertain whether the benefits and 
burdens of NIV and PEGs had been fully described, and then whether 
pharmaceutical options which may mean a shorter life, were communicated to 
the person with MND and their families. Of concern was that PEG insertion was 
described to families as a way to minimise or prevent aspiration pneumonia, for 
which the research literature shows there is no benefit (F1, F2, F6) (Potack & 
Chokhavatia, 2008). The families confirmed that much of what they understood 
about MND, NIV and PEGs was either found or clarified via the Internet. 
Families also stated that being asked to think about the research questions had 
made them realise the implications of aspects of NIV and end-of-life 
communication they had not fully understood at the time; for example, the 
withdrawal of NIV when a person with MND no longer benefited from it and the 
option of pharmaceutical alternatives. The content of communication given to 
the family and person with MND regarding treatment options was found to 
greatly influence the decisions surrounding symptom intervention and care 
choices. 
 
It became evident that the family participants were presented with 
overwhelming and confusing information particularly relating to NIV. This 
research did not ask about family health literacy, however, many of the 
participants (family and clinician) spoke about the need for a good 
understanding of the health system and health literacy. Family participant 
understanding for the potential of withdrawing NIV when it was no longer 
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providing symptom relief or at the person’s request, was not clearly understood 
by the families. Communicating the need to insert a PEG (if the person with 
MND wants one) prior to any swallowing difficulty, has caused some confusion 
for people with MND. Understanding that MND causes respiratory weakness 
which in turn increases a person’s anaesthetic risk for inserting a PEG requires 
a fair level of health literacy. Clinicians recommending inserting a PEG when 
the person’s swallowing remains unaffected, the benefits and burdens of such a 
measure, requires good communication skills and confidence, and patients and 
families need the knowledge necessary to ask relevant questions. Many of the 
family participants within this study were confused by the timing of PEG 
insertion and were unaware of any risks of aspiration pneumonia (F1, F2, F3 
and F6) (Potack & Chokhavatia, 2008). Despite guidelines recommending 
communication of the benefits and burdens of NIV and PEG tubes prior to or, at 
the latest, at the development of respiratory weakness, clinicians and families in 
this research state that this did not necessarily occur (NICE, 2016).   
 
 Generally, the family participants and the one person interviewed with 
MND agreed that they understood the workings of the NIV machine as 
explained by the respiratory clinician. This corresponds with the respiratory 
clinicians in this research stating that they focus on the workings and benefits of 
NIV. The families also understood that the NIV did not provide any cessation of 
the disease process and that they would become more dependent on NIV as 
the disease progressed. However, the families did not fully appreciate the 
difficulties they may then encounter such as any influence FTD may have on 
their family member (not discussed with any of the family participants) and the 
increase in caregiver involvement to ensure the NIV continued to work (F1, F2, 
F3). The burdens of wearing and adjusting an NIV mask cannot be fully 
understood until trialled, and the understanding that whilst the person with MND 
may be able to initially adjust their own mask, as muscle weakness becomes 
more pronounced their caregivers will by default become more involved. 
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The family participants were asked if they were aware of the inevitable 
disease progression despite NIV and PEG insertion and if this had been 
communicated to them. The families all understood the severity of the diagnosis 
but not the speed at which the disease could progress nor the limitations of the 
interventions available. None of the bereaved families had anticipated how their 
family member with MND would die even though they all understood respiratory 
failure to be the main cause of death in MND. In this study one person with 
MND starved himself to death (F3); another kept trying to pull off her NIV mask 
for unknown reasons, possibly indicating “enough” (F1, F2); another pulled out 
her PEG refusing further intervention (F4); and another died of respiratory 
complications (F6). Of the six family participants interviewed, all but one had a 
negative experience of the terminal stage of their family members’ life. 
 
  Within the sociological framework of SI, the way the family participants 
interpreted the communication during the social interaction with their clinicians 
affected the meaning they took from those interactions. The participants 
identified barriers including being overwhelmed by the concept of an early 
referral to palliative care. Family participant understanding of the burdens of NIV 
and benefits of PEGs was unclear from the communication they had with 
clinicians and was supplemented by their Internet sourced knowledge. 
Suggestions to improve communication incorporating end-of-life issues and the 
benefits and burdens of NIV/PEGS by the family participants are considered in 
Chapter 6, when the final research question is answered. 
 
 
5.5. Research Question 4:  
To what degree do MND families/significant others feel that the NIV 
communication provided by the clinicians at the time of the offer of NIV 
prepared them for and helped them to understand the implications of 
potential NIV withdrawal resulting in the death of their family member? 
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 The family participants in this research were questioned on many 
aspects of their communication with clinicians and how their resultant 
knowledge enabled them to adequately make choices. The ability to adequately 
understand how to navigate an increasingly multifaceted health system requires 
considerable health literacy. The lack of communication about how the health 
systems worked and could be accessed, was voiced by the families who were 
at times overwhelmed. As they endeavoured to navigate the care and services 
required, the family participants described the difficulties they experienced in 
understanding why they had to attend different appointments with different 
clinicians in different locations. In an editorial by O’Connor (2012), discussing 
palliative care recommendations in Europe, the point is made that some skill or 
health literacy is required to traverse health systems.  
 
 The variability and accessibility of palliative care services for people with 
MND is apparent within this research. The gap between rural and metropolitan 
palliative care services and even within the same city appears to be mirrored in 
some other countries (O'Connor, 2012). This variability makes provision for a 
specific plan of care for people with MND, which incorporates an MDT difficult to 
design. There is a need for a more patient-focused plan with emphasis on early 
recognition of symptoms and information on who to contact locally. Such a plan 
requires further development and research, but from discussion with 
participants within this study, this was considered a useful ideal.  
 
Apparent within this study were the emotional consequences for all 
concerned, particularly the grieving families, when the end-of-life care options 
had been misunderstood (F1, F2). Whether the option of NIV withdrawal was 
inadequately communicated, undocumented or not communicated at all to 
families by the time the person with MND had lost the ability to communicate 
remains unclear from this relatively small participant group. Generally, the 
clinicians could see some benefit of early communication about NIV withdrawal, 
particularly in terms of ensuring transparency of information. However, the 
majority felt the information was excessively confronting for the person with 
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MND at the time of offering NIV. If end-of-life choices have not previously been 
discussed or understood this communication should occur when the respiratory 
system fails and NIV/PEGs are offered (Andersen et al., 2012; MNDAust, 2014; 
NICE, 2016).  
 
Previous studies have found that many people with MND and their 
families would like clinicians to commence end-of-life communication early in 
the diagnosis in order to organise their lives and make health care choices 
(Anderson et al., 2007; Blackhall, 2012). Crisis decisions and presentations to 
hospitals can occur if documented care plans relating to NIV in MND are not in 
place and understood by families (Connolly et al., 2015). The family participants 
(F3, F5) within this research, whilst acknowledging a degree of their own denial 
in some instances, did suggest that in hindsight some of the decisions made 
would have been different if they had fully understood the choices of symptom 
control and end-of-life care.  
 
The influences on communication and understanding have been 
illustrated throughout this research and has demonstrated how denial and 
health literacy have affected how the family participants communicated with the 
clinicians (F3, F5, and F6). The perception among some of the clinicians that 
the preservation of hope outweighs the requirement to fully communicate the 
end-of-life choices suggests the clinician has assumed the dominant role within 
the patient/health professional relationship.  
 
From an SI perspective, the role of the clinician and the families and how 
they interact and communicate can potentially be affected by stress and attitude 
within the process of role interaction (Hochschild & Machung, 1989).  The SI 
focus on process and the influence of interacting personalities was proposed by 
Burgess (1931) in relationship to family personalities and roles. Applying the 
concept introduced by Burgess and identifying family in a broader sense to 
include the clinicians, person with MND and the family, roles are developed and 
defined by the interacting personalities (Burgess, 1931). This process may be 
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fluid, however, values and attitudes are transmitted between all concerned in 
communicating the prospects of MND, which may ultimately affect the way the 
patient interprets their options for care.  
 
 Research into the dying process in MND in Australia and the United 
Kingdom, found negative caregiver experiences were mainly due to the 
unexpected death of their family member from co-morbidities, not respiratory 
failure as originally anticipated (Ray et al., 2014). The study by Ray, French and 
Street (2014) indicated that if families and people with MND were fully informed, 
including about the progressive nature of the disease and how death may 
eventuate, the family members were found to have had a more positive 
experience of their family member’s end of life. This finding by Ray et al. 
correlates with the results of this research where those experiencing ongoing 
grieving and regrets in the way their family member died, or their symptom 
control prior to death, were those who felt they either did not have or did not 
understand the potential complexities of end-of-life choices (F1, F2 and F6). A 
limitation to answering the fourth research question may be that those families 
wishing to participate in this study are those who may have ongoing grieving 
issues related to the way their family member had died.  
  
The difficulties in communicating and encouraging planning in a disease 
which offers no hope of a cure and only offers symptom control measures is an 
area that requires further understanding. As some variants of MND may have a 
life span of 10 years, the concept and treatment of the disease as chronic rather 
than terminal may be more appropriate in some cases, particularly concerning 
end-of-life communication (Lerum et al., 2016). None of the participant families 
within this research experienced the variant of MND which can last for many 
years. However, despite the length of their family member’s life from diagnosis 
to death being less than three years, all felt palliative care involvement and end-
of-life communication at or soon after diagnosis was too premature. This 
research found that the family participants had an image of palliative care as 
terminal care and death-related. This concept may be perpetuated when 
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clinicians want to preserve hope in people with MND and, therefore, avoid 
referring to palliative care at a time they consider too early in the disease. 
Perhaps if the person with MND and their families better understood the 
significance of any symptoms they were experiencing they may feel more 
inclined to seek specialist advice. From the time of diagnosis then, the 
emphasis could be on explaining symptoms and who to contact in the event of 
such symptoms occurring, instead of focussing on the end of the disease. The 
timing of end-of-life communication and the involvement of a palliative care 
service requires further exploration to alleviate the anguish of families planning 
for their family member’s terminal stage.  
 
The ethical and legal aspects of NIV withdrawal was raised as an issue 
which could be confusing for families and health professionals alike. When 
discussing the withdrawal of NIV, clinicians must be able to reassure families 
that the withdrawal is not euthanasia nor an illegal or immoral act. This 
communication should acknowledge the grief and sadness the family may 
experience, but also reiterate that the disease itself will bring the person with 
MND to their death. The importance of having conversations which include 
disease progression despite any clinical intervention prior to the 
commencement of NIV and that NIV withdrawal is a possibility at any time the 
person with MND wishes is paramount to clear communication. Communication 
ambiguity was illustrated by a family participant (F1) whose family member was 
using NIV in her terminal stage and kept pulling the mask off. The family did not 
know that their family member could have chosen much earlier on, or at that 
stage, to cease using NIV and have pharmacological assistance for her 
distressing symptoms (F1, F2). The bereaved participants involved stated that 
in hindsight, the clinicians may have alluded to such a course of action, but the 
family had not understood the communication or the implications. The clinicians 
generally tried to assess how much the person with MND and their family had 
understood of the communication incorporating end-of-life care by asking what 
they already knew and repeating the information where necessary. However, 
 228 
 
this was often hampered by the level of health literacy of the person with MND 
and family and where the person was in their disease trajectory.  
  
The family participant component of this study was small, yet the results 
did concur with the study by Anderson et al. (2007) which found clear 
communication relating to end-of-life options was welcomed by most people 
with MND and their families. Previously published literature found that most 
people with MND and their families would like clinicians to initiate end-of-life 
communication soon after diagnosis and to further discuss this as deterioration 
of the disease occurs (Anderson et al., 2007; Astrow et al., 2008).  
 
The “in hindsight” comments of some of the family participants within this 
research described how, had they understood the course of MND more 
completely, particularly the symptoms and speed of deterioration of the disease, 
their end-of-life decisions on behalf of their family member (at the stage when 
the person with MND was too ill to clearly communicate their wishes) may have 
been different (F1, F2, P1). Potential withdrawal of NIV prior to the 
commencement of the symptom relieving device was not clearly communicated 
to any of the family participants within this study, although two families had 
discovered this was a possibility from the Internet (F3 and F6). The 
communication and emotional difficulties surrounding NIV withdrawal faced by 
clinicians and families are encapsulated within studies (Faull & Oliver, 2016; 
Faull, Phelps, Regen, Oliver, et al., 2014) and these difficulties were restated by 
clinician participants within this study (C1, C4, C8, C10, C11 and C19). Some of 
the complications expressed by the clinicians entailed ensuring the medications 
were adequate to guarantee comfort on withdrawal of the NIV and coping with 
the emotions of family members present. This was particularly evident if the 
family of the person with MND had not fully understood or were not in 
agreement with the wishes of their family member with MND. 
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5.6. Research Question 5:  
What, if any, unmet needs for information, support, palliative care, or 
other services do the clinicians and the families/significant others (or 
patients themselves) with experience of MND identify? 
The family participants were asked how satisfied they were with the end-
of-life communication delivered by the clinicians, and how this communication 
enabled them to make their care choices (Appendix E). The family participants 
were also asked whether there were discussions which they would have liked to 
occur, but which did not. The following sections are intended to highlight areas 
as described by the families, which this research has identified as being 
problematic for them. The communication and logistic issues are presented in 
the context of areas recommended within the most recent MND Assessment 
and Management Guidelines (2016) and other substantiating literature. 
 
Faull, Rowe-Haynes et al. (2014) highlighted a need to support all 
involved with NIV withdrawal in MND and for detailed communication between 
all parties regarding symptom management and NIV withdrawal. Increased 
palliative care nurse involvement from diagnosis, perhaps taking the role of a 
case manager coordinating with an MDT where available, is a recommendation 
of this study and further examined in Chapter 6. Specific published research 
into a nurse as an MND coordinator of care could not be found, although this 
research found two situations in New South Wales where the clinician 
participants stated this was occurring very efficiently (C14, C16). 
5.6.1. Communication identifying differences in the concept of 
suffering 
 This research found, as Lemoignan and Ells (2010) have, that quality of 
life and the concept of suffering (which may equate to living longer with 
symptom control devices) was poorly understood by those with MND and the 
families involved with their care. Several of the families (and confirmed by some 
of the respiratory specialists interviewed) stated that the technical component of 
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NIV information was prioritised by the clinicians over the understanding of 
respiratory failure and quality of life. In this research it was queried whether the 
often-stated clinician view that the suffering of a person with MND would be 
improved by alleviating respiratory distress with NIV, potentially extending a 
person’s life (by a few months), was actually increasing their suffering. 
However, when family participants considered length of survival as a priority 
over distressing symptoms such as agitation, mask discomfort, frustration and 
increased caregiver burden it was apparent that an increase in longevity was 
not a priority, particularly as the disease progressed.  
 
 The issues surrounding caregiver burden in MND were not specifically 
explored within this research as previously noted and has been well researched 
by others (Aoun et al., 2013). However, it was highlighted as a problem by 
some families (F1, F4, and F6) and nurses. The interviews from this study 
revealed that caregiver burden was exacerbated by prolonging their family 
member’s life when all options for the end of life and symptom control had not 
been clearly explained. The fatigue, confusion and desperation experienced by 
the family members F1 and F2 in not understanding that their family member 
with MND could have had the NIV withdrawn, was profound.  
5.6.2. Where a person with MND lives influences communication 
and care 
 This research interviewed clinicians from different areas of Australia and 
found that even within cities it depended on whether a person with MND fell into 
a certain catchment area as to whether they could access a specialised MND 
MDT, particularly one incorporating specialist palliative care. People with MND 
who fell under the umbrella of a city service with a specific MND team, living 
close enough so that either they could access a comprehensive clinic, or the 
palliative care specialist/nurse could easily visit appear to be at a huge 
advantage. The comprehensive clinics are able to assist people with MND and 
their families to understand their equipment (and back up provision), the 
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services on offer (including support groups), and to navigate all aspects of allied 
health (Rooney et al., 2015). Delays in people with MND accessing a specialist 
MDT (incorporating palliative care), were partly due to the time diagnosis may 
have taken (during which time the person could have become more 
symptomatic), and partly due to patient and system barriers. This research 
concurs with a retrospective study which followed patients from early 
identification of MND symptoms to the time they were referred to an MDT 
incorporating palliative care (Galvin et al., 2015). Galvin et al. (2015) found a 
failure by some clinicians to refer patients to an MDT caused delay in patients 
having the assistance they may have required.  
 
 At the commencement of this study, consideration was given to possible 
differences in availability of palliative care services and specialists generally 
between metropolitan and rural areas. A systematic review by Kirby et al., 
(2016) identified that diagnosis and treatment of people with a terminal illness 
was less well managed in rural situations when compared to metropolitan 
areas. The review focused on the caregiver needs of urban and rural patients 
with a terminal illness and led the authors to suggest further research was 
needed into how a lack of rural accessibility to palliative care shapes the needs 
of the person with a terminal illness (Kirby et al., 2016). The difference in 
availability of specialist palliative care services between rural and metropolitan 
areas may have played a part in referral time for palliative care, however, this 
research has also identified the variation of access to palliative care services 
available within the same city.  
5.6.3. Early incorporation of palliative care  
 Nearly 10 years ago the suggestion was made that in order to refer a 
patient beneficially and appropriately to a palliative care service the referring 
clinician could ask themselves a simple question: “Would I be surprised if the 
patient died within the next twelve months?”, thereby ensuring the referring 
clinician thought of probable rather than possible death (Moss et al., 2008).  In a 
more recent systematic review, the “surprise question” was found to be an 
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inadequate prognostic tool particularly with non-cancer conditions (Downar, 
Goldman, Pinto, Englesakis, & Adhikari, 2017). This has relevance to this 
research and certainly to further research, as it is unknown how many clinicians 
may have asked themselves this question and, therefore, not referred people 
with MND to a palliative care service. This would likely apply more to respiratory 
specialists than GPs (who may only encounter a few cases of MND in their 
career) because respiratory clinicians see people with MND as the respiratory 
muscles are adversely affected. Within the guidelines early referral to palliative 
care, soon after diagnosis, is recommended for people with MND (Connolly et 
al., 2015; MNDAust, 2014; NICE, 2016). The bereaved family participants, 
person with MND and the clinicians all acknowledged that referral to specialists 
for symptom control measures often happen too late during the disease to be 
helpful. However, early referral to palliative care was viewed by the families and 
person with MND and some clinicians (C1, C2, C3) rather differently.  
 
The Australian Institute of Health and Welfare (2014) suggests that 
specialist palliative care, end-of-life care and palliative care are all terms used 
interchangeably. The institute suggests that end-of-life care is commonly 
understood to mean caring for a person with the diagnosis of a life-limiting 
illness, whilst palliative care is considered to be the approach to terminal care. 
One of the key areas identified was the need for clarity in understanding 
terminology among patients, their families and healthcare workers to avoid 
miscommunication, particularly with terms such as palliative care and advance 
care planning (Australian Institute of Health and Welfare, 2012). Given the 
common misunderstanding of the term palliative care - found also within this 
research (F5, F3) - to mean no hope and death rather than symptom control 
and support, early referral to the specialist service can be confronting for 
patients (Galvin et al., 2015). A European study focused on the early referral of 
people with lung cancer to a palliative care service found that patients do not 
like being referred to specialist palliative care services (despite available 
specialist palliative care services) and were, therefore, frequently referred late in 
the disease process (Charalambous, Pallis, Hasan, & O’Brien, 2014). Despite 
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an early referral to specialist palliative care being a current recommendation for 
people with lung cancer (Smith et al., 2012), the study by Charalambous, Pallis, 
Hasan and O”Brien (2014) found this was not being translated into clinical 
practice. In a study by Oliver et al. (2011) palliative care specialists have found 
that people with MND are often referred late in the disease process. Several 
studies have found clinicians like to preserve hope by not initiating early 
communication surrounding the end of life (Aoun et al., 2016; Faull, Rowe-
Haynes, et al., 2014) and this finding is confirmed and discussed 
comprehensively within this chapter.   
 
  Whilst most of the palliative care clinicians felt they were generally 
involved later in the course of MND than they would have liked, there was some 
thought that contrary to the recommended guidelines, referral at diagnosis may 
be too soon (C1, C2, C3). As MND could in some instances be considered a 
life-limiting chronic disease, early palliative care may not always be appropriate. 
This study concurred with the suggestion in an editorial by Burgess, Braunack 
Mayer, Crawford and Beilby (2013) that people with a life-limiting chronic 
disease, which may describe some variants of MND, be initiated on patient 
symptoms and not solely on diagnosis. Most of the palliative care and 
respiratory clinicians stated that referral at diagnosis of MND was 
recommended but went on to qualify this by stating it did not often occur as it 
was too confronting for the person with MND and their families in some 
instances.  
 
As none of the families with MND were referred to palliative care at 
diagnosis, the acceptability of this cannot be determined from this study. Overall 
the families thought that palliative care involvement was appropriate as their 
family member deteriorated. Conversely, some of the clinicians argued that if 
palliative care teams were not involved early, symptoms may be missed that 
could have been ameliorated and prevent unwanted hospital admissions (C1, 
C11, and C12). The finding in this research that if families (P1) were not fully 
informed early of their choices of care it may lead to emergency hospital 
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presentations agreed with Connolly, Galvin and Hardiman (2015). However, the 
manner in which this communication occurs and whether it necessarily needs to 
be given by palliative care specialists is highlighted within this study.  
 
The symbolic association of palliative care with no hope emerged from 
this research, both from the clinicians’ reluctance for early referral to the 
specialist service, and from the families’ pre-conceived opinions. Certain 
environments can create feelings of uncertainty and how the individual interacts 
with that environment may change depending on previous experiences or 
experiences of others which may have influenced the individual (Blumer, 1969). 
Palliative care for many people is assumed to be solely involved with the end of 
life. The individual interpretation and meaning of an environment such as 
palliative care is not necessarily conforming to a social construct, but more to 
experiences and individual analysis. This negative image of palliative care has 
the potential of being reinforced by clinicians who hesitate to explain and 
communicate the many aspects of the service in the belief any hope a person 
with MND may have, will be eliminated. 
   
There were also practical reasons mentioned by the clinical participants 
as to why early referral to palliative care was not happening in their districts. In 
particular, the unpredictability of the course of MND, the availability, funding 
rules and budget of the local palliative care teams and in some instances the 
preferences of those clinicians involved with the diagnosis of MND (C19, C1, 
and C2). None of the family participants interviewed thought that palliative care 
from diagnosis was appropriate and felt it to be too confronting.  
 
All the family participants involved with this study were very prepared to 
be referred and understood the value of referral to a respiratory or gastric 
specialist as symptoms became evident or worsened. However, the concept of 
early referral to a palliative care specialist for symptom relief seemed 
unacceptable. If this is an “image problem” for palliative care, then perhaps 
there needs to be a subset of the specialty which is called MND symptom 
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control. The inconsistencies within health areas for the provision of palliative 
care, particularly in the more urban areas in Australia, the varying levels of 
palliative care offered and the mixed opinions of when palliative care should be 
usefully offered, appear diverse from this study.  
5.6.4. Multidisciplinary teams 
 The inclusion of palliative care within the MDT is a current 
recommendation for the management of MND (NICE, 2016). There is evidence 
that MDTs can offer health benefits to patients in most areas of disease 
management (Marsilio, Torbica, & Villa, 2016; Rooney et al., 2015). In Europe, 
there are MND guidelines which not only recommend referral to a recognised 
MND Association on diagnosis but also referral to a specialist MND MDT 
(Andersen et al., 2012). A recent study in Ireland found that people with MND 
survived approximately seven months longer if under the supervision and care 
of a MND specific MDT (Rooney et al., 2015). In the study by Rooney et al. 
(2015) the benefits of a well-structured, centralised MDT were suggested to 
have the ability to increase the life span of those diagnosed with MND. Rooney 
et al. explored and compared whether centralised MDT services would have a 
better survival outcome than community-based care which incorporated a care 
coordinator. The study concluded that centralised MDT offered a holistic clinical 
environment for the person with MND and their families, which improved their 
clinical well-being and survival. The study proposed that this may be due in part 
to the variation in perspectives and in communicating choices of care between 
clinicians, patient and caregiver. Rooney et al. imply that this varied input into 
decision-making can enable clearer understanding of clinical possibilities which 
can then be incorporated into an AHD.  
 However, as found in this research, structured MDTs are not always 
readily available in Australia. There was considerable variation found in the 
geographical co-location of the health professionals that work together to form 
an MDT. Ideally the MDT members offer their various skills to improve the 
disease process of those they help and in doing so share their knowledge with 
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those within their team. The involvement of multiple organisations; not just 
those making up the MDT, but those involved as neurological, respiratory or 
palliative care nurses plus those offering personal care were often 
uncoordinated and disassociated.  
 There were comments from all the families regarding the number of 
people involved with the care of their family member with MND, particularly for 
those who remained at home. This related to involvement of multiple 
organisations, even within the MDT, causing confusion for the family and 
person with MND as to who was responsible for what, and who was organising 
ongoing care. The MDTs described by family participants appeared, in many 
instances, to be made up of independent health professionals rather than a 
formal MDT within one organisation. It is possible that within the more 
structured, centralised MND MDT this situation does not arise. However, within 
the small number of family participants, and reiterated by the neurological 
nurses, confusion does occur. For example, people with MND who lived in 
country areas were sent home from city hospitals without organised battery 
backup or contingency plans for power outages or technical problems. Other 
difficulties voiced by the families included having to attend different specialty 
appointments in different places, as the MDT was scattered within various 
organisations. One of the MND nurse specialists involved with trying to 
coordinate care for people with MND voiced frustration with the lack of feedback 
she was receiving from within the organisations involved with multidisciplinary 
care in her area. Another city specialist was frustrated by the lack of 
cooperation of a country palliative care team post discharge home. It seems 
that within Australia the level of community palliative care offered varies 
enormously and depends on the preference of the state or territory health 
service.  
 The role of breast cancer nurses has been briefly explored to see 
whether their model of patient support could be utilised for MND (Jiwa et al., 
2013). In the study by Jiwa et al. (2013) the role and availability of the breast 
cancer nurse negated the need for the person with breast cancer to personally 
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attend the MDT meetings. The appropriately trained nurse, as case coordinator, 
was fully cognisant of the health status of the person with breast cancer and 
was able to report on their behalf to the MDT. The study also found that the 
sharing of information between health disciplines was challenging, which 
certainly concurs with the findings from this research (C1, C2, C16). Specialist 
care nurses, in this case for MND, have been found to play a vital role in the 
care of people with MND in Scotland (Ferrie, Robertson Rieck, & Watson, 
2015). In the comprehensive report by Ferrie, Robertson-Rieck and Watson 
(2015) into planning care for people living with MND, one of the findings was the 
importance of the role the specialist care nurses played in coordinating 
services, care provision and providing advocacy for the person with MND. The 
nurses, where available, were able to advise availability of local services and 
provide accurate information which enabled informed decision-making by the 
person and family coping with MND. However, despite the vital role the 
specialist nurses played, the report went on to say there were many instances 
where no one person was identified as taking overall responsibility for 
assessment and care of the person with MND and their family. Whilst the 
specialist nurse service is to some extent emulated by the community 
neurological nurses in Western Australia, their role can overlap with the 
community palliative care nurses and support workers from MNDAWA. This 
finding of multiple organisations causing confusion for people with MND was 
also highlighted in the Scottish MND report by Ferrie et al. (2015) who 
described the different care and funding systems as a “bewildering array of 
services and people” (p. 182). Each available service in Australia is extremely 
valuable but can become confusing for the people with MND and their families.  
5.6.5. The usefulness of the advance health directive (AHD) or 
documented care plan 
 A documented advance care plan is a recommendation of the most 
recent MND Assessment and Management Guidelines (2016) and it is 
suggested that it is discussed prior to the person with MND losing the ability to 
clearly communicate. Detailed exploration of the content of an AHD was not a 
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priority of this study; however, the participants were asked at what stage they 
were discussed and whether they had proved useful. The palliative care 
specialists generally initiated the AHD. Considering how late in the disease they 
were involved, perhaps the contents of the AHD may not have assisted the 
patient appropriately in enabling choices of care. Where the palliative care 
clinicians had experience with following AHDs the documents were generally 
vague and inadequate (C11, C15, C18). Conditions such as aspiration 
pneumonia were not covered, despite recommendation in the current MND 
guidelines to detail how concurrent infections should be treated (or not) (NICE, 
2016). Rather than writing a formal documented care plan, the families seemed 
to have informal inter-family agreements about what the person with MND 
would have wanted as they entered the terminal stage of their disease. None of 
the families interviewed were encouraged to write AHDs early in the disease, 
but most admitted they probably would not have wanted to do so. The AHD 
appeared to be as confrontational as the early referral to palliative care. This 
made treatment choices difficult for clinicians having to rely on the family 
making difficult decisions, such as to withhold feeding and hydration to enable 
one person with MND to starve himself to death (C3). The clinician participants 
were asked if they ever re-visited the AHDs with a patient when a symptom 
control measure was initiated or if a decision to withdraw NIV under certain 
circumstances (such as not being able to communicate) was made. Few 
clinicians other than palliative care specialists involved themselves with AHDs 
and fewer yet re-visited them to make relevant additions or adjustments, 
although all thought this a good idea (C11, C15, C18). The American Academy 
of Neurology (2012) recommends annual communication and documentation of 
a patient’s preference for continuation and potential withdrawal of NIV and any 
reasons for not having those discussions to also be clearly documented. Annual 
discussions, and documentation of these discussion, with patients about 
continuation of NIV and related symptom control preferences could be an 
inclusion into an MND specific pathway, was one to be developed (further 
discussed in Chapter 6). 
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A recently published journal article which explored NIV in patients’ (with 
varying diagnoses) perspectives on advance care planning or AHDs found 
evidence that discussing advance care may increase hope rather than diminish 
it in people with respiratory failure (Smith et al., 2017). As found in this 
research, having end-of-life communication and clear understanding on the part 
of the patient and family may have alleviated some of the concerns and distress 
leading towards the terminal stage of life (F1, F2, F3, and C7). 
5.6.6. Barriers to clinician and family communication  
In summary, there were many barriers to effectively communicating 
symptom control and end-of-life to people with MND and their families. The 
points below encapsulate the barriers as described by the participants in this 
research: 
 Many of the clinicians were reluctant to discuss the poor prognosis of the 
person with MND too early but admitted that leaving those conversations 
too late was not a good option for the person with MND either (C6, C4) 
 Clinicians worried that even the conversation will upset the family and 
person with MND and take away hope (C19, C6, C7, C14) 
 Insufficient time available for detailed communication was mentioned by 
clinicians (C2, C3, C4, C11, C12, C19, and C8) and family participants 
(F1, F2) 
 Time (life) left - communication should happen early, particularly as 
families are from all over the world, conflict may be involved and planning 
for the whole family is important (C3, C2) 
 A person may be told the same thing several times but must be “ready to 
hear it” (denial) (C8, C9) 
 The uncertainty of the disease and clinicians who did not want to face 
such uncertainty (C11); clinicians reticent to say they do not know how, 
when or what will exactly happen and not being honest from the 
beginning (C11) 
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 Denial about the disease or patient and family reluctance to engage in 
communicating with their specialists was highlighted by several clinicians 
(C1, C4, C12 and C16) 
 Uncertainty around the ethical situation and the law can be a barrier for 
clinicians to discuss withdrawal of NIV (C1, C5) 
 People with MND and their families who lack assertiveness, adequate 
health literacy and the confidence to ask questions (F5, F6, C3).  
 
5.7. Research question 6:  
Following the literature review and clinician and family/significant other 
interviews regarding NIV communication, what recommendations can be 
identified that would improve end-of-life communication and process for 
the patients, families and clinicians involved with the end-of-life care of 
people with MND? 
The final research question is answered in the final chapter of this thesis 
and encapsulates the recommendations of all the participants in this research, 
and those recommendations suggested by the candidate. Further areas for 
research are identified, and improvements for the vision of care and 
communication are suggested. 
 
5.8. Chapter Summary 
 At the time of writing 50 years have passed (1967-2017) since the 
founding of modern palliative and hospice care at St Christopher’s Hospice, and 
in that time there has been much progress towards improving all aspects of 
end-of-life care including communication. The importance of allowing time to 
ensure clarity in communicating and documenting the patient’s end-of-life 
choices irrespective of the diagnosis has been identified. 
   
 Within this research there have been three main perspectives to explore, 
and these were identified by gaps in the literature reviewed (January 1990 to 
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July 2016). The most recent MND guidelines recommended communication 
relating to NIV initiation, potential withdrawal and the end of life were compared 
to the clinician participant interviews (NICE, 2016). The bereaved family 
participants, who were also the caregivers for the person with MND, were asked 
what they remembered being communicated to them and what they understood 
about NIV and end-of-life. The comparison of all material derived from 
participant interviews to the most recent guidelines has continued throughout 
the results and the discussion chapters. 
 
 Complex processes are at play between those delivering and those 
receiving communication encompassing end-of-life choices, yet in many 
instances it is the clinician who decides whether the person with MND is ready 
to hear such communication. The theoretical approach which underpins this 
study reveals how varied people are in making sense of their own and others’ 
behaviours and communication. Symbolic Interactionism has identified how the 
same experience can have different meanings for everyone. This aspect of the 
study could be explored further to understand how communication can be 
delivered in various ways to minimise misapprehension and confusion with end-
of-life choices.  
 
 The potential burdens of NIV and PEG tubes should be communicated 
early in the disease process to prevent futile treatment which may prolong 
suffering. Time to reinforce or repeat end-of-life choices to ensure patient and 
family comprehension as well as patient and family willingness to participate in 
such communication are all factors considered by clinicians before commencing 
sensitive discussions. Patient initiation of sensitive communication and the 
ability to ask relevant questions in a stressful situation may depend on the 
health literacy and assertiveness of the person with MND and their family. This 
was recognised to be the case by some of the family participants within this 
study, who tended to turn to the Internet for their information. Again, insufficient 
time is a factor in commencing sensitive discussions and was reiterated by 
clinicians of all specialties interviewed in this research. 
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Communication between people with MND, their families and health 
professionals can be clouded by a mixture of technical jargon, insufficient time 
to have insightful conversations, the barriers of patient denial and perceived 
lack of empathy in the clinician. Whilst this is not unique to MND communication 
(Humphris, 2015), clinician avoidance of difficult discussions has been identified 
by Faull, Rowe-Haynes and Oliver (2014) in MND and seen again in this 
research. 
  
 The clinicians may find clear direction for end-of-life care in well written 
AHDs; however, the point has been made by participants within this study that 
few directives are written down, sufficiently explicit or readily available. None of 
the clinician or family participants re-visited their AHDs (or where there were no 
written documents, re-discussed with family members) when situations 
changed, or the disease progressed. Denial of the incurable nature of the 
disease is a barrier to clear written treatment choices but even such a barrier 
may only affect formality in documentation; this research has shown that the 
preferred end-of-life patient choices often appear to be known by the clinicians 
either by discussions with family members, or remarks made to the specialist 
palliative care team at some stage of the disease.  
 
 Finally, the recommendations which all participants proposed and those 
recommendations which the candidate has suggested based on the completed 
research are encapsulated in the last chapter of this thesis, answering the last 
research question.  
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A qualitative study into the communication surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in people with motor neurone disease 
Chapter 6: 
Recommendations and Conclusion 
6.1. Chapter Overview 
 This study has explored the relevant literature extensively and involved 
26 participants in detailed interviews exposing the experience and difficulties 
encountered with communication surrounding the initiation and withdrawal of 
NIV and end-of-life discussions in MND. The clinical participants have provided 
insight into barriers to sensitive communication into end-of-life choices and the 
benefits and burdens of NIV. Improving communication and managing end-of-
life in MND and minimising undue prolonging of suffering are the objects of the 
recommendations derived from this research. The bereaved family participants, 
who have been involved with a family member with MND, have provided a 
glimpse into their experiences and understandings of the options for symptom 
relief as communicated to them. The family participants have also described the 
health systems they learnt to navigate, any frustrations they encountered and 
made some suggestions for other families negotiating the MND path.  
  
 This concluding chapter commences with the key issues and   
recognition of what this research has contributed to the knowledge and 
understanding of end-of-life choices and communication in people with MND. 
The recommendations from all the participants who were involved in the study 
cover aspects of MND which they felt could be improved upon. Whilst some of 
the suggestions are not directly related to the original research topic, the 
candidate felt these valuable comments should be included as they may 
indicate areas of potential research and avenues for improvement in caring for 
people with MND and their families.  
 
 The final chapter answers the last research question posed by the 
candidate by providing recommendations for improvement in communicating 
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the difficult, sensitive discussions surrounding the end of life. The final and sixth 
research question is:  
 
Following the literature review and clinician and family/significant other 
interviews regarding NIV communication, what recommendations can be 
identified that would improve end-of-life communication and process for 
the patients, families and clinicians involved with the end-of-life care for 
people with MND? 
 
 
6.2. Key Issues Identified from this Study 
The following findings were identified as issues within this study, and 
recommendations regarding these are found in Section 6.5: 
 
1. Communication is adversely affected by specialists having insufficient 
time to ensure people with MND and their families are sufficiently well 
informed about their end-of-life choices. Specialists, particularly 
respiratory clinicians, have difficulty having the necessary sensitive 
communication about treatment choices and the progressive nature of 
the disease due to limited consultation time. 
 
2. There appears to be some disparity between what the MND guidelines 
recommend regarding early referral to a palliative care service and what 
families stated was appropriate for them. From this study it is also 
apparent that clinicians do not always refer newly diagnosed people with 
MND to palliative care. This study has highlighted that the bereaved 
families of people with MND have not understood the benefits and 
capabilities of palliative care as explained to them and perceive palliative 
care, with some fear, to mean death. Clinicians and families agree that 
the optimal time to refer people with MND to a palliative care service is 
challenging. 
 245 
 
 
3.  Families reported that too many agencies/health professionals are 
involved with general and specialist care for people with MND. Families 
spoke of the need to repeat the same issues to several different people, 
which consumed valuable time and effort. The families were very aware 
that time was not on their side and resented the intrusion from so many 
different services. This potentially affected end-of-life care and symptom 
control as stated by one family (F1, F2).  
 
4. Communication barriers exist for people with MND and their families 
particularly when discussing end-of-life care and particularly when there 
is no structured MDT or single individual responsible for patient care 
involved. Families with little experience or knowledge of the health care 
system and who have lower levels of health literacy often do not have the 
skills to ask relevant questions related to symptom control and end-of-life 
issues.  
 
5. Complex communication barriers have been identified in this research 
when clinicians initiate NIV in people with MND. Trigger points have been 
suggested in the literature as a time when communication regarding end-
of-life choices be commenced; the offering of NIV is one such trigger 
point. However, this research has found that in many instances, 
insufficient time and a fear by clinicians of taking away hope often 
prevents the necessary NIV and end-of-life conversations from taking 
place. 
 
6. The clinicians acknowledged that advance end-of-life care planning 
was not as honest as it might be because doctors are reluctant to say 
they do not know what will happen or how long until death. Most 
clinicians did not re-visit AHDs once written despite changes in symptom 
control such as a PEG use which might cause an adverse health 
situation necessitating an instant decision for ongoing care.  
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7. This study found that some of the families would have liked more 
understanding of the disease trajectory and prognosis so they could 
make plans and organise their lives. Whilst all the families acknowledged 
the variability of the disease and its progression, comment was made 
that when certain symptoms developed, a better idea of the remaining 
duration of time might be given. 
6.2.1. How this research contributes to knowledge 
The issues identified from this research as listed above have provided a 
platform for making improvements for people with MND and the communication 
of their end-of-life choices particularly surrounding the initiation and withdrawal 
of NIV. The communication surrounding death and palliative care remains 
offensive to many, clinicians and patients alike. This research revealed the gap 
between clinicians’ understandings of MND communication recommendations 
and guidelines on the one hand, and the communication they consider 
appropriate on the other. Valuable insights to the barriers preventing such 
communication between clinicians and people with MND and their families have 
been provided (Chapter 4; Table 4.5). Family participants stated that referral to 
palliative care at or soon after diagnosis was confronting, despite it being a 
guideline recommendation. This research suggests the possibility that the 
further away from a clinician’s original formal medical education and, therefore, 
the more experienced they are in their field, the less likely they may be to read 
and comply with MND recommendations and guidelines.  
 
This research provides a much-needed addition to the literature on the 
experiences of caregivers and families who have had a family member die from 
MND and had experience with, or refusal of, NIV as a palliation measure. The 
research also adds valuable insight into the clinician’s perspective of what, 
when and how communication is delivered and the barriers they encounter.  
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6.3. Participant Recommendations for Improved Communication  
The family participants were asked to “please comment on any discussions 
which you would have liked to have taken place, with whom and how would you have 
liked those discussions?” (Question 21; Appendix E). 
 Some of the families (F2, F5, and P1) within this research expressed a 
lack of understanding of the distressing symptoms and available options for 
care particularly at the terminal stage of the disease. Whilst all had some 
knowledge of what could occur, and that death would very likely be from 
respiratory distress, some of the families appeared unprepared for what 
eventuated. There was general lack of understanding that the person with MND 
would find increasing difficulty in communicating clearly and, therefore, a poor 
comprehension as to why early discussions of end-of-life choices were 
necessary. There was confusion about some clinical aspects of the end of life 
which had not been discussed either by clinicians or between family members 
during the disease.  
  
 The families made many valuable points and recommendations within 
this study. First, the person with MND interviewed (P1) suggested that clinicians 
be more proactive and able to anticipate potential issues instead of responding 
to a situation. Two family members (F1 and F2) recommended that families 
could be more in control of their situation by asking the difficult questions of the 
clinicians to understand what could eventuate within the disease progression. 
However, that involves a level of health literacy and confidence, plus the 
emotional capacity to cope with the potentially confronting answers. Several 
family participants made the point that in hindsight, they would have asked 
different questions because now they knew what was important to ask. Some 
families may have required guidance to ask the right questions, as levels of 
health literacy varied. One family member (F4) stated that if he did not 
understand what a clinician had said, he turned to the Internet to find answers, 
whilst other families used the Internet for information as soon as their family 
member had been diagnosed (F3, F5, F6). The families were asked whether it 
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would have been useful to be provided with more written information on the 
relevance of the progressive symptoms in relation to the relevant specialist 
intervention. All suggested it would have been helpful as negotiating the health 
system was confusing and very time consuming. The family participants (F3, 
F4) and the person with MND (P1) said they would have liked an idea of the 
progression timeline of the disease to plan their lives better. All acknowledged 
specific prognostic timing was difficult with MND but suggested an indication of 
where the disease was heading when a particular symptom occurred would 
have helped them manage their lives. 
 
 The family participants recommended earlier referral to specialists once 
a symptom was evident but not necessarily explained clinically. Importantly, the 
more rural families felt they should have the same access to services as 
metropolitan families, although the specifics of those comments were not 
advanced further. For example, F5 stated that there was a lack of informed 
MND caregivers in her rural area and it was the ability to talk to others in a 
similar caring situation that she longed for. Mentoring at an early stage of MND 
from others who have gone through the MND experience before was 
recommended by F5.  
 
 One family (F3) would have liked information about genetic testing and 
its availability communicated to them by the clinicians. The content of 
communication which one person with MND and their family may require may, 
however, be too confronting for another.  Better communication between a 
clinician and those involved with the person with MND, may mean that many of 
these concerns could be explored and discussed. 
 
 In summary family participants recommended that: 
 
 There is better explanation from clinicians about the symptoms which 
may occur in MND and the meaning of those symptoms in relation to the 
progression of the disease.  
 249 
 
 Involvement of a palliative care specialist does not occur until symptoms 
became more obvious and symptom control is required. 
  A mentoring (online or in person) system is established to enable regular 
contact with others going through the MND experience for more rural 
families. 
 There is a single agency (or care coordinator) appointed instead of 
multiple agency involvement. 
 
The clinician participants were asked two questions (Questions 35 and 
36; Appendix D) which yielded recommendations for communication and care 
for people with MND: “What are the barriers to discussion between clinician and 
patient, significant others and caregivers about commencement and 
subsequent withdrawal of NIV?” and “Anything else you think I should know 
about your experience in communicating about the MND experience for 
patients?” 
 
 Various themes emerged from the clinician participant interviews and 
one of the most common was the need to be able to allocate sufficient time for 
communicating all aspects of symptom relief and end-of-life choices. Informed 
communication, developing a rapport and establishing trust with the person with 
MND and their family were considered important, but these involve a 
considerable amount of time spread over several occasions. The frustration 
voiced by the clinicians was the difficulty in allocating the amount of time 
required to ensure understanding and being able to repeat the communication. 
As stated by C2 (palliative care specialist) doctors don’t know where they can 
find this time. None of the clinicians could give a satisfactory answer as to how 
to solve this issue, only that they had to try to make time for those discussions. 
Many of the specialists felt that they were rushed and probably inadequately 
communicating end-of-life care options. People with MND from the country, who 
only came to see the MND MDT for symptom management interventions such 
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as NIV, had informative discussions about NIV but without follow up to address 
the more sensitive issues. This was frustrating for the clinicians and 
unsatisfactory for the person with MND and their family (C13). 
 
Some of the clinicians admitted difficulties with having end-of-life 
discussions when initiating NIV: although they felt they were offering something 
which may help the patient they did not want to remove hope by discussing 
potential withdrawal. The point was made that some people with MND and their 
families do not want to have those discussions, despite the clinician trying to do 
so. Denial, the understanding held by the person with MND and/or their family 
plus variable levels of health literacy were barriers to end-of-life communication 
occurring at the time the current guidelines recommend (NICE, 2016). 
Frontotemporal dementia was found in this research to be a symptom of MND 
which some clinicians are not fully conversant with or is not easily recognised.  
Frontotemporal dementia could be affecting decisions made by some people 
with MND but, again, time is required for the clinicians to be able to listen to and 
understand the individual to recognise the FD behavioural nuances. 
 
The sharing of relevant information between clinicians and closer 
collaboration within MDTs and with their patients was found to be an area which 
can be improved, concurring with previous studies (Danel-Brunaud et al., 2017).  
In areas where the palliative care specialist, respiratory specialist and allied 
health professionals were not part of a formalised MND MDT, communication 
between all the clinicians involved was described as particularly poor at times.  
Differing opinions can exist within clinical teams which could confuse a person 
with MND and their family, or communication may be assumed to have 
occurred with the patient when it hasn’t. These problems may well be eliminated 
if there was a person coordinating and responsible for the care of the person 
with MND and their family.  
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In summary clinician participants recommended that: 
 
 There is better explanation for people with MND and their families about 
the emotional end-of-life issues and not just the practical symptom 
control issues such as the workings of NIV. 
 More appointment time is allocated to enable a rapport to develop with 
the patient and to ensure clear communication.  
 Improved communication between health care providers, and even within 
the MDT. 
 
6.4. Recommendations for Further Research and Suggestions for Policy 
and Funding Reform 
There is a need for further research to assist people with MND and their 
families to understand the implications of the course of this devastating disease. 
In light of the research findings, the following section considers how changes to 
policy and funding may be achieved. 
6.4.1. Coordination of care incorporating sensitive end-of-life 
communication 
Specialist clinician time needs to be allocated for sensitive 
communication so that people with MND and their families better understand 
the benefits and burdens of symptom control measures and end-of-life choices. 
Communication may be improved if there was an overall coordinator 
responsible for the needs of the person with MND and their family. As 
discussed in Chapter 5 (Section 5.6.4), other health disciplines incorporate a 
specialist nurse to guide a person through the complexities of decision-making 
at diagnosis, and onwards with symptom control and either disease progression 
or cure. MND is different from most other diseases in that there is no hope of a 
cure and such hope that there is remains within the realms of symptom control 
and the assurance of a comfortable death.  
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 Throughout Chapter 5 barriers have been identified relating to clear 
delivery of information from clinicians, and the understanding of important 
issues by people with MND and their families. Also revealed was an apparent 
lack of overall responsibility for the person with MND, unless in a highly 
specialised MND MDT. Allocating a health professional to take overall 
responsibility within the MDT is not always practical if the MDT is fractured and 
disparately located. However, ensuring one health professional is responsible 
for coordinating the care and changing requirements for the person with MND 
and their family is needed. The recommendation that sensitive end-of-life 
choices and potential NIV withdrawal is communicated to the person with MND 
prior to its commencement suggest that a case manager, possibly an MDT 
member, is allocated at the time of diagnosis. Allocating responsibility for 
planning ongoing care with the family of a person with MND and taking the lead 
in communication with them is a recommendation of this study and is in line with 
current MND recommendations (Faull, de Caestecker, Nicholson, & Black, 
2012; NICE, 2016). One of the recommendations of this research is for a 
multidiscipline (trained in palliative care and neurological diseases) nurse case 
manager to be appointed from diagnosis, and preferably to be one of several 
nurses in the role. The case manager would be involved from diagnosis until 
either hospital admission or death at home. To avoid coordinator nurse “burn 
out”, it may be preferable to have a small team who can organise the early 
requirements and support for the person with MND and their family. The case 
manager would assist people with MND to navigate their local specialists for 
symptom control, allied health services and general entitlements to community 
care. The case manager/team would also ensure that the patient’s GP was kept 
informed with all the specialist interventions and recommendations. Many of the 
long and sensitive discussions relating to end-of-life choices can be undertaken 
or reiterated by the nurse, thereby alleviating the need for patients (and 
specialists) to have repetitive time-consuming communication. This would 
facilitate continuity of care and trust and may avoid duplication of services in 
some areas. 
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 An area for further research is to develop and trial the recommended 
model of allocating a palliative care/neurological nurse case manager from the 
diagnosis of MND. Of interest would be exploring the communication with the 
patient’s GP and how well the GP is kept informed of their patient’s progress 
and any interventions. This research found that GPs remain involved with the 
day-to-day wellbeing and support of people with MND and their families. An 
individualised care plan could be developed to assist sharing of information 
between GPs and local specialists, (such as when symptoms begin), and 
specialists who are willing to bulk-bill (direct billing to Medicare). The case 
manager would also report back to the MDT for ongoing advice and support, 
eliminating the need for the person with MND to be present and thereby 
reserving precious personal time for the person with MND and their family.  
  
This model allows for continuity of care, development of trust and, 
therefore, the ability to engage in sensitive communication relating to end-of-life 
choices and the useful aspects of early palliative care. An audit of the efficacy of 
a case manager can measure the savings made in terms of specialist time, 
multiple lengthy appointments, and associated financial costs. The case 
manager would attend the first specialist appointment and then be able to 
reiterate and clarify communication involving all aspects of MND care to the 
person with MND and their family. The possibility for funding a case manager 
might be investigated under the National Disability Insurance Scheme in 
conjunction with state health departments. 
6.4.2. Reducing the number of people involved with patient care 
This research recommends trying to minimise the number of agencies 
involved with long-term people with MND under palliative care. The possibility of 
coordinating home care within one organisation, may alleviate some of the 
issues of too many people being involved, as identified by the families within 
this study. This may require further research into policy and funding to 
determine the feasibility of allocating one agency to provide community 
palliative care (including all aspects of nursing requirements such as dressings, 
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urinary catheters and equipment), personal and home care. An issue only 
touched upon in the current study was the variability in funding in relation to 
accessing long-term specialist palliative care. This was identified as a significant 
barrier for people living with MND and other potentially long-term neurological 
diseases. 
6.4.3. Addressing the communication barriers for people with MND, 
their families and clinicians  
This research did not study how health literacy affects communication 
and choices of symptom control in people with MND. However, during the 
interviews the family and clinician participants recognised that inadequate 
health literacy may affect how some families understand health issues and their 
ability or confidence to communicate concerns. Ideally health literacy can be 
assessed by the clinician, so they can ensure end-of-life choices have been 
understood. However, the subtle changes which can be associated with FTD 
can mask patient choices for care which could ultimately adversely affect 
caregivers (caregiver burden). A trial of an online discussion group or mentoring 
facility is recommended to investigate the value or providing the opportunity for 
caregivers and people with MND talk to others who are also going through 
complex MND experiences and decisions. Such a mentoring facility may also 
inform and encourage people with MND and their families to have the courage 
to ask questions of their clinicians and may assist in overcoming some of the 
communication barriers. 
Disease specific guidelines have a very detailed purpose in providing 
evidence of certain treatments and ongoing care advice for a person with that 
specific disease. Most diagnosed illnesses offer an element of hope of cure 
and, therefore, the guidelines relating to that illness assist clinicians to offer 
current best practice for finding a cure. However, in many of the neurological 
diseases, MND in particular, there is neither a specific diagnostic test nor any 
hope of a cure. Therefore, the present guidelines offer recommendations for 
symptom control, general management and support which, whilst generally 
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known by clinicians, are not always followed. Whilst communication 
recommendations are incorporated into the most recent MND guidelines, there 
is little specific guidance on best practice communication for the clinicians to 
follow. This research has highlighted the area of recommended communication 
surrounding the initiation of NIV and PEG tube insertion and found the 
comprehensive recommended end-of-life communication infrequently occurs. A 
further recommendation of this study is for research involving families and 
people with MND so that they can give their views on when the sensitive 
communication relating to the end of life should occur, and with whom they may 
prefer those conversations. This would lead to greater involvement of bereaved 
MND families in the writing of recommendations. 
 
A palliative care nurse (or a case manager) who liaises with the 
respiratory clinician at commencement of NIV (if the person with MND has not 
previously been involved with a palliative care team), would be advantageous 
for rural patients particularly, who have not had the benefits of a structured 
MDT. This would facilitate continuation and elaboration by the nurse of any 
communication tentatively commenced by the respiratory clinician. The 
palliative care nurse also offers a conduit between the deteriorating patient, 
symptom control via NIV and PEGs and the palliative care specialist team 
(which includes all members of the MDT). This would be the equivalent of a 
breast care/cancer nurse being included in the specialist appointments to 
support and coordinate ongoing care for people with breast cancer. This role 
could be either a neurological nurse upskilled to palliation or a palliative care 
nurse trained more comprehensively in neurological conditions, as previously 
recommended in this section.  
6.4.5. Establishing a progressive timeline of information 
The development of a written and/or an electronic instrument which 
describes the various symptoms people with MND may experience (rather than 
describing what is happening within the disease process), who to question 
(which health professional) about any symptom and some of the alternative 
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symptom-relieving choices available (including their benefits and burdens) is 
recommended. This would also incorporate a timeline which gives families and 
people with MND an idea whether they need to act fast. For example, if the 
patient is experiencing headaches on waking or generally feeling breathless, it 
is time to speak to a doctor about a referral to a respiratory specialist. Symptom 
relieving options offered by a respiratory specialist would be identified, and 
some relevant questions listed to assist the person with MND know what to ask 
the specialist. The timeline would include a list of the specialists in the patient’s 
area (linked into Google Maps) and which specialists will bulk-bill (Medicare 
fund) for appointments. 
 
An instrument such as this may prove useful for people with MND to pre-
empt their needs, understand their choices and be more proactive with 
implementing their symptom relieving requirements. This could be developed as 
an interactive app for smart phones, and/or as a written hand-held document for 
people with MND. The instrument would include instructions, comments and 
recommendations inserted by specialists (or case manager) at the time of their 
appointment. This tool may assist people with MND and their families to 
remember, understand and revisit sensitive communication. It would also 
incorporate advice on when to consider writing an AHD and outline the 
advantages for optimising care when patient preferences are clearly known and 
documented. This would be suggested to occur at trigger points identified in the 
literature (NICE, 2016; Rafiq et al., 2012). An electronic timeline would enable 
up-to-date care wishes concerning end-of-life care to be identified and changed 
as required by the person with MND. The instrument would also incorporate the 
ability to SKYPE (or similar) with specialists at an allocated appointment time, 
so any updated information would be shared between clinicians, patient and 
family plus the case manager. This would minimise the need for the person to 
travel which becomes difficult as the disease progresses. 
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6.4.6. Study the timing of preferred referral to a specialist palliative 
care service 
The recommendation in the NICE MND Assessment and Management 
Guidelines (2016) for early referral to palliative care, whilst known by clinicians, 
does not translate into clinical practice. The barriers and clinician concerns for 
early palliative care referral have been identified throughout this research. 
However, it is the family participants who clearly stated their reluctance for early 
referral and were shocked by the suggestion of palliative care when their family 
member with MND was relatively asymptomatic. The clinicians have identified 
that family members may not be ready for this discussion early on. This 
research recommends that palliative care is introduced and described to people 
with MND after they have identified a symptom requiring treatment or control, 
using the symptom as a reason to explain the benefits of palliative care 
involvement. Greater involvement of MND families regarding explanation, timing 
and level of involvement of palliative care, timing of end-of-life communication 
would be provided by the case manager as proposed in Section 6.4.1.  
6.4.7. Funding of palliative care services as a barrier to ongoing 
care 
 This study has encountered several clinicians who have described 
access to a specialist palliative care service (in their area) for people with MND 
to be limited to their last three months of life. Others described the palliative 
care service not being able to keep people with MND on their books long-term 
due to the palliative care funding in their area. This finding neither complies with 
the MND guideline recommendation of referral to palliative care at or soon after 
diagnosis, nor makes the time of referral any easier to determine for clinicians. 
The recommendation of this research is intermittent referral to a palliative care 
service which would provide advice on symptom control, without a specific 
prerequisite for survival time or diagnosis for admission to the service. This 
model of intermittent palliative care, which has been discussed in Chapter 5 
(Section 5.6.3), may encourage recognition of symptoms and provide ongoing 
high-level care. An intermittent palliative care service is recommended in 
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conjunction with an MND case manager. The cost of an intermittent palliative 
care service may be offset by fewer emergency admissions to hospital which 
occur particularly when people with MND have symptom complications. 
 
6.6. Limitations  
 This study has covered many aspects of communicating end-of-life 
choices focusing particularly on the stage of MND when the respiratory muscles 
weaken, and the effects of respiratory difficulty become apparent to the person 
with MND. Several limitations are identified within this study. Importantly and 
unfortunately there were no neurologists available or willing to participate in this 
study. The neurologist view-point would have added greater depth of 
understanding of both communication content and responsibility for overall care 
of the person with MND. The lack of neurologists may also have influenced the 
recruitment strategy of family participants. As GPs are involved with the ongoing 
general health care of people with MND, it may have been relevant to have 
included their perspective and this may be considered a limitation of the study. 
However, the focus of the research questions was on those participants with 
considerable clinical experience of MND, and GPs may not have such 
experience. 
 The clinician participants have given examples of how they communicate 
and candid examples of when they found it difficult. As this study could not link 
the family participants with any clinicians interviewed, the study was limited in 
being able to verify how clearly each clinician communicated end-of-life options. 
However, the bereaved family participants were clearly confused on many 
aspects of the terminal stage of their family member’s MND, although this 
confusion may have been a symptom of their grief. Unfortunately, a relatively 
small number of bereaved families applied to participate (six) and this is 
recognised as a limitation of the study. This may be due to participant fatigue as 
there have been various MND research projects in Western Australia involving 
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bereaved families undertaken recently, or simply that as MND is a rare disease 
there were few families available. 
 
 A further limitation identified is the interview process which involves 
retrospective recall as well as aspects of life which impact on memory, which in 
turn may affect how their reality is recalled. In considering the methodology, 
research questions and participant semi-structured questions, the research 
method was developed to obtain the most accurate and dependable 
information. There were some disadvantages to using semi-structured 
questions to interview all the participants. The main disadvantage was the 
extended time of the interviews which meant that the analysis of the data was 
also time consuming. In analysing the data from the in-depth interviews, 
generalisation of the information was not always obvious and at times, difficult. 
The possibility exists that the data collected for this study may have been 
different if a method other than the one chosen was selected. The candidate 
did, however, take trustworthiness measures to ensure objectivity was 
maintained as much as possible (Chapter 3, Section 3.13.1). 
  
6.7. Conclusion 
 Whilst acknowledging that MND offers no hope of a cure and early end-
of-life communication is often laden with emotional difficulties, it nonetheless 
remains vital for the person with MND and their family to be provided with the 
information they need to be able to make informed choices. The research 
questions within this study aimed to determine whether the international and 
national guideline recommendations into NIV communication which included the 
benefits and burdens of NIV, end-of-life choices and the potential of being able 
to withdraw NIV were being integrated into clinical practice. The significance of 
whether this sensitive communication was occurring had implications for the 
management of how people with MND planned their end of life and the choices 
they could make for their care. The questions sought to determine whether the 
guideline recommendations were being followed, and if the people with MND 
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and their family members understood their care options. The research also 
explored the clinician and family view of the timing of referral to a palliative care 
service, and the barriers to implementing the recommendations for 
communication.  
  
Despite the bereaved family participant cohort of this study being small 
(six participants of which two were siblings interviewed together), their 
experiences provided valuable information. Of particular interest was the family 
perspective on the value of early referral to specialist palliative care. The most 
recent guidelines and recommendations advise referral to palliative care soon 
after diagnosis (NICE, 2016). However, none of the family participants nor the 
one person with MND interviewed, stated that palliative care was a service they 
required soon after diagnosis when they had so much to come to terms with in 
their lives already. Their reluctance could be due to the influence of a 
community-wide view of palliative care as a service associated with death, or 
that the services that palliative care provides were not adequately explained. In 
this research, those who were referred early felt it too confronting to 
contemplate at that time (F3, F5), particularly as the person with MND had 
minimal symptoms. The person interviewed with MND and three other families 
experienced late palliative care referrals when the symptoms had significantly 
worsened. Whilst beneficial to them for symptom control at that point, it was too 
late to adequately commence end-of-life care communication, fully understand 
the potential of NIV withdrawal and be able to plan for what was left of their 
lives. The understanding amongst the family participants of what palliative care 
could offer and how it can improve the experience for people with MND and 
their families appears to not be communicated by some clinicians. This finding 
was readily admitted to by many of the clinicians, particularly those involved 
early in the disease trajectory. The rationale for not referring or discussing 
specialist palliative care was stated to be a combination of the time required to 
have adequate end-of-life communication and the sense of taking away any 
hope the person with MND may have. There was also the barrier of the access 
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to palliative care services which differed geographically, in many instances 
determined according to a patient’s time left to live (in months).  
 
A nurse case manager involved soon after diagnosis of MND would offer 
continuity of service, facilitate collaboration between specialties and act as a 
conduit between clinicians, patient and their family. Rather than clinical 
speciality boundaries for care and communication, collaboration and sharing the 
cost of a nurse coordinator would not only save the specialists time (and 
money) but improve the experience for the person with MND and their family. 
The idea of a progressive timeline document for the patient, either hardcopy or 
an electronic app, that provides clear information about symptom description 
and significance, was informally discussed with the family participants and 
person with MND and was welcomed as a helpful idea to improve 
understanding and planning. However, further research into the design and 
structure of such an instrument is required. 
 
The opposition by families for multiple organisation involvement with 
patient care and the complaint of valuable time being taken by repetition of 
issues and perceived personal intrusion was a valuable finding of this thesis. 
However, it is a difficult issue to solve. Presently, Australia is very variable in 
how MDTs and community services are structured and offered to patients and 
families. Even within cities it depends on which area a person with MND lives as 
to how the services are structured and how accessible they are. This study 
recommends one single local organisation being charged with providing 
community nursing, palliative care, personal care, home help as well as a 
structured MDT to optimise patient care, efficiency and cost. Within this 
structure a nurse case manager would manage the patient requirements, assist 
with appointments and communicate between all health professionals involved. 
Such a model of care ought to be trialled and evaluated. 
 
As more research is undertaken into MND, hopefully all aspects of 
communication will be improved. In a very recent systematic review of 
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evidence-based studies into all aspects of multidisciplinary care in MND/ALS, 
timely symptom management and end-of-life communication are highlighted as 
areas needing improvement (Hogden, Foley, Henderson, James, & Aoun, 
2017).  The review incorporates many of the published research articles which 
broadly make up the most recent MND management recommendations 
(Andersen et al., 2012; National Institute for Health and Care Excellence, 2016). 
Hogden et al. (2017) discuss optimal management of palliative care as well as 
the effectiveness of MDTs for people with MND. Hogden et al. recommend the 
development of further guidelines to improve communication between clinicians 
to provide coordinated care for people with MND and their families. The 
research reported in this thesis echoes the findings and suggested further work 
by Hogden et al. (2017) and offers additional recommendations which may help 
to provide solutions to the barriers encountered in communicating end-of-life 
options in MND. 
  
Communication surrounding the initiation and withdrawal of NIV was the 
principle issue for this research. The experiences of the families and person 
with MND showed that despite the guidelines recommending communication of 
potential NIV withdrawal prior to initiation, this seldom occurred. This was 
reiterated by the health professionals responsible for NIV initiation and verified 
by the palliative care clinicians who in many cases felt they were the first to 
suggest this option. The reluctance to communicate NIV withdrawal and by 
default, end-of-life options prior to the terminal stage, had emotional 
consequences for the families and clinicians alike. This study established that 
whilst many of the clinicians involved with the early symptoms of MND vaguely 
knew the content of the most recent MND guidelines regarding communicating 
NIV withdrawal and end-of-life options, few followed the recommended timing of 
such communication. Some of the clinicians were not fully aware of the 
recommendations, and some decided to do what they considered best practice 
rather than follow the recommendation. The incorporation of an appropriately 
trained nurse case manager from diagnosis, in cooperation with the specialist 
clinicians, would help develop rapport with the patient and family, encouraging 
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such communication. In conjunction with either an electronic or hand-held 
progressive timeline instrument, end-of-life and symptom control options and 
communication would be documented for the family and patient to revisit and 
reacquaint themselves with their choices. By exploring family, patient and health 
professional perspectives on NIV and end-of-life communication, opportunities 
for further research have been identified from this study.  
 
This research adds valuable information and expands on the most recent 
literature with insights into family and patient preferred timing of palliative care 
and why communication between organisations and between clinicians and 
people with MND and their families is frequently difficult. MND is a progressively 
debilitating disease with some appalling symptoms and complex tangential 
dimensions such as FD. MND is also a complex disease, varied in its course 
and timing of symptoms and its rarity makes clinician experience in coping with 
those involved difficult. This research has taken a distinctive in-depth approach, 
covered many areas of importance and taken the time to extensively interview 
and listen to clinicians and families involved with MND.  
  
Whilst understanding that recall and retrospective memories can be 
confusing and influenced by situational variables, this thesis has provided 
insightful and valuable descriptive information which, it is hoped, may improve 
how people with MND are helped to understand and communicate their end-of-
life care. 
 
 The epilogue which follows explores the personal growth the candidate 
experienced whilst undertaking this study and the candidate’s appreciation of 
the enormity of receiving a diagnosis of MND for the person and family involved.  
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Epilogue 
Thesis Reflections 
 Exploring the communication surrounding the initiation and potential 
withdrawal of NIV in people with MND has provided the candidate with a 
profound understanding not just of the people with MND but their families, 
caregivers and clinicians. The participants spoke with sincerity and reflection 
which provided insightful information both for this study and to enable the 
candidate to improve her nursing and communication skills. 
 
 All the participants involved in this study were English-speaking as a first 
language. However, communication between clinicians and those with MND 
was often reported as confused, unclear and sometimes involved avoidance of 
the inevitable outcome of MND. The emotional impact and difficulty of delivering 
such devastating news to people with MND and their caregivers created 
communication barriers. This was clearly stated by C3: “So, I think it’s all about 
the quality of the communication leading up to that process (symptom relief, NIV 
withdrawal and end-of-life communication) and investing the time in the 
process.” 
 
Despite the English language being understood by all concerned, what 
was reported to be said and what was understood often appeared at odds. 
Perhaps the English language itself is partly to blame, with many words having 
different meaning to different people. An example of this was the word 
“prognosis” whose dictionary definition is “A medical prediction of the future 
course of a disease and the chance for recovery. Note: Prognosis is often used 
as a general term for predicting the unfolding of events” 
(www.dictionary.com/browse/prognosis). This term was most frequently used by 
clinicians to mean a prediction of length of time a person had left to live. 
However, in their conversations with clinicians many caregivers and people with 
MND appeared to understand the term to mean ”what to expect; symptoms and 
control methods, benefits and burdens of NIV and gastrostomy tubes” 
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Therefore, conversations appeared to disengage at that point unless the person 
with MND or their caregiver had the confidence or sufficient health literacy to 
ask further questions about symptom control or other aspects of prognosis. It 
would be unreasonable for a clinician to ensure that those involved with MND 
had the same literal meaning to every word used, but it might be an indication 
that verbal communication maybe insufficient to ensure understanding of the 
vital aspects of MND.  
 
 By the completion of data collection, no participant had had to cease the 
interview or request emotional support, and all sent affirming post-interview 
emails to the researcher. Most offered to answer more questions or be re-
interviewed should further information be required. All the bereaved participants 
stated that the interview was a cathartic experience for them and hoped the 
information they provided might enhance communication for those people with 
MND and their families in the future. The enthusiasm, insight and thought with 
which the family participants and the one participant with MND spoke meant the 
experience was as enlightening and profound for the candidate as it was a 
therapeutic for the participants. 
 
 As an investigator into understanding clinician’s delivery of end-of-life 
and symptom control communication and having listened to the experiences of 
the bereaved families, the candidate is left with an overwhelming feeling that 
clinicians are communicating as time dictates. There are too many variable 
influences at play to completely remove ambiguity and guarantee that crucial 
information is always fully understood by the recipient via verbal communication 
alone. It is hoped that some of the recommendations of this study will lead to 
further research and improved communication between clinicians and people 
with MND. Some of the clinical participants provided feedback either during or 
after the interviews which may indicate potential change, and these comments 
have been included within this thesis and epilogue. Time for professional 
reflection whilst answering the study questions appeared to be appreciated by 
all the clinicians interviewed: 
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C19: I think that set of questions is an excellent set of – if I may say so, Lottie, 
because you’ve covered so much there, and very astringently.  You know, 
you’ve gone into depth with each of those areas.  So, I think that that’s 
excellent.  No, that’s really good.  Yeah, yeah, I think that that’s good. 
  
C18: No, no, look, this is very important.  You’re doing great work.   
 
C15: That’s a very good question, Lottie, and I have to say I haven’t really 
pushed that differentiation on advance care directives.  But I think it is 
important, and perhaps in future I will. 
  
 I am immensely grateful for the opportunity to have undertaken this study 
and to have enhanced my own comprehension of the importance of clear 
communication not only with those involved with MND but generally in palliative 
care. It is my sincere desire that this study will lead to further investigation into 
the delivery of end-of-life communication and the understanding of the 
measures required by people with MND to ensure choices of symptom control 
are explained and understood. 
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ALS 
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Use of the Decision Process 
for Improving the Quality of 
Medical Decisions; a 
discussion paper. 
A theory of using a 
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/care provider to set a 
treatment strategy to 
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gap between 
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preferences. 
+ Suggested theory 
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in MND; a generalised 
approach to medical 
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By identifying an information gap 
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to care provider due to overwhelming 
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regret. 
 
Blackhall, L. (2012).  Amyotrophic lateral sclerosis 
and palliative care: where we 
are and the road ahead: data 
review. 
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specialists early in 
diagnosis and the 
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communication. 
 
 
 
 
 
 
+ A review of MND 
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of the role of American 
palliative care; some 
aspects of medical 
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Australia. 
Research from perspective of various 
medical specialties may assist in 
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Bourke, S., Tomlinson, M., 
Williams, T., Bullock, R., 
Shaw, P., & Gibson, G. 
(2006).  
Effects of non-invasive 
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amyotrophic lateral sclerosis: 
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Study showed NIV can 
maintain quality of life and 
offer some increase in 
survival, but not in people 
with MND with bulbar 
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 Identified NIV as a symptom control 
measure in some variants of MND. 
This study tries to understand which 
people with MND are offered and 
benefit from NIV. 
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Clinch, A., & Le, B. (2011).  Withdrawal of mechanical 
ventilation in the home: A 
case report and review of the 
literature. 
Identified the complexities 
when medical treatment is 
no longer useful and is 
withdrawn. 
+This study was based 
on a single case of 
mechanical ventilation.  
Identifies issues surrounding the 
withdrawal of treatment and the 
extensive communication required to 
ensure barriers removed. 
Connolly, S., Galvin, M, & 
Hardiman, O. (2015).  
 
End of life management in 
patients with amyotrophic 
lateral sclerosis: a review.  
This review encourages 
clinicians to ensure people 
with MND are prepared and 
appropriately supported for 
end-of-life. 
 The review recommends a greater 
emphasis on health professionals’ 
communication skills and palliative 
care approaches. 
Dharmadasa, T., Matamala, 
J., & Kiernan, M. (2016). 
Treatment approaches in 
MND: a review of health care 
professional’s attitudes to 
treatments/symptom control. 
The end-of-life phase is 
poorly defined, but the 
review suggests that 
symptoms of MND can be 
effective. 
 This review finds the end of life 
phase is poorly defined. A well-
structured MDT represents optimal 
care.  
Eng, D. (2006).  Literature review1966-2004; 
Cochrane library of 
systemic reviews, gray 
literature    through 
Caresearch. Management 
Guidelines for people with 
motor neurone disease on 
non-invasive ventilation at 
home. 
Exploration of issues 
surrounding the use of NIV 
with the objective of 
suggesting guidelines to 
ensure appropriate, 
structured and coordinated 
approach to NIV use in 
MND with a palliative care 
focus. 
 Highlighted the need for good, 
structured communication for 
NIV/MND and the ethical dilemma 
when NIV is withdrawn. 
 
European Federation of 
Neurological Societies and 
European Association of 
Palliative Care. (2014).  
New European Consensus 
on Palliative Care in Neuro 
Disease. 
A plan for palliative care 
medicine and neurology 
that includes advance 
health planning, 
family/caregiver support 
and end-of-life care. 
  Recommends early planning and 
open communication to enable 
patient involvement and goal setting. 
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Faull, C., Phelps, K., Regen, 
E., Oliver, D., McDermott, C., 
& Rowe-Haynes, C. (2014).  
Withdrawal of NIV at the 
patient's request in MND: 
exploration of the issues 
related to communication. A 
retrospective qualitative study 
involving 20 specialist 
doctors. 
Poster presentation: 
Withdrawal of NIV closely 
related to loss of patient 
ability to communicate. 
Clinicians require skills in 
communicating to ensure 
patient wishes and comfort. 
+ Study did not appear 
to include doctors 
involved with the 
initiation of NIV and 
the communication 
they provided to 
patients regarding 
withdrawal. 
Highlights the time-consuming and 
worrying aspect of communicating 
withdrawal of NIV, with attention 
drawn to the frequent lack of 
knowledge about patients’ wishes 
prior to their loss of ability to 
communicate clearly.  
Faull, C., Rowe Haynes, C., 
& Oliver, D. (2014).  
Issues for palliative care 
doctors surrounding the 
withdrawal of non-invasive 
ventilation at the request of a 
patient with motor neurone 
disease: a scoping study: 
electronic questionnaire to 
palliative care doctors.   
Withdrawal of NIV involves 
many challenges for 
palliative care doctors 
including emotionally, 
practically and ethically. 
*Possible that only 
doctor who had 
experienced problems 
was more inclined to 
respond to survey. 
NIV withdrawal guidelines suggested 
which incorporate an ethical 
statement. The study identified a 
better understanding of the difficulties 
of NIV withdrawal.    
 
Foley, G., Timonen, V., & 
Hardiman, O. (2014).  
Understanding psycho-social 
processes underpinning 
engagement with services in 
motor neurone disease: A 
qualitative study. 
Identified control, 
reassurance and trust vital 
for people with MND to 
communicate and engage 
with healthcare 
professionals. 
* Authors suggest 
findings may not be 
fully representative 
globally for people with 
MND. 
Findings suggest study group did not 
prioritise life-prolonging measures 
and there was some confusion in 
relation to the understanding of the 
role of PEGs. 
Greenaway, L., Martin, N., 
Lawrence, V., Janssen, A., 
Al-Chalabi, A., Leigh, P. N., 
& Goldstein, L. H. (2015).  
Accepting or declining non-
invasive ventilation or 
gastrostomy in amyotrophic 
lateral sclerosis: patients’ 
perspectives. Patient sample 
size of 78 offered PEG and/or 
NIV.  None of the 21 
interviewed had refused NIV. 
Individualised support is 
suggested to be preferable 
to responding to treatment 
guidelines, as this may be a 
too pressured approach for 
some patients.  
* Few NIV patients 
involved and no 
interviews with 
patients who had 
refused NIV. 
* Caregivers spoke on 
behalf of people with 
MND. 
This study recommended clear and 
high-quality information be provided 
for people with MND and their 
caregivers and suggested those with 
less understanding of their illness 
were potentially more likely to refuse 
an intervention.  
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Hardiman, O. (2011).  Management of respiratory 
symptoms in ALS; clinician’s 
discussion incorporating 
recent literature. 
Advance care directives 
should be suggested with 
respiratory failure to 
prevent emergency 
mechanical ventilation. 
 Implications of NIV and respiratory 
failure be discussed early in disease; 
no suggestion as to content of 
discussions and by whom. 
Jenkins, M, Hiollinger, H, & 
McDermott, C. (2014). 
The evidence for 
symptomatic treatments in 
amyotrophic lateral sclerosis; 
a discussion paper. 
NIV can improve quality of 
life however unclear if 
same applies to 
gastrostomy. 
+ Identifies symptoms 
of respiratory failure 
and implementation of 
NIV, but timing of 
discussions relating to 
end-of-life unclear. 
Suggests good evidence for NIV and 
some evidence for MDT involvement. 
Emphasis’s needs of the caregivers.  
Lemoignan, J., & Ells, C., 
(2010).  
ALS and assisted ventilation: 
How patients decide: 10 
semi-structured patient 
interviews (phenomenology). 
Discussions relating to NIV 
should be individualised 
and allow for patient 
autonomy. 
*Interviewer knew 
participants prior to 
research, which the 
author identifies, may 
have influenced the 
findings. *A small 
study.  
Further research necessary which 
explores ALS patient decision 
making. 
 
 
 
Lerum, S., Solbrække, K., 
Nyheim, H., & Frich, J. 
(2016).  
Family caregivers' accounts 
of caring for a family member 
with motor neurone disease 
in Norway. 25 participants; 17 
active and 8 bereaved 
caregivers. A qualitative 
study 
 People with MND with 
cognitive impairment may 
not have the concept of 
burden of care by their 
caregivers. 
*Researchers 
identified possible 
skewed information by 
family members when 
communicating on 
behalf of their family 
member with MND. 
Rapidly changing situation may 
compromise caregiver ability to 
access adequate help from health 
professionals. 
Lerum, S., Solbrække, K., 
Nyheim, H., & Frich, Jan C. 
(2015).  
Unstable terminality: 
negotiating the meaning of 
chronicity and terminality in 
motor neurone disease. A 
systematic review. 
Limiting futile palliating 
treatments, good symptom 
management, respect and 
dignity remain key aspects 
of patient centered care. 
 Effective communication and shared 
decisions of care remain the most 
important palliative care 
requirements found in people with 
MND. 
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Author and year 
 
Research Design: 
sample, size and sites 
Comments and key 
findings 
Limitations Implications of findings for 
thesis research and questions 
 
Martin, N., Landau, S., 
Janssen, A., Lyall, R., 
Higginson, I., Burman, R., 
Goldstein, L. (2014).  
 
Psychological as well as 
illness factors influence 
acceptance of non-invasive 
ventilation (NIV) and 
gastrostomy in amyotrophic 
lateral sclerosis (ALS): a 
prospective population study 
in 78 ALS and 50 caregivers. 
Provides insight into 
complexity of patient 
factors to be considered 
when providing patients 
with information relating to 
NIV and PEG use e.g. IQ, 
education level. 
* Follow-up data was 
limited particularly 
relating to patients 
refusing NIV. Decision 
making about NIV and 
PEG grouped 
together. 
Study suggests how further work 
should try to clarify that MND/ALS 
patients are not either denied or 
pressured into treatment and 
decisions; and that cognitive and 
psychosocial factors need to be 
considered. 
McConigley, R., Kristjanson, 
L. J., Aoun, S. M., Oldham, 
L., Currow, D. C., O'Connor, 
M., & Holloway, K. (2014).  
Staying just one step ahead: 
providing care for patients 
with motor neurone disease. 
Interviews and focus groups 
with 31 specialists. 
Highlights the need for 
further education for 
clinicians relating to MND 
and the complex 
communication issues. 
*Results limited by 
small number of 
participants. Focus 
group limited as run 
during national 
conference. 
Introducing palliative care to people 
with MND/family provided 
communication difficulties for 
clinicians.  
Miller, R., Rosenberg, J., 
Gelinas, D., Mitsumoto, H., 
Newman, D., Sufit, R., Force, 
and the ALS Practice 
Parameters Task. (1999).  
Practice Parameter: The 
Care of the Patient with 
Amyotrophic Lateral 
Sclerosis; An Evidence-
Based Review. 
Report of the sub-
committee of the quality 
standards of American 
Academy of Neurology. 
 Recommends an area of further 
research into the decision-making 
process in patients to understand 
most important factors.  
Mitsumoto, H., & Rabkin, 
J.G. (2007). JAMA, 298(2), 
207-216. 
Palliative Care for Patients 
with Amyotrophic Lateral 
Sclerosis: "Prepare for the 
Worst and Hope for the 
Best". A clinician’s personal 
perspective. 
Fast deterioration phase, 
impairing communication 
and respiration. Burden for 
clinician to preserve hope 
whilst discussing AHD’s. 
 The author acknowledges that the 
terminal phase of MND is often too 
fast for caregivers and patient to 
adjust to changes. Clinician must 
have communication early in the 
disease process to enable 
adjustment. 
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Author and year Research design: sample, 
size 
Comments and key 
findings 
Limitations Implications of findings for 
thesis research and questions 
 
Motor Neurone Disease 
Australia. (2012).  
Palliative Care in  
Australia; senate inquiry. 
 
Efficient use of palliative 
care resources and access 
to MND specific palliative 
care information and 
funding for research to 
provide a national 
framework. 
 Promotes timely and targeted 
information and benefits of palliative 
care for people with MND. 
 
 
National Institute for Health 
and Care Excellence. (2014).  
 
Treatment with NIV for 
patients with Motor Neurone 
Disease; a pathway designed 
to assist clinicians inform 
people with MND of their 
choices of symptom 
management. 
An interactive pathway to 
assist clinicians guide 
people with MND; section 
on NIV use and 
recommendations. 
+ designed for the UK 
with slightly different 
availability of 
specialists and 
proximity to hospitals. 
Reiterates discussion regarding the 
benefits and burdens of NIV and 
regular opportunities to discuss 
continuing or withdrawal of NIV. 
Neudert, C., Oliver, D., 
Wasner, M., & Borasio, G. 
(2001).  
Telephone interviews with 
121 caregivers, 8 nurses and 
3 physicians present at the 
time of death of people with 
MND. 
The course of the terminal 
phase in patients with 
amyotrophic lateral 
sclerosis is generally a 
peaceful one. 
* German/UK data 
which may not 
compare with if patient 
groups different. *Also, 
a third of caregivers 
could not be 
contacted. 
NIV reported by caregivers to be 
beneficial but no report on the 
communication surrounding the 
initiation or withdrawal. 
 
 
 
 
 
 
Oliver, D., Borasio, G., & 
Walsh, D. (2006).  
Palliative Care in 
Amyotrophic Lateral Sclerosis 
from diagnosis to 
bereavement; a book 
covering all aspects of MND 
care. 
 
Comprehensive book from 
diagnosis to death of MND 
patient, covering all aspects 
of symptom and 
psychological care for 
patients and families. 
Recommendations 
broadly based on 
NICE (2010) and 
American Academy of 
Neurology guidelines 
for NIV/MND. 
Emphasis on the need for explicit 
and honest communication regarding 
benefits and burdens plus disease 
progression on NIV.   
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Author and year Research design: 
sample, size 
Comments and key 
findings 
Limitations Implications of findings for 
thesis research and questions 
 
Oliver, D., Campbell, C., 
Sykes, N., Tallon, C., & 
Edwards, A. (2011).  
Decision-making for 
gastrostomy and ventilator 
support for people with motor 
neurone disease: variations 
across UK hospices: a 
telephone audit of 22 
palliative care specialists. 
Identifies a need for greater 
application of guidelines for 
NIV and PEG; also 
identifies combined 
approach inclusive of other 
services. 
 Whilst contact is made between 
specialists, communication could be 
improved by clear, known and 
utilised guidelines. The aim of study 
was to encourage discussion. 
Oliver, D, & Faull, C. (2013).  
 
Non-invasive ventilation in 
amyotrophic lateral 
sclerosis/motor neurone 
disease; a discussion paper. 
Careful discussions 
essential prior to 
commencement of NIV so 
patients are aware of 
benefits and burdens. 
 States the importance of 
communicating the benefits and risks 
associated with NIV to people with 
MND prior to initiation. Recommends 
further research on impact of 
withdrawal on families. 
Pagnini, F., Banfi, P., Rossi, 
G., Castelnuovo, G., 
Marconi, A., Fossati, F.,  
Molinari, E. (2012).  
Respiratory function of 
people with amyotrophic 
lateral sclerosis and caregiver 
distress level: a correlation 
study using questionnaires.  
Correlations between a 
caregiver’s level of distress 
and a patient’s respiratory 
function; shows importance 
of caregiver’s function. 
*No contributory 
inferences can be 
made as this is a 
cross-sectional study 
*small study 
sample.  
If a caregiver has the potential to 
influence the person with MND’s 
respiratory function, then the 
relevance of complete understanding 
of the benefits and burdens of NIV 
may influence not only the patient 
choices but quality of the remaining 
life as well as the quality of life of 
their caregivers. 
Phelps, K, Regen, E, Oliver, 
D, McDermott, C, & Faull, C. 
(2015).  
Withdrawal of ventilation at 
the patient's request in MND: 
a retrospective exploration of 
the ethical and legal issues 
that have arisen for doctors in 
the UK. Qualitative research: 
24 interviews with doctors. 
Ethical and legal advice 
and guidance required to 
support clinicians in NIV 
withdrawal in MND. 
 The ethical and moral dimensions for 
communication surrounding the 
initiation and withdrawal of NIV are 
discussed with doctors. Study 
suggests greater integration of 
neurology and palliative care 
specialties. 
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Author and year Research design: 
sample, size and sites 
Comments and key 
findings 
Limitations Implications of findings for 
thesis research and questions 
 
Phukan, J., & Hardiman, O. 
(2009). Journal of Neurology, 
256, 176-186.  
The management of 
amyotrophic lateral sclerosis; 
a review of current practice.  
Recognises strategies in 
cognitive management, 
caregiver burden and 
depression guided by the 
American Academy 
Practice Parameter. 
 Symptom relief and slight increase in 
survival, caregiver burden should be 
discussed early in diagnosis, and 
discussions relating to the withdrawal 
of NIV should be included. 
Phukan, J, Elamin, M, Bede, 
P, Jordan, N, Gallagher, L, 
Byrne, S, . . . Hardiman, O. 
(2012).  
 
The syndrome of cognitive 
impairment in amyotrophic 
lateral sclerosis: A 
prospective population-based 
study in 160 ALS patients 
and 110 control patients. 
Co-morbid dementia found 
to occur in 14% of newly 
diagnosed ALS patients 
and some cognitive 
impairment in 40 % of ALS. 
*Study limited to 
analysis of cognitive 
dementia; subtle 
behavioral changes 
did not fulfill study 
criteria.  
Cognitive impairment may occur in 
40% of ALS patients; the implications 
of cognitive impairment may affect 
communication and understanding 
skills? 
Preston, H., Fineberg, I., 
Callagher, P., & Mitchell, D. 
(2011).  
 
 
The preferred priorities for 
care document in motor 
neurone disease: Views of 11 
bereaved relatives and 
caregivers; semi-structured 
interviews. 
Discusses the use of a 
document which describes 
a patient’s priority of care 
(PPC). Document seen as 
a good prompt for difficult 
decisions between 
clinicians and patients.  
*Due to limited 
resources, a small 
study the findings of 
which cannot be 
generalized. 
*Possible 
unintentional male 
gender bias.  
Used as a communication aide; 
A document of this type may help to 
improve or offer triggers to clinicians 
to initiate end-of-life discussions. 
Participants felt the document had 
little impact on actual end-of-life care. 
 
Rafiq, M., Proctor, A., 
McDermott, C., & Shaw, P. 
(2012).  
Respiratory management of 
motor neurone disease: a 
review of the current literature 
and discussion paper. 
 
The impact of the use of 
NIV for treating respiratory 
weakness. Palliative care 
needs and stopping NIV 
support /end-of-life issues 
should be regularly 
discussed with people with 
MND. 
 Outlines the problems which can be 
associated with NIV plus the benefits 
if patients are able to tolerate it. 
Discusses palliative care strategies 
as alternatives to NIV and reiterates 
the importance of ascertaining the 
patient’s wishes regarding their end-
of-life care at the time of or soon after 
the initiation of NIV. 
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Author and year Research design: 
sample, size 
Comments and key 
findings 
Limitations Implications of findings for 
thesis research and questions 
 
Radunovic, A., Annane, D., 
Rafiq, M., & Mustfa, N. 
(2013).  
Mechanical ventilation for 
amyotrophic lateral sclerosis / 
motor neurone disease. 
Search and review of 
Cochrane Neuromuscular 
Disease Group literature 
regarding NIV use. 
Review suggests that NIV 
can increase and improve 
the life of people with ALS. 
 Suggests further research to 
understand the influences which 
affect access to NIV, the cost 
personally and economically for 
patients and their families. 
Ray, R., Brown, J., & Street, 
A. (2014).  
Dying with motor neurone 
disease, what can we learn 
from family caregivers? 
Secondary analysis from two 
data sets employing similar 
data collection and analysis. 
Recommends effective 
planning for death; 
normalise the dying 
process in MND from 
caregiver perspective.  
*Sample size limited 
despite data from two 
countries. 
Identifies the need for strategies to 
encourage and normalise end-of-life 
discussions and AHDs. 
 
 
 
Virdun, C., Luckett, T., 
Davidson, P. M., & Phillips, J. 
(2015).  
Dying in the hospital setting: 
A systematic review of 
quantitative studies 
identifying the elements of 
end-of-life care patients and 
their families rank important. 
This review reiterates the 
domains of palliative care 
most important to patients 
and their families. 
 Effective communication and shared 
decisions regarding treatment are 
fundamentally important at the end-
of-life particularly relating to the 
hospital environment. 
Wood-Allum, C., & Shaw, P. 
(2010).  
Motor neurone disease: a 
practical update on diagnosis 
and management based on a 
lecture given by author. 
A general update on MND 
care, reinforcing the need 
for discussions with 
patients and families 
relating to NIV ahead of 
need. 
 Due to proven prolonged survival, 
clear discussions must be held with 
patients and families well ahead of 
commencement of NIV. 
  
Note:  Symbols used within table:     * Authors identified limitation     + Candidates suggested limitation  
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Appendix A: 2) Summary of Additional Literature Relevant to Study: July 2016-July 2017 
Author and year Research design Comments and key 
findings 
Limitations Implications of findings for 
thesis research and questions 
 
Danel-Brunaud, V., 
Touzet, L., Chevalier, L., 
Moreau, C., Devos, D., 
Vandolaeghe, S., & 
Defebvre, L. (2017b).  
A review. Ethical considerations and 
palliative care in patients 
with amyotrophic lateral 
sclerosis. 
 A good perspective of the ethical 
issues to be considered in MND/ALS. 
Smith, T., Disler, R., 
Jenkins, C., Ingham, J., & 
Davidson, P. (2017).  
A qualitative study using 
thematic analysis. 
Perspectives on advance 
care planning among 
patients recently requiring 
non-invasive ventilation for 
acute respiratory failure. 
 Explains the complexities and 
perspective of NIV use in acute 
respiratory failure illustrating similar 
ethical and communication difficulties 
as in MND. 
Hogden, A., Foley, G., 
Henderson, R.James, N., 
& Aoun, S. (2017)  
A review. Amyotrophic lateral 
sclerosis: improving care 
with a multidisciplinary 
approach. 
 Further exemplifies the desired care 
for people with MND by improving the 
MDT approach. 
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Appendix C: Ethics ECU Amendments. 
 
Hi Lottie 
 
Project: 12099 CHAPMAN 
Project Name: A retrospective study into the communication surrounding 
the initiation and withdrawal of non-invasive ventilation (NIV) in patients 
with motor neurone disease 
 
Thank you for your email requesting amendment to your ethics application. The 
following amendment has been reviewed by members of the Human Research 
Ethics Committee: 
 
 Inclusion of the stories of people with MND who spontaneously contacted 
the researcher to participate in the project. The researcher will not be not 
recruiting people with MND however has requested to include these 
people as part of the project. 
The Information Letter and Consent Form for family members (already 
approved) will be used for people with MND to provide consent for 
inclusion in the project.  
 
Ethics approval has been granted for this amendment. 
 
Kind Regards 
 
Faye 
 
Faye Walmsley 
Ethics Support Officer 
Office of Research & Innovation, Edith Cowan University,  
270 Joondalup Drive, Joondalup, WA 6027  
Tel: +61 08 6304 5032 | Fax: +61 08 6304 5044 | CRICOS IPC 00279B 
Email: research.ethics@ecu.edu.au 
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Hi Lottie 
 
Project: 12099 CHAPMAN 
Project Name: A retrospective study into the communication surrounding 
the initiation and withdrawal of non-invasive ventilation (NIV) in patients 
with motor neurone disease 
 
Thank you for your email requesting an amendment to your ethics 
application. The following amendment has been reviewed by members of the 
Human Research Ethics Committee: 
 
 Advertise the project through interstate contacts via palliative, MNDA 
(general) websites or word of mouth 
 
Ethics approval has been granted for this amendment. 
 
Kind Regards 
 
Faye 
 
Faye Walmsley 
Ethics Support Officer 
Office of Research & Innovation, Edith Cowan University,  
270 Joondalup Drive, Joondalup, WA 6027  
Tel: +61 08 6304 5032 | Fax: +61 08 6304 5044 | CRICOS IPC 00279B 
Email: research.ethics@ecu.edu.au 
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Appendix D: Clinician Participant Questions 
Semi structured questions and prompts for clinicians 
Target group Clinicians 
Clinicians involved/experienced with patients with MND who are: 
 At the stage of respiratory decline and NIV initiation, and /or  
 Involved with the terminal stage of the disease process when the 
withdrawal of the NIV is considered.  
These may be general practitioners, respiratory physicians, neurologists, 
palliative care specialists, palliative care nurses (Registered and Enrolled 
Nurses) and allied health professionals.  
 
Questions are prompts only and will not be asked if they have been 
answered previously.  
Introduction 
 Thank you for making the time to help with this research.  
 As you know my name is and my background is….  
Aim 
 As you know from the information sheet, the aim of this research is to 
understand the communication surrounding the initiation and withdrawal 
of non-invasive ventilation in patients with MND, including the benefits, 
burdens and limitations in order to optimise future health care provided.  
Consent & control of the interview and support if required 
 Everything you tell me is confidential.  I will not reveal your identity to 
anyone and I will de-identify the information you give me by using 
codes known only to me. If you give me permission I may use some of 
your quotes but these comments will remain anonymous. I’d like to 
thank you in advance for your contributions to this research, as it will 
help improve care provided to people with MND and their families.  
 
 I would like to tape the interview so that I can concentrate on listening 
to you rather than writing. 
  
 Is that okay?   YES    NO 
  
 It is up to you how much you want to say and if there’s a question you 
would rather not answer, you can just say you don’t want to answer it.  
If at any point you want to stop, pause for thought or reschedule the 
interview, you simply have to say so.  
  
 (I would like to remind you of your employer assistance program (EAP) 
should you feel you would like to discuss any issues that have 
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adversely affected you, and the availability of a Lifeline Counsellor 
(92614444) or Lifeline Crisis Line (131114)  
I will turn the tape on now. 
General introduction open-ended questions which may 
negate the need for some of the question prompts 
1. Before we start on the more structured questions, do you mind my asking 
general questions relating to your area of expertise is and how long have 
you been practicing in your specific area?  
 
2. What is your ‘role’ here at [NAME OF CLINIC, HOSPITAL, GP 
PRACTICE]?  
 
3. Have you undertaken any ‘specialty’ training either related to or not 
directly related to your own discipline?  What/Where/When? 
 
4. Can you provide an estimate of your current practice in terms of 
percentage of people with MND (e.g., 80%)? 
 
5. Understanding that MND is a rare disease, how much experience in 
terms of years, have you had working with patients diagnosed with 
MND? 
 
6. Do you work within a multidisciplinary team?  YES  NO 
  
IF NO: Do you refer the MND patient at diagnosis to the 
multidisciplinary team associated with you? 
 
 
7. How involved are the MND patient’s general practitioners with ongoing, 
day-to-day care?  
Next I’d like to discuss what information you provide to people with MND 
and their families:  
8. The NICE MND NIV guidelines and much of the recent literature, 
recommends various trigger points for ‘honest’ communication with 
patients and families relating to end-of-life care and the benefits and 
burdens of NIV. With that in mind; 
 8.1 Please can you tell me when in the patient’s journey you usually 
have these conversations?  
 8.2 At which stage are end-of-life issues addressed by your team, 
and is there standardised information offered to patients and families? 
 8.3 Are there specific trigger points within the disease trajectory that 
you use as an opening for these honest discussions? 
 8.4 Is the patient’s prognosis included in these ‘honest’ discussions? 
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 8.5 Is there anything else you would normally include in ‘honest’ 
communication? 
 8.6 Is there usually only one “honest” communication session or are 
there usually more than one, and do these conversations include 
family members? 
 8.6 How do you assess whether the MND patient and family have 
fully comprehended the information regarding prognosis, end-of-life 
and NIV implications communicated by you?  
 8.7 In your experience are people with MND, families and significant 
others adequately aware of the prognosis and limitations of treatment 
options for the disease prior to your involvement with them? 
 8.8 If the patient with MND declined to have family members present 
at the time of sensitive discussions, how is medical and general 
support information provided to the families/caregivers? 
 
9. Thinking how you approach the discussion with patients with MND at the 
start of NIV, what information do you usually give? 
 9.1 Is end-of-life care discussed at this time? 
 9.2 What are the specifics of the benefits, burdens (including carer 
burden) and limitations of NIV that you always discuss with people with 
MND? 
 9.3 Is the potential of increased dependency on NIV discussed? 
 9.4 Is hydration and nutrition mentioned i.e. PEG/RIG insertion? 
 9.5 Do you usually include information about physical support i.e. 
potential equipment needs, and psychological support for both patient 
and family when NIV is commenced? 
 
10. What, in your opinion, do people with MND need to know to be able to 
make an informed decision regarding the use of NIV? 
 
11. Do you feel that the communication between you and other healthcare 
providers relating to MND patient treatment and/or medical care is 
adequate to ensure patient and family understanding of: 
 11.1 Symptom relief options i.e. PEG/NIV 
 11.2 What to expect relating to disease progression and death 
 11.3 Psychological support for patients 
12. Do you consider NIV a palliating measure in people with MND, and if so, 
do you describe it as such?  
13. When in your opinion, should people with MND become involved with the 
palliative care team?  
14. Have you had experience of any people with MND declining the use of 
NIV at the stage when the respiratory muscles and diaphragm start to fail 
and if so what were the MND patient’s reasons and what alternatives did 
you give (palliative care options?)   
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15. When do you usually discuss the potential/eventual withdrawal of NIV 
with the patient/family:  is there a trigger point or indication that this 
conversation should occur?  
16. Were discussions relating to possible NIV withdrawal reiterated during 
the course of the MND patient’s use of NIV?  
17. How is the specific information given; verbal and written form? Who by? 
Now I’d like to discuss the communication you may have with people 
with MND and their families around the actual terminal phase of the 
disease, or the end-of-life issues: 
18. As the patient’s swallow is adversely affected (or prior to), is the use of 
PEG/RIG tube discussed with the family and patient in relation to 
prolonged survival? When would this be discussed? 
 
19. Do you differentiate between nutrition and hydration in the context of 
ongoing patient survival, particularly if the patient has 
indicated/documented a desire not to be kept alive? 
 
20. Do you mention hydration via a PEG/RIG for patient comfort of alleviating 
feelings of dehydration? 
 
21. Do you weigh your MND patient prior to the PEG insertion, in order to 
monitor weight changes? 
 
22. Have you ever had issues with people with MND in the end-of-life stage 
indicating they were dry or dehydrated? YES/NO: 
23. Do you think dehydration is a problem for some people with MND at the 
end of life? 
 
24. When NIV and PEG/RIG’s are initiated, what if any further directions are 
incorporated into the AHD? (Are nutrition and hydration discussed in 
relation to the end-of-life stage and as separate entities, and how are 
these documented?) 
25. When do you discuss Advance Health Directives with people with MND?  
26. When an exacerbation of the disease occurs, are the Advance Health 
Directives re discussed and clarified? If so by whom?  
 
27. Understanding that dementia/personality changes can be subtle and can 
affect people with MND decision making, have you had changes to the 
patient’s wishes/AHD which have surprised you i.e. not as understood by 
family and yourself to be the wishes of that patient or lack of 
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understanding of the importance? (should AHD’s be discussed at 
diagnosis and at revisited at various trigger points onwards?) 
 
28. Are the family incorporated into discussions relating to the Advance 
Heath Directives? If not, when are the patient’s wishes discussed with 
families or significant others? 
29. Generally, in your experience, are the Advance Care Directives clearly 
detailed enough to ensure the wishes of the patient are upheld? 
30. Are potential emergency presentations to hospital with shortness of 
breath discussed in relation to tracheostomy (discussions which include 
family/significant others?)? 
31. Is the difference between NIV and tracheostomy (invasive ventilation) 
explained?  
32. Have you ever been involved with the withdrawal of NIV in an MND 
patient and if so can you describe the situation(s)? 
33. Do you have any other comments about the withdrawal of NIV? 
34. Do you have any comments relating to the communication surrounding 
NIV initiation or withdrawal? 
  Anything about the issues relating to NIV use? 
 Anything about the terminal stage of the disease? 
  
35. What are the barriers to discussion between clinician and patient, 
significant others and caregivers about commencement and subsequent 
withdrawal of NIV? 
 
36. Anything else you think I should know about your experience in 
communicating about the MND experience for patients? 
 
Thank you for participating in this research 
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Appendix E: Family Participant Questions 
The following questions and statements are considered prompts for 
interviews with family members and significant others of people who have lived 
with Motor Neurone Disease. Questions will not be asked if they have been 
answered previously.  
 
Introduction 
 Thank you for making the time to help with this research.  
 As you know my name is and my background is….  
Aim 
 As you know from the information sheet, the aim of this research 
is to understand the communication surrounding the initiation and 
withdrawal of non-invasive ventilation in patients with MND, 
including the benefits, burdens and limitations in order to optimise 
future health care provided.  
Consent & control of the interview and support if required 
 Everything you tell me is confidential.  I will not reveal your 
identity to anyone and I will de-identify the information you give 
me by using codes known only to me. If you give me permission I 
may use some of your quotes but these comments will remain 
anonymous. I’d like to thank you in advance for your contributions 
to this research, as it will help improve care provided to people 
with MND and their families.  
 I would like to tape the interview so that I can concentrate on 
listening to you rather than writing. 
 Is that okay?  YES    NO 
 It is up to you how much you want to say and if there’s a question 
you would rather not answer, you can just say you don’t want to 
answer it.  If at any point you want to stop, pause for thought or 
reschedule the interview, you simply have to say so.  
 Details of a free counselling service and the MNDAWA Care 
Advisory team offering emotional support and advocacy (Motor 
Neurone Disease Association of WA Inc Phone: 9346 7355) are 
supplied to you should you wish to discuss any issues which may 
arise from the research interview.  
 
Individuals who may become upset may choose to cease the interview or 
continue. I will provide information about support available through the Motor 
Neurone Disease Association of Western Australia (MNDA [WA]) emotional 
support program which they may choose to access soon after or at a later date. 
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I will also offer a written handout with details on Lifeline Counsellor (92614444) 
or Lifeline Crisis Line (131114). Individual participants may elect not to answer 
any of the questions given as prompts. 
I will turn the tape on now. 
General introduction open ended questions which may negate the need 
for some of the question prompts 
 If you feel comfortable with discussing your family member, (may I call 
him/her by his/her Christian name?) perhaps you would like to tell me 
something about his/her life prior to the diagnosis on MND?  
 Are you able to tell me about how the diagnosis was made and how you 
both came to understand that he/she had MND? 
 When you heard the diagnosis, did you have any concept of MND and 
the implications of the disease?  
 May I ask how or whether you searched for further information and if so 
from where did you seek this information? 
 As time and the disease progressed, how did this affect you both and 
those within your extended families and friends? 
 May I ask how long from the time of a definite diagnosis until your family 
member died? 
 Do you mind my asking your family member’s age on diagnosis and in 
which area were you living? This is just for general demographic 
information and anonymity by using coding as previously described, is 
assured. 
Question prompts 
1. Who initially discussed NIV with you and your family member with MND? 
(prompt: GP, Respiratory specialist, Neurologist) 
 
2.It is a recommendation of MND guidelines and some journal articles that 
‘honest’ communication occurs between doctors and people with MND and their 
families. Do you consider that your conversations with the doctors contained the 
‘honest’ information you required? 
 
3.Thinking back to when non-invasive ventilation (NIV) was first discussed, what 
information was given to you at that time about it? (prompt:I will explain about 
NIV if this is required). What information was provided about: 
 the benefits,  
 the burdens and  
 the limitations?  
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4. When NIV was first discussed, was there information given about the 
possible need of a feeding tube to be inserted into the abdomen? (prompt: 
PEG/RIG) 
 Did you understand that your family member’s ability to swallow could 
be affected by the disease? 
 Was there a discussion about nutrition and hydration via the feeding 
tube? 
 
5. What information was given to assist you and your family member make a 
decision to start or decline NIV?  
 For example any paperwork relating to support groups in your 
area, palliative care or equipment availability? 
 
 Were any alternatives offered such as general support and 
palliating medications? 
6. Do you recall mention of NIV eventually no longer being useful and having to 
be withdrawn? 
 Please tell me what you understood then about what “withdrawal” 
meant? 
 Did you understand that the disease would still progress even 
with NIV? 
7.Can you remember the clinician who initiated NIV having conversations with 
you about the end-of-life of your family member with MND?  
 Can you recall how you understood what was discussed?  
 Can you remember when an Advance Health Directive (AHD) 
was first discussed? 
 Do you recall what was included within the AHD? 
 
8. Was positive invasive ventilation (tracheostomy) mentioned or explained? 
(prompt: sometimes, patients have an emergency tracheostomy unless they 
have made it very clear they do not want this kind of emergency treatment) 
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9. Knowing what you know now:  
 Is there anything you did not understand about NIV? 
 Is there anything you wish you had known? 
 Is there anything that would have changed the decisions or 
choices relating to NIV made by your family member with MND or 
yourself? 
 Who would you like to have explained those choices to you? 
 When do you think would have been the best time to explain this? 
10.What do you think are the important things to know in order to be able to 
make an informed decision about using NIV? 
 In hindsight, how satisfied are you with the use of NIV and the 
end-of-life process? 
 Did the communication prior to the commencement (or refusal) of 
NIV cover the relevant information on the benefits, burdens and 
limitations? 
11.In the case of the person you knew who had MND: 
 How informed do you think their decision (commencement or 
refusal) regarding the use of NIV was? 
 Was the withdrawal of NIV discussed and if so when and by 
whom? 
 Were you present when this discussion took place? 
 Was the Advance Health Directive re discussed during the 
progression of the illness?  
 At what stage was this discussed? 
 Did this AHD include the commencement and withdrawal of NIV? 
12.If the patient with MND declined to have family members present at the time 
of discussions about NIV, were you (as a family member or significant other) 
able to obtain information relating to ongoing patient care? 
 
13.During the last few days of your family member’s life, are you aware if they 
experienced any feelings of dehydration or dryness?  
 If so was it felt that to offer water via the feeding tube (if they had 
one) would prolong their life?   
 Was this potential issue discussed clearly with you by the 
doctors? 
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14.If the NIV was withdrawn can you describe what happened and whether you 
were fully informed for the sequence of events before the withdrawal?  
 
15.Who explained what was going to happen? 
 
16.Was this the same as the explanation given before the NIV was 
commenced? 
 
17.Would you have liked more information before the NIV was withdrawn? 
 From whom? 
 When? 
18) Do you recall if the person you knew who had MND had involvement with a 
multidisciplinary team; specialists to cover all different areas of their care?         
 Speech Pathologist 
 Respiratory Physician 
 Social Worker 
 Palliative Care  
 Occupational Therapist  
 Physiotherapist 
 General Practitioner 
 Neurologist  
  
 18. B) of all the specialists involved, which of the health 
professionals had overall responsibility for your family member’s 
ongoing care? 
19.If the MND patient you knew decided not to commence on NIV, what options 
were suggested i.e. palliative involvement/symptom control and support? 
 
20.How satisfied were you with your family member with MND end-of-life care 
and the communication between the patient, family/significant other and the 
clinicians? 
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21.Please comment on any discussions which you would have liked to have 
taken place, with whom and how would you have liked those discussions? 
 
22.Please add any comments relating to your understanding of the person you 
knew that had MND and their choices of treatment.  
 
                                                      Thank you for participating in this research 
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Appendix F: Participant Consent Form 
 
 
A retrospective study into the communication surrounding the 
initiation and withdrawal of non-invasive ventilation (NIV) in 
patients with motor neurone disease 
 
This study has been approved by the Edith Cowan University Human Research 
Ethics Committee. 
 I have been provided with a copy of the “Participant Information Letter”, 
explaining the research project. 
 I have read and understood the information provided. 
 I have been given the opportunity to ask questions and have had any 
questions answered to my satisfaction. 
 I am aware that if I have any additional questions I can contact the research 
team. 
 I understand that participation in the research project will involve participating 
in a face to face or telephone interview. 
 I understand that the information provided will be kept confidential; the 
identity of participants will not be disclosed; and that all information will be 
securely stored. 
 I understand the information provided will be used for the purposes of this 
research and may be included in future research projects, and I understand 
how the information is to be used. 
 I understand the research content will be presented for publication and I will 
be given the opportunity to read the research prior to publication 
 I understand that my involvement is voluntary and I can withdraw at any time 
without an explanation or penalty. 
 I understand that the content of this research may cause some possible 
sadness and that professional counsellor information and contact details will 
be offered to all participants 
 
 
____________________  ____________________ 
 _______________ 
Signature    Print name    Date 
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Appendix G: Clinician Participant Information  
A retrospective study into the communication surrounding the initiation and withdrawal 
of non-invasive ventilation (NIV) in patients with motor neurone disease 
 
Dear ………(doctor or nurse) 
My name is Lottie Chapman, a Registered Nurse, and Ph.D. candidate in the School of Nursing 
and Midwifery, Edith Cowan University.  I am writing to you to ask for your participation in the 
research I am conducting for my Ph.D.   
The aim of my research is to explore the communication process that occurs between 
clinicians, patients and significant others regarding the initiation (or refusal) and withdrawal of 
non-invasive ventilation (NIV) for people diagnosed with Motor Neurone Disease (MND).  
Communication around NIV has been identified as an area needing further research (National 
Institute for Health and Clinical Excellence, 2010). In this study, I am looking specifically at how 
clinicians, patients and families make treatment decisions and how this decision-making can be 
improved. This study has been approved by the Edith Cowan University Human Research 
Ethics Committee as research for a PhD.  
You are invited to discuss your experiences with MND and specifically NIV, contributing 
to recommended research into NIV communication.  Participation involves one face-to-face or 
telephone interview with me, a nurse researcher, which will last 20-30 minutes and will occur at a 
time and place most convenient for you. Your participation is entirely voluntary and you may cease 
or withdraw from the interview at any time. 
 The interview will be audio taped for accuracy.  All information will be kept private and 
confidential, and no identifying information will be released to any source except where required 
by law. A research identification number will be assigned to the interview and associated 
transcripts and only I will know the identity of the respondent.  All data will be stored on password-
protected computers in the researcher’s office at ECU. Only authorised persons, who understand 
that this information must be kept confidential, will have access to it.  When the study has been 
completed, all anonymous recordings and written documentation will be archived and stored in 
securely locked files for a minimum period of five years, as required by law.  Your answers will be 
combined with the answers from other people for analysis and reporting purposes. Findings will 
be reported in my dissertation and may be published in relevant health related peer-reviewed 
journals. No personal or identifying information will be conveyed in any of the publications arising 
from this research. By taking part in this study you agree not to restrict the use of any data, even 
if you withdraw. 
Although this study might not benefit you or your patients directly, this study should 
contribute to a better understanding of the complex issues involved in treatment decision-making 
for seriously ill patients. Should this research raise any emotional concerns or questions, and you 
wish to have someone to talk with you, support information from your free employer counselling 
scheme (EAP) is available or information for Lifeline counsellors will be supplied to you.       
 All clinical participants (respiratory, neurologists, palliative doctors and nurses) must have 
experience with MND discussions particularly surrounding the initiation/refusal and/or withdrawal 
of NIV or personal experience of being present at the initiation or withdrawal of NIV, and be able 
to converse in English in order to be eligible to participate in this research. 
  To take part in the interview or obtain further information, please contact me: Phone: 
0417960430   cschapma@our.ecu.edu.au. You may also speak to my Ph.D. Supervisor about 
this study, Professor Anne Wilkinson at (08) 6304-3540 or  or email her at: 
anne.wilkinson@ecu.edu.au.  If you have any concerns about the research project or wish to 
talk to an independent person, you may contact the Research Ethics Officer at Edith Cowan 
University, 270 Joondalup Drive, Joondalup WA 6027 Phone: 08 6304 2170 or email 
research.ethics@ecu.edu.au.  
Many thanks for your interest and assistance,  
Sincerely,      
Lottie Chapman, PhD Candidate, Edith Cowan University 
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Appendix H: MNDA WA Newsletter Entry 
 
 
 
 
Opportunity to participate in Research 
A retrospective study into the communication 
surrounding the initiation and withdrawal of non-
invasive ventilation (NIV) in patients with motor neurone 
disease 
 
The aim of my research is to explore the communication process that occurs between 
clinicians, patients and significant others regarding the initiation (or refusal) and 
withdrawal of non-invasive ventilation (NIV) for people diagnosed with Motor Neurone 
Disease (MND).  Communication around NIV has been identified as an area needing 
further research (National Institute for Health and Clinical Excellence, 2010).  In this 
study, I am looking specifically at how clinicians, patients and families make treatment 
decisions and how this decision-making can be improved. This study has been approved 
by the Edith Cowan University Human Research Ethics Committee as research for a 
PhD, and has the support of MNDA WA/NSW.  
You are invited to participate and discuss your experiences in this area, 
contributing to much needed research into NIV communication. All family/significant 
other participants must have been closely involved with the MND patient particularly if 
the patient used or refused NIV.  
 Participation involves one face-to-face or telephone interview with me, a nurse 
researcher, which will last only 30-40 minutes and will take place at a time and place 
most convenient to you. Your participation is entirely voluntary and you may cease or 
withdraw from the interview at any time.  
 Although this study might not benefit you or your family directly, this study 
should contribute to a better understanding of the complex issues involved in treatment 
decision-making for seriously ill patients.   
 To be included in this research, participants must speak English and be over 
eighteen years, be a family member or significant other of a deceased MND patient, be 
able to give informed consent, and will be assessed on these criteria if interested in 
participating, by the researcher at the stage of the return of the consent form prior to 
the interview commencing. 
If you are interested in assisting this research, further information can be 
obtained by contacting the researcher Lottie Chapman RN., M. Palliative Care at: 
cschapma@our.ecu.edu.au. Or by phone  
 You may also speak to my Ph.D. Supervisor about this study, Professor Anne 
Wilkinson at (08) 6304-3540 or  or email her at: 
anne.wilkinson@ecu.edu.au. 
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Appendix I: Silver Chain Notice of Research 
 
 
Approved Research Project for Palliative Care, 
Respiratory, Neurology Doctors and Nurses or Allied 
Health professionals with experience with MND and NIV 
 
A retrospective study into the communication 
surrounding the initiation and withdrawal of non-invasive ventilation 
(NIV) in patients with motor neurone disease 
 
The aim of my research is to explore the communication process that 
occurs between clinicians, patients and significant others regarding the initiation 
(or refusal) and withdrawal of non-invasive ventilation (NIV) for people diagnosed 
with Motor Neurone Disease (MND).  Communication surrounding NIV has been 
identified as an area causing some confusion and needing further research 
(National Institute for Health and Clinical Excellence, 2010). 
In this study, I am looking specifically at how clinicians, patients and 
families make treatment decisions and how communication influencing decision-
making can be enhanced. The PhD research also incorporates a small study 
interviewing clinicians at a UK hospice as a comparison with Western Australia. 
This project has been approved by the Edith Cowan University Human Research 
Ethics Committee as research for a PhD and by the Silver Chain Human 
Research Ethics Committee.  
You are invited to discuss your experiences with MND, and specifically 
NIV, contributing to recommended research into NIV communication.  
Participation involves one face-to-face or telephone interview with me, a nurse 
researcher, which will last 
20-30 minutes and will occur at a time and place most convenient for you. Your 
participation is entirely voluntary and you may cease or withdraw from the 
interview at any time. 
  
 To take part in the interview or obtain further information, please 
contact me:  
  Lottie.Chapman,RN.,M.PalliativeCare:  
cschapma@our.ecu.edu.au. Phone:  
 
You may also speak to my Ph.D. Supervisor about this study, Professor Anne 
Wilkinson at (08) 6304-3540 or   075 or email her at: 
 anne.wilkinson@ecu.edu.au 
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Appendix J: Family Participant Information Letter 
A retrospective study into the communication surrounding the initiation 
and withdrawal of non-invasive ventilation (NIV) in patients with motor 
neurone disease 
  
Dear Family Member: 
 My name is Lottie Chapman, Registered Nurse and Ph.D. Candidate in 
the School of Nursing and Midwifery, Edith Cowan University.  I am writing to you 
to ask for your participation in the research I am conducting for my Ph.D.  The 
aim of my research is to explore the communication process that occurs between 
clinicians, patients and significant others regarding the initiation (or refusal) and 
withdrawal of non-invasive ventilation (NIV) for people diagnosed with Motor 
Neurone Disease (MND).  Communication around NIV has been identified as an 
area needing further research (National Institute for Health and Clinical 
Excellence, 2010)(National Institute for Health and Care Excellence, 2016).  
  In this study, I am looking specifically at how clinicians, patients and 
families make treatment decisions and how this decision-making can be 
improved.  This study has been approved by the Edith Cowan University Human 
Research Ethics Committee as research for a PhD.  
You are invited to discuss your experiences in this area and contributing 
to much needed research into NIV communication.  Participation involves one 
face-to-face or telephone interview with me, a nurse researcher, which will last 
only 30-40 minutes and will take place at a time and place most convenient to 
you. Your participation is entirely voluntary and you may cease or withdraw from 
the interview at any time. 
The interview will be audio taped for accuracy.  All information will be kept 
private and confidential, and no identifying information will be released to any 
source except where required by law. A research identification number will be 
assigned to the interview and associated transcripts and only I will know the 
identity of the respondent.  All data will be stored on password-protected 
computers in the researcher’s computer at ECU. Only authorised persons, who 
understand that this information must be kept confidential, will have access to it.  
When the study has been completed, all anonymous recordings and written 
documentation will be archived and stored in securely locked files for a minimum 
period of five years, as required by law.  Your answers will be combined with the 
answers of other people for analysis and reporting purposes. Findings will be 
reported in the researcher’s dissertation and may be published in relevant health 
related peer-reviewed journals. No personal or identifying information will be 
conveyed in any of the publications arising from this research. By taking part in 
this study you agree not to restrict the use of any data, even if you withdraw. 
 Although this study might not benefit you or your family directly, this 
study should contribute to a better understanding of the complex issues 
involved in treatment decision-making for seriously ill patients.  Discussing 
medical decision-making for your family member is not expected to create any 
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emotional distress for you, the participant, but it may raise minor concerns for 
some individuals. If you would like to have a support person present during the 
interview that may be very helpful for your support. Details of a free counselling 
service and the MNDA Care Advisory team offering emotional support and 
advocacy (Motor Neurone Disease Association of WA Inc Phone: (08 9346 
7355) and MND NSW (02 8877 0999) are supplied to you should you wish to 
discuss any issues which may arise from the research interview.  
If you have any questions raised about this survey or to have someone to talk 
with you, support information and contact information for counsellors will be 
supplied to you. 
The following information provides the specifications required for 
participation in this research: 
Inclusion criteria: 
1) All family/significant other participants, must have either been closely 
involved with the MND patient particularly if the patient used or refused NIV  
2)All participants must speak English and be over eighteen years, be able to 
give informed consent, and will be assessed on these criteria if interested in 
participating, by the researcher at the stage of the return of the consent form 
which includes a description of these criteria.  
Exclusion criteria:  
1) Anyone under 18 years 
2) Anyone unable to give consent 
3) Anyone unable to communicate in English 
4) Anyone with no connection to people with MND  
5) Any family previously associated with the researcher as a nurse who cared 
for their family member with MND 
6) A person with MND (unless the person with MND specifically wishes to tell 
their story) 
 
To take part in the interview or obtain further information, please contact 
me at: cschapma@our.ecu.edu.au. You may also speak to my Ph.D. Supervisor 
about this study, Professor Anne Wilkinson at (08) 6304-3540 or  or 
email her at: anne.wilkinson@ecu.edu.au. 
If you have any concerns about the research project or wish to talk to an 
independent person, you may contact the Research Ethics Officer at Edith 
Cowan University, 270 Joondalup Drive, Joondalup WA 6027 : Phone: 08 6304 
2170 or Email: research.ethics@ecu.edu.au  
I really appreciate your interest and time in reading this letter,  
Sincerely, 
 
Charlotte (Lottie) Chapman, PhD Candidate, Edith Cowan University  
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Appendix K: Nvivo10 Node Screen Shot 
.  
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Appendix L: Nvivo10 Information Screen Shot 
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Appendix M: 1) Example of Initial Interview Coding 
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Appendix M: 2) Secondary Random Participant Coding 
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Appendix N: Silver Chain Ethics Approval 
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Appendix O: St John of God Hospitals Ethics Approval 
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Appendix P: Research Approval Neurological Council of WA
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Appendix Q: Transcription Confidentiality Agreement 
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Appendix R: Ethics Approval Wisdom Hospice 
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Appendix S: PRISMA Checklist 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 
 
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number. 
 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. 
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS). 
 
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration information including registration 
number. 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria for 
eligibility, giving rationale. 
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and date last searched. 
Search 8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated. 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis). 
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data from 
investigators. 
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data 
synthesis. 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in 
means). 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, 
if done, including measures of consistency (e.g., I2 ) for each meta-analysis. 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting within studies). 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified. 
 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in 
the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
Study characteristics 18 For each study, present characteristics for which data were extracted 
(e.g., study size, PICOS, follow-up period) and provide the citations. 
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12). 
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Results of individual studies 20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot. 
Synthesis of results 21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency. 
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies 
(see Item 15). 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]). 
 
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for 
each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers). 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias). 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research. 
 
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review. 
 
 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097 
For more information, visit: www.prisma-statement.org. 
Page 2 of 2
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Appendix: T: COREQ checklist Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist 
No  Item  Guide questions/description   
Domain 1: 
Research team 
and reflexivity  
    
 
Personal 
Characteristics  
    
 
1.  Interviewer/facilitator  Which author/s conducted the interview or focus group?  PhD Candidate 
2.  Credentials  What were the researcher's credentials? E.g. PhD, MD  M. Palliative Care, RN, CFIAC, CT(ASC) 
3.  Occupation  What was their occupation at the time of the study?  Clinical Nurse/Case co-ordinator 
4.  Gender  Was the researcher male or female?  Female 
5.  
Experience and 
training  
What experience or training did the researcher have?  
Previous research prior to attaining M. Palliative Care, 
and Cytotechnologist Fellow International Academy of 
Cytology  
Relationship 
with 
participants  
    
All family participants previously unknown to 
candidate. Two of the nineteen clinician participants 
were known to the candidate as worked in the same 
area. 
6.  
Relationship 
established  
Was a relationship established prior to study 
commencement?  
A working relationship with the two clinicians known 
to the candidate. No relationship established with the 
other twenty-four participants. 
7.  
Participant knowledge 
of the interviewer  
What did the participants know about the researcher? e.g. 
personal goals, reasons for doing the research  
A letter via email explaining the research was sent to 
each participant and this is attached as Appendices G 
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No  Item  Guide questions/description   
and J. Further verbal explanation if participants 
enquired, at commencement of the interview. 
8.  
Interviewer 
characteristics  
What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, assumptions, reasons and 
interests in the research topic  
Trustworthiness is reported in Chapter 3 of this thesis. 
No issues reported by the candidates   
Domain 2: 
study design  
    
 
Theoretical 
framework  
    
 
9.  
Methodological 
orientation and 
Theory  
What methodological orientation was stated to underpin 
the study? e.g. grounded theory, discourse analysis, 
ethnography, phenomenology, content analysis  
Interpretive Description (framework) and Symbolic 
Interactionism (theoretical perspective) 
Participant 
selection  
    
 
10.  Sampling  
How were participants selected? e.g. purposive, 
convenience, consecutive, snowball  
Purposive and snowball 
11.  Method of approach  
How were participants approached? e.g. face-to-face, 
telephone, mail, email  
Initially the family participants applied to partake in 
the research having read an advertisement in the 
MND Australia newsletter. The clinicians were 
approached via their places of work who sent out an 
email advertising the research, and interested 
clinicians applied. This was snowballed by word of 
mouth between clinicians.  
12.  Sample size  How many participants were in the study?  Twenty-six 
13.  Non-participation  
How many people refused to participate or dropped out? 
Reasons?  
None 
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No  Item  Guide questions/description   
Setting       
14.  
Setting of data 
collection  
Where was the data collected? e.g. home, clinic, 
workplace  
The family participants were interviewed at their place 
of choices which in each case, was their home. The 
clinicians were interviewed at their place of work 
15.  
Presence of non-
participants  
Was anyone else present besides the participants and 
researchers?  
No 
16.  Description of sample  
What are the important characteristics of the sample? e.g. 
demographic data, date  
Experience of the participant of caring for a person 
with MND. Demographic data was collected 
Data 
collection  
    
 
17.  Interview guide  
Were questions, prompts, guides provided by the authors? 
Was it pilot tested?  
Yes, and included in the Appendices (D and E) 
18.  Repeat interviews  Were repeat interviews carried out? If yes, how many?  No 
19.  
Audio/visual 
recording  
Did the research use audio or visual recording to collect 
the data?  
Yes, each interview was recorded with two recorders 
and were able to be transcribed verbatim. 
20.  Field notes  
Were field notes made during and/or after the interview or 
focus group?  
Minimally as everything was recorded to enable 
completed transparency. 
21.  Duration  What was the duration of the interviews or focus group?  Between 60-90 mins 
22.  Data saturation  Was data saturation discussed?  Yes, between candidate and supervisors 
23.  Transcripts returned  
Were transcripts returned to participants for comment 
and/or correction?  
Yes, each participant had their transcript returned. 
Only one participant made a correction, and this was 
grammatical. 
Domain 3: 
analysis and 
findings  
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No  Item  Guide questions/description   
Data analysis       
24.  
Number of data 
coders  
How many data coders coded the data?  
Primarily the candidate, but one of the supervisors 
selected transcripts at random for coding 
25.  
Description of the 
coding tree  
Did authors provide a description of the coding tree?  
Yes, and further described in Appendices K, L, M and 
N. 
26.  Derivation of themes  
Were themes identified in advance or derived from the 
data?  
Derived from the data 
27.  Software  
What software, if applicable, was used to manage the 
data?  
Nvivo10  
28.  Participant checking  Did participants provide feedback on the findings?  
Some provided feedback at the time of the interview 
and some of the clinicians sent positive feedback via 
email when commenting on their transcribed 
interviews. As yet, the full findings have not been 
provided to the participants 
Reporting       
29.  Quotations presented  
Were participant quotations presented to illustrate the 
themes / findings? Was each quotation identified? e.g. 
participant number  
Yes, the quotations are clearly attributed to the 
participant and the themes identified. 
30.  
Data and findings 
consistent  
Was there consistency between the data presented and 
the findings?  
Yes 
31.  
Clarity of major 
themes  
Were major themes clearly presented in the findings?  
Yes 
32.  
Clarity of minor 
themes  
Is there a description of diverse cases or discussion of 
minor themes?  
Yes 
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